NZ760199A - Methylene carbamate linkers for use with targeted-drug conjugates - Google Patents
Methylene carbamate linkers for use with targeted-drug conjugatesInfo
- Publication number
- NZ760199A NZ760199A NZ760199A NZ76019914A NZ760199A NZ 760199 A NZ760199 A NZ 760199A NZ 760199 A NZ760199 A NZ 760199A NZ 76019914 A NZ76019914 A NZ 76019914A NZ 760199 A NZ760199 A NZ 760199A
- Authority
- NZ
- New Zealand
- Prior art keywords
- unit
- drug
- rop
- group
- alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 579
- 229940079593 drug Drugs 0.000 title claims abstract description 578
- 238000000034 method Methods 0.000 claims abstract description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 222
- 239000001257 hydrogen Substances 0.000 claims description 222
- -1 benzoate ester Chemical class 0.000 claims description 169
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 148
- 125000000524 functional group Chemical group 0.000 claims description 129
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 127
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 113
- 150000001875 compounds Chemical class 0.000 claims description 112
- 230000004913 activation Effects 0.000 claims description 105
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 102
- 125000005647 linker group Chemical group 0.000 claims description 99
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 82
- 125000006850 spacer group Chemical group 0.000 claims description 77
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 73
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 68
- 229910052757 nitrogen Inorganic materials 0.000 claims description 65
- 125000003118 aryl group Chemical group 0.000 claims description 55
- 239000002243 precursor Substances 0.000 claims description 55
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 125000000623 heterocyclic group Chemical group 0.000 claims description 49
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 45
- 229910052799 carbon Inorganic materials 0.000 claims description 44
- 125000004432 carbon atom Chemical group C* 0.000 claims description 40
- 125000001424 substituent group Chemical group 0.000 claims description 39
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 36
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 34
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 32
- 125000003386 piperidinyl group Chemical group 0.000 claims description 30
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 28
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 27
- 125000004429 atom Chemical group 0.000 claims description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 235000000346 sugar Nutrition 0.000 claims description 15
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 14
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 12
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 12
- 108010044540 auristatin Proteins 0.000 claims description 12
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims description 11
- 125000001743 benzylic group Chemical group 0.000 claims description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 11
- 150000008134 glucuronides Chemical group 0.000 claims description 10
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- QXJIABOUHLYVHP-UHFFFAOYSA-N n-chloromethanamine Chemical compound CNCl QXJIABOUHLYVHP-UHFFFAOYSA-N 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 238000006969 Curtius rearrangement reaction Methods 0.000 claims description 8
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 8
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- 238000006664 bond formation reaction Methods 0.000 claims description 7
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 claims description 5
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 5
- 102000004243 Tubulin Human genes 0.000 claims description 5
- 108090000704 Tubulin Proteins 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 5
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 claims description 5
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- ANPYLYUCGAFKNQ-UHFFFAOYSA-N ethoxymethoxymethoxyethane Chemical compound CCOCOCOCC ANPYLYUCGAFKNQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- DBCTYNOJEFQAPK-UHFFFAOYSA-N C[SiH](OCC[Si](C)(C)C)O[SiH](C)OCC[Si](C)(C)C Chemical compound C[SiH](OCC[Si](C)(C)C)O[SiH](C)OCC[Si](C)(C)C DBCTYNOJEFQAPK-UHFFFAOYSA-N 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 205
- 239000000543 intermediate Substances 0.000 abstract description 29
- 230000008685 targeting Effects 0.000 abstract description 29
- 230000021615 conjugation Effects 0.000 abstract description 26
- 210000004881 tumor cell Anatomy 0.000 abstract description 20
- 230000030833 cell death Effects 0.000 abstract description 2
- 239000000562 conjugate Substances 0.000 description 194
- 239000000203 mixture Substances 0.000 description 89
- 210000004027 cell Anatomy 0.000 description 73
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 70
- 229940024606 amino acid Drugs 0.000 description 69
- 235000001014 amino acid Nutrition 0.000 description 69
- 150000001413 amino acids Chemical class 0.000 description 69
- 206010028980 Neoplasm Diseases 0.000 description 68
- 125000001570 methylene group Chemical class [H]C([H])([*:1])[*:2] 0.000 description 60
- 125000005842 heteroatom Chemical group 0.000 description 53
- 229920001223 polyethylene glycol Polymers 0.000 description 52
- 125000003396 thiol group Chemical class [H]S* 0.000 description 52
- 125000000217 alkyl group Chemical group 0.000 description 50
- 201000011510 cancer Diseases 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 39
- 150000001412 amines Chemical class 0.000 description 38
- 235000002639 sodium chloride Nutrition 0.000 description 37
- 229910052717 sulfur Inorganic materials 0.000 description 33
- 238000010348 incorporation Methods 0.000 description 31
- 150000003839 salts Chemical class 0.000 description 31
- 238000003786 synthesis reaction Methods 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 229910052760 oxygen Inorganic materials 0.000 description 30
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 29
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 29
- 239000002253 acid Substances 0.000 description 28
- 229910001868 water Inorganic materials 0.000 description 28
- 238000003776 cleavage reaction Methods 0.000 description 27
- 230000007017 scission Effects 0.000 description 26
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 125000004122 cyclic group Chemical group 0.000 description 24
- 125000006239 protecting group Chemical group 0.000 description 23
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 22
- 125000003277 amino group Chemical group 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 125000004103 aminoalkyl group Chemical group 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 239000001301 oxygen Substances 0.000 description 21
- 150000002829 nitrogen Chemical class 0.000 description 20
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- 150000001408 amides Chemical class 0.000 description 17
- 125000002393 azetidinyl group Chemical group 0.000 description 17
- 125000006575 electron-withdrawing group Chemical group 0.000 description 17
- 150000002148 esters Chemical class 0.000 description 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 16
- 150000001414 amino alcohols Chemical group 0.000 description 16
- 229940127089 cytotoxic agent Drugs 0.000 description 16
- 125000004434 sulfur atom Chemical group 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 230000001472 cytotoxic effect Effects 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 239000011593 sulfur Substances 0.000 description 15
- 208000023275 Autoimmune disease Diseases 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- 125000003368 amide group Chemical group 0.000 description 13
- 125000000732 arylene group Chemical group 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 229940049595 antibody-drug conjugate Drugs 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 231100000433 cytotoxic Toxicity 0.000 description 12
- 230000002255 enzymatic effect Effects 0.000 description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 125000001931 aliphatic group Chemical group 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- PWFXLXMPGSLEOZ-UHFFFAOYSA-N precursor Z Chemical compound O1C2COP(O)(=O)OC2C(=O)C2C1NC(N=C(NC1=O)N)=C1N2 PWFXLXMPGSLEOZ-UHFFFAOYSA-N 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- YSZSLPRWNYBWRS-LSFNHRITSA-N (2S,9S,12R)-2-cyclohexyl-12-[2-(3,4-dimethoxyphenyl)ethyl]-24,27-dimethoxy-11,18,22-trioxa-4-azatetracyclo[21.2.2.113,17.04,9]octacosa-1(25),13(28),14,16,23,26-hexaene-3,10-dione Chemical compound COC1=C(C=C(C=C1)CC[C@@H]2C3=CC(=CC=C3)OCCCOC4=C(C=C(C=C4OC)[C@@H](C(=O)N5CCCC[C@H]5C(=O)O2)C6CCCCC6)OC)OC YSZSLPRWNYBWRS-LSFNHRITSA-N 0.000 description 10
- 239000000824 cytostatic agent Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000011068 loading method Methods 0.000 description 10
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 230000001085 cytostatic effect Effects 0.000 description 9
- 238000003379 elimination reaction Methods 0.000 description 9
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 235000004400 serine Nutrition 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 150000001299 aldehydes Chemical class 0.000 description 8
- 125000004104 aryloxy group Chemical group 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 239000002254 cytotoxic agent Substances 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 125000004404 heteroalkyl group Chemical group 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 235000018977 lysine Nutrition 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 7
- 102220518656 Enhancer of filamentation 1_R19A_mutation Human genes 0.000 description 7
- 102000053187 Glucuronidase Human genes 0.000 description 7
- 108010060309 Glucuronidase Proteins 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 239000000611 antibody drug conjugate Substances 0.000 description 7
- 235000003704 aspartic acid Nutrition 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 235000014304 histidine Nutrition 0.000 description 7
- 125000002883 imidazolyl group Chemical group 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 108010093470 monomethyl auristatin E Proteins 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 150000004982 aromatic amines Chemical group 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 235000004554 glutamine Nutrition 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- 235000008729 phenylalanine Nutrition 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 150000003335 secondary amines Chemical class 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 229960002317 succinimide Drugs 0.000 description 6
- 235000008521 threonine Nutrition 0.000 description 6
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 102220518658 Enhancer of filamentation 1_R17A_mutation Human genes 0.000 description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 5
- GDIHDSKOVXEJQQ-UHFFFAOYSA-N NC(O)=O.NC(O)=O.NC(O)=O.N Chemical compound NC(O)=O.NC(O)=O.NC(O)=O.N GDIHDSKOVXEJQQ-UHFFFAOYSA-N 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 229960004308 acetylcysteine Drugs 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 125000003158 alcohol group Chemical group 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 125000003827 glycol group Chemical group 0.000 description 5
- 150000002338 glycosides Chemical group 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 229920000768 polyamine Chemical group 0.000 description 5
- 230000002028 premature Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 5
- 229910052721 tungsten Inorganic materials 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- 235000014393 valine Nutrition 0.000 description 5
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 4
- 102220465932 Beta-1,3-glucuronyltransferase LARGE2_R13A_mutation Human genes 0.000 description 4
- 102220465933 Beta-1,3-glucuronyltransferase LARGE2_R15A_mutation Human genes 0.000 description 4
- 102000004631 Calcineurin Human genes 0.000 description 4
- 108010042955 Calcineurin Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 230000010777 Disulfide Reduction Effects 0.000 description 4
- 102220503972 Endogenous retrovirus group K member 6 Rec protein_R16A_mutation Human genes 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 102000000521 Immunophilins Human genes 0.000 description 4
- 108010016648 Immunophilins Proteins 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 125000002843 carboxylic acid group Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229960005167 everolimus Drugs 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 235000006109 methionine Nutrition 0.000 description 4
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229960001639 penicillamine Drugs 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 150000003334 secondary amides Chemical class 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960001967 tacrolimus Drugs 0.000 description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- 125000006655 (C3-C8) heteroaryl group Chemical group 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
- IUTPJBLLJJNPAJ-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)CCN1C(=O)C=CC1=O IUTPJBLLJJNPAJ-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 239000012661 PARP inhibitor Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 3
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 3
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 3
- 229940122803 Vinca alkaloid Drugs 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 150000003949 imides Chemical group 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- LINBWYYLPWJQHE-UHFFFAOYSA-N 3-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCC(=O)O)C3=CC=CC=C3C2=C1 LINBWYYLPWJQHE-UHFFFAOYSA-N 0.000 description 2
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 2
- VGGWNGWXGFWLRK-UHFFFAOYSA-N 8,9-dihydro-1H-[1,3]oxazolo[4,5-i][1,2]benzodiazepine Chemical class C1=CC=NNC2=C(OCN3)C3=CC=C21 VGGWNGWXGFWLRK-UHFFFAOYSA-N 0.000 description 2
- 101150034533 ATIC gene Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 239000012626 DNA minor groove binder Substances 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical group [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 101800003344 Vaccinia growth factor Proteins 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- RAJISUUPOAJLEQ-UHFFFAOYSA-N chloromethanamine Chemical compound NCCl RAJISUUPOAJLEQ-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 125000005981 pentynyl group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000003139 primary aliphatic amines Chemical class 0.000 description 2
- 125000001749 primary amide group Chemical group 0.000 description 2
- IFOHPTVCEBWEEQ-UHFFFAOYSA-N pyrrolo[2,3-i][1,4]benzodiazepine Chemical class N1=CC=NC2=C3C=CN=C3C=CC2=C1 IFOHPTVCEBWEEQ-UHFFFAOYSA-N 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- IHUKVJKKTBLTEE-QMMMGPOBSA-N (2s)-2-acetamido-5-[[amino-(methylcarbamoylamino)methylidene]amino]-n-methylpentanamide Chemical compound CNC(=O)NC(N)=NCCC[C@H](NC(C)=O)C(=O)NC IHUKVJKKTBLTEE-QMMMGPOBSA-N 0.000 description 1
- JIDDDPVQQUHACU-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbaldehyde Chemical group O=C[C@@H]1CCCN1 JIDDDPVQQUHACU-YFKPBYRVSA-N 0.000 description 1
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
- OUFUAQXCSKICMF-UHFFFAOYSA-N 1-[(1-carboxy-2-hydroxy-2h-naphthalen-1-yl)methyl]-2-hydroxy-2h-naphthalene-1-carboxylic acid Chemical class OC1C=CC2=CC=CC=C2C1(C(O)=O)CC1(C(O)=O)C2=CC=CC=C2C=CC1O OUFUAQXCSKICMF-UHFFFAOYSA-N 0.000 description 1
- CWLUFVAFWWNXJZ-UHFFFAOYSA-N 1-hydroxypyrrolidine Chemical compound ON1CCCC1 CWLUFVAFWWNXJZ-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- UFCRQKWENZPCAD-UHFFFAOYSA-N 2-(2-aminophenyl)propanamide Chemical class NC(=O)C(C)C1=CC=CC=C1N UFCRQKWENZPCAD-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- MIVRMHJOEYRXQB-UHFFFAOYSA-N 2-diazonio-1-methoxyethenolate Chemical compound COC(=O)C=[N+]=[N-] MIVRMHJOEYRXQB-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- WCVPFJVXEXJFLB-UHFFFAOYSA-N 4-aminobutanamide Chemical class NCCCC(N)=O WCVPFJVXEXJFLB-UHFFFAOYSA-N 0.000 description 1
- 150000007578 6-membered cyclic compounds Chemical class 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000003902 Cathepsin C Human genes 0.000 description 1
- 108090000267 Cathepsin C Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- 235000019227 E-number Nutrition 0.000 description 1
- 239000004243 E-number Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000228957 Ferula foetida Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- QNOJCNMJPUYJGK-UHFFFAOYSA-N NC(=O)OOOC(N)=O Chemical group NC(=O)OOOC(N)=O QNOJCNMJPUYJGK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100029197 SLAM family member 6 Human genes 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- AKDLZRSCZBAIQF-UHFFFAOYSA-N [N].C1(C=CC(N1)=O)=O Chemical compound [N].C1(C=CC(N1)=O)=O AKDLZRSCZBAIQF-UHFFFAOYSA-N 0.000 description 1
- HKNSIVFWRXBWCK-UHFFFAOYSA-N [N].NC1=CC=CC=C1 Chemical compound [N].NC1=CC=CC=C1 HKNSIVFWRXBWCK-UHFFFAOYSA-N 0.000 description 1
- CHKFLBOLYREYDO-SHYZEUOFSA-N [[(2s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)C[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 CHKFLBOLYREYDO-SHYZEUOFSA-N 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001723 carbon free-radicals Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- VQXINLNPICQTLR-UHFFFAOYSA-N carbonyl diazide Chemical compound [N-]=[N+]=NC(=O)N=[N+]=[N-] VQXINLNPICQTLR-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 239000012975 dibutyltin dilaurate Substances 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- UKSVDPLOPDJECP-UHFFFAOYSA-N ethyl 3-(2h-quinolin-1-yloxy)propanoate Chemical compound C1=CC=C2N(OCCC(=O)OCC)CC=CC2=C1 UKSVDPLOPDJECP-UHFFFAOYSA-N 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002665 ion therapy Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- GNVCVTHOZZYZRK-UHFFFAOYSA-N naphtho[2,1-e][2]benzofuran Chemical compound C1=CC2=CC=CC=C2C2=C1C1=COC=C1C=C2 GNVCVTHOZZYZRK-UHFFFAOYSA-N 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 150000005619 secondary aliphatic amines Chemical class 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical group NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DVFXLNFDWATPMW-IWOKLKJTSA-N tert-butyldiphenylsilyl Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DVFXLNFDWATPMW-IWOKLKJTSA-N 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 150000003510 tertiary aliphatic amines Chemical class 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- PYHOFAHZHOBVGV-UHFFFAOYSA-N triazane Chemical compound NNN PYHOFAHZHOBVGV-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 150000008505 β-D-glucopyranosides Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides Ligand-Drug Conjugates and Drug-Linker Compounds comprising a methylene carbamate unit. The invention provides inter alia, Ligand-Drug Conjugates, wherein the Ligand-Drug Conjugate is comprised of a Self-immolative Assembly Unit having a methylene carbamate unit for conjugation of a drug to a targeting ligand, methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates of the present invention are stable in circulation, yet capable of inflicting cell death once free drug is released from a Conjugate in the vicinity or within tumor cells.
Description
METHYLENE ATE LINKERS FOR USE WITH
TARGETED-DRUG CONJUGATES
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of New Zealand patent application 721877, which is
the national phase entry in New Zealand of PCT international application
shed as WO2015/095755). This non-provisional application
claims priority under 35 U.S.C. § 119(e) to pending US Appl. Ser. No. 61/918,539, filed on
December 19, 2013, all of which are incorporated herein by reference in their ty.
BACKGROUND OF THE INVENTION
A great deal of interest has surrounded the use of monoclonal dies (mAbs) for
the targeted delivery of cytotoxic agents to tumor cells. While a number of different drug
classes have been evaluated for delivery via antibodies, only a few drug s have proved
sufficiently active as antibody drug conjugates, while having a suitable toxicity profile, to
warrant clinical development. One such class is the auristatins, related to the natural t
dolastatin 10. Representative auristatins include MMAE (N-methylvaline-valinedolaisoleuine-dolaproine-norephedrine
) and MMAF (N-methylvaline-valine-dolaisoleuinedolaproine-phenylalanine
The design of Antibody Drug Conjugates (ADCs), by attaching a cytotoxic agent to
antibody, typically via a linker, involves consideration of a variety of factors, including the
presence of a conjugation handle on the drug for attachment to the linker and linker
technology for attaching the drug to an antibody in a conditionally stable manner. Certain
drug classes thought to be lacking appropriate conjugation handles have been considered
unsuitable for use as ADCs. gh it may be possible to modify such a drug to include a
conjugation handle, such a modification can negatively ere with the drug’s activity
profile.
Linkers sing esters and carbonates have typically been used for conjugation
of alcohol-containing drugs and result in ADCs having variable stability and drug release
profiles. A non-optimal profile can result in reduced ADC potency, insufficient
logic specificity of the conjugate and sed toxicity due to ecific release of
the drug from the conjugate. Although it has been shown that certain phenolic alcohols can be
directly attached through ether linkages to the self-immolative Spacer Unit p-amidobenzyl
alcohol, these linker gies are unlikely to work for all alcohol-containing drugs, including
many aliphatic alcohol-containing drugs (see, for example, Toki, et al. J. Org. Chem. 2002,
67, 1866-1872). One reason for that may be due to the high pKa of aliphatic alcohol-
containing drugs.
Therefore, a need exists for new linker technologies that can be used to attach drugs
fore ed to be unsuitable for use as ADCs, and Ligand Drug Conjugates (LDCs) in
general, including a need for more versatile methods for linking ic alcohol- and
aliphatic alcohol-containing drugs to other targeting ligands in addition to antibodies. It is an
object of the present invention to go some way towards addressing those and other needs;
and/or to at least provide the public with a useful choice.
BRIEF SUMMARY OF THE INVENTION
The invention provides inter alia, Ligand-Drug Conjugates, wherein the Ligand-
Drug Conjugate is comprised of a mmolative Assembly Unit having a methylene
carbamate unit for conjugation of a drug to a targeting ligand, methods of preparing and using
them, and ediates thereof. The Ligand-Drug Conjugates of the present invention are
stable in circulation, yet capable of inflicting cell death once free drug is released from a
Conjugate in the vicinity or within tumor cells.
In a first aspect the present inventipn provides a method of preparing an
ediate of a Drug-Linker compound, which has a Linker Unit and a Drug Unit
covalently attached thereto, wherein the intermediate has the structure of:
said method comprising:
contacting a modified free drug having the structure of:
with a self-immolative intermediate ented by: A'-X-OH,
wherein any hydroxyl group within A’ or X is protected as an acetate, propionate or te
ester, a methyl or tetrahydropyranyl ether, a methoxymethyl or ethoxymethyl ether, or a
trimethylsilyl, triethylsilyl, tert-butyldiphenylsilyl, tert-butyldimethylsilyl, triisopropylsilyl,
or imethylsilyl)ethoxy]-methylsilyl ether,
such that the ted MAC Unit is produced through Curtius rearrangement,
wherein D is the Drug Unit wherein the Drug Unit corresponds in structure to free
drug in which a hydroxyl functional group has been incorporated into the MAC Unit, the
oxygen heteroatom from which is designated by O*;
A' is a Connector Unit precursor to a Connector Unit (A) having a functional group
for bond formation to the remainder of the Linker Unit, wherein A is selected from the group
consisting of:
, , and ,
wherein the wavy lines indicate attachment of the Connector Unit within the Linker Unit,
wherein in each instance R13 is independently ed from the group consisting of -C1-C6
alkylene-, -C3-C8carbocyclo-, -arylene-, -C1-C10 heteroalkylene-, heterocyclo-, -C1-
C10alkylene-arylene-, -arylene-C1-C10alkylene-, -C1-C10alkylene-(C3-C8carbocyclo)-, -(C3-
C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-, and -(C3-C8
heterocyclo)-C1-C10 alkylene-, and the subscript c is an integer g from 1 to 4;
or A is selected from the group consisting of:
, , ,
O , , , ,
and ,
wherein R13 is -C1-C6 alkylene-, -C3-C8carbocyclo-, -arylene-, -C1-C10 heteroalkylene-
, heterocyclo-, -C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, -C1-C10alkylene-
(C3-C8carbocyclo)-, -(C3-C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8
heterocyclo)-, or -(C3-C8 heterocyclo)-C1-C10 ne- or –C(=O)C1-C6 ne- or -C1-C6
alkylene-C(=O)-C1-C6 alkylene,
wherein the wavy lines indicate attachment of the Connector Unit within the Linker
Unit;
wherein R111 is independently selected from the group consisting of hydrogen, phydroxybenzyl
, methyl, isopropyl, isobutyl, sec-butyl, -CH2OH, -CH(OH)CH3, -
CH2CH2SCH3, NH2, -CH2COOH, -CH2CH2CONH2, -CH2CH2COOH, -
(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, -
(CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -
(CH2)3NHCONH2, 4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-
pyridylmethyl-, 4-pyridylmethyl-,
n the wavy line indicates covalent attachment to the remainder of the Connector Unit;
each R100 is independently selected from hydrogen or -C1-C3 alkyl, preferably hydrogen or
CH3; and
c is independently selected integer ranging from 1 to 10;
X is an activatable self-immolative moiety of formula (i):
(i)
wherein the wavy line indicates covalent attachment of W to A’, and the asterisk (*)
indicates covalent attachment of Y to a methylene ate unit;
W is an Activation Unit of the formula:
wherein the wavy line adjacent to the carbonyl is attached to the self-immolative
Spacer Unit and the other wavy line is attached to the tor Unit precursor (A’), and the
subscript w is an r ranging from 1 to 12; and
wherein R19 is, in each instance, independently selected from the group consisting of
hydrogen, methyl, pyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, -
CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH, -CH2CH2CONH2, -
CH2CH2COOH, -(CH2)3NHC(=NH)NH2, 3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO,
-(CH2)4NHC(=NH)NH2, 4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -
(CH2)3NHCONH2, 4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-
pyridylmethyl-, 4-pyridylmethyl-, phenyl, cyclohexyl,
, , ,
, , , ,
, and ; and
Y is a self-immolative Spacer Unit having the structure:
wherein the wavy line indicates covalent attachment to the Activation Unit and the
hashtag (#) indicates nt attachment of the benzylic carbon to the methylene carbamate
unit; and
Q is C1-C8 alkyl, -O-(C1-C8 alkyl), halogen, nitro, or cyano, and m is an integer
ranging from 0 to 4;
or X is a Glucuronide Unit having the ure of formula XIXa or XIXb:
(XIXa) (XIXb)
wherein Su is a Sugar moiety, -O'- represents the oxygen atom of a glycosidic bond
cleavable by a glycosidase to initiate release of the Drug Unit; and
R1S, R2S and R3S ndently are hydrogen, a n, -CN or -NO2,
wherein the wavy line nt to the nitrogen atom indicates covalent attachment to
A’;
and the asterisk (*) adjacent to the benzylic carbon atom indicates covalent attachment to the
oxygen atom of the methylene carbamate unit, n activation of the activateable selfimmolative
moiety releases the free drug;
R is hydrogen; and
R1 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C6-C14 aryl,
or optionally substituted C-linked heteroaryl:
wherein each optional substituent is selected from the group consisting of -X, -Rop, -OH, -
ORop , -SRop, -N(Rop)2, -N(Rop)3, =NRop, -CX3, -CN, -NO2, -NRopC(=O)Rop, -C(=O)Rop, -
C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, -OP(=O)(ORop)2, -P(=O)(ORop)2, -
PO3=, PO3H2, Rop, -C(=S)Rop, p, -CO2-, -C(=S)ORop, -C(=O)SRop, -C(=S)SRop,
-C(=O)N(Rop)2, - C(=S)N(Rop)2, and -C(=NRop)N(Rop)2, wherein each X is independently
selected from the group consisting of a halogen: -F, -Cl, -Br, and -I; and each Rop is
independently ed from the group consisting of hydrogen, -C1- C20 alkyl, -C6-C20 aryl,
and -C3-C14 heterocycle.
[0007a] In a second aspect the present invenmtion provides a method of
preparing an intermediate of a inker Compound wherein the intermediate has the
structure of:
said method sing:
contacting a drug having a free hydroxyl functional group with a N-
chloromethylamine having the structure of:
under conditions such that the chlorine atom is substituted with the oxygen
heteroatom from said free drug functional group,
wherein any hydroxyl group within A’ or X is protected as an acetate, propionate or
benzoate ester, a methyl or tetrahydropyranyl ether, a methoxymethyl or methyl ether,
or a trimethylsilyl, triethylsilyl, utyldiphenylsilyl, tert-butyldimethylsilyl,
propylsilyl, or [2-(trimethylsilyl)ethoxy]-methylsilyl ether,
A’ is a Connector Unit precursor to a Connector Unit (A) having a functional
group for bond formation to the remainder of the Linker Unit, wherein A is selected from the
group ting of:
, , and ,
wherein the wavy lines indicate attachment of the Connector Unit within the Linker Unit,
wherein in each instance R13 is independently selected from the group consisting of -C1-C6
alkylene-, -C3-C8carbocyclo-, -arylene-, -C1-C10 heteroalkylene-, -C3-C8heterocyclo-, -C1-
C10alkylene-arylene-, -arylene-C1-C10alkylene-, 0alkylene-(C3-C8carbocyclo)-, -(C3-
C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-, and -(C3-C8
heterocyclo)-C1-C10 alkylene-, and the subscript c is an integer ranging from 1 to 4;
or A is selected from the group consisting of:
, , ,
O , , , ,
and ,
wherein R13 is -C1-C6 alkylene-, carbocyclo-, -arylene-, -C1-C10 heteroalkylene-
, -C3-C8heterocyclo-, -C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, -C1-C10alkylene-
(C3-C8carbocyclo)-, -(C3-C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8
heterocyclo)-, or -(C3-C8 heterocyclo)-C1-C10 alkylene- or –C(=O)C1-C6 alkylene- or -C1-C6
alkylene-C(=O)-C1-C6 alkylene,
wherein the wavy lines indicate attachment of the Connector Unit within the Linker
Unit;
wherein R111 is independently selected from the group consisting of hydrogen, phydroxybenzyl
, methyl, isopropyl, isobutyl, sec-butyl, -CH2OH, -CH(OH)CH3, -
CH2CH2SCH3, -CH2CONH2, -CH2COOH, 2CONH2, -CH2CH2COOH, -
NHC(=NH)NH2, -(CH2)3NH2, 3NHCOCH3, -(CH2)3NHCHO, -
NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -
(CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-
pyridylmethyl-, 4-pyridylmethyl-,
wherein the wavy line tes covalent attachment to the remainder of the Connector Unit;
each R100 is independently selected from hydrogen or -C1-C3 alkyl, preferably hydrogen or
CH3; and
c is independently ed integer ranging from 1 to 10;
X is an table self-immolative moiety of a (i):
(i)
wherein the wavy line indicates covalent attachment of W to A’, and the asterisk (*)
indicates covalent attachment of Y to a methylene carbamate unit;
W is an tion Unit of the formula:
wherein the wavy line nt to the carbonyl is attached to the self-immolative
Spacer Unit and the other wavy line is attached to the Connector Unit precursor (A’), and the
ipt w is an integer ranging from 1 to 12; and
wherein R19 is, in each instance, independently selected from the group consisting of
hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, -
CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH, -CH2CH2CONH2, -
COOH, -(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO,
-(CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -
(CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-
pyridylmethyl-, 4-pyridylmethyl-, phenyl, cyclohexyl,
, , ,
, , , ,
, and ; and
Y is a self-immolative Spacer Unit having the structure:
wherein the wavy line indicates covalent ment to the Activation Unit and the
hashtag (#) indicates covalent attachment of the benzylic carbon to the methylene ate
unit; and
Q is C1-C8 alkyl, -O-(C1-C8 alkyl), halogen, nitro, or cyano, and m is an integer
ranging from 0 to 4;
or X is a Glucuronide Unit having the structure of formula XIXa or XIXb:
(XIXa) (XIXb)
wherein Su is a Sugar , -O'- ents the oxygen atom of a idic bond
cleavable by a glycosidase to initiate release of the Drug Unit; and
R1S, R2S and R3S independently are hydrogen, a halogen, -CN or -NO2,
wherein the wavy line adjacent to the nitrogen atom indicates covalent attachment to
A’;
and the asterisk (*) adjacent to the benzylic carbon atom tes covalent attachment to the
oxygen atom of the methylene carbamate unit, wherein activation of the activateable selfimmolative
moiety es the free drug;
R is hydrogen, unsubstituted C1-C6 alkyl or unsubstituted C6-C14 aryl; and
R1 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C6-C14 aryl,
or optionally substituted C-linked heteroaryl, or R and R1 er with the nitrogen and
carbon atoms to which they are attached form a pyrrolodinyl or piperidinyl moiety,
wherein each optional substituent is selected from the group consisting of -X, -Rop, -OH, -
ORop , -SRop, -N(Rop)2, -N(Rop)3, =NRop, -CX3, -CN, -NO2, -NRopC(=O)Rop, Rop, -
C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, -OP(=O)(ORop)2, -P(=O)(ORop)2, -
PO3=, PO3H2, -C(=O)Rop, -C(=S)Rop, -CO2Rop, -CO2-, -C(=S)ORop, -C(=O)SRop, -C(=S)SRop,
-C(=O)N(Rop)2, - C(=S)N(Rop)2, and -C(=NRop)N(Rop)2, wherein each X is independently
selected from the group consisting of a halogen: -F, -Cl, -Br, and -I; and each Rop is
independently selected from the group consisting of hydrogen, -C1- C20 alkyl, -C6-C20 aryl,
and 4 heterocycle.
[0007b] In one principle embodiment, a Ligand Drug Conjugate (LDC), or
composition thereof, is comprised of a Ligand Unit, a Drug Unit and a Linker Unit that
ts the Ligand Unit to the Drug Unit, wherein the Linker Unit is comprised of a Selfimmolative
Assembly Unit having a methylene carbamate unit and an activateable self-
immolative moiety, wherein activation of the activateable mmolative moiety results in
release of free drug from the LDC from self-immolation, and wherein the methylene
carbamate unit is covalently attached to the Drug Unit and the teable mmolative
moiety, wherein the methylene carbamate unit covalently attached to the Drug Unit is
represented by the structure of formula I:
or a pharmaceutically acceptable salt thereof, wherein
the wavy line indicates nt attachment of the ene carbamate unit to an
activateable self-immolative moiety (X);
D is a Drug Unit having a onal group (e.g., hydroxyl, thiol, amide or amine
functional group) that has been incorporated into the methylene carbamate unit,
T* is a heteroatom from said functional group (e.g., oxygen, sulfur, optionally
substituted nitrogen) that becomes incorporated into the methylene ate unit;
X is an activateable self-immolative moiety;
R, R1 and R2 independently are hydrogen, optionally substituted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally tuted C-linked C3-C8 heteroaryl,
or R and R1 together with the nitrogen and carbon atoms to which they are attached
comprise an azetidinyl, pyrrolodinyl, piperidinyl or homopiperidinyl moiety, and R2 is
hydrogen.
In some of those embodiments, a Ligand Drug Conjugate, or composition thereof,
having the methylene carbamate unit of formula I is represented by the structure of a
or a pharmaceutically acceptable salt thereof; wherein
L is a Ligand Unit;
Z is a her Unit;
B is an optional Branching Unit and is present when t is greater than 1 and is absent
when t is 1;
A is an optional Connector Unit;
X is an activateable self-immolative moiety;
the subscript t ranges from 1 to 4;
the subscript p is an integer (for an individual LDC) or a number (for a tion of
LDCs in a LDC composition) ranging from 1 to 16; and
and D, T*, R, R1 and R2 are as defined in formula I.
Other principle embodiments are Drug-Linker Compounds useful as intermediates for
preparing -Drug Conjugates, n the inker Compound is comprised of a
Drug Unit and a Linker Unit, wherein the Linker Unit is comprised of a Stretcher Unit
precursor (Z') capable of forming a covalent bond to a targeting ligand that es for a
Ligand Unit, a Self-immolative Assembly Unit having a methylene carbamate unit and an
activateable self-immolative moiety, wherein activation of the activateable self-immolative
moiety in a LDC in which the Drug-Linker Compound is incorporated results in release of
free drug from the LDC by self-immolation, and wherein the methylene carbamate unit is
covalently attached to the Drug Unit and the activateable self-immolative moiety.
[0010] In some of those embodiments the Drug-Linker Compound having the methylene
carbamate unit of formula I has the structure of formula V:
or a pharmaceutically acceptable salt thereof, wherein
Z' is a Stretcher Unit precursor to a Stretcher Unit (Z) and is comprised of a functional
group that provides for covalent attachment of a Ligand Unit to Z;
and B, A, X, R, R1, R2, T*, D, and the subscript t are as defined for Formula (II).
[0010a] In the description in this ication reference may be made to subject matter
that is not within the scope of the claims of the current ation. That subject matter
should be readily identifiable by a person skilled in the art and may assist in putting into
practice the invention as defined in the claims of this application.
BRIEF DESCRIPTION OF THE GS
Figure 1 demonstrates the stability ex vivo in rat and mouse plasma of an ADC
composition having an average drug loading of 4 in which the ADCs of the composition are
comprised of a methylene alkoxy carbamate unit (MAC unit) that incorporates the oxygen
heteroatom from the hydroxyl functional group of Auristatin E.
Figure 2 demonstrates efficient release of a tetrahydroquinoline-containing free
drug, 3, from an N-acetyl cysteine (NAC) drug conjugate upon self-immolative
activation by a glucuronidase, wherein the cyclic aniline nitrogen of that compound was
incorporated into a methylene carbamate unit of the conjugate’s Self-immolative Assembly
Unit.
Figure 3 demonstrates the intracellular accumulation of free drug from targeted
delivery by a Ligand Drug Conjugate having a t MAC Unit attached to a drug unit from
the PARP inhibitor 3.
DESCRIPTION OF THE INVENTION
General
The t invention is based, in part, on the discovery that attachment of a drug-
linker moiety having a Self-Immolative Assembly Unit comprising a atable self-
immolative moiety (X) and a methylene alkoxy (or aryloxy) carbamate unit (also referred to
herein as a MAC unit) that incorporates the oxygen heteroatom from a hydroxyl functional
group of a drug (e.g., a drug having an aromatic or aliphatic alcohol) to a Ligand Unit
permits the synthesis of conditionally stable Ligand-Drug Conjugates (LDCs) via the drug’s
hydroxy functional group. The resultant LDCs and are able to liberate free drug on
activation, which rates the hydroxyl functional group.
Other embodiments are based, in part, on the ery that the MAC unit can be
adapted to provide other methylene carbamate units for use with drugs having functional
groups other than hydroxyl, including drugs containing thiol, amide or amine functional
groups. Accordingly, exemplary Self-immolative Assembly Units provided herein comprise
methylene carbamate units that are directly attached to heteroatoms from drug functional
groups having varying leaving group abilities. In some aspects, the functional group is
hydroxyl (including that of primary, secondary and tetiary aliphatic alcohols and aromatic
alcohols), thiol (including alkylthiol and arylthiol), amide (including amide,
sulfonamide, and phosphoramide), or amine (including, primary aliphatic amines, secondary
aliphatic amines and tertiary aliphatic amines that are cyclic or lic, or y or
secondary aryl amines) from a drug so that the heteroatom attached to the methylene
carbamate unit (T*) is an oxygen, sulfur or nitrogen atom nally substituted, as for
example, when the functional group is a secondary amide, a tertiary amine, a cyclic aliphatic
amine or an N-substituted aryl amine). In those instances conditional activation of a Self-
immolative Assembly Unit releases H-T*-D, or in the case of tertiary , T*-D. A MAC
unit is one type of methylene carbamate unit, wherein the functional group heteroatom used
for covalent ment of a yl-containing drug is the oxygen atom from the drug’s
hydroxyl functional group.
In some embodiments, a methylene ate unit covalently attached to a Drug
Unit in a Self-immolative Assembly Unit of an LDC or a Drug-Linker Compound has
Formula I represented below:
wherein the wavy line indicates covalent attachment to an teable self-immolative
moiety (X) of the Self-immolative Assembly Unit; D is a Drug Unit having a functional
group that has been incorporated into a drug-linker moiety of an LDC or a Drug-Linker
Compound, T* is the oxygen, sulfur, or optionally substituted nitrogen heteroatom from said
onal group that is incorporated into the methylene carbamate unit; R and R1 and R2 are
ndently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl or
optionally substituted C-linked C3-8 heteroaryl, or both R and R1 together with the nitrogen
and carbon atoms to which they are attached comprise an azetidinyl, odinyl,
piperidinyl or homopiperidinyl moiety (preferably a pyrrolodinyl or piperidinyl moiety) and
R2 is hydrogen.
[0017] Exemplary embodiments include those n R2 is en as set forth in
Formula (Ia)
(Ia),
and the wavy line, T*, D, R, and R1 are as defined for Formula I. R and R1 are preferably
hydrogen, optionally substituted C1-6 alkyl, or optionally substituted C6-14 aryl (more
preferably en, ally substituted C1-4 alkyl or optionally substituted phenyl, most
preferably hydrogen or optionally substituted C1-4 alkyl). In some embodiments of formula
Ia, R and R1 are hydrogen. In other embodiments of formula Ia, one of R and R1 is a PEG
Unit or a Basic Unit and the other is hydrogen or tituted C1-4 alkyl.
Exemplary embodiments include those wherein R1 and R2 together with the
nitrogen and carbon atoms to which they are attached comprise a cyclo as set forth in
Formula (Ib):
wherein T*, and D and the wavy line are as defined for Formula I and s is 0, 1, 2 or 3
(preferably 0, 1, or 2; more preferably 1 or 2).
[0019] In some aspects, the methylene carbamate unit is a MAC unit. In such
embodiments, D is a Drug Unit having a hydroxyl functional group and the MAC unit
covalently attached to a Drug Unit in a Self-immolative Assembly Unit of an LDC or a Drug-
Linker Compound has the Formula I' represented below:
(I'),
wherein the wavy line, R, R1, and R2 are as defined for Formula I, D is a Drug Unit having a
yl functional group that has been incorporated into a drug-linker moiety of an LDC or
a inker nd, and O* is the oxygen heteroatom from said functional group that
is orated into the methylene carbamate unit. In some embodiments of formula I’ one of
R1 and R2 is a Basic Unit and the other is hydrogen or unsubstituted C1-C4 alkyl. In other
embodiments of formula I’, one of R1 and R2 is a PEG Unit and the other is hydrogen or
unsubstituted C1-C4 alkyl.
Exemplary embodiments include those wherein R2 is hydrogen as set forth in
a (Ia')
(Ia'),
wherein the wavy line, R, and R1 are as defined for a I, D is a Drug Unit having a
hydroxyl functional group that has been incorporated into a drug-linker moiety of an LDC or
a Drug-Linker Compound, and O* is the oxygen heteroatom from said functional group that
is incorporated into the methylene carbamate unit. R and R1 are preferably independently
selected hydrogen, optionally tuted C1-6 alkyl, or optionally substituted C6-14 aryl, (more
preferably hydrogen, optionally substituted C1-4 alkyl or optionally substituted phenyl, most
preferably hydrogen or optionally substituted C1-4 alkyl). In some embodiments of formula
Ia’, R1 and R2 are hydrogen. In other embodiments of formula Ia’ one of R and R1 is a PEG
Unit or a Basic Unit and the other is hydrogen or unsubstituted C1-4 alkyl.
Exemplary embodiments e those wherein R1 and R2 together with the
nitrogen and carbon atoms to which they are attached comprise a heterocyclo as set forth in
Formula (Ib')
(Ib')
n the wavy line,is as defined for Formula I, D is a Drug Unit having a hydroxyl
functional group that has been orated into a drug-linker moiety of an LDC or a Drug-
Linker Compound, O* is the oxygen heteroatom from said functional group that is
incorporated into the methylene carbamate unit, and the subscript s is 0, 1, 2, or 3 (preferably
0, 1, or 2; more preferably 1 or 2).
[0022] The MAC Unit is the terminus of a Self-immolative Assembly Unit. The main
on of the Self-immolative Assembly Unit is to release free drug (e.g., H-O*-D) after a
selective (i.e., conditional) activation event that initiates self-immolation of the selfimmolative
moiety within the Self-immolative Assembly Unit. The mmolative
Assembly Unit is designed to have in addition to a MAC unit, a self-immolative Spacer Unit
(Y), which is the self-immolative portion of the activeatable self-immolative moiety (X) and
an Activation Unit (W) that is conditionally acted upon to initiate the mmolation
reaction sequence within the self-immolative Spacer Unit. Activation of self-immolation is by
a cleavage event that leads to rapid fragmentation of Y to liberate free drug (e.g., free
alcohol-containing drug). The drug incorporated into a LDC of the present invention can
contain multiple onal , although attachment of the Drug Unit to the MAC Unit in
those instances is through a heteroatom from only one of the functional groups. For example,
in the case of l-containing drugs, the drug may contain more than one alcohol moieties
(i.e., more than one hydroxy functional group), although attachment of the Drug Unit to the
MAC Unit in those instances is through the oxgen heteroatom from only one of the hydroxyl
functional groups.
It will be understood for embodiments wherein the Drug Unit has an amine as the
functional group whose nitrogen becomes part of a methylene carbamate unit that T* as N*
ents the -NH- moiety from a primary amine-containing compound or an (hetero)aryl
amine-containing drug comprising the moiety of —(hetero)arylene-NH2 or –(hetero)arylene-
NH- (i.e., a drug having a primary, secondary or cyclic aromatic amine functional group
wherein (hetero)aryl or (hetero)arylene includes an ally substituted phenyl or
phenylene or a 5- or 6-membered heteroaryl or heteroarylene. Accordingly, T* as N* is
referred to as an optionally substituted nitrogen. se, when the Drug Unit has an amide
as the functional group whose nitrogen becomes part of a methylene carbamate unit that T*
as N* represents the moiety –NH(C=O)- from a primary amide-containing drug (i.e., having
the functional group of NH2C(=O)-, a secondary amide (i.e., having the functional group of
NH(RN)C(=O) -, wherein RN includes alkyl, aryl, C-linked heteroaryl, alkyl(aryl)sulfonyl,
and alkyl(aryl)phosphoryl, then T* as N* is also referred to as an optionally substituted
nitrogen. For a secondary amine-containing free drug having that nitrogen withinin a
heterocarbocycle or hetereocarbocyclo, including an aromatic amine-containing drug wherein
its aryl or arylene is substituted by -NH-alkylene- in which the alkylene moiety is bonded to
the aryl or arylene thus g a fused ring system, it will be further understood that T*-D
represents that cyclic amine structure.
Definitions
Unless stated otherwise, the following terms and phrases as used herein are intended
to have the following meanings. When trade names are used , the trade name es
the product formulation, the c drug, and the active ceutical ingredient(s) of the
trade name product, unless otherwise indicated by context.
The term “antibody” as used herein is used in the broadest sense and specifically
covers intact monoclonal antibodies, polyclonal antibodies, monospecific antibodies,
multispecific antibodies (e.g., bispecific antibodies), and dy fragments that exhibit the
desired biological activity. The native form of an antibody is a tetramer and consists of two
identical pairs of globulin chains, each pair having one light chain and one heavy
chain. In each pair, the light and heavy chain variable regions (VL and VH) are together
primarily responsible for binding to an antigen. The light chain and heavy chain variable
domains consist of a framework region interrupted by three hypervariable regions, also called
“complementarity determining regions” or “CDRs.” The constant regions may be ized
by and ct with the immune system. (see, e.g., Janeway et al., 2001, Immunol. Biology,
5th Ed., Garland hing, New York). An antibody can be of any type (e.g., IgG, IgE,
IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass. The
antibody can be derived from any suitable species. In some embodiments, the antibody is of
human or murine . An antibody can be, for example, human, zed or chimeric.
The term “monoclonal antibody” as used herein refers to an antibody obtained from
a population of substantially homogeneous antibodies, i.e., the individual antibodies
comprising the population are identical except for possible naturally-occurring mutations that
may be present in minor amounts. Monoclonal antibodies are highly specific, being directed
against a single antigenic site. The er “monoclonal” tes the character of the
dy as being obtained from a substantially homogeneous population of antibodies, and is
not to be construed as requiring production of the antibody by any particular method.
An “intact antibody” is one which comprises an n-binding variable region as
well as a light chain constant domain (CL) and heavy chain constant domains, CH1, CH2, CH3
and CH4, as appropriate for the antibody class. The constant s may be native ce
nt domains (e.g., human native sequence constant domains) or amino acid sequence
variant thereof.
An “antibody fragment” comprises a portion of an intact antibody, comprising the
antigen-binding or variable region thereof. Examples of antibody fragments include Fab,
Fab’, F(ab’)2, and Fv fragments, diabodies, triabodies, tetrabodies, linear antibodies, singlechain
antibody molecules, scFv, scFv-Fc, multispecific antibody nts formed from
antibody fragment(s), a fragment(s) produced by a Fab expression library, or an ebinding
fragments of any of the above which immunospecifically bind to a target antigen
(e.g., a cancer cell antigen, a viral antigen or a microbial antigen).
An “antigen” is an entity to which an antibody specifically binds.
The terms “specific binding” and “specifically binds” mean that the antibody or
dy derivative will bind, in a highly selective manner, with its corresponding e of
a target n and not with the multitude of other antigens. Typically, the antibody or
antibody derivative binds with an affinity of at least about 1x10-7 M, and preferably 10-8 M to
-9 M, 10-10 M, 10-11 M, or 10-12 M and binds to the predetermined antigen with an affinity
that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g.,
BSA, casein) other than the predetermined antigen or a closely-related antigen.
The term "inhibit" or "inhibition of" means to reduce by a measurable amount, or to
prevent entirely.
The term “therapeutically effective amount” refers to an amount of a ate
effective to treat a disease or disorder in a mammal. In the case of cancer, the therapeutically
ive amount of the conjugate may reduce the number of cancer cells; reduce the tumor
size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into
peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis;
inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the
symptoms associated with the cancer. To the extent the drug may t growth and/or kill
existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy, efficacy can,
for example, be ed by assessing the time to disease progression (TTP) and/or
determining the response rate (RR).
The term “substantial” or “substantially” refers to a majority, i.e. >50% of a
population, of a mixture or a , ably more than 50%, 55%, 60%, 65%, 70%, 75%,
80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% of a population.
The term “cytotoxic activity” refers to a cell-killing effect of a drug or Ligand-Drug
Conjugate or an intracellular metabolite of a Ligand- Drug Conjugate. Cytotoxic activity
may be expressed as the IC50 value, which is the concentration (molar or mass) per unit
volume at which half the cells survive.
[0035] The term tatic activity” refers to an anti-proliferative effect of a drug or
Ligand-Drug Conjugate or an intracellular metabolite of a Ligand- Drug ate.
The term “cytotoxic agent” as used herein refers to a nce that has cytotoxic
activity and causes destruction of cells. The term is intended to include chemotherapeutic
agents, and toxins such as small le toxins or enzymatically active toxins of bacterial,
fungal, plant or animal origin, including synthetic analogs and derivatives thereof.
The term “cytostatic agent” as used herein refers to a substance that inhibits a
function of cells, including cell growth or multiplication. Cytostatic agents include inhibitors
such as protein inhibitors, e.g., enzyme inhibitors. Cytostatic agents have cytostatic activity.
The terms “cancer” and “cancerous” refer to or describe the physiological condition
or disorder in s that is typically characterized by unregulated cell growth. A “tumor”
comprises one or more cancerous cells.
An “autoimmune disease” as used herein refers to a disease or disorder arising from
and directed against an individual’s own tissues or proteins.
“Patient” as used herein refers to a subject to whom is administered a Ligand-Drug
Conjugate of the present ion. Patient includes, but are not limited to, a human, rat,
mouse, guinea pig, non-human primate, pig, goat, cow, horse, dog, cat, bird and fowl.
Typically, the patient is a rat, mouse, dog, human or non-human primate, more typically a
human.
The terms “treat” or “treatment,” unless otherwise indicated by context, refer to
therapeutic treatment and lactic wherein the object is to inhibit or slow down (lessen)
an undesired physiological change or er, such as the development or spread of .
For purposes of this ion, beneficial or desired clinical results include, but are not
d to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not
worsening) state of disease, delay or slowing of disease progression, amelioration or
palliation of the disease state, and remission (whether partial or total), whether detectable or
undetectable. “Treatment” can also mean prolonging survival as compared to expected
survival if not receiving treatment. Those in need of treatment include those already with the
condition or disorder as well as those prone to have the condition or disorder.
In the context of cancer, the term “treating” includes any or all of: killing tumor
cells; inhibiting growth of tumor cells, cancer cells, or of a tumor; ting ation of
tumor cells or cancer cells, lessening of overall tumor burden or decreasing the number of
ous cells, and ameliorating one or more symptoms associated with the disease.
In the context of an autoimmune disease, the term “treating” includes any or all of:
inhibiting replication of cells associated with an autoimmune disease state including, but not
limited to, cells that produce an autoimmune dy, lessening the autoimmune-antibody
burden and ameliorating one or more symptoms of an autoimmune disease.
The phrase “pharmaceutically acceptable salt,” as used herein, refers to
pharmaceutically acceptable organic or nic salts of a compound (e.g., a Drug, Drug-
Linker, or a Ligand-Drug Conjugate). In some aspects, the compound can contain at least
one amino group, and accordingly acid on salts can be formed with the amino group.
Exemplary salts include, but are not limited to, sulfate, oroacetate, e, acetate,
oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate,
lactate, late, acid citrate, tartrate, oleate, tannate, pantothenate, rate, ascorbate,
ate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate,
benzoate, glutamate, esulfonate, ethanesulfonate, benzenesulfonate,
p-toluenesulfonate, and pamoate (i.e., 1,1’-methylene-bis-(2-hydroxynaphthoate)) salts. A
pharmaceutically acceptable salt may involve the ion of r molecule such as an
acetate ion, a succinate ion or other counterion. The counterion may be any organic or
nic moiety that stabilizes the charge on the parent compound. rmore, a
pharmaceutically acceptable salt may have more than one charged atom in its structure.
Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can
have multiple counter ions. Hence, a ceutically able salt can have one or more
charged atoms and/or one or more counterion.
A Linker Unit is a bifunctional moiety that ts a Drug Unit to a Ligand Unit in
a Ligand Drug Conjugate. The Linker Units of the present invention have several
components (e.g., a Stretcher Unit having an optional Basic Unit, optional Branching Unit,
optional Connector Unit, and Self-Immolative Assembly Unit).
[0046] “Basic unit” as used herein is an organic moiety of a Stretcher Unit (Z), or Stretcher
Unit sor (Z'), comprised of a succinimide or maleimide system, respectively, or an
instance of R, which is a substituent on the carbamate nitrogen of a methylene carbamate unit
or an instance of R1 or R2, which are substituents of the methylene carbon of a methylene
ate unit. When part of a Stretcher Unit, a Basic Unit is capable of catalyzing addition
of a water molecule to one of the succinimide carbonyl-nitrogen bonds of Z and can be
initiated under controlled conditions tolerable by the Ligand Unit, which is attached to that
Stretcher Unit. For that e, the basic functional group of the Basic Unit (BU) and its
relative position in Z with respect to its succinimide ring system is selected for its ability to
hydrogen bond to a carbonyl group of that ring system to effectively increase its
electrophilicity and hence its susceptibility to water attack. Alternatively, those variables are
selected so that a water molecule, whose nucleophilicity is increased by hydrogen bonding to
the basic functional group of BU, is directed to a carbonyl group of the succinimide ring
system of Z. Typically, such a Basic Unit, acting through either mechanism, is comprised of
1-6 contiguous carbon atoms that connect its basic amino functional group to the der
of the Stretcher Unit. For increasing the electrophilicity of a succinimide carbonyl in Z by
hydrogen bonding, BU is required to have a primary or secondary amine functional group,
whereas increasing water nucleophilicity in the manner described may be done with a
primary, secondary or ry amine as the basic functional group of BU. In order that the
basic amine functional group be in the required proximity to assist in the hydrolysis of the
succinimide of Z by either mechanism, the amine-bearing carbon chain of BU is typically
attached to an alpha carbon of an optionally substituted alkyl moiety that is boned to the
maleimide nitrogen of the corresponding Stretcher Unit precursor Z’.
[0047] When part of a Stretcher Unit precursor, a basic amine functional group of a Basic
Unit is typically protected as a salt form or with a suitable protecting group to avoid
premature hydrolysis of the maleimide moiety or direct attach by nucleophillic nitrogen of
the basic amine functional group onto a carbonyl of the maleimide moiety ring system. A
suitable protecting group for that purpose is an acid-labile ting group such an
alkyloxycarbonyl group. When part of a ene carbamate unit, the moiety in a Basic Unit
ting the carbamate nitrogen to the basic functional group (and/or the methylene carbon
of a methylene carbamate unit to the basic onal group) which typically is a comprised
of 2-6 contiguous carbon atoms, is chosen to have the ed proximity to the T*-D moiety
of the methylene carbamate unit having that Basic Unit to decrease the tendency of that
moiety to be prematurely lost as H- T*-D due to spontaneous solvolysis. ary, but nonlimiting
examples of Basic Units are –(CH2)xNH2, –(CH2)xNHRop, or –(CH2 )xN(Rop)2,
wherein x is an integer ranging from 1-4 and Rop in these examples is C1-6 alkyl.
“PEG Unit” as used herein is an organic moiety comprised of repeating ethylene-
oxy subunits and may be polydisperse, monodisperse or discrete (i.e., having discrete number
of ethylene-oxy ts). Polydisperse PEGs are a heterogeneous e of sizes and
molecular weights whereas monodisperse PEGs are typically purified from heterogeneous
es and are therefore provide a single chain length and molecular weight. Preferred
PEG Units are discrete PEGs, compounds that are synthesized in step-wise fashion and not
via a polymerization process. te PEGs provide a single molecule with defined and
specified chain length.
The PEG Unit provided herein comprises one or multiple polyethylene glycol chains,
each comprised of one or more ethyleneoxy subunits, covalently attached to each other. The
polyethylene glycol chains can be linked er, for example, in a linear, branched or star
shaped configuration. Typically, at least one of the hylene glycol chains prior to
incorporation into a Ligand Drug ate is tized at one end with an alkyl moiety
substituted with an electrophilic group for covalent attachment to the carbamate nitrogen of
its methylene carbamate unit (i.e., represents an instance of R). In other instances a PEG Unit
is an instance of R1 or R2, which are substituents of the methylene carbon of a methylene
carbamate unit. Typically the terminal ethyleneoxy subunit in each polyethylene glycol
chains not involved in covalent ment to the carbamate nitrogen or methylene carbon of
the methylene ate unit is modified with a PEG Capping Unit, typically an optionally
substituted alkyl such as –CH3, CH2CH3 or CH2CH2CO2H. A preferred PEG Unit has a
single hylene glycol chain with 8 to 24 –CH2CH2O- subunits covalently attached in
series and terminated at one end with a PEG Capping Unit.
Unless otherwise indicated, the term "alkyl" by itself or as part of another term
refers to a substituted or unsubstituted straight chain or branched, saturated or rated
hydrocarbon having the indicated number of carbon atoms (e.g., “-C1-C8 alkyl” or “-C1-C10”
alkyl refer to an alkyl group having from 1 to 8 or 1 to 10 carbon atoms, respectively). When
the number of carbon atoms is not indicated, the alkyl group has from 1 to 8 carbon atoms.
Representative straight chain “-C1-C8 alkyl” groups include, but are not limited to, -methyl, -
ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl and -n-octyl; while branched -C1-C8
alkyls include, but are not limited to, -isopropyl, -sec-butyl, tyl, -tert-butyl, -isopentyl,
and methylbutyl; unsaturated -C2-C8 alkyls include, but are not limited to, -vinyl, -allyl, -
1-butenyl, butenyl, -isobutylenyl, -1 pentenyl, -2 pentenyl, -3 methylbutenyl, -2 methyl-
2-butenyl, -2,3 dimethyl butenyl, yl, 2-hexyl, hexyl, -acetylenyl, -propynyl, -1
butynyl,-2 butynyl, -1 pentynyl, -2 pentynyl and -3 methyl 1 l. Sometimes an alkyl
group is unsubstituted. An alkyl group can be substituted with one or more . In other
aspects, an alkyl group will be saturated.
Unless otherwise indicated, "alkylene,” by itself of as part of another term, refers to
a substituted or unsubstituted ted, branched or straight chain or cyclic hydrocarbon
radical of the stated number of carbon atoms, typically 1-10 carbon atoms, and having two
monovalent radical centers derived by the removal of two hydrogen atoms from the same or
two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not
limited to: methylene (-CH2-), 1,2-ethyl H2-), 1,3-propyl (-CH2CH2CH2-), 1,4-butyl
(-CH2CH2CH2CH2-), and the like. In preferred s, an alkylene is a branched or straight
chain arbon (i.e., it is not a cyclic hydrocarbon).
[0052] Unless otherwise ted, "aryl," by itself or as part of another term, means a
substituted or unsubstituted monovalent carbocyclic aromatic hydrocarbon radical of the
stated number of carbon atoms, typically 6-20 carbon atoms, derived by the removal of one
hydrogen atom from a single carbon atom of a parent ic ring system. Some aryl
groups are represented in the exemplary structures as “Ar”. Typical aryl groups include, but
are not limited to, radicals derived from benzene, substituted benzene, naphthalene,
anthracene, yl, and the like. An exemplary aryl group is a phenyl group.
[0053] Unless otherwise indicated, an “arylene,” by itself or as part of another term, is an
aryl group as defined above which has two covalent bonds (i.e., it is divalent) and can be in
the ortho, meta, or para orientations as shown in the ing structures, with phenyl as the
exemplary group:
, , ,
[0054] Unless otherwise indicated, a “C3-C8 heterocycle,” by itself or as part of another term,
refers to a lent substituted or unsubstituted aromatic or non-aromatic clic or
bicyclic ring system having from 3 to 8 carbon atoms (also referred to as ring s) and
one to four heteroatom ring members independently selected from N, O, P or S, and derived
by removal of one hydrogen atom from a ring atom of a parent ring . One or more N,
C or S atoms in the heterocycle can be oxidized. The ring that includes the heteroatom can
be aromatic or nonaromatic. Heterocycles in which all or the ring atoms are involved in
aromaticity are referred to as heteroaryls and otherwise are referred to heterocarbocycles.
Unless otherwise noted, the heterocycle is attached to its pendant group at any heteroatom or
carbon atom that results in a stable structure. As such a heteroaryl may be bonded h
an aromatic carbon of its aromatic ring system, referred to as a C-linked aryl, or
through a non-double-bonded N atom (i.e., not =N-) in its aromatic ring system, which is
ed to as an N-linked heteroaryl. Thus, nitrogen-containing heterocycles may be C-
linked or N-linked and include pyrrole moieties, such as pyrrolyl (N-linked) and pyrrol
yl (C-linked), and imidazole moieties such as imidazolyl and imidazolyl (both N-
linked), and imidazolyl, imidazolyl and imidazolyl es (all of which are C-
linked).
Unless otherwise indicated, a“C3-C8 heteroaryl,” is an aromatic C3-C8 heterocycle in
which the subscript denotes the total number of carbons of the cyclic ring system of the
heterocycle or the total number of aromatic s of the aromatic ring system of the
heteroaryl and does not implicate the size of the ring system or the presence or absence of
ring fusion. Representative es of a C3-C8 heterocycle include, but are not limited to,
pyrrolidinyl, azetidinyl, dinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl,
benzofuranyl, hiophene, indolyl, benzopyrazolyl, pyrrolyl, thiophenyl (thiophene),
l, thiazolyl, imidazolyl, pyrazolyl, pyrimidinyl, pyridinyl, pyrazinyl, pyridazinyl,
isothiazolyl, and isoxazolyl. When explicitly given, the size of the ring system of a
heterocycle or heteroaryl is indicated by the total number of atoms in the ring. For example,
designation as a 5- or 6-membered heteroaryl indicates the total number or aromatic atoms
(i.e., 5 or 6) in the heteroaromatic ring system of the heteroaryl, but does not imply the
number of aromatic heteroatoms or ic carbons in that ring system. Fused heteroaryls
are explicitly stated or implied by context as such and are typically indicated by the number
of aromatic atoms in each ic ring that are fused together to make up the fused
heteroaromatic ring . For example a 5,6-membered aryl is an aromatic 5-
membered ring fused to an aromatic 6-membered ring in which one or both of the rings have
aromatic heteroatom(s) or where a heteroatom is shared n the two rings.
[0056] A heterocycle fused to an aryl or heteroaryl such that the heterocycle s non-
aromatic and is part of a larger structure through ment with the non-aromatic n of
the fused ring system is an example of an optionally substituted heterocycle in which the
heterocycle is substituted by ring fusion with the aryl or heteroaryl. Likewise, an aryl or
heteroaryl fused to heterocycle or ycle that is part of a larger structure through
attachment with the aromatic portion of the fused ring system is an example of an optionally
substituted aryl or heterocycle in which the aryl or heterocycle is substituted by ring fusion
with the heterocycle or carbocycle.
Unless otherwise indicated, “C3-C8 heterocyclo,” by itself or as part of another term,
refers to a C3-C8 cyclic defined above wherein one of the hydrogen atoms of the
heterocycle is replaced with a bond (i.e., it is divalent). Unless otherwise indicated, a “C3-C8
heteroarylene,” by itself or as part of another term, refers to a C3-C8 heteroaryl group defined
above wherein one of the heteroaryl group’s hydrogen atoms is replaced with a bond (i.e., it
is divalent).
Unless otherwise indicated, a “C3-C8 carbocycle,” by itself or as part of another
term, is a 3-, 4-, 5-, 6-, 7- or 8-membered monovalent, substituted or unsubstituted, saturated
or unsaturated non-aromatic monocyclic or bicyclic carbocyclic ring derived by the removal
of one hydrogen atom from a ring atom of a parent ring system. Representative -C3-C8
carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,
cyclopentadienyl, exyl, cyclohexenyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl,
cycloheptyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrienyl, cyclooctyl, and cyclooctadienyl.
Unless otherwise indicated, a “C3-C8 carbocyclo,” by itself or as part of another
term, refers to a C3-C8 carbocycle group defined above wherein another of the carbocycle
groups’ hydrogen atoms is replaced with a bond (i.e., it is divalent).
Unless otherwise indicated, the term "heteroalkyl," by itself or in combination with
another term, means, unless otherwise stated, a stable straight or branched chain hydrocarbon,
or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation,
consisting of the stated number of carbon atoms and from one to ten, preferably one to three,
heteroatoms selected from the group ting of O, N, Si and S, and wherein the nitrogen
and sulfur atoms may optionally be ed and the nitrogen heteroatom may optionally be
quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the
heteroalkyl group or at the position at which the alkyl group is attached to the remainder of
the molecule. The heteroatom Si may be placed at any position of the heteroalkyl group,
including the position at which the alkyl group is attached to the remainder of the molecule.
Examples include H2-O-CH3, -CH2-CH2-NH-CH3, H2-N(CH3)-CH3, -CH2-SCH2-CH3
, H2-S(O)-CH3, -NH-CH2-CH2-NH-C(O)-CH2-CH3, H2-S(O)2-CH3, -
CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-O-CH3, and -N(CH3)-CH3. Up to two
heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and –CH2-OSi
(CH3)3. Typically a C1 to C4 heteroalkyl or heteroalkylene has 1 to 4 carbon atoms and 1 or
2 heteroatoms and a C1 to C3 heteroalkyl or heteroalkylene has 1 to 3 carbon atoms and 1 or 2
heteroatoms. In some aspects, a alkyl or heteroalkylene is saturated.
Unless otherwise ted, the term "heteroalkylene" by itself or in combination
with another term means a divalent group derived from heteroalkyl (as discussed above), as
exemplified by –CH2-CH2-S-CH2-CH2- and –CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene
groups, heteroatoms can also occupy either or both of the chain termini. Still further, for
alkylene and heteroalkylene linking , no orientation of the linking group is implied.
Unless otherwise indicated, “aminoalkyl” by itself or in combination with another
term means a heteroalkyl wherein an alkyl moiety as d herein is substituted with an
amino, alkylamino, dialkylamino or cycloalkylamino group. Exemplary non-limiting
aminoalkyls are –CH2NH2, 2NH2, 2NHCH3 and -CH2CH2N(CH3)2 and
further includes ed s such as –CH(CH3)NH2 and -C(CH3)CH2NH2 in the (R)- or
(S)- configuration. Alternatively, an aminoalkyl is an alkyl moiety, group, or substituent as
d herein wherein a sp3 carbon other than the radical carbon has been replaced with an
amino or alkylamino moiety wherein its sp3 nitrogen replaces the sp3 carbon of the alkyl
provided that at least one sp3 carbon remains. When referring to an aminoalkyl moiety as a
substituent to a larger structure or another moiety the aminoalkyl is covalently attached to the
ure or moiety through the carbon radical of the alkyl moiety of the aminoalkyl.
Unless otherwise indicated “alkylamino” and “cycloalkylamino” by itself or in
combination with another term means an alkyl or cycloalkyl radical, as described ,
wherein the radical carbon of the alkyl or cycloalkyl radical has been ed with a nitrogen
radical, provided that at least one sp3 carbon remains. In those instances where the
alkylamino is substituted at its nitrogen with another alkyl moiety the resulting substituted
radical is sometimes referred to as a dialkylamino moiety, group or substituent wherein the
alkyl moieties substituting nitrogen are independently selected. Exemplary and non-limiting
amino, alkylamino and dialkylamino substituents, include those having the structure of –
2, wherein Rop in these es are independently selected from hydrogen or C1-6
alkyl, typically hydrogen or methyl, whereas in cycloalkyl amines, which are included in
heterocycloalkyls, both Rop together with the nitrogen to which they are ed define a
heterocyclic ring. When both Rop are hydrogen or alkyl, the moiety is sometimes described
as a primary amino group and a tertiary amine group, tively. When one Rop is
hydrogen and the other is alkyl, then the moiety is sometimes described as a secondary amino
group. y and secondary alkylamino moieties are more reactive as philes
towards carbonyl-containing electrophilic centers s tertiary amines are more basic.
"Substituted alkyl” and “substituted aryl" mean alkyl and aryl, respectively, in
which one or more hydrogen atoms, typically one, are each independently replaced with a
substituent. Typical substituents include, but are not limited to a Basic Unit a PEG
Unit, -X, -Rop, -OH, -ORop, -SRop, , -N(Rop)2, -N(Rop)3, =NRop, -CX3, -CN, -NO2, -
NRopC(=O)Rop, Rop, -C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, -
OP(=O)(ORop)2, -P(=O)(ORop)2, -PO- 3=, PO3H2, -C(=O)Rop, -C(=S)Rop, -CO2Rop, -CO2-, -
C(=S)ORop, -C(=O)SRop, -C(=S)SRop, -C(=O)N(Rop)2, - C(=S)N(Rop)2, and -C(=NR)N(Rop)2,
where each X is ndently selected from the group consisting of a halogen: -F, -Cl, -Br,
and -I; and wherein each Rop is independently selected from the group consisting of -H, -C1-
C20 alkyl, -C6-C20 aryl, -C3-C14 heterocycle, a ting group, and a prodrug moiety.
More lly substituents are selected from the group consisting of a Basic, Unit a
PEG Unit -X, -Rop, -OH, -ORop, -SRop, -N(Rop)2, -N(Rop)3, =NRop, -NRopC(=O)Rop, -
C(=O)Rop, -C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, -C(=O)Rop, -C(=S)Rop, -
C(=O)N(Rop)2, - C(=S)N(Rop)2, and -C(=NR)N(Rop)2, n each X is independently
selected from the group consisting of –F , or are selected from the group consisting of
a Basic, Unit a PEG Unit -X, -Rop, -OH, -ORop, -N(Rop)2, -N(Rop)3, (=O)Rop, -
C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, -C(=O)Rop, -C(=O)N(Rop)2, -
C(=NR)N(Rop)2, a protecting group, and a prodrug moietywherein each X is –F; and wherein
each Rop is independently selected from the group consisting of hydrogen, -C1- C20 alkyl, -C6-
C20 aryl, -C3-C14 heterocycle, a ting group, and a prodrug moiety. In some aspects, an
alkyl substituent is selected from the group ting -N(Rop)2, -N(Rop)3 and -
C(=NR)N(Rop)2, n Rop is a defined above, which may provide for a Basic Unit as when
Rop is independently selected from the group consisting of hydrogen and -C1- C20 alkyl. In
other aspects, alkyl is substituted with a series or neoxy moieties to define a PEG Unit.
Alkylene, carbocycle, carbocyclo, arylene, heteroalkyl, heteroalkylene, heterocycle,
heterocyclo, heteroaryl, and heteroarylene groups as bed above may also be similarly
substituted.
Protecting group” as used here means a moiety that prevents or reduces the ability
of the atom or functional group to which it is linked from participating in unwanted reactions.
Typical protecting groups for atoms or functional groups are given in Greene (1999),
“Protective groups in organic synthesis, 3rd ed.”, Wiley Interscience. Protecting groups for
heteroatoms such as oxygen, sulfur and en are sometime used to minimize or avoid
unwanted their reactions with electrophilic compounds. Other times the protecting group is
used to reduce or eliminate the nucleophilicity and/or ty of the unprotected heteroatom.
Non-limiting examples of protected oxygen are given by -ORPR, wherein RPR is a protecting
group for hydroxyl, n hydroxyl is typically protected as an ester (e.g. acetate,
propionate or benzoate). Other protecting groups for hydroxyl avoid ering with the
nucleophilicity of organometallic reagents or other highly basic reagents, where yl is
typically protected as an ether, including alkyl or heterocycloalkyl ethers, (e.g., methyl or
tetrahydropyranyl ethers), alkoxymethyl ethers (e.g., methoxymethyl or ethoxymethyl
ethers), optionally substituted aryl ethers ,and silyl ethers (e.g., trimethylsilyl (TMS),
triethylsilyl (TES), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBS/TBDMS),
triisopropylsilyl (TIPS) and [2-(trimethylsilyl)ethoxy]-methylsilyl (SEM)). Nitrogen
protecting groups include those for primary or ary amines as in -NHRPR or -N(RPR)2-,
wherein least one of RPR is a nitrogen atom protecting group or both RPR together se a
protecting group.
A protecting group is a suitable protecting when it is capable of preventing or
avoiding unwanted side-reactions or premature loss of the protecting group under reaction
conditions required to effect desired chemical transformation elsewhere in the molecule and
during purification of the newly formed molecule when d, and can be removed under
conditions that do not adversely affect the structure or stereochemical integrity of that newly
formed molecule. By way of example and not limitation, a suitable protecting group may
include those previously described for protecting onal groups. A suitable protecting
group is sometimes a protecting group used in e coupling reactions.
“Aromatic alcohol” by itself or part of a larger structure refers to an aromatic ring
system substituted with the hydroxyl functional group -OH. Thus, aromatic alcohol refers to
any aryl, heteroaryl, arylene and heteroarylene moiety as described herein having a hydroxyl
functional group bonded to an aromatic carbon of its aromatic ring system. The aromatic
l may be part of a larger moiety as when its aromatic ring system is a substituent of this
moiety, or may be embeded into the larger moiety by ring , and may be optionally
substituted with es as described herein including one or more other hydroxyl
substitutents. A phenolic alcohol is an aromatic alcohol having a phenol group as the
aromatic ring.
“Aliphatic alcohol” by itself or part of a larger structure refers to a moiety having a
non-aromatic carbon bonded to the hydroxyl functional group -OH. The hydroxy-bearing
carbon may be unsubstituted (i.e., methyl alcohol) or may have one, two or three optionally
substitued branched or unbranched alkyl substituents to define a primary alcohol, or a
secondary or tertiary tic alcohol wihin a linear or cyclic structure. When part of a
larger structure, the l may be a substituent of this structure by bonding through the
y bearing carbon, through a carbon of an alkyl or other moiety as described herein to
this hydroxyl-bearing carbon or h a substituent of this alkyl or other moiety. An
aliphatic alchohol contemplates a non-aromatic cyclic structure (i.e., carbocycles and
heterocarbocycles, optionally substitued) in which a hydroxy functional group is bonded to a
omatic carbon of its cyclic ring system.
lkyl” or “heteroarylalkyl” as used herein means a substituent, moiety or
group where an aryl moiety is bonded to an alkyl moiety, i.e., aryl-alkyl-, where alkyl and
aryl groups are as described above, e.g., C6H5-CH2- or C6H5-CH(CH3)CH2-. An arylalkyl or
heteroarylalkyl is associated with a larger structure or moiety through a sp3 carbon of its alkyl
moiety.
“Electron withdrawing group” as used herein means a functional group or
onegative atom that draws electron density away from an atom to which it is bonded
either inductively and/or h resonance, whichever is more dominant (i.e., a functional
group or atom may be electron withdrawing inductively but may overall be electron donating
through resonance), and tends to stabilize anions or electron-rich moieties. The electron
withdrawing effect is typically transmitted inductively, albeit in ated form, to other
atoms ed to the bonded atom that has been made on deficient by the electron
withdrawing group (EWG), thus affecting the electrophilicity of a more remote ve
center. Exemplary electron withdrawing groups include, but are not limited to -C(=O), -CN,
-NO2, -CX3, -X, -C(=O)ORop, -C(=O)N(Rop)2, -C(=O)Rop, -C(=O)X, -S(=O)2Rop, -
S(=O)2ORop, -S(=O)2NHRop, -S(=O)2N(Rop)2, -P(=O)(ORop)2, -P(=O)(CH3)NHRop, -NO, -
N(Rop)3+, wherein X is -F, -Br, -Cl, or -I, and Rop in some s is, at each ence,
independently selected from the group consisting of hydrogen and C1-6 alkyl, and certain O-
linked moieties as bed herein such as acyloxy.
[0072] Exemplary EWGs can also include aryl groups (e.g., phenyl) ing on
substitution and certain heteroaryl groups (e.g., pyridine). Thus, the term “electron
withdrawing groups” also es aryls or heteroaryls that are further substituted with
electron withdrawing groups. Typically, electron withdrawing groups on aryls or heteroaryls
are -C(=O), -CN, -NO2, -CX3, and –X, wherein X independently selected is halogen,
typically –F or -Cl. Depending on their substituents, an alkyl moiety may also be an electron
withdrawing group.
“Electron donating group” as used herein means a functional group or
electropositive atom that increases electron density of an atom to which it is bonded either
inductively and/or through resonance, whichever is more dominant (i.e., a functional group or
atom may be electron donating h resonance but may overall be electron withdrawing
inductively) and tends to stabilize s or electron poor systems. The electron donating
effect is typically transmitted through resonance to other atoms attached to the bonded atom
that has been made on rich by the electron donating group (EWG) thus affecting the
nucleophilicity of a more remote reactive center. Exemplary electron donating groups
include, but are not limited to amines and certain O-linked substituents as described herein
such as –OH and ethers. Depending on their substituents, an aryl or heteroaryl moiety may
also be an electron donating group. Unsubstituted alkyl moieties are typically on
“O-linked moiety” as used herein means a moiety that is ed to a larger
structure or moiety ly through an oxygen atom of the ed moiety. An O-linked
moiety may be a monovalent moiety, including moieties such as hydroxyl, i.e., -OH, acetoxy,
i.e., -OC(=O)CH3, acyloxy, i.e., -OC(=O)R, wherein R is hydrogen, or alkyl, cycloalkyl,
alkenyl, alkynyl, aryl or heterocycle, optionally substituted, and aryloxy (Aryl-O-), phenoxy
(Ph-O-) and heteroaryloxy (heteroaryl-O), optionally substituted, or silyloxy, i.e., R3SiO-,
wherein R independently are alkyl, aryl, or heteroaryl, optionally substituted, an ether, i.e., -
OR, wherein R is as defined for silyloxy, and -ORPR, n RPR is a protecting group as
previously defined. A monovalent O-linked moiety may be electron donating or electron
withdrawing depending on the electronegativity of the bonded oxygen heteroatom and the
bility of its lone pair electrons. For example, –OH or an ether, when its oxygen atom is
a substituent to a carbon atom, is an electron donating moiety, while an acyloxy similarly
substituted is an electron withdrawing moiety. An O-linked moiety may also be divalent, i.e.
=O or a ketal moiety, e.g., -X-(CH2)n-Y-, n X and Y independently are S and O and n
is 2 to 3, to form a spiro ring system with the carbon to which X and Y are attached.
“Leaving group ability” relates to the ability of an alcohol-, thiol-, amine- or amide-
containing compound corresponding to a Drug Unit in a Ligand Drug Conjugate to be
released from the Conjugateas a free drug subsequenct to activation of a self-immolative
event within the ate. That release can be variable without the benefit of a methylene
carbamate unit to which its Drug Unit is attached (i.e., when the Drug Unit is directly
attached to a self-immolative moiety and does not have an intervening methylene carbamate
unit). Good g groups are usually weak bases and the more acidic the functional group
that is expelled from such conjugates the weaker the conjugate base is. Thus, the leaving
group ability of an alcohol-, thiol-, amine- or containing free drug from a Drug Unit
will be related to the pKa of the drug’s functional group that is expelled from a conjugate in
cases where methylene ate unit (i.e., one in which a Drug Unit is ly attached to a
self-immolative moiety) is not used. Thus, a lower pKa for that functional group will
increase its leaving group ability. Although other factors may contribute to release of free
drug from conjugates not having the benefit of a ene carbamate unit, generally a drug
having a functional group with a lower pKa value will typically be a better leaving group tha
a drug attached via a functional group with a higher pKa value. Another consideration is
that, a functional group having too low of a pKa value may result in an unacceptable ty
profile due to premature loss of the Drug Unit via spontaneous hydrolysis. For conjugates
employing a methylene carbamate unit, a common functional group (i.e., a ic acid)
having a pKa value that allows for efficient release of free drug, t ing
unacceptable loss of Drug Unit, is produced upon self-immolation.
[0076] “Succinimide moiety” as used herein refers to an organic moiety comprised of a
succinimide ring , which is present in one type of Stretcher Unit (Z) that is typically
further comprised of an alkylene-containing moiety bonded to the imide nitrogen of that ring
system. A succinimide moiety lly s from Michael addition of an sulfhydryl group
of a Ligand Unit to the maleimide ring system of a Stretcher Unit precursor (Z'). A
succinimide moiety is ore comprised of a ubstituted succinimide ring system and
when present in a LDC has its imide nitrogen substituted with the remainder of the Linker
Unit of the LDC and is optionally substituted with substituent(s) that were present on the
maleimide ring system of Z'.
“Acid-amide moiety” as used herein refers to succinic acid having an amide
substituent that results from the thio-substituted succinimide ring system of a succinimide
moiety having undergone breakage of one of its carbonyl-nitrogen bonds by hydrolysis.
Hydrolysis resulting in a succinic acid-amide moiety provides a Linker Unit less likely to
suffer premature loss of the Ligand Unit to which it is bonded through elimination of the
antibody-thio substituent. Hydrolysis of the succinimide ring system of the thio-substituted
imide moiety is expected to provide regiochemical isomers of acid-amide moieties that
are due to ences in reactivity of the two carbonyl s of the succinimide ring
system attributable at least in part to any substituent present in the maleimide ring system of
the Stretcher Unit precursor and to the thio substituent introduced by the targeting ligand.
The term “Prodrug” as used herein refers to a less biologically active or inactive
compound which is transformed within the body into a more biologically active compound
via a chemical or ical process (i.e., a chemical reaction or an enzymatic
biotransformation). Typically, a biologically active compound is rendered less biologically
active (i.e., is converted to a g) by chemically modifying the compound with a prodrug
moiety. In some aspects the prodrug is a Type II g, which are bioactivated outside
cells, e.g., in digestive fluids, or in the body's ation system, e.g., in blood. Exemplary
prodrugs are esters and β-D-glucopyranosides.
[0078a] The term “comprising” as used in this specification and claims means “consisting at
least in part of”. When interpreting statements in this specification, and claims which include
the term “comprising”, it is to be understood that other features that are additional to the
features prefaced by this term in each statement or claim may also be present. Related terms
such as “comprise” and “comprised” are to be interpreted in similar manner.
Embodiments
A number of ments of the invention are described below, which are no
meant to limit the invention in any way, and are followed by a more ed discussion of the
components that make up the conjugates. One of skill in the art will understand that each of
the conjugates identified and any of the selected ments thereof is meant to include the
full scope of each component and linker.
Ligand-Drug Conjugates
In one group of embodiments, provided herein are Ligand-Drug Conjugates (LDCs)
and compositions thereof comprising populations of these LDCs (i.e., LDC compositions).
In one aspect, a Ligand-Drug ate ses a Ligand Unit, a Drug Unit, and
a Linker Unit that connects the Ligand Unit to the Drug Unit, wherein the Linker Unit is
comprised of a Self-immolative Assembly Unit through which the Ligand Unit is connected
to the Drug Unit. The Drug Unit is directly attached to a methylene carbamate unit of the
Self-immolative Assembly Unit, wherein the methylene carbamate unit ntly attached to
a Drug Unit in the Ligand-Drug Conjugate has the structure of Formula I:
(I)
or a pharmaceutically acceptable salt thereof;
wherein
D is a Drug Unit having a functional group (e.g., yl, thiol, amide or amine
functional group) that has been incorporated into the methylene carbamate unit;
T* is a heteroatom from said functional group (e.g., oxygen, sulfur, optionally
substituted nitrogen) that becomes incorporated into the methylene carbamate unit;
R, R1 and R2 independently are en, optionally substituted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally substituted C-linked C3-C8 heteroaryl;
both R and R1 together with the nitrogen and carbon atoms to which they are attached
comprise an azetidinyl, pyrrolodinyl, piperidinyl or peridinyl moiety rably a
odinyl or piperidinyl moiety) and R2 is hydrogen; and
the wavy line indicates covalent ment of the formula I structure to the remainder
of the Self-Immolative Assembly Unit (i.e., attachment within the LDC), and wherein the
Self-Immolative Assembly Unit releases free drug (i.e., D-T*H) following activation of the
Self-Immolative Assembly Unit.
In some ments of formula I, one of R, R1 ,R2 is a Basic Unit or a PEG Unit
and the others are as defined above. In some embodiments of formula I the released D-T*H
has a pKa of n about 9 to about 36 for its T*H functional group. In other embodiments
of formula SI the ed D-T*H has a pKa of between about 12 to about 36 or between
about 15 to about 36 for its T*H functional group.
Typically, the methylene carbamate unit is attached to an activateable self-
immolative moiety, X, as represented by Formula (SI):
or a pharmaceutically acceptable salt thereof; wherein
the wavy line indicates covalent attachment of the Formula SI structure within the
R, R1, R2, T* and D are as defined for formula I;
X is an activateable self-immolative moiety; and wherein the indicated Selfimmolative
Assembly Unit releases free drug (i.e., D-T*H) following activation of X.
In some embodiments of formula SI, one of R, R1 ,R2 is a Basic Unit or a PEG Unit and the
others are as defined for formula I. In some embodiments of formula I the ed D-T*H
has a pKa of between about 9 to about 36 for its T*H functional group. In other
embodiments of a SI the released D-T*H has a pKa of between about 12 to about 36 or
between about 15 to about 36 for its T*H functional group.
Exemplary embodiments include those wherein R2 is en as set forth in
Formula SIa:
(SIa)
or a pharmaceutically able salt thereof, wherein the wavy line, X, R, R1, T* and D are
as defined for formula SI. R and R1 are preferably hydrogen, optionally substituted C1-6
alkyl, or ally substituted C6-14 aryl, (more preferably hydrogen, ally substituted
C1-4 alkyl or optionally substituted phenyl, most preferably hydrogen or optionally substituted
C1-4 alkyl).
In some preferred embodiments of formula SIa, R is unsubstituted C1-4 alkyl. In other
preferred embodiments one of R and R1 is a Basic Unit or a PEG Unit and the other is
hydrogen or unsubstituted C1-4 alkyl. In other preferred embodiments R is hydrogen, a Basic
Unit or a PEG Unit and R1 is hydrogen
Exemplary embodiments include those wherein R1 and R2 together with the nitrogen
and carbon atoms to which they are attached comprise a heterocyclo as set forth in Formula
(SIb):
(SIb),
or a pharmaceutically acceptable salt thereof, wherein the wavy line, X, R, R2, T* and D are
as defined for formula SI, and the subscript s is 0, 1, 2, or 3. In some embodiments of
formula SIb, the subscript s is 0, 1 or 2; preferably s is 1 or 2.
[0087] In some embodiments, the methylene carbamate unit is a MAC Unit. In those
embodiments, D is a Drug Unit having a hydroxyl functional group that has been
incorporated into the methylene ate unit. In such embodiments, the Self-Immolative
Assembly Unit covalently attached to the Drug Unit is represented by a SI':
(SI')
or a pharmaceutically acceptable salt thereof; wherein
the wavy line, X, R, R1, and R2, are as defined for a SI, D is a Drug Unit
having a hydroxyl functional group prior to its incorporation into the indicated methylene
carbamate unit and O* is the oxygen atom from said hydroxyl functional group; and wherein
the ted Self-immolative Assembly Unit releases free drug (i.e., D-O*H) following
activation of X.
In some embodiments of formula SI’ the released D-O*H has a pKa of between
about 10 to about 19 for its hydroxyl functional group. In other embodiments of formula I
the ed D-O*H has a pKa of between about 12 to about 19 or between 15 to about 19 for
its hydroxyl functional group.
Exemplary embodiments include those wherein R2 is hydrogen as set forth in
formula SIa':
(SIa')
wherein the wavy line, X, R, R1, O* and D are as defined for formula SI'. R and R1 are
preferably hydrogen, optionally substituted C1-6 alkyl, or optionally substituted C6-14 aryl,
(more preferably en, optionally substituted C1-4 alkyl or optionally substituted phenyl,
most preferably hydrogen or ally substituted C1-4 alkyl ). In some embodiments of
formula SIa’, one of R and R1 is a Basic Unit or a PEG Unit and the other is hydrogen or
unsubstituted C1-4 alkyl. In other embodiments R is hydrogen, a Basic Unit or a PEG Unit
and R1 is hydrogen.
Exemplary embodiments include those wherein R1 and R2 together with the
nitrogen and carbon atoms to which they are attached comprise a heterocyclo as set forth in
Formula :
(SIb'),
wherein the wavy line, X, R2, O* and D are as defined for formula SI', and the subscript s is
0, 1, 2, or 3. Preferably the subscript s is 0, 1, or 2 (more ably s is 1 or 2).
In one aspect, a Ligand-Drug Conjugate comprises a Ligand Unit, a Drug Unit and a
Linker Unit that connects the Ligand Unit to the Drug Unit, wherein the Linker Unit is
comprised of a Self-immolative Assembly Unit and a Stretcher Unit. The drug is
incorporated into a drug-linker moiety of an LDC by incorporation of a hydroxyl, thiol,
amine or amide functional group of the drug through the oxygen, sulfur or optionally
substituted nitrogen heteroatom of that functional group to a methylene carbamate unit of the
Self-immolative Assembly Unit. The Self-immolative Assembly unit is then connected to the
Ligand Unit through the Stretcher Unit.
[0092] In some embodiments there can be from 1 to 4 Self-immolative Assembly Units
within a drug-linker moiety for each site of attachment to a Ligand Unit (represented by the
subscript t) and from 1 to 16 drug-linker moieties per Ligand Unit sented by the
subscript p). In those embodiments n there are two or more Self-immolative ly
Units connected to each site of attachment on the Ligand Unit, a Branching Unit is present to
allow for the required ing.
In some aspects, an additional Connector Unit (A) covalently attaches a Stretcher
Unit (Z) or Branching Unit (B), depending on the presence or absence of B, to a molative
Assembly Unit.
In some ments a -Drug Conjugate, or a composition thereof that is
comprised of a population of these LDCs (i.e., a LDC composition), is represented by
Formula II below:
(II),
or a pharmaceutically acceptable salt; wherein
D is a Drug Unit having a onal group (e.g., hydroxyl, thiol, amide or amine
functional group) that has been incorporated into the methylene carbamate unit;
T* is a heteroatom from said functional group (e.g., , sulfur, optionally
substituted nitrogen) that becomes incorporated into the methylene carbamate unit;
R, R1 and R2 independently are hydrogen, optionally substituted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally substituted C-linked C3-C8 heteroaryl, or
R and R1 together with the nitrogen and carbon atoms to which they are attached
comprise an azetidinyl, pyrrolodinyl, piperidinyl or homopiperidinyl moiety and R2 is
hydrogen;
X is an activateable self-immolative moiety;
L is a Ligand Unit;
Z is a Stretcher Unit;
B is an optional Branching Unit that is present when t is 2, 3 or 4, and absent when t is
A is an al Connector Unit;
the subscript s is 1 or 2;
the subscript t ranges from 1 to 4; and
the subscript p is an integer (for an individual LDC) or a number (for a population of
LDCs) ranging from 1 to 16; and wherein the indicated Self-immolative Assembly Unit
es free drug (i.e., D-T*H) following activation of X.
[0095] In some embodiments of formula I the released D-T*H has a pKa of between about
9 to about 36 for its T*H functional group. In other embodiments of formula SI the released
D-T*H has a pKa of n about 12 to about 36 or between about 15 to about 36 for its
T*H functional group.
In some embodiments of formula II one of R, R1 and R2 is a Basic Unit or a PEG
Unit and the others are as defined. In other embodiments of formula II, R is a Basic Unit or a
PEG Unit and R1 and R2 are as defined.
Exemplary ments include those wherein R2 is hydrogen as set forth in
Formula IIa or R1 and R2 together with the nitrogen atom to which they are attached comprise
an inyl, odinyl, piperidinyl or homopiperidinyl as set forth in Formula IIb:
(IIa)
(IIb)
or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, L, Z, B, X, A, T*, D, and the
subscripts t and p are as defined for formula II, and the subscript s is 0, 1, 2, or 3.
In a IIa, R and R1 are preferably en, optionally substituted C1-C6 alkyl
or optionally substituted C6-14 aryl (more preferably en, ally substituted C1-C4
alkyl or optionally substituted , most preferably hydrogen or optionally substituted C1-
C4 alkyl). In some preferred embodiments of formula IIa, R is a Basic Unit or a PEG Unit
and R1 is hydrogen or unsubstituted C1-C4 alkyl or R is hydrogen or unsubstituted C1-C4 alkyl
and R2 is a Basic Unit or a PEG Unit. In Formula IIb the subscript s is preferably 0, 1, or 2;
more preferably s is 1 or 2.
Drugs to be used in the present invention include alcohol (e.g., aromatic and aliphatic
hydroxyl)-containing drugs, thiol-containing drugs, amine (e.g., aliphatic and aryl amine)-
containing drugs, amide (e.g., amide)-containing drugs. Thus, attachment of a Drug
Unit to the Self-immolative Assembly Unit can be, for example, from incorporation of drug
via the oxygen heteroatom from the hydroxyl functional group from an alcohol-containing
drug, the sulfur atom from the thiol functional group of a thiol-containing drug, or the
optionally substituted nitrogen heteroatom from the amine or amide functional group of an
amine- or amide-containing drug. Such oxygen, sulfur or nitrogen heteroatoms are
designated by T*. It will be understand that whereas incorporation of drug may be through
an alcohol functionality (i.e., through the oxygen heteroatom of a yl functional group),
the drug may have additional l functionalities or thiol, amine or amide functionalities
that are not so linked. Similarly, whereas incorporation of drug may be through its thiol,
amine or amide functionalities, the drug may have additional alcohol, thiol, amine or amide
functionalities that are not so linked.
The methylene carbamate unit in formulas II, IIa, and IIb can be a methylene
alkoxy(aryloxy) carbamate unit (MAC Unit) as shown by Formulas II', IIa', and IIb' below
(II'),
(IIa') or
(IIb')
or a pharmaceutically acceptable salt; wherein
D is a Drug Unit having a hydroxyl functional group prior to its incorporation into the
indicated methylene alkoxy(aryloxy) carbamate unit (MAC Unit), the oxygen heteroatom
from which is designated by O*;
R is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C6-14 aryl or
optionally substituted C-linked C3-C8 heteroaryl;
R1 and R2 are independently hydrogen, optionally substituted C1-C6 alkyl, optionally
substituted C6-14 aryl or optionally substituted C-linked C3-C8 heteroaryl, or
R and R1 together with the nitrogen and carbon atoms to which they are attached
comprise an azetidinyl, pyrrolodinyl, piperidinyl or homopiperidinyl moiety and R2 is
hydrogen;
X is an activateable self-immolative ;
L is a Ligand Unit;
Z is a Stretcher Unit;
B is an optional Branching Unit that is present when t is 2, 3 or 4, and absent when t is
A is an optional Connector Unit;
the subscript s is 1 or 2;
the subscript t ranges from 1 to 4;
the subscript s is 0, 1, 2 or 3 and
the subscript p is an r (for an individual LDC) or a number (for a population of
LDCs) ranging from 1 to 16; and wherein the indicated Self-immolative Assembly Unit
es free drug (i.e., D-O*H) following activation of X.
In some embodiments of formula II’, IIa’ or IIb’, the released D-O*H has a pKa of
between about 10 to about 19 for its hydroxyl functional group. In other embodiments of
a II’, IIa’ or IIb’ the released D-O*H has a pKa of between about 12 to about 19 or
between 15 to about 19 for its yl functional group.
In some embodiments of formula II’ one of R, R1 and R2 is a Basic Unit or a PEG
Unit and the others are as defined. In other preferred embodiments of formula II’, R is a
Basic Unit or a PEG Unit and R1 and R2 are as defined.
In some ments of Formula IIa', R and R1 are hydrogen, optionally
tuted C1-C6 alkyl or optionally substituted C6-14 aryl rably hydrogen, optionally
substituted C1-C4 alkyl or optionally substituted phenyl, more preferably hydrogen or
optionally substituted C1-C4 alkyl). In some embodiments of a IIb', preferably the
subscript s is 0, 1, or 2; more preferably 1 or 2.
In some preferred embodiments of formula IIa’, R is a Basic Unit or a PEG Unit
and R1 is hydrogen or unsubstituted C1-C4 alkyl or R is en or unsubstituted C1-C4 alkyl
and R1 is a Basic Unit or a PEG Unit.
In other preferred embodiments of formula II’ or a IIa’ R and R1 together
with the nitrogen and carbon atoms to which they are attached se a pyrrolodinyl or
piperidinyl moiety.
[0106] The hydroxyl functional group referred to herein can be the hydroxyl onal
group of an aromatic alcohol or an aliphatic alcohol. The tic alcohol can be a primary,
secondary or tertiary aliphatic alcohol. ably the alcohol is an aliphatic alcohol, more
preferably a primary or secondary aliphatic alcohol.
A Self-Immolative Assembly Unit comprises, in addition to a methylene carbamate
unit, an activateable self-immolative moiety. That activateable moiety is comprised of an
Activation Unit and a self-immolative Spacer Unit. The Spacer Unit can comprise one or
multiple mmolative spacer subunits each capable of self-immolation (e.g., from 1 to 4).
The Activation Unit initiates a self-immolative reaction sequence within the Spacer Unit or a
subunit thereof that s in the e of free drug. Either the Activation Unit or the self-
immolative Spacer Unit (A) can provide the site of covalent attachment to A, B or Z within a
LDC or an Intermediate thereof depending on the presence or absence of A and/or B. In
some embodiments the self-immolative moiety (X), of a Self-immolative Assembly Unit is
represented as follows by formula i or ii
(i) (ii)
wherein
W is an Activation Unit; and
Y is a self-immolative Spacer Unit;
and the wavy line indicates the site of attachment to the remainder of the conjugate
(i.e., to A, B or Z depending on the presence or e of A and/or B) and the asterisk (*)
indicates the site of attachment to the methylene carbamate linker.
In some aspects, a Ligand-Drug Conjugate (LDC), or a composition thereof that is
comprised of a population of these LDCs (i.e., a LDC composition), is represented by
formula III(i), III(ii), ), IIIa(ii), IIIb(i), or IIIb(ii):
III(i)
III(ii)
(IIIa(i))
(IIIb(i))
(IIIb(ii))
or a pharmaceutically acceptable salt thereof; wherein
W is an Activation Unit;
Y is a self-immolative Spacer Unit; and
L, Z, B, A, R, R1, R2, T*, D, and the subscripts t, s, and p are as defined for Formulas
II, IIa and IIb.
In some embodiments of formula , III(ii), IIIa(i), IIIa(ii), IIIb(i) or IIIb(ii) the
released D-T*H has a pKa of between about 9 to about 36 for its T*H functional group. In
other embodiments of formula III(i), III(ii), IIIa(i), i), ) or IIIb(ii), the released DT
*H has a pKa of between about 12 to about 36 or between about 15 to about 36 for its T*H
functional group.
In some embodiments of formula III(i) or ), one of R, R1 and R2 is a Basic Unit
or a PEG Unit and the others are as d. In other preferred embodiments of a
III(i) or III(ii), R is a Basic Unit or a PEG Unit and R1 and R2 are as defined. In other
preferred embodiments of formula III(i) or III(ii), R and R1 together with the nitrogen and
carbon atoms to which they are attached comprise a pyrrolodinyl or piperidinyl moiety and
R2 is hydrogen.
In some embodiments of formula IIIa(i) and IIIa(ii), R and R1 are hydrogen,
optionally substituted C1-C6 alkyl or optionally substituted C6-14 aryl (preferably hydrogen,
optionally substituted C1-C4 alkyl or optionally substituted phenyl, more preferably hydrogen
or optionally substituted C1-C4 alkyl). In some embodiments of formula ) and IIIb(ii),
preferably the subscript s is 0, 1, or 2, preferably 1 or 2.
In some red embodiments of formula IIIa(i) or IIIa(ii), R is a Basic Unit or a
PEG Unit and R1 is hydrogen or unsubstituted C1-C4 alkyl or R is en or unsubstituted
C1-C4 alkyl and R2 is a Basic Unit or a PEG Unit.
In other preferred ments of formula ) or IIIa(ii) , R and R1 together with
the nitrogen and carbon atoms to which they are attached comprise a pyrrolodinyl or
piperidinyl moiety.
In other preferred embodiments of formula IIIa(i) or IIIa(ii), R is hydrogen or
unsubstituted C1-C4 alkyl and R1 is en. In other preferred embodiments of formula
IIIa(i) or IIIa(ii) R is a Basic Unit or a PEG Unit and R1 is hydrogen.
[0115] The methylene carbamate unit in formulas III (i), III (ii), IIIa (i), IIIa (ii), IIIb (i), or
IIIb (ii) can be a methylene alkoxy(aryloxy) carbamate unit (MAC Unit) as shown by formula
III(i)', III(ii)', IIIa(i)', IIIa(ii)', IIIb(i)', or IIIb(ii)' below:
(III(i’))
(III(ii)’)
(IIIa(ii)')
(IIIb(i)')
(IIIb(ii)')
or a pharmaceutically acceptable salt thereof; n
D is a Drug Unit having a hydroxyl onal group prior to incorporation into the
indicated methylene alkoxy(aryloxy) carbamate unit (MAC Unit), the oxygen heteroatom
from which is designated by O*;
L, Z, B, A, Y, W, R, R1, R2, and the subscripts t, p, and s are as defined for formulas
III(i), III(ii), IIIa(i), IIIa(ii), IIIb(i), or IIIb(ii).
In some embodiments of formula ', III(ii)', IIIa(i)', IIIa(ii)', IIIb(i)', or IIIb(ii)',
the released D-O*H has a pKa of between about 10 to about 19 for its hydroxyl functional
group. In other embodiments of III(i)', III(ii)', IIIa(i)', IIIa(ii)', IIIb(i)', or IIIb(ii)', the released
D-O*H has a pKa of between about 12 to about 19 or n 15 to about 19 for its hydroxyl
onal group.
In some embodiments of formula III(i)’ or III(ii)’, one of R, R1 and R2 is a Basic
Unit or a PEG Unit and the others are as defined. In other preferred embodiments of
formula III(i)’ or III(ii)’, R is a Basic Unit or a PEG Unit and R1 and R2 are as defined.
In some embodiments of Formula IIIa(i)' and IIIa(ii) ', R and R1 are hydrogen,
optionally substituted C1-C6 alkyl or optionally substituted C6-14 aryl (more preferably
hydrogen, optionally substituted C1-C4 alkyl or optionally substituted phenyl, most preferably
hydrogen or optionally tuted C1-C4 alkyl). In some embodiments of a IIIb(i)'
and IIIb(ii)', R2 is preferably hydrogen and the subscript s is 0, 1, or 2 (preferably 1 or 2).
In some preferred embodiments of formula IIIa(i)’ or i)’, R is a Basic Unit or a
PEG Unit and R1 is en or unsubstituted C1-C4 alkyl or R is hydrogen or unsubstituted
C1-C4 alkyl and R2 is a Basic Unit or a PEG Unit.
In other preferred embodiments of formula IIIa(i)’ or IIIa(ii)’, R and R1 together
with the nitrogen and carbon atoms to which they are attached define a pyrrolodinyl or
dinyl moiety.
In other preferred embodiments of formula IIIa(i)’ or IIIa(ii)’, R is hydrogen or
unsubstituted C1-C4 alkyl and R1 is hydrogen. In other red embodiments of a
IIIa(i)’ or IIIa(ii)’ R is a Basic Unit or a PEG Unit and R1 is hydrogen.
[0122] The hydroxyl functional group referred to herein can be the hydroxyl functional
group of an aromatic alcohol or an aliphatic alcohol. The aliphatic alcohol can be a y,
secondary or tertiary aliphatic l. Preferably the alcohol is an aliphatic alcohol, more
preferably a primary or ary aliphatic alcohol.
In some preferred Ligand Drug Conjugates having or comprised of formula I, SI, II,
Ia, SIa, IIa, III(i), III(ii), IIIa(i), or IIIa(ii), R1 is hydrogen.
In many of the embodiments described herein R can hydrogen, optionally
substituted C1-C6 alkyl, including substituents ng a Basic Unit or a PEG Unit,
ally substituted C6-14 aryl, or optionally substituted C-linked C3-C8 heteroaryl. R need
not be substituted but when substituted, R is preferably substituted a so as to define a Basic
Unit or a PEG Unit. Contemplated herein are those embodiments where R is an optionally
substituted C1-6 alkyl, more preferably an optionally substituted C1-4 alkyl. The alkyl group
can be unsubstituted or substituted. In some s when substituted, it is preferably
substituted with a basic amino functional group to define a Basic Unit. In other aspects when
substituted the alkyl group is preferably substituted with a series of ethylene-oxy groups to
define a PEG Unit, Representative basic amino functional groups in a Basic Unit include
amines and C-linked or N-linked nitrogen-containing 3, 4, 5, or 6 ed heterocycles
that can be optionally substituted. Representative amines include –N(Rop)2 and –N(Rop)
wherein R3a and R4a are independently selected from hydrogen, -C1- C20 alkyl, -C6-C14 aryl,
or -C3-C8 heterocycle, preferably H or C1-6 alkyl, more preferably hydrogen or methyl. The
present inventors have surprisingly found that the addition of a basic onal group on an
R alkyl substituent (i.e., R is a Basic Unit) can impart extra stability to the resultant LDCs.
In Ligand Drug Conjugates having or comprised of Formula I, Ia, SI, SIa, II, IIa,
III(i), III(ii), IIIa(i), IIIa(ii), I', Ia', SI', SIa', II', IIa', III(i)', III(ii)', IIIa(i)', or IIIa(ii)', R can be
en, optionally substituted C1-C6 alkyl, optionally substituted C6-14 aryl, or optionally
substituted C-linked C3-C8 heteroaryl. Also contemplated are those Ligand Drug Conjugates
where R is as defined herein, but excludes optionally substituted C6-14 aryl, excludes
optionally substituted ed heteroaryl, or excludes optionally substituted C6-14 aryl and
optionally substituted C-linked heteroaryl. Also contemplated are those Ligand Drug
Conjugates where R is as defined , but excludes optionally substituted phenyl. Also
contemplated are those Ligand Drug Conjugates where R is as defined herein, but excludes
electron withdrawing groups. (i.e., R is hydrogen, optionally substituted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally tuted C-linked C3-C8 heteroaryl, provided
that R is not an electron awing group). Also contemplated are those Ligand Drug
Conjugates where R is as d herein, but the optional substituent of R is not an electron
withdrawing group. Also contemplated are those Ligand Drug Conjugates where R is not
substituted. Also plated are those Ligand Drug Conjugates where R and R1 together
with the nitrogen and carbon atoms to which they are attached comprise a pyrrolodinyl or
piperidinyl moiety. These Ligand Drug Conjugates wherein R is as defined in this paragraph
can be included in combination with any of the various possibilities for the other substituent
groups on the Ligand Drug Conjugates (e.g., L. Z, B, A, X, R1, R2 , T*, D, and the subscripts
s, p, and t).
In Ligand Drug ates having or comprised of formula I, Ib, SI, SIb, II, IIb,
III(i), III(ii), IIIb(i), IIIb(ii), I', Ib', SI', SIb', II', IIb', III(i)', III(ii)', IIIb(i)', and IIIb(ii)', R2 can
be en, optionally substituted C1-C6 alkyl, optionally substituted C6-14 aryl, or
optionally substituted C-linked C3-C8 heteroaryl. Also contemplated are those Ligand Drug
Conjugates where R2 is simply hydrogen. These Ligand Drug Conjugates wherein R2 is
simply hydrogen can be ed in combination with any of the various possibilities for the
other substituent groups on the Ligand Drug Conjugates (e.g., L. Z, B, A, X, R, R1 , T*, D,
and the ipts s, p, and t).
Ligand Drug Conjugates having formula II, IIa, IIb, II', IIa' IIb', III(i), III(ii), IIIa(i),
IIIa(ii), IIIb(i), IIIb(ii), III(i)', III(ii)', IIIa(i)', IIIa(ii)', )', or i)' include those
wherein:
1) t ranges from 1 to 4, p is an integer or number ranging from 1 to 16, and there
are from 1 to 36 Drug Units attached to each Ligand Unit,
2) t is 1 and the Branching Unit, B, is absent,
3) t is 2 to 4 and the Branching Unit, B, is present,
4) t is 2, and the Branching Unit, B, is present,
) p is an integer or a number ranging from 1 to 12 or 2 to 12, and, in any one of
the embodiments set forth in 1-4 of this paragraph, p is an integer or number ranging from
1 to 12 or 2 to 12,
6) p is an integer or number ranging from 1 to 10 or 2 to 10 and in any one of the
embodiments set forth in 1-4 of this aph, p is an integer or number ranging from 1 to
or 2 to 10,
7) p is an integer or number ranging from 1 to 8 or 2 to 10, and in any one of the
embodiments set forth in 1-4 of this paragraph, p is an integer or number ranging from 1 to
8 or 2 to 10,
and LDCs having formula II, IIa, II', IIa', III(i), III(ii), IIIa(i), IIIa(ii), III(i)', III(ii)',
IIIa(i)', or IIIa(ii)', further include those wherein
8) R is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-14
aryl, or optionally substituted C-linked C3-8 heteroaryl and in any one of the embodiments
set forth in 1-7 of this paragraph, R is hydrogen, optionally substituted C1-6 alkyl,
optionally substituted C6-14 aryl, or optionally substituted ed C3-8 heteroaryl
9) R is hydrogen, optionally tuted C1-6 alkyl, or optionally substituted C6-14
aryl, and in any one of the embodiments set forth in 1-7 of this paragraph, R is hydrogen,
ally tuted C1-6 alkyl, or optionally substituted C6-14 aryl,
) R is hydrogen, methyl, ethyl or propyl, and in any one of the embodiments set
forth in 1-7 of this paragraph, R is hydrogen, methyl, ethyl or ,
11) R is en, methyl, ethyl, propyl, isopropyl, butyl or isobutyl, and in any
one of the embodiments set forth in 1-7 of this paragraph, R is hydrogen, methyl, ethyl,
propyl, pyl, butyl or isobutyl,
12) R is hydrogen or methyl, and in any one of the embodiments set forth in 1-7 of
this paragraph, R is hydrogen or methyl,
13) R is as defined herein but excludes electron-withdrawing groups and in any
one of the embodiments set forth in 1-7 of this aph, R excludes electronwithdrawing
groups,
14) R is as defined herein but the optional substituents that can be present on R
exclude electron awing groups, and in any one of the embodiments set forth in 1-7
of this aph, the al substituents that can be present on R exclude electronwithdrawing
groups,
15) R is C1-4 alkyl or C1-6 alkyl, optionally substituted with an amine, or C-linked
or ed nitrogen-containing 3, 4, 5, or 6 membered heterocycle and in any one of the
embodiments set forth in 1-7 of this paragraph, R is C1-4 alkyl or C1-6 alkyl optionally
substituted with an amine, or C-linked or N-linked nitrogen-containing 3, 4, 5, or 6
membered heterocycle,
16) R is C1-4 alkyl or C1-6 alkyl, optionally substituted with –N(R3a)(R4a) wherein
R3a and R4a are independently selected from hydrogen, -C1- C20 alkyl, -C6-C14 aryl, or -C3-
C8 heterocycle, preferably H or C1-6 alkyl, more preferably hydrogen or methyl, and in any
one of the embodiments set forth in 1-7 of this paragraph, R is C1-4 alkyl or C1-6 alkyl
optionally substituted with –N(R3a)(R4a) wherein R3a and R4a are independently selected
from en, -C1- C20 alkyl, -C6-C14 aryl,or -C3-C8 heterocycle, ably H or C1-6
alkyl, more preferably hydrogen or methyl,
17) R is C1-4 alkyl or C1-6 alkyl, ally substituted with a basic unit and in any
one of the embodiments set forth in 1-7 of this paragraph, R is C1-4 alkyl or C1-6 alkyl
optionally substituted with a basic unit,
18) R is ally tuted C1-C4 alkyl, wherein the optionally substituted C1-
C4 alkyl is an optionally substituted aminoalkyl (preferably dimethylaminoalkyl; more
preferably dimethylaminoethyl), and in any one of the embodiments set forth in 1-7 of this
paragraph, R is optionally substituted C1-C4 alkyl, wherein the optionally substituted C1-
C4 alkyl is an optionally substituted aminoalkyl (preferably dimethylaminoalkyl; more
preferably dimethylaminoethyl),
19) R is optionally substituted C1-C4 alkyl, wherein the optionally substituted C1-
C4 alkyl is tituted aminoalkyl (preferably unsubstituted dimethylaminoalkyl; more
preferably ylaminoethyl), and in any one of the embodiments set forth in 1-7 of this
paragraph, R is optionally substituted C1-C4 alkyl, wherein the optionally substituted C1-
C4 alkyl is unsubstituted aminoalkyl (preferably unsubstituted dimethylaminoalkyl; more
preferably dimethylaminoethyl),
) The alkyl of R is saturated and in any one of the embodiments set forth in 1-17
of this paragraph, the alkyl of R is saturated,
21) R is –CH2CH2N(R3a)(R4a) wherein R3a and R4a are independently ed
from hydrogen or methyl, and in any one of the embodiments set forth in 1-7 of this
paragraph, R is –CH2CH2N(R3a)(R4a) wherein R3a and R4a are independently selected from
hydrogen or methyl,
22) R1 is hydrogen, methyl, ethyl or propyl, and in any one of the ments set
forth in 1-21 of this paragraph, R1 is hydrogen, methyl, ethyl or propyl,
23) R1 is en or methyl, and in any one of the embodiments set forth in 1-21
of this paragraph, R1 is hydrogen or methyl,
24) R1 is hydrogen and in any one of the embodiments set forth in 1-21 of this
paragraph, R1 is hydrogen,
) R1 is C1-4 alkyl or C1-6 alkyl, optionally tuted with an amine, or C-linked
or N-linked nitrogen-containing 3, 4, 5, or 6 membered heterocycle and in any one of the
embodiments set forth in 1-21 of this paragraph, R1 is C1-4 alkyl or C1-6 alkyl optionally
substituted with an amine, or C-linked or N-linked nitrogen-containing 3, 4, 5, or 6
membered cycle,
26) R1 is C1-4 alkyl or C1-6 alkyl, optionally substituted with –N(R3a)(R4a) wherein
R3a and R4a are independently ed from hydrogen, -C1- C20 alkyl, -C6-C14 aryl, or -C3-
C8 heterocycle, preferably H or C1-6 alkyl, more preferably hydrogen or methyl, and in any
one of the embodiments set forth in 1-21 of this paragraph, R1 is C1-4 alkyl or C1-6 alkyl
optionally substituted with –N(R3a)(R4a) wherein R3a and R4a are independently selected
from hydrogen, -C1- C20 alkyl, -C6-C14 aryl,or -C3-C8 heterocycle, preferably H or C1-6
alkyl, more preferably en or methyl,
27) R1 is C1-4 alkyl or C1-6 alkyl, optionally substituted with a basic unit and in
any one of the embodiments set forth in 1-21 of this paragraph, R1 is C1-4 alkyl or C1-6
alkyl optionally substituted with a basic unit,
28) R1 is optionally substituted C1-C4 alkyl, wherein the optionally substituted C1-
C4 alkyl is an optionally tuted aminoalkyl (preferably dimethylaminoalkyl; more
preferably dimethylaminoethyl), and in any one of the embodiments set forth in 1-21 of
this paragraph, R1 is optionally substituted C1-C4 alkyl, wherein the optionally substituted
C1-C4 alkyl is an optionally substituted aminoalkyl (preferably dimethylaminoalkyl; more
preferably dimethylaminoethyl),
29) R1 is ally tuted C1-C4 alkyl, wherein the ally substituted C1-
C4 alkyl is unsubstituted aminoalkyl (preferably unsubstituted dimethylaminoalkyl; more
preferably dimethylaminoethyl), and in any one of the embodiments set forth in 1-21 of
this paragraph, R1 is optionally substituted C1-C4 alkyl, wherein the optionally substituted
C1-C4 alkyl is unsubstituted aminoalkyl (preferably tituted dimethylaminoalkyl;
more preferably dimethylaminoethyl),
) The alkyl of R1 is saturated and in any one of the embodiments set forth in 1-
21 of this aph, the alkyl of R1 is saturated,
31) R1 is –CH2CH2N(R3a)(R4a) wherein R3a and R4a are independently selected
from hydrogen or methyl, and in any one of the embodiments set forth in 1-21 of this
paragraph, R1 is –CH2CH2N(R3a)(R4a) wherein R3a and R4a are independently selected
from hydrogen or methyl,
32) One of R and R1 is a PEG Unit or a Basic Unit and the other is hydrogen or
unsubstituted C1-4 alkyl and in any one of the embodiments set forth in 1-7 of this
paragraph, one of R and R1 is a PEG Unit or a Basic Unit and the other is hydrogen or
unsubstituted C1-4 alkyl,
33) R2 is hydrogen and in any one of the embodiments set forth in 1-32 of this
aph, R2 is hydrogen
and LDCs having formula II, IIa, IIb, II', IIa' IIb', III(i), III(ii), IIIa(i), IIIa(ii), IIIb(i),
IIIb(ii), , III(i)', III(ii)', IIIa(i)', IIIa(ii)', IIIb(i)', or IIIb(ii)', further e those
wherein
34) A is present, and in any one of the ments set forth in 1-33 of this
paragraph A is present,
) A is absent, and in any one of the embodiments set forth in 1-33 of this
paragraph, A is absent,
36) The Ligand Unit is an antibody, and in any one of the embodiments set forth
in 1-35 of this paragraph, the Ligand Unit is an antibody,
37) W is comprised of 1 to no more than 12 amino acids, and in any one of the
embodiments set forth in 1-36 of this aph, W is comprised of 1 to no more than 12
amino acid residues,
38) W is a sugar or a idic-bonded carbohydrate, and in any one of the
embodiments set forth in 1-36 of this paragraph W is a sugar or a idic-bonded
carbohydrate,
39) activation of the activateable self-immolative moiety (X) is by enzymatic
cleavage within W or enzymatic cleavage of the peptidic bond between W and the selfimmolative
Spacer Unit (Y), and in any one of the embodiments set forth in 1-36 of this
paragraph, tion of the activateable self-immolative moiety is by enzymatic cleavage
within W or enzymatic cleavage of the ic bond between W and the self-immolative
Spacer Unit (Y),
40) tion of the activateable self-immolative moiety is by a disulfide
reduction (i.e., W is comprised of a reducible disulfide functional group involving a sulfur
atom substituent of the self-immolative Spacer Unit), and in any one of the embodiments
set forth in 1-36 of this paragraph wherein activation of the activateable self-immolative
moiety is by a disulfide reduction (i.e., W is comprised of a reducible disulfide functional
group involving a sulfur atom substituent of the self-immolative Spacer Unit),
41) the Activation Unit is a sugar or a glycosidic-bonded carbohydrate and
attachment of the Ligand Unit within its LDC is through the self-immolative Spacer Unit
(Y), and in any one of the embodiments set forth in 1-36 of this paragraph, the activation
unit is a sugar or a glycosidic-bonded carbohydrate and attachment of the Ligand Unit
within it LDC is through Y,
42) the Activation Unit is comprised of 1 to no more than 12 amino acid residues
and attachment of the Ligand Unit is via the Activation Unit, and in any one of the
embodiments set forth in 1-36 of this paragraph, wherein the activation unit is comprised
of 1 to no more than 12 amino acid residues and attachment of the Ligand Unit is via the
tion Unit,
43) T* or O* is an oxygen heteroatom of a methylene carbamate unit covalently
attached to a Drug Unit corresponding to the heteroatom from the functional group of an
aliphatic alcohol-containing drug, and in any one of the embodiments set forth in 1-42 of
this paragraph, T* or O* is an oxygen heteroatom of a ene carbamate unit
ntly attached to a Drug Unit corresponding to the heteroatom from the functional
group of an aliphatic alcohol-containing drug,
44) T* or O* is an oxygen heteroatom of a methylene carbamate unit covalently
ed to a Drug Unit ponding to the heteroatom from the functional group of an
ic alcohol-containing drug, and in any one of the embodiments set forth in 1-42 of
this aph, T* or O* is an oxygen heteroatom of a methylene carbamate unit
covalently attached to a Drug Unit corresponding to the heteroatom from the onal
group of from an aromatic alcohol-containing drug ,
45) T* or O* is an oxygen heteroatom of a methylene carbamate unit covalently
attached to a Drug Unit corresponding to the heteroatom from the functional group of an
aromatic alcohol-containing drug wherein the aromatic alcohol is not a phenolic alcohol,
and in any one of the ments set forth in 1-42 of this paragraph, T* or O* is an
oxygen heteroatom of a methylene carbamate unit covalently attached to a Drug Unit
corresponding to the heteroatom from the functional group of an aromatic alcoholcontaining
drug, wherein the aromatic alcohol is not a phenolic alcohol,
46) D is a Drug Unit covalently attached to a methylene carbamate unit having an
oxygen atom as T* or O* corresponding to that of a hydroxyl functional group of a
drug, wherein the hydroxyl functional group is an aromatic hydroxyl functional group, ,
and R is optionally substituted saturated C1-C6 alkyl, and in any one of the embodiments
set forth in 1-7 of this paragraph, D is a Drug Unit covalently attached to a methylene
carbamate unit having oxygen heteroatom as T* or O* corresponding to that of a hydroxyl
functional group of a drug, wherein the hydroxyl functional group is an ic yl
functional group, and R is optionally substituted C1-C6 saturated alkyl,
47) D is a Drug Unit covalently ed to a methylene carbamate unit having an
oxygen heteroatom as T* or O* corresponding to that of a hydroxyl functional group of a
drug, wherein the hydroxyl functional group is an aromatic hydroxyl functional group, and
R is optionally substituted C1-C4 alkyl, wherein the optionally substituted C1-C4 alkyl is an
optionally substituted aminoalkyl rably dimethylaminoalkyl; more preferably
ylaminoethyl), and in any one of the embodiments set forth in 1-7 of this paragraph,
D is a Drug Unit covalently ed to a methylene carbamate unit having an oxygen
heteroatom as T* or O* corresponding to that of a a hydroxyl functional group of a drug, ,
and R is optionally substituted C1-C4 alkyl, wherein the ally substituted C1-C4 alkyl
is an optionally tuted aminoalkyl (preferably dimethylaminoalkyl; more preferably
ylaminoethyl),
48) D is a Drug Unit ntly attached to a methylene carbamate unit having an
oxygen heteroatom as T* or O* ponding to that of a hydroxyl functional group of a
drug, wherein the hydroxyl functional group is an aliphatic hydroxyl functional group, ,
and R is optionally substituted saturated C1-C6 alkyl, and in any one of the embodiments
set forth in 1-7 of this paragraph, D is a Drug Unit covalently attached to a methylene
carbamate unit having an oxygen heteroatom as T* or O* ponding to that of a
hydroxyl functional group, wherein the hydroxyl functional group is an aliphatic hydroxyl
functional group of a drug, , and R is optionally substituted saturated C1-C6 alkyl,
49) D is a Drug Unit covalently attached to a methylene ate unit having an
oxygen heteroatom as T* or O* corresponding to that of a hydroxyl functional group,
wherein the hydroxyl functional group is a aliphatic hydroxyl functional group of a drug, ,
and R is optionally tuted C1-C4 alkyl, wherein the optionally substituted C1-C4 alkyl
is an optionally substituted aminoalkyl (preferably dimethylaminoalkyl; more preferably
dimethylaminoethyl), and in any one of the embodiments set forth in 1-7 of this paragraph,
D is a Drug Unit covalently attached to a methylene carbamate unit having an oxygen
heteroatom as T* or O* corresponding to that of a hydroxyl functional group of a drug, ,
and R is optionally substituted C1-C4 alkyl, wherein the optionally substituted C1-C4 alkyl
is an optionally substituted aminoalkyl (preferably dimethylaminoalkyl; more preferably
ylaminoethyl),
50) T* is the oxygen heteroatom of a MAC Unit covalently attached to a Drug
Unit corresponding to the heteroatom from a hydroxyl onal group of an aliphatic or
aromatic alcohol-containing drug, and in any one of the embodiments set forth in 1-42 of
this paragraph, T* is the oxygen atom of MAC Unit covalently attached to a Drug
Unit corresponding to the heteroatom from a hydroxyl functional group of an aliphatic or
aromatic alcohol-containing drug, and wherein the self-immolative SI Assembly Unit
sed of the MAC Unit covalently attached to the Drug Unit is capable of releasing
an aliphatic or aromatic alcohol-containing drug,
51) T* is the sulfur heteroatom of a methylene carbamate unit covalently attached
to a Drug Unit corresponding to the heteroatom from a sulfhydryl functional group of a
thiol-containing drug, and in any one of the embodiments set forth in 1-42 of this
paragraph, T* is the sulfur heteroatom of a methylene carbamate unit ntly attached
to a Drug Unit corresponding to the atom from a sulfhydryl functional group of a
thiol-containing drug, and n the self-immolative SI Assembly Unit sed of the
methylene carbamate unit covalently attached to the Drug Unit is capable of releasing a
containing drug,
52) T* is the optionally substituted nitrogen heteroatom of a methylene carbamate
unit covalently attached to a Drug Unit corresponding to the heteroatom of an amide or
amine functional group of an amine- or carboxamide-containing drug, and in any one of
the embodiments set forth in 1-42 of this paragraph, T* is the nitrogen heteroatom of a
methylene carbamate unit covalently attached to a Drug Unit corresponding to the
atom from an amine or amide onal group of an amine- or carboxamide-
containing drug, and wherein the self-immolative SI Assembly Unit comprised of the
methylene carbamate unit covalently attached to the Drug Unit is e of releasing and
amide- or amine-containing drug
53) T* is the optionally substituted nitrogen heteroatom that covalently es a
methylene carbamate unit to a Drug Unit and corresponds to the heteroatom of a primary
or ary amine functional group of a drug, and in any one of the embodiments set
forth in 1-42 of this paragraph T* is the optionally substituted nitrogen heteroatom that
covalently attaches a ene ate unit to a Drug Unit and corresponds to the
heteroatom of a primary or secondary amine onal group of a drug ,and wherein the
self-immolative SI Assembly Unit comprised of the methylene ate unit covalently
attached to the Drug Unit is capable of releasing a primary or secondary amine-containing
drug,
54) T* is the optionally substituted nitrogen heteroatom that covalently attaches a
methylene carbamate unit to a Drug Unit and corresponds to the heteroatom of a primary
or secondary amide functional group of a drug, and in any one of the embodiments set
forth in 1-42 of this paragraph T*, is the optionally substituted en atom that
covalently attaches a methylene carbamate unit to a Drug Unit and corresponds to the
heteroatom of a drug having a primary or secondary amide functional group prior, and
wherein the SI Assembly Unit comprised of the ene carbamate unit covalently
attached to the Drug Unit is capable of releasing a primary or ary -containing
free drug.
55) T* or O* is an oxygen atom of a methylene carbamate unit covalently
attached to a Drug Unit corresponding to the heteroatom from the functional group of the
drug everolimus, tacrolimus or sirolimus.
Drug-Linker Compounds
In some aspects, when ing the Ligand-Drug Conjugates, it will be desirable to
synthesize the full drug-linker prior to conjugation to a targeting ligand. In such
embodiments, Drug-Linker Compounds act as Intermediate compounds. The Stretcher Unit
in a Drug-Linker Compound is not yet covalently attached to the Ligand Unit and therefore
has a functional group for conjugation to a targeting ligand (i.e., is a Stretcher Unit precursor,
Z'). In one aspect, a Drug-Linker Compound comprises a Ligand Unit, a Drug Unit, and a
Linker Unit comprising a Self-immolative Assembly Unit through which the Ligand Unit is
connected to the Drug Unit. The Linker Unit comprises, in addition to the SI assembly Unit,
a Stretcher Unit precursor (Z') sing a functional group for conjugation to a Ligand
Unit and capable of (directly or indirectly) connecting the Self-immolative Assembly Unit to
the Ligand Unit. A Branching Unit is typically present in embodiments when it is desired
that more than one drug is to be conjugated to each attachment site of the Ligand Unit. A
Connector Unit is typically present when it is desirable to add more distance between the
Stretcher Unit and the Self-immolative Assembly Unit. In one aspect, a Drug-Linker
Compound has a methylene carbamate unit covalently attached to a Drug Unit with the
structure of a I, Ia, Ib, SI, SIa, SIb, I', Ia', Ib', SI', SIa', or SIb' as previously defined
.
In one aspect, a Drug-Linker Compound is comprised of a Drug Unit and a Linker
Unit, wherein that unit is comprised of an activateable self-immolative moiety (X) of a selfimmolative
ly Unit directly attached to a Stretcher Unit precursor (Z') or indirectly to
Z' through attachment to intervening component(s) of the Drug-Linker Compound’s Linker
Unit (i.e., A and/or B), wherein Z' is comprised of a functional group capable of forming a
covalent bond to a targeting ligand, and a Drug Unit that is ly attached to a methylene
carbamate unit of the SI Assembly Unit. In some embodiments there are from 1 to 4 SI
Assembly Units in each Linker Unit or Drug-Linker moiety at each site of attachment to the
Ligand Unit. In embodiments wherein there are two or more SI Assembly Units in a Drug-
Linker nd’s Linker Unit due to branching in the Linker Unit, a branching unit, B, (or
its precursor B’ when a Branching Unit becomes directly attached to the Ligand Unit), is
present to allow for such branching. In those embodiments an exemplary Drug-Linker
Compound is ented by formula V below:
or a pharmaceutically able salt thereof; wherein
D is a Drug Unit having a hydroxyl, thiol, amine or amide functional group that has
been incorporated into the indicated methylene carbamate unit;
T* is the oxygen, sulfur or optionally substituted nitrogen heteroatom from said
functional group that becomes orated into the indicated ene carbamate unit;
R, R1 and R2 independently are hydrogen, optionally substituted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally substituted C-linked C3-C8 heteroaryl, or
both R and R1 together with the nitrogen and carbon atoms to which they are attached
comprise an azetidinyl, pyrrolodinyl, piperidinyl or homopiperidinyl moiety (preferably a
pyrrolodinyl or piperidinyl moiety) and R2 is hydrogen;
X is an activateable self-immolative moiety;
Z' is a her Unit precursor to a Stretcher Unit (Z) and is comprised of a
functional group that provides for covalent ment of a Ligand Unit to Z;
B is an optional Branching Unit that is present when t is 2, 3 or 4 and absent when t is
1;
A is an optional Connector Unit; and
the subscript t ranges from 1 to 4.
In other embodiments the Self-immolative Assembly Unit of formula SI in the
Drug-Linker nd of Formula V is replaced with that of formula SIa or SIb to define
Formulas Va and Vb Drug-Linker Compounds, respectively. Preferred ations and
bination of R, R, R1 and R2 in formula V, Va or Vb are as given for formula II, IIa or
In some s, a Drug-Linker Compound has the structure of Formula V' as
follows:
(V')
or a pharmaceutically acceptable salt thereof; wherein
D is a Drug Unit having a hydroxyl functional group prior to its incorporation into the
indicated methylene alkoxy(aryloxy) carbamate unit (MAC Unit), the oxygen atom from
which is designated by O*;
R, R1 and R2 independently are hydrogen, optionally substituted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally substituted ed C3-C8 heteroaryl, or
both R and R1 together with the nitrogen and carbon atoms to which they are attached
se a azetidinyl, pyrrolodinyl, piperidinyl or homopiperidinyl moiety(preferably a
pyrrolodinyl or dinyl moiety) and R2 is hydrogen;
X is an activateable self-immolative moiety;
Z' is a her Unit precursor to a Stretcher Unit (Z) and is comprised of a functional
group that provides for covalent attachment of a Ligand Unit to Z;
B is an optional Branching Unit that is present when t is from 2, 3 or 4 and absent
when t is 1;
A is an optional Connector Unit; and
the subscript t ranges from 1 to 4.
In other embodiments the Self-immolative Assembly Unit of formula SI’ in the
inker Compound of formula V’ is replaced with that of formula SIa' or SIb' to define
formula Va' and Vb' Drug-Linker Compounds, respectively. Preferred combinations and
subcombination of R, R, R1 and R2 in formula V’, Va’ or Vb’ are as given for formula II’,
IIa’ or IIb’.
The hydroxyl functional group ed to with respect to providing for a Drug Unit
of a Drug-Linker Compound of formula V', Va' or Vb' is the hydroxyl functional group of an
aromatic alcohol or an aliphatic alcohol. The aliphatic alcohol can be a primary, secondary
or tertiary aliphatic l. Preferably, the l is an aliphatic alcohol, more preferably, a
primary or secondary aliphatic alcohol.
The Self-immolative Assembly Unit is comprised of an activateable self-immolative
moiety (X) and a methylene carbamate unit. In some embodiments that activateable moiety
is comprised of an Activation Unit (W) and a self-immolative Spacer Unit (Y). The
tion Unit initiates a self-immolative on sequence within the Spacer Unit, which
results in the release of free drug from the Drug Linker Compound. Either the Activation
Unit or the self-immolative Spacer Unit can form the site of nt attachment to the
remainder of the Drug-Linker Compound (i.e., to A, B, or Z' depending on the presence or
e of A and/or B). In some embodiments a Drug-Linker Compound is comprised of a
Self-immolative Assembly Unit attached to a Drug Unit and is represented by formula VI(i)
or VI(ii):
(VI(i))
(VI(ii))
or a pharmaceutically acceptable salt thereof; wherein
A is an optional Connector Unit;
W is an Activation Unit;
Y is a Self-Immolative Spacer Unit;
Z' is a Stretcher Unit sor to a Stretcher Unit (Z) and is comprised of a functional
group that provides for covalent attachment of a Ligand Unit to Z;
B is an optional Branching Unit that is present when t is 2, 3 or 4, and absent when t is
R, R1 and R2 independently are hydrogen, optionally substituted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally substituted ed C3-C8 heteroaryl or both R
and R1 er with the nitrogen and carbon atoms to which they are ed comprise a
azetidinyl, pyrrolodinyl, piperidinyl or peridinyl moiety(preferably a pyrrolodinyl or
piperidinyl moiety) and R2 is hydrogen;
D is a Drug Unit having a hydroxyl, thiol, amine or amide functional group prior to its
incorporation into the indicated methylene alkoxy carbamate unit;
T* is the oxygen, sulfur or optionally substituted nitrogen atom from said
functional group that becomes incorporated into the indicated methylene carbamate unit; and
the subscript t ranges from 1 to 4.
Formulas VI (i) and VI (ii) have the methylene carbamate unit from formula Ia. In
other embodiments of Drug-Linker Compound that methylene carbamate unit structure is
replaced by that of formula Ia to define Drug Linker Compounds of formula VI(a)(i) and
), respectively. In other embodiments of Drug-Linker Compound that methylene
carbamate unit structure is replaced by that of formula Ib to define Drug Linker Compounds
of formula i) and ), tively. Preferred combinations and subcombination of
R, R, R1 and R2 in formula VI(i), VI(ii), VIa(i), VIa(ii), VIb(i) or VIb(ii) are as given for
formula III(i), III(ii), IIIa(i), IIIa(ii), ) or IIIb(ii).
In some embodiments a inker Compound is comprised of a Self-immolative
Assembly Unit attached to Drug Unit and is represented by Formula VI (i)' or VI (ii)':
(VI (i)')
(VI (ii)')
or a pharmaceutically acceptable salt thereof; wherein
A is an al Connector Unit;
W is an Activation Unit;
Y is a Self-Immolative Spacer Unit;
Z' is a precursor to a Stretcher Unit (Z) and is comprised of a functional group that
provides for covalent attachment of a Ligand Unit to Z;
B is an optional Branching Unit that is present when t is from 2 to 4 and absent when t
is 1;
R, R1 and R2 independently are hydrogen, optionally substituted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally substituted C-linked C3-C8 heteroaryl, or both
R and R1 together with the nitrogen and carbon atoms to which they are ed comprise an
azetidinyl, pyrrolodinyl, piperidinyl or homopiperidinyl moiety (preferably a pyrrolodinyl or
dinyl moiety) and R2 is hydrogen;
D is a Drug Unit having a hydroxyl functional group prior to its incorporation into the
indicated methylene alkoxy carbamate unit;
T* is the oxygen heteroatom from said functional group that s incorporated
into the indicated ene alkoxy(aryloxy) carbamate unit (MAC Unit); and
the subscript t is an integer ranging from 1 to 4.
Formula VI (i)' and VI (ii)' have a MAC structure of formula I'. In other aspects the
MAC Unit from formula I' in formula III (i)' or in formula III (ii)' LDCs is replaced with the
MAC Unit from formula Ia', which provide Drug-Linker nds that are ated as
formula VIa(i)' and formula VIa(ii)' Drug Linker Compounds, respectively. In other aspects
the MAC Unit from formula I' in formula VI(i)' or formula VI(ii)' is replaced with the MAC
Unit from formula I', which provide Drug-Linker Compounds that are designated as formula
III (i)' and formula III(ii)' Drug Linker nds, respectively. Preferred combinations and
subcombination of R, R, R1 and R2 in formula VI(i)’, VI(ii)’, VIa(i)’, VIa(ii)’, VIb(i)’ or
VIb(ii)’ are as given for formula III(i)’, III(ii)’, IIIa(i)’, IIIa(ii)’, IIIb(i)’ or IIIb(ii)’.
[0138] As indicated, Drug-Linker nds can act as ediate compounds for the
LDCs of the present invention. Accordingly, any of the embodiments set forth for the LDCs
are applicable as well for the Drug-Linker Compounds of the present invention. In other
words, any of the definitions for B, A, X, R, R1, R2, T*, D, O*, and the subscripts s and t and
combinations thereof are applicable and plated for the Drug-Linker Compounds of the
present invention.
Component groups
Ligand Units:
In some embodiments of the invention, a Ligand Unit is present, as for e in a
Ligand Drug Conjugate. The Ligand unit (L-) is a targeting agent that specifically binds to a
target moiety. In one group of ments, the Ligand Unit specifically and selectively
binds to a cell component (a Cell Binding Agent) or to other target molecules of interest. The
Ligand Unit acts to target and present the Drug Unit of a Ligand Drug Conjugate to the
particular target cell tion with which the Ligand Unit interacts due to the ce of
its targeted component or molecule and allows for subsequent release of free drug within
(i.e., intracellularly) or within the vicinity of the target cells (i.e., extracellularly). Ligands
include, but are not limited to, proteins, polypeptides and peptides. Suitable Ligand units
e, for example, antibodies, e.g., full-length antibodies and antigen binding fragments
thereof, interferons, kines, hormones, growth factors and colony-stimulating factors,
vitamins, nutrient-transport les (such as, but not limited to, transferrin), or any other
cell binding molecule or substance. In some embodiments the Ligand Unit is from an
antibody or a non-antibody protein targeting agent.
[0140] In one group of embodiments a Ligand Unit is bonded to a Stretcher unit (Z). In
some of those embodiments the Ligand Unit is bonded to Z of the Linker Unit via a
atom of the Ligand Unit. Heteroatoms that may be present on a Ligand Unit for that
bonding include sulfur (in one embodiment, from a dryl group of a targeting ligand),
oxygen (in one embodiment, from a carboxyl or hydroxyl group of a targeting ligand) and
en, ally substituted (in one embodiment, from a primary or secondary amine
functional group of a targeting ligand or in another embodiment from an optionally
substituted amide nitrogen). Those heteroatoms can be present on the targeting ligand in the
ligand’s natural state, for example in a naturally-occurring antibody, or can be introduced into
the targeting ligand via chemical cation or ical engineering.
[0141] In one embodiment, a Ligand Unit has a sulfhydryl functional group so that the
Ligand Unit is bonded to the Linker Unit via the sulfur atom of the sulfhydryl functional
group.
In another embodiment, a Ligand Unit has one or more lysine residues that are
capable of reacting with activated esters (such esters include, but are not limited to, N-
ysuccimide, pentafluorophenyl, and p-nitrophenyl esters) of a Stretcher Unit precursor
of a Drug-Linker Compound intermediate and thus es an amide bond consisting of the
nitrogen atom of the Ligand Unit and the C=O group of the Linker Unit’s Stretcher Unit.
In yet another aspect, a Ligand Unit has one or more lysine residues capable of
chemical modification to introduce one or more sulfhydryl groups. In those embodiments the
Ligand Unit is bonded to the Linker Unit via the sulfhydryl functional group’s sulfur atom.
The reagents that can be used to modify lysines in that manner include, but are not limited to,
N-succinimidyl S-acetylthioacetate (SATA) and 2-Iminothiolane hydrochloride (Traut’s
Reagent).
In another embodiment, a Ligand Unit one or more carbohydrate groups capable of
modification to provide one or more sulfhydryl functional groups. The chemically modified
Ligand Unit in a Ligand Drug Conjugate is bonded to a Linker Unit component (e.g., a
Stretcher Unit) via the sulfur atom of the sulfhydryl functional group.
In yet another embodiment, the Ligand Unit has one or more carbohydrate groups
that are capable of being ed to e an aldehyde (-CHO) functional group (see, e.g.,
Laguzza, et al., 1989, J. Med. Chem. 32(3):548-55). In that embodiment, the corresponding
aldehyde interacts with a reactive site on a Stretcher Unit precursor to form a bond between
the Stretcher Unit and the Ligand Unit. Reactive sites on a Stretcher Unit precursor that
capable of interacting with a reactive carbonyl-containing onal group on a targeting
ligand include, but are not limited to, hydrazine and ylamine. Other protocols for the
modification of proteins for the attachment of Linker Units or Drug-Linker Compounds are
described in Coligan et al., Current Protocols in n Science, vol. 2, John Wiley & Sons
(2002) (incorporated herein by reference).
In some aspects, a Ligand Unit is capable of g a bond by cting with a
ve functional group on a Stretcher Unit precursor (Z') to form a covalent bond between
the Stretcher Unit (Z) and the Ligand Unit corresponding to the targeting ligand. The
functional group of Z' having that capability for interacting with a ing ligand will
depend on the nature of the Ligand Unit. In some embodiments, the reactive group is a
ide that is present on a Stretcher Unit prior to its attachment to form a Ligand
Unit.(i.e., a ide moiety of a Stretcher Unit precursor). Covalent attachment of a
Ligand Unit to a her Unit is accomplished through a sulfhydryl functional group of a
Ligand Unit interacting with the maleimide functional group of Z' to form a thio-substituted
succinimide. The sulfhydryl functional group can be present on the Ligand Unit in the
Ligand’s natural state, for example, in a naturally-occurring residue, or can be introduced into
the Ligand via chemical modification or by biological engineering.
In still another embodiment, the Ligand Unit is from an antibody and the sulfhydryl
group is generated by ion of an interchain disulfide of the antibody. Accordingly, in
some embodiments, the Linker Unit is conjugated to a cysteine residue from reduced
interchain disulfide(s).
In yet another embodiment, the Ligand Unit is from an antibody and the sulfhydryl
functional group is chemically introduced into the antibody, for example, by introduction of a
cysteine residue. Accordingly, in some embodiments, the Linker Unit is conjugated to a
Drug Unit h an introduced cysteine residue of a Ligand Unit.
[0149] It has been observed for bioconjugates that the site of drug conjugation can affect a
number of parameters including ease of conjugation, drug-linker stability, effects on
biophysical properties of the resulting bioconjugates, and in-vitro cytotoxicity. With respect
to drug-linker stability, the site of conjugation of a drug-linker moiety to a Ligand Unit can
affect the ability of the conjugated inker moiety to undergo an elimination reaction to
cause premature release of free drug and for the drug linker moiety to be transferred from the
Ligand of an LDC to an alternative reactive thiol present in the milieu of the LDC, such as,
for example, a reactive thiol in albumin, free cysteine, or glutathione present in plasma. Sites
for conjugation on a targeting ligand e, for example, a reduced interchain disulfide as
well as select cysteine residue at engineered sites. In some embodiments conjugation
s to form Ligand-Drug Conjugates as described herein use thiol residues at genetically
engineered sites that are less susceptible to the elimination reaction (e.g., positions 239
according to the EU index as set forth in Kabat) in comparison to conjugation methods that
use thiol residues from a reduced disulfide bond. In other embodiments conjugation methods
to form Ligand-Drug Conjugates as described herein use thiol es at sites that are more
susceptible to the elimination reaction (e.g. resulting from interchain ide reduction).
When a Ligand Drug Conjugate is sed of a munoreactive protein,
polypeptide, or peptide, its Ligand Unit , instead of being from dy, is from a nonimmunoreactive
protein, polypeptide, or peptide which includes, but are not limited to,
transferrin, epidermal growth factors (“EGF”), bombesin, gastrin, n-releasing e,
platelet-derived growth factor, IL-2, IL-6, transforming growth factors (“TGF”), such as
TGF-α and TGF-β, vaccinia growth factor (“VGF”), n and insulin-like growth factors I
and II, somatostatin, lectins and apoprotein from low density lipoprotein.
Particularly preferred Ligand Units are from antibodies. In fact, in any of the
embodiments described herein, the Ligand Unit can be from an antibody. Useful polyclonal
antibodies are heterogeneous populations of antibody les derived from the sera of
zed animals. Useful monoclonal antibodies are homogeneous populations of
antibodies to a particular antigenic determinant (e.g., a cancer cell antigen, a viral antigen, a
microbial n, a protein, a peptide, a carbohydrate, a chemical, nucleic acid, or fragments
thereof). A monoclonal antibody (mAb) to an antigen-of-interest can be prepared by using
any technique known in the art which es for the production of antibody molecules by
continuous cell lines in culture.
[0152] Useful onal antibodies include, but are not limited to, human monoclonal
antibodies, humanized monoclonal dies, or chimeric human-mouse (or other species)
monoclonal antibodies. The antibodies include full-length antibodies and antigen binding
fragments thereof. Human monoclonal antibodies may be made by any of numerous
techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. USA. 80:7308-
7312; Kozbor et al., 1983, Immunology Today 4:72-79; and Olsson et al., 1982, Meth.
Enzymol. 92:3-16).
The antibody can be a functionally active fragment, derivative or analog of an
antibody that immunospecifically binds to target cells (e.g., cancer cell antigens, viral
antigens, or microbial ns) or other antibodies bound to tumor cells or matrix. In this
regard, “functionally active” means that the fragment, derivative or analog is able to
immunospecifically binds to target cells. To determine which CDR sequences bind the
antigen, synthetic peptides containing the CDR sequences can be used in binding assays with
the antigen by any g assay method known in the art (e.g., the BIA core assay) (See,
e.g., Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Fifth Edition,
National Institute of Health, Bethesda, Md; Kabat E et al., 1980, J. Immunology 125(3):961-
969).
Other useful antibodies include fragments of dies such as, but not limited to,
F(ab’)2 fragments, Fab fragments, Fvs, single chain antibodies, diabodies, triabodies,
tetrabodies, scFv, scFv-FV, or any other molecule with the same specificity as the dy.
[0155] Additionally, recombinant antibodies, such as chimeric and humanized monoclonal
antibodies, comprising both human and non-human ns, which can be made using
standard recombinant DNA techniques, are useful antibodies. A chimeric antibody is a
molecule in which ent portions are d from ent animal species, such as for
example, those having a variable region derived from a murine monoclonal and human
immunoglobulin constant regions. (See, e.g., U.S. Patent No. 4,816,567; and U.S. Patent No.
4,816,397, which are incorporated herein by reference in their entirety.) Humanized
antibodies are antibody molecules from man species having one or more
complementarity determining regions (CDRs) from the man species and a framework
region from a human immunoglobulin molecule. (See, e.g., U.S. Patent No. 5,585,089, which
is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal
antibodies can be ed by recombinant DNA techniques known in the art, for example
using methods described in International Publication No. WO 87/02671; European Patent
Publication No. 0 184 187; European Patent Publication No. 0 171 496; European Patent
Publication No. 0 173 494; International Publication No. WO 86/01533; U.S. Patent No.
4,816,567; European Patent Publication No.012 023; Berter et al., 1988, Science 240:1041-
1043; Liu et al., 1987, Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al., 1987, J.
Immunol. 139:3521-3526; Sun et al., 1987, Proc. Natl. Acad. Sci. USA 84:214-218;
ura et al., 1987, Cancer. Res. 47:999-1005; Wood et al., 1985, Nature 314:446-449;
and Shaw et al., 1988, J. Natl. Cancer Inst. 80:1553-1559; on, 1985, Science
229:1202-1207; Oi et al., 1986, BioTechniques 4:214; U.S. Patent No. 5,225,539; Jones et
al., 1986, Nature 321:552-525; yan et al., 1988, Science 239:1534; and Beidler et al.,
1988, J. Immunol. 141:4053-4060; each of which is incorporated herein by reference in its
entirety.
tely human antibodies in some instances (e.g., when immunogenicity to a
non-human or chimeric antibody may occur) are more ble and can be produced using
transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light
chains genes, but which can express human heavy and light chain genes.
Antibodies include analogs and tives that are either modified, i.e., by the
covalent attachment of any type of molecule as long as such covalent attachment permits the
antibody to retain its antigen binding immunospecificity. For example, but not by way of
limitation, tives and analogs of the antibodies include those that have been further
modified, e.g., by glycosylation, ation, PEGylation, orylation, amidation,
derivitization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular
antibody unit or other protein, etc. Any of numerous chemical modifications can be d
out by known techniques including, but not limited to, specific chemical cleavage,
acetylation, formylation, metabolic synthesis in the ce of tunicamycin, etc.
Additionally, the analog or derivative can contain one or more unnatural amino acids.
Antibodies can have modifications (e.g., substitutions, deletions or additions) in
amino acid residues that interact with Fc receptors. In particular, antibodies can have
modifications in amino acid residues identified as involved in the interaction between the
anti-Fc domain and the FcRn receptor (see, e.g., ational Publication No. WO 97/34631,
which is orated herein by nce in its ty).
Antibodies immunospecific for a cancer cell antigen can be obtained commercially
or produced by any method known to one of skill in the art such as, recombinant expression
techniques. The nucleotide sequence encoding antibodies immunospecific for a cancer cell
n can be obtained, e.g., from the GenBank database or a database like it, the literature
publications, or by routine cloning and sequencing.
In a specific embodiment, a known antibody for the treatment of cancer can be used.
[0161] In another specific embodiment, antibodies for the treatment of an autoimmune
disease are used in accordance with the compositions and methods of the invention.
In certain embodiments, useful antibodies can bind to a receptor or a receptor
complex expressed on an activated lymphocyte. The receptor or or complex can
comprise an immunoglobulin gene superfamily member, a TNF receptor superfamily
member, an integrin, a cytokine receptor, a chemokine receptor, a major ompatibility
n, a lectin, or a ment control protein.
In some aspects, the antibody that is incorporated into a Ligand Drug ate will
specifically bind CD19, CD20, CD30, CD33, CD70, NTBA, alpha-v-beta-6, Liv-1 or Lewis
Y antigen.
Drug Units (D):
The Drug Unit (D) can be from any cytotoxic, cytostatic or immunosuppressive
drug (also ed to herein as a cytotoxic, atic or immunosuppressive agent), that has
a hydroxyl, thiol, amine or amide functional group whose oxygen, sulfur or optionally
substituted nitrogen heteroatom is capable of incorporation into a methylene carbamate unit,
and is capable of being released from the methylene carbamate unit as the functional group of
a free drug. In some aspects, that functional group provides the only site on a drug available
for attachment to that Linker Unit component. The resulting drug-linker moiety is one that
can release active free drug from an LDC having that moiety at the site targeted by its Ligand
Unit in order to exert a cytotoxic, cytostatic or immunosuppressive effect.
“Free drug” refers to drug, as it exists once released from the inker moiety.
The free drug differs from the conjugated drug in that the onal group of the drug for
attachment to the self-immolative assembly unit is no longer associated with components of
the Ligand-Drug Conjugate (other than a previously shared heteroatom). For example, the
free yl functional group of an alcohol-containing drug can be represented as D-O*H,
whereas in the conjugated form the oxygen heteroatom designated by O* is incorporated into
the methylene carbamate unit of a Self-immolative Assembly Unit. Upon activation of the
self-immolative moiety and release of free drug, the nt bond to O* is replaced by a
hydrogen atom so that the oxygen heteroatom designated by O* is present on the free drug as
-O-H. In another example, O* is from a free hydroxyl functional group of a precursor to
alcohol-containing drug, which is represented as D’-O*H. After O* from that precursor is
incorporation into a methylene carbamate unit of a Self-immolative Assembly Unit D’-O*-
that moiety in the Self-immolative Assembly Unit is subsequently converted to D-O*-.
Useful classes of cytotoxic or immunosuppressive agents having a hydroxyl,
sulfhydryl, amine or amide onal group, or can be modified to have such functional
groups t incurring unacceptable loss of biological activity, that are suitable for
attachment to a methylene carbamate unit include, for example, bulin agents, DNA
minor groove binders, DNA replication tors, alkylating agents, antibiotics, antifolates,
antimetabolites, chemotherapy sensitizers, topoisomerase inhibitors, vinca alkaloids, or the
like. es of particularly useful s of cytotoxic agents include, for example, DNA
minor groove binders, DNA alkylating agents, and tubulin inhibitors. Exemplary cytotoxic
agents include, for example, auristatins, camptothecins, duocarmycins, ides,
maytansines and maytansinoids, taxanes, benzodiazepines or benzodiazepine containing
drugs (e.g., pyrrolo[1,4]-benzodiazepines (PBDs), indolinobenzodiazepines, and
oxazolidinobenzodiazepines) and vinca alkaloids.
In some embodiments, the Drug unit is from an anti-tubulin agent. Examples of
anti-tubulin agents include, but are not limited to, taxanes, vinca alkaloids maytansine and
maytansinoids, dolastatins and auristatins.
In n embodiments, the cytotoxic agent is from maytansine or a maytansinoid.
[0169] In some embodiments, the Drug unit is from an auristatin, with those having a
hydroxyl functional group whose heteroatom is incorporation into a MAC Unit preferred.
ary preferred auristatins e compounds having one of the following structures:
wherein R10 and R11 are independently hydrogen or C1-C8 alkyl; R12 is hydrogen, C1-C8 alkyl,
C3-C8 lkyl, aryl, -X1-aryl, -X1-(C3-C8 cycloalkyl), C3-C8 heterocycle or -X1-(C3-C8
heterocycle); R13 is hydrogen, C1-C8 alkyl, C3-C8 cycloalkyl, aryl, -X1-aryl, -X1-(C3-C8
cycloalkyl), C3-C8 cycle and -X1-(C3-C8 heterocycle); R14 is hydrogen or methyl, or R13
and R14 taken together with the carbon to which they are attached comprise a C3-C8
lkyl; R15 is en or C1-C8 alkyl; R16 is hydrogen, C1-C8 alkyl, C3-C8 cycloalkyl,
aryl, -X1-aryl, -X1-(C3-C8 cycloalkyl), C3-C8 heterocycle and -X1-(C3-C8 cycle); R17
independently are hydrogen, -OH, C1-C8 alkyl, C3-C8 cycloalkyl and O-(C1-C8 alkyl); R18 is
hydrogen or C1-C8 alkyl; R19 is −C(R19A)2−C(R19A)2−aryl, A)2−C(R19A)2−(C3-C8
heterocycle) or −C(R19A)2−C(R19A)2−(C3-C8 cycloalkyl), wherein each R19A independently is
hydrogen, C1-C8 alkyl, -OH or –O-C1-C8 alkyl, provided that at least one R19A is –OH; R20 is
hydroxylalkyl, including 3)-OH; Z is O, S, NH, and X1 is C1-C10 alkylene.
[0170] The syntheses and structures of auristatins having an hydroxyl functional group
whose oxygen heteroatom capable of being incorporated into a MAC unit are described in
U.S. Patent Application Publication Nos. 2003-0083263, 2005-0238649 2005-0009751,
2009-0111756, and 2011-0020343; International Patent Publication No. WO 04/010957,
International Patent ation No. WO 02/088172, and U.S. Patent Nos. 7,659,241 and
8,343,928; each of which is incorporated by reference in its entirety and for all purposes.
Exemplary alcohol-containing auristatins released from LDCs of the present invention bind
tubulin and exert a cytotoxic or cytostatic effect on the desired cells (i.e., target cells) as a
result of that binding.
More preferred atins having a yl functional group whose heteroatom is
incorporation into a MAC Unit is monomethyl auristatin E and auristatin T.
In some embodiments, the Drug Unit is from a benzodiazepine (including
benzodiazepine-containing drugs (e.g., pyrrolo[1,4]benzodiazepines ,
indolinobenzodiazepines, and oxazolidinobenzodiazepines) having or modified to have a
hydroxyl, amine, amide or thiol functional group suitable for incorporation into a Drug Unit
covalently attached to a methylene carbamate unit through a heteroatom of that functional
group.
In other aspects, the drug unit is an immunophilin of the FKBP class (as described in
Wiederrecht and Etzhorn “Immunophilins” Perspec. Drug Discov. Des. (1994) 2(1): 57-84),
referred herein as a FKBP immunophilin, having a hydroxyl functional group suitable for
incorporation into a Drug Unit covalently attached to a MAC unit through the oxygen
heteroatom of that functional group.
In one group of embodiments the immunophilin suitable for incorporation into a Drug
Unit covalent ment to a MAC unit binds to 2 as the free drug to inhibit effector
function of eurin required for T-cell proliferation. In one embodiment, the FKBP
immunophilin that is e of incorporation into a MAC unit and as the free drug binds to
FKBP-12 to inhibit effector function of calcineurin has the general structure of formula VIIa
(VIIa)
wherein u is 0 or 1 to define a yl or pipecolic acid moiety, wherein R, R1 and R2
ndently are –OH, an ally substituted C1-C6 ether or an optionally substituted C1-
C6 ester (preferably R, R1 and R2 are –OMe); R3 is optionally tuted C1-C4 alkyl
(preferably methyl, ethyl, -CH2CH=CH2 , -CH2CH2CH2CH3; R4 is oxo (i.e., =O), or –OH or
C1-C6 ester in the α- or β-configuration (preferably =O or α-OH); and R5 is hydrogen or
optionally substituted C1-C4 alkyl (preferably hydrogen or methyl).
In preferred embodiments of formula VIIa, u is 2; R, R1 and R2 are –OMe; R3 is ethyl;
R4 is α-OH; and R5 is methyl, or u is 2; R, R1 and R2 are –OMe; R3 is methyl; R4 is α-OH;
and R5 is methyl, or u is 1; R, R1 and R2 are –OMe; R3 is -CH2CH=CH2; R4 is α-OH; and R5
is methyl, or u is 2; R, R1 and R2 are –OMe; R3 is ethyl, R4 is α-OH; and R5 is hydrogen, or u
is 1; R, R1 and R2 are –OMe; R3 is ethyl, R4 is α-OH; and R5 is methyl, or u is 2; R, R1 and R2
are –OMe, R3 is =CH2; R4 is α-OH; and R5 is methyl, or u is 2; R is –OMe; R1 is –
OH; R2 is methyl, R3 is -CH2CH=CH2; R4 is α-OH; and R5 is methyl.
In other embodiments the moiety A in formula VIIa of
is replaced by the moiety B
to define FKBP immunophilins of formula VIIb, wherein the wavy line indicate covalent
attachment to the remainder of the macrolide; u, R, R1, R2, R3, R4 and R5 are as defined
formula VIIa. In preferred ments of formula VIIb, u is 2, R is –OMe; R1 is –OH; R2
is –OMe; R3 is methyl, ethyl or -CH2CH=CH2; R4 is α-OH; and R5 is hydrogen or methyl.
In other embodiments the moiety A in formula VIIa is replaced by the moiety of C or
(C) (D)
to define FKBP immunophilins of formula VIIc or VIId, respectively, wherein R6 is
hydrogen, oxo (i.e., =O), -OH in the α- or β-configuration, epoxide (i.e., -CH2O-), =N(R6’) or
)2; R7 is –OH or –N(R6’)2; and u, R, R1, R2, R3, R4 and R5 are as defined formula VIIa,
wherein in each ence R6’ is independently selected from the group consisting of
hydrogen and optionally substituted C1-C4 alkyl.
In other ments the moiety A in formula VIIa is replaced by moiety E or F
(E) (F)
to define FKBP philins of formula VIIe or VIIf, respectively, wherein u, R, R1, R2,
R3, R4 and R5 are as defined in Formula VIa and R7 is as defined in formula VIc/Vid.
Preferably in formula VIIe, R, R1 and R2 are –OMe; R3 is methyl, ethyl or –CH2CH=CH2; R4
is α-OH; R5 is hydrogen or methyl; and R7 is –OH, and preferably in formula VIIf, u is 2, R
is –OMe, R1 is –OH; R2 is –OMe; R3 is methyl, ethyl or -CH2CH=CH2; R4 is α-OH; R5 is
hydrogen or methyl; and R7 is -OH.
[0179] In other embodiments the moiety of formula A in formula VIa is replace by moiety G,
H or J
(G) (H) (J)
to define FKBP philins of formula VIIg, VIIh and VIIj, respectively, wherein R1, R2,
R3, R4, R5 and R6 are as defined in formula VIIa; and R8 is hydrogen or optionally substituted
C1-C6 alkyl. Preferably in those formulae u is 2; R, R1 and R2 are –OMe; R3 is methyl, ethyl
or –CH2CH=CH2; R4 is α-OH; R5 is hydrogen or methyl; and R8 is methyl or ethyl.
In other ments the moiety A in formula VIIa is replaced by moiety K
to define FKBP immunophilins of formula VIIk, wherein u, R, R1, R2, R3, R4 and R5 are as
defined formula VIIa.
[0181] In other embodiments the moiety A’ in formula VIIa, VIIb, VIIc, VIId, VIIe, VIIf,
VIIg, VIIh, VIIj or VIIk is replaced by the moiety,
is replaced by the moiety M
to define FKBP immunophilins of formula VIIm(i), i), VIIm(iii), VIIm(iv), VIIm(v),
VIIm(vi), ii), VIIm(viii), VIIm(ix) and VIIm(x), respectively, wherein the variable
groups are as defined in their corresponding parent structure. A preferred A’ replacement
with moiety M is for formula VIa defining FKBP immunophilins of formula VIIm(i),
wherein R, R1 and R2 are –OMe; R3 is methyl, ethyl or –CH2CH=CH2; R4 is α-OH; and R5 is
en or methyl.
In other embodiments the moiety A’ in formula VIIa, VIIb, VIIc, VIId, VIIe, VIIf,
VIIg, VIIh, VIIj, or VIIk is replace by the moiety N
(N)
to define FKBP immunophilins of formula VIIn(i), VIIn(ii), VIIn(iii), VIIn(iv), VIIn(v),
VIIn(vi), VIIn(vii), VIIn(viii), VIIn(ix) and VIIn(x), wherein R3 is R3A, R3B (i.e., C-21 is
bonded to R3A and R3B), wherein R3A in the α-configuration is ally substituted C1-C6
alkyl (preferably methyl, ethyl, -CH2CH=CH2, -CH2CH2CH2CH3) and R3B in the β-
configuration is hydrogen or -OH, or R3A in the iguration is –OH and R3B in the guration
is optionally substituted C1-C6 alkyl (preferably methyl, ethyl, -CH2CH=CH2 , -
CH2CH2CH2CH3); R9 is oxo or -OH in the α- or β-configuration; and R10 is hydrogen or
fluoro in the α- or β-configuration, provided that when R3B is hydrogen and R9 is oxo, then
R10 is not hydrogen; and the remaining variable groups are as defined in their corresponding
parent structure.
[0183] A preferred A’ ement with moiety N is for formula VIa defining FKBP
immunophilins of a VIIn(i), n R, R1 and R2 are –OMe; R3A is methyl or ethyl
and R3B is hydrogen; R4 is α-OH; R5 is hydrogen or methyl; R9 is oxo; and R10 is fluoro in
the α- or β-configuration or R, R1 and R2 are –OMe; R3A is methyl or ethyl and R3B is –OH or
R3A is –OH and R3B is methyl or ethyl; R4 is α-OH; R5 is hydrogen or methyl; R9 is oxo; and
R10 is hydrogen or –OH in the α- or β-configuration.
In other embodiments the moiety A’ in formula VIIa, VIIb, VIIc, VIId, VIIe, VIIf,
VIIg, VIIh, VIIj, or VIIk is replaced by the moiety O
to define FKBP immunophilins of formula VIIo(i), VIIo(ii), VIIo(iii), VIIo(iv), VIIo(v),
VIIo(vi), VIIo(vii), VIIo(viii), VIIo(ix) and VIIo(x), respectively, n R, R3, R4 and R5
are as d for the VIIn-immunophilins and the remaining variable groups are as defined
in their corresponding parent structure.
A preferred A’ replacement with moiety O is for a VIa defining FKBP
immunophilins of formula VIIo(i), wherein R, R1 and R2 are –OMe; R3A in the α-
configuration is optionally substituted C1-C6 alkyl (preferably methyl, ethyl, -CH2CH=CH2, -
CH2CH2CH2CH3); R3B in the β-configuration is hydrogen; R4 is α-OH; R5 is hydrogen or
methyl.
In more red embodiments of formula VIIa, u is 2; R, R1 and R2 are –OMe, R3 is
-CH2CH=CH2; R4 is α-OH; and R5 is methyl, or u is 2; R is –OMe; R1 is –OH; R2 is methyl,
R3 is -CH2CH=CH2; R4 is α-OH; and R5 is methyl. In more preferred embodiments of
formula VIIb, u is 2; R is –OMe; R1 is –OH; R2 is methyl, R3 is -CH2CH=CH2; R4 is α-OH;
and R5 is methyl. In more red embodiments of formula VIIc, u is 2; R, R1 and R2 are –
OMe, R3 is -CH2CH=CH2; R4 is α-OH; R5 is methyl; R6 is hydrogen, =CH2, or -OH in the αor
iguration (preferably –OH); and R7 is –OH. In more preferred embodiments of
formula VIId, u is 2; R is –OMe; R1 is –OH; R2 is methyl, R3 is -CH2CH=CH2; R4 is α-OH;
R5 is methyl; R6 is hydrogen, =CH2, or -OH in the α- or β-configuration (preferably –OH);
and R7 is –OH. In more preferred embodiments of formula VIIe, R, R1 and R2 are –OMe; R3
is–CH2CH=CH2; R4 is α-OH; R5 is methyl; and R7 is –OH. In more preferred embodiments
of formula VIIf, u is 2, R is –OMe, R1 is –OH; R2 is –OMe; R3 is -CH2CH=CH2; R4 is α-OH;
R5 is methyl; and R7 is –OH.
In more preferred ments of VIIg, VIIh or VIIj, R, R1 and R2 are –OMe; R3 is–
CH2CH=CH2; R4 is α-OH; R5 is methyl; and R8 is methyl. In more preferred embodiments of
formula VIIk or formula VIIm(i), u is 2; R, R1 and R2 are –OMe, R3 is -CH2CH=CH2; R4 is
α-OH. In more preferred embodiments of formula VIIn(i), R, R1 and R2 are –OMe; R3 is
ethyl; R4 is α-OH; R5 is methyl; R9 is oxo; and R10 is –OH in the α- or β-configuration. In
more preferred embodiments of formula VIIn(i), R, R1 and R2 are –OMe; R3A in the αconfiguration
is -CH2CH=CH2, -CH2CH2CH2CH3); R3B in the iguration is hydrogen;
R4 is α-OH; and R5 is methyl.
In other more red embodiments the Drug Unit in any one of a I, I’, Ia, Ia’,
II, II’, IIIa(i), IIIa(ii), IIIb(i), IIIb(ii), IIIc(i), IIIc(ii), Va, Vb, Vc, Va’, Vb’, Vc’, VIa, VIb,
VIc, VIa’, VIb’, VIc’, VIa(i), VIa(ii), VIb(i), VIb(ii), VIc(i), VIc(ii), VIa(i)’, VIa(ii)’, VIb(i)’,
VIb(ii)’, VIc(i)’ and VIc(ii)’, is from the FKBP philin of a VIIa, VIIb, VIIc,
VIId, VIIe, VIIf, VIIg, VIIh, VIIj, VIIm(i), VIIm(ii), VIIm(iii), VIIm(iv), VIIm(v), VIIm(vi),
VIIm(vii), VIIm(viii), VIIm(ix), VIIm(x), VIIn(i), VIIn(ii), VIIn(iii), VIIn(iv), VIIn(v),
VIIn(vi), VIIn(vii), VIIn(viii), VIIn(ix) VIIn(x), VIIo(i), VIIo(ii), VIIo(iii), VIIo(iv), VIIo(v),
VIIo(vi), VIIo(vii), VIIo(viii), x) and VIIo(x), wherein the oxygen heteroatom from the
hydroxyl functional group at position C-32 in any one of these FKBP immunophilins is
represented by O* or T* in formula I, I’, Ia, Ia’, II, II’, IIIa(i), IIIa(ii), IIIb(i), IIIb(ii), ),
i), Va, Vb, Vc, Va’, Vb’, Vc’, VIa, VIb, VIc, VIa’, VIb’, VIc’, VIa(i), VIa(ii), VIb(i),
VIb(ii), VIc(i), ), VIa(i)’, VIa(ii)’, VIb(i)’, VIb(ii)’, VIc(i)’ and )’.
In particularly preferred embodiments the Drug Unit in any one of formula I, I’, Ia,
Ia’, II, II’, IIIa(i), IIIa(ii), IIIb(i), IIIb(ii), IIIc(i), IIIc(ii), Va, Vb, Vc, Va’, Vb’, Vc’, VIa, VIb,
VIc, VIa’, VIb’, VIc’, VIa(i), VIa(ii), VIb(i), VIb(ii), VIc(i), VIc(ii), VIa(i)’, VIa(ii)’, VIb(i)’,
VIb(ii)’, VIc(i)’ and )’, is from the FKBP immunophilin tacrolimus (FK-506), the
structure for which is the ing:
wherein the indicated O* is the O* or T* heteroatom that is incorporated into a methylene
ate unit in any one of these formulae, or is from another macrolide inhibitor of
calcineurin effector function having a hydroxyl functional group whose oxygen heteroatom is
capable of incorporation into a MAC unit or is from another macrolide inhibitor of
calcineurin effector on having a hydroxyl functional group whose oxygen heteroatom is
capable of incorporation into a MAC unit. The hydroxyl functional group heteroatom
incorporated into a MAC unit is indicated by O* for imus.
In r group of embodiments the immunophilin suitable for incorporation into a
Drug Unit covalent attachment to a MAC unit binds to FKBP-12 as the free drug to inhibit
effector function of mammalian target of rapamycin (mTOR) required for increased n
synthesis to support cancer cell eration and survival.
In one embodiment the FKBP immunophilin that is capable of incorporation into a
MAC unit and as the free drug binds to FKBP-12 to inhibit effector function of mTOR has
the general structure of formula VIIaa
` (VIIaa)
wherein u is 1 or 2 to define a prolinyl or pipecolic acid moiety; R14 and R12 independently
are , –OH, an optionally substituted C1-C6 ether or an ally substituted C1-C6 ester
(preferably –OH or an optionally substituted C1-C6 ether; more preferably –OH or –OCH3);
R11 is hydrogen, –OH, an optionally substituted C1-C6 ether or an optionally substituted C1-
C6 ester (preferably en, -OH or an optionally substituted C1-C6 ether; more ably
hydrogen, -OH or –OCH3); and R13 is O (i.e., defines =O at C15) or CH2 (i.e., defines =CH2
at C15).
In other embodiments the moiety AA in formula VIIaa of
(AA)
is replaced with the moiety of formula BB
to define FKBP immunophilins of formula VIIbb, wherein u, R, R11, R12 and R13 are as
defined for formula VIIaa. In preferred embodiments of formula VIIaa, u is 2; R and R12
independently are , –OH or an optionally substituted C1-C6 ether (more preferably –OH or –
OCH3); R11 is hydrogen, –OH or an optionally substituted C1-C6 ether (more ably
hydrogen, -OH or –OCH3); and R13 is O (i.e., defines =O at C-15) or CH2 (i.e., defines =CH2
at C-15) (more preferably R13 is O).
In other embodiments the moiety AA is replaced by the moiety of formula CC
to define FKBP immunophilins of formula VIIcc, wherein u is 1 or 2; X is O or –
OCH2CH2S-;R13 is O, NOR13’ (i.e., defines an oxime at C15) or NHNHR13’ (i.e., defines a
hydrazone at C15), wherein R13’ is ndently selected from the group ting of
hydrogen and optionally substituted C1-C4 alkyl; R13 is R13A, R13B (i.e., C-15 is bonded to
R13A and R13B), n R13A in the α-configuration is hydrogen and R13B in the β-
configuration is –OH or R13A in the α-configuration is -OH and R13B in the β-configuration is
hydrogen; R15 is O or R15 is R15A, R15B (i.e., C-15 is bonded to R15A and R15B), wherein R15A
in the α-configuration is en and R15B in the β-configuration is –OH or R15A in the αconfiguration
is -OH and R15B in the β-configuration is hydrogen.
In other embodiments the moiety AA’ in formula VIIaa, VIIbb or VIIcc of
(AA’)
is replaced by the moiety of formula DD
to defined FKBP immunophilins of formula VIIdd(i), VIIdd(ii) and VIIdd(iii), respectively,
wherein R11 and R12 are as d in formula VIIaa, R16 is O (i.e., to define =O at C-31) or
R16 is R16A, R16B (i.e., C-31 is bonded to R16A and R16B), wherein R16A in the α-configuration
is hydrogen and R16B in the β-configuration is –OH or R16A in the α-configuration is -OH and
R16B in the β-configuration is hydrogen; R17 is O (i.e., to define =O at C-33) or R17 is R17A,
R17B (i.e., C-33 is bonded to R17A and R17B), n R17A in the α-configuration is hydrogen
and R17B in the β-configuration is –OH, an optionally substituted C1-C6 ether (preferably –
OR17B’) or an optionally substituted O-linked carbamate (preferably –O(C=O)NHR17B’) or
R17A in the α-configuration is –OH, an optionally substituted C1-C6 ether (preferably –
OR17A’) or an optionally substituted O-linked carbamate (preferably –O(C=O)NHR17B’) and
R17B in the β-configuration is hydrogen, wherein R17A’ and R17B’ are independently hydrogen
or C1-C4 alkyl (preferably en, methyl or ethyl), or R16 and R17 are N (to define =N at
C-31 and C-32) and together with the C-32 and C-32 carbon to which they are ed
define a pyrazole heterocyclo; and the remaining le groups are as defined in their
corresponding parent structure.
[0195] In other embodiments the moiety AA’ in formula VIIaa, VIIbb or VIIcc is replaced by
the moiety of formula EE, FF or GG
(EE) (FF)
to define from formula EE, FKBP immunophilins of formula VIIee(i), VIIee(ii) and
iii), respectively, from formula FF, FKBP immunophilins of formula VIIff(i), VIIff(ii)
and iii), respectively or from formula GG, FKBP immunophilins of a VIIff(i),
VIIff(ii) and iii), wherein R11 and R12 are as defined in formula VIIaa; R16 and R17 are
as defined in formula DD and the remaining le groups are as defined by their respective
parent structure.
In other embodiments the moiety AA’ in formula VIIaa, VIIbb or VIIcc is replaced by
the moiety of formula HH or JJ
R11 R17
Me Me
to define from formula HH, FKBP immunophilins of formula VIIhh(i), VIIhh (ii) and
VIIhh(iii), respectively, or from formula JJ, FKBP immunophilins of formula VIIjj(i),
ii) and VIIff(iii), respectively.
[0197] In particularly preferred embodiments the Drug Unit in any one of formula I, I’, Ia,
Ia’, II, II’, IIIa(i), IIIa(ii), IIIb(i), IIIb(ii), IIIc(i), IIIc(ii), Va, Vb, Vc, Va’, Vb’, Vc’, VIa, VIb,
VIc, VIa’, VIb’, VIc’, VIa(i), ), VIb(i), VIb(ii), VIc(i), VIc(ii), VIa(i)’, VIa(ii)’, VIb(i)’,
VIb(ii)’, VIc(i)’ and VIc(ii)’, is from the FKBP immunophilin, everolimus, sirolimus
(rapamycin) or other macrolide inhibitor of mammalian target of rapamycin (mTOR) effector
function having a hydroxyl functional group whose oxygen heteroatom is capable of
oration into a MAC unit. The hydroxyl functional group heteroatom incorporated into
a MAC unit is indicated by O* for tacrolimus, imus and mus in the following
structures.
In other embodiments a Drug Unit of an ADC or a Drug-Linker Compound represents
a tetrahydroquinoline-containing drug that is incorporated into a methylene carbamate unit
through its amine functional group (i.e., its aniline amino). In any one of the embodiments
disclosed herein of formula I, Ia, II, IIIa(i), IIIa(ii), IIIb(i), IIIb(ii), IIIc(i), IIIc(ii), Va, Vb, Vc,
VIa, VIb, VIc, VIa(i), VIa(ii), VIb(i), VIb(ii), VIc(i) or VIc(ii), T* represents the cyclic
amine (i.e. the aniline) nitrogen corresponding to the tetrahydroquinoline-containing free
drug and accordingly is encompassed by T* as an optionally tuted nitrogen. In those
ments PARP inhibitors whose structures are comprised of a tetrahydroquinoline
moiety having an aniline en capable of incorporation into a methylene carbamate unit
are preferred. In one such embodiment the PARP inhibitor has the following structure:
In some aspects, a Drug Unit is an alcohol-containing drug wherein the hydroxyl
functional group of the alcohol is orated into the methylene carbamate unit of a Selfimmolative
Assembly Unit via the oxygen atom of that onal group. In some such
aspects, the alcohol of the drug is an aliphatic alcohol (e.g., a primary, secondary or tertiary
alcohol). In other such aspects, the drug is an aromatic alcohol. In other embodiments, the
drug comprises an amine (e.g., a primary or ary aliphatic or aromatic amine)
functional group that becomes incorporated into the methylene ate unit of a Selfimmolative
Assembly Unit via the optionally substituted nitrogen heteroatom of the amine.
In other embodiments, the drug is thiol-containing drug and incorporation into the methylene
carbamate unit of a Self-immolative Assembly Unit is via the sulfur atom of the sulfhydryl
functional group of the thiol-containing drug. In other aspects, the drug comprises an amide
functional group and incorporation into the methylene carbamate unit of a Self-immolative
Assembly Unit is via an optionally substituted nitrogen heteroatom of the amide, (e.g., a
carboxamide).
There are a number of ent assays that can be used for determining whether a
Ligand-Drug Conjugate exerts a cytostatic or cytotoxic effect on a cell line. In one example
for determining whether a Ligand-Drug Conjugate exerts a cytostatic or cytotoxic effect on a
cell line, a thymidine incorporation assay is used. For e, cells at a density of 5,000
cells/well of a 96-well plated is cultured for a 72-hour period and d to 0.5 μCi of 3H-
thymidine during the final 8 hours of the 72-hour , and the incorporation of 3H-
thymidine into cells of the e is measured in the presence and absence of Ligand-Drug
Conjugate. The Ligand-Drug Conjugate has a cytostatic or cytotoxic effect on the cell line if
the cells of the culture have reduced 3H-thymidine incorporation compared to cells of the
same cell line cultured under the same conditions but not contacted with the Ligand-Drug
Conjugate.
In another example, for determining whether a Ligand-Drug Conjugate exerts a
cytostatic or cytotoxic effect on a cell line, cell ity is measured by ining in a cell
the uptake of a dye such as neutral red, trypan blue, or ALAMAR™ blue (see, e.g., Page et
al., 1993, Intl. J. of Oncology 3:473-476). In such an assay, the cells are ted in media
containing the dye, the cells are washed, and the remaining dye, reflecting cellular uptake of
the dye, is measured spectrophotometrically. The protein-binding dye sulforhodamine B
(SRB) can also be used to measure cytotoxicity (Skehan et al., 1990, J. Nat’l Cancer Inst.
7-12). Preferred Ligand-Drug Conjugates include those with an IC50 value (defined as
the mAb concentration that gives 50% cell kill) of less than 1000 ng/ml, preferably less than
500 ng/ml, more preferably less than 100 ng/ml, even most ably less than 50 or even
less than 10 ng/ml on the cell line.
[0202] General procedures for linking a drug to a linker moiety to provide a Linker Drug
Compound and conjugating such nds to a ligand moiety to provide a Linker Drug
Conjugate are known in the art and can be used in ation with the methods described
herein. See, for example, U.S. Patent Nos. 8,163,888, 7,659,241, 7,498,298, U.S. Publication
No. 0256157 and International Application Nos. WO2011023883, and
WO2005112919.
Stretcher Unit (Z) or (Z'):
A Stretcher Unit (Z) is a component of an LDC or a Drug-Linker Compound or
other ediate that acts to connect the Ligand Unit to the Self-immolative Assembly
Unit. In that regard a Stretcher Unit, prior to attachment to a Ligand Unit (i.e. a Stretcher
Unit precursor, Z'), has a functional group that can form a bond with a onal group of a
targeting ligand. In aspects when there is branching within the Linker Unit, attachment to the
Self-immolative Assembly Unit is through a ing Unit, B (optionally through an
intervening Connector Unit, A). In aspects where it is desirable to provide more distance
between the Self-immolative Assembly Unit and the Stretcher Unit, attachment of the Self-
immolative Assembly Unit to B or Z, depending on the presence of absence of B, can be
through a Connector Unit (A).
In some s, a Stretcher Unit precursor (Z') has an electrophilic group that is
capable of interacting with a reactive nucleophillic group t on a Ligand Unit (e.g., an
antibody) to provide a covalent bond n a Ligand Unit and the Stretcher Unit of a
Linker Unit. Nucleophillic groups on an antibody having that capability include but are not
limited to, sulfhydryl, hydroxyl and amino functional groups. The heteroatom of the
nucleophillic group of an antibody is reactive to an electrophilic group on a Stretcher Unit
precursor and provides a covalent bond between the Ligand Unit and Stretcher Unit of a
Linker Unit or Drug-Linker moiety. Useful electrophilic groups for that purpose include, but
are not limited to, maleimide, haloacetamide groups, and NHS esters. The electrophilic group
provides a ient site for antibody attachment to form a LDC or Ligand-Linker
ediate.
In another embodiment, a Stretcher Unit precursor has a reactive site which has a
nucleophillic group that is reactive to an electrophilic group present on a Ligand Unit (e.g., an
antibody). Useful electrophilic groups on an antibody for that e include, but are not
limited to, aldehyde and ketone carbonyl groups. The heteroatom of a phillic group of
a Stretcher Unit precursor can react with an electrophilic group on an antibody and form a
covalent bond to the dy. Useful nucleophillic groups on a Stretcher Unit precursor for
that purpose include, but are not limited to, hydrazide, hydroxylamine, amino, hydrazine,
thiosemicarbazone, hydrazine carboxylate, and arylhydrazide. The electrophilic group on an
antibody provides a convenient site for antibody attachment to form a LDC or Ligand-Linker
intermediate.
In some embodiments, a sulfur atom of a Ligand Unit is bound to a succinimide ring
system of a Stretcher Unit formed by reaction of a thiol functional group of a targeting ligand
with a ide moiety of the corresponding Stretcher Unit precursor. In other
embodiments a thiol functional group of a Ligand Unit reacts with an alpha haloacetamide
moiety to provide a sulfur-bonded Stretcher Unit by nucleophillic displacement of its n
substituent.
Representative Stretcher Units of those embodiments include those within the
square ts of Formulas Xa and Xb:
wherein the wavy line indicates attachment to the Branching Unit (B) or Connector Unit (A)
if B is absent or Self-Immolative Assembly Unit (X), if A and B are absent and R17 is -C1-C10
alkylene-, C1-C10 heteroalkylene-, -C3-C8 carbocyclo-, -C8 alkyl)-, -arylene-, -C1-C10
alkylene-arylene-, -arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8
carbocyclo)-C1-C10 ne-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -
(C3-C8 heterocyclo)-C1-C10 alkylene-, -C1-C10 alkylene-C(=O)-, C1-C10 heteroalkylene-
C(=O)-, -C3-C8 carbocyclo-C(=O)-, -O-(C1-C8 alkyl)-C(=O)-, -arylene-C(=O)-, -C1-C10
alkylene-arylene-C(=O)-, -arylene-C1-C10 alkylene-C(=O)-, -C1-C10 alkylene-(C3-C8
carbocyclo)-C(=O)-,-(C3-C8 yclo)-C1-C10 alkylene-C(=O)-, -C3-C8 heterocyclo-C(=O)-
, -C1-C10 alkylene-(C3-C8 heterocyclo)-C(=O)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-C(=O)-,
-C1-C10 alkylene-NH-, C1-C10 alkylene-NH-, -C3-C8 carbocyclo-NH-, -O-(C1-C8 alkyl)-
NH-, -arylene-NH-, -C1-C10 alkylene-arylene-NH-, -arylene-C1-C10 alkylene-NH-, -C1-C10
alkylene-(C3-C8 carbocyclo)-NH-, -(C3-C8 carbocyclo)-C1-C10 alkylene-NH-, -C3-C8
heterocyclo-NH-, -C1-C10 alkylene-(C3-C8 heterocyclo)-NH-, -(C3-C8 cyclo)-C1-C10
alkylene-NH-, -C1-C10 alkylene-S-, C1-C10 alkylene-S -, -C3-C8 carbocyclo-S -, -O-
(C1-C8 -S -, -arylene-S-, 0 alkylene-arylene-S-, -arylene-C1-C10 alkylene-S-, -
C1-C10 alkylene-(C3-C8 carbocyclo)-S-, -(C3-C8 carbocyclo)-C1-C10 alkylene-S-, -C3-C8
heterocyclo-S-, -C1-C10 alkylene-(C3-C8 heterocyclo)-S-, or -(C3-C8 heterocyclo)-C1-C10
alkylene-S-.
In some aspects, the R17 group of formula Xa is optionally substituted by a Basic
Unit (BU) such as an aminoalkyl moiety, e.g. –(CH2 )xNH2, –(CH2 )xNHRa, and –(CH2 )xNRa
a is ndently selected from the group
2, wherein x is an integer of from 1-4 and each R
consisting of C1-6 alkyl and C1-6 haloalkyl, or two Ra groups are ed with the nitrogen
to which they are ed to form an azetidinyl, idinyl or piperidinyl group.
An illustrative Stretcher Unit is that of a Xa or Xb wherein R17 is -C1-C10
alkylene-C(=O)-, -C1-C10 heteroalkylene-C(=O)-, -C3-C8 carbocyclo-C(=O)-, -O-(C1-C8
alkyl)-C(=O)-, -arylene-C(=O)-, -C1-C10 alkylene-arylene-C(=O)-, -arylene-C1-C10 alkylene-
C(=O)-, -C1-C10 alkylene-(C3-C8 carbocyclo)-C(=O)-,-(C3-C8 carbocyclo)-C1-C10 alkylene-
C(=O)-, -C3-C8 heterocyclo-C(=O)-, -C1-C10 alkylene-(C3-C8 heterocyclo)-C(=O)-, or -(C3-C8
heterocyclo)-C1-C10 alkylene-C(=O)-.
[0210] Another illustrative Stretcher Unit is that of formula Xa wherein R17 is -C2-C5
alkylene-C(=O)-, wherein the alkylene is optionally substituted by a Basic Unit (BU) such as
an optionally substituted aminoalkyl, e.g., –(CH2 )xNH2, –(CH2 )xNHRop, and –(CH2)xN(Rop)2,
wherein x is an integer of from 1-4 and each Rop is independently selected from the group
consisting of C1-6 alkyl and C1-6 haloalkyl, or two Rop groups are combined with the nitrogen
to which they are ed to form an azetidinyl, pyrrolidinyl or piperidinyl group. During
synthesis, the basic amino functional group of the Basic Unit can be protected by a protecting
group.
ary embodiments of Stretcher Units bonded to a Ligand Unit are as follows:
wherein the wavy line adjacent the yl indicates attachment to B, A, or X of the
Self Immolative Assembly Unit in formula II, IIa, IIb, II', IIa' or IIb',
or to B, A or W of formula III (i), IIa(i), IIb(i), III (i)’, IIIa(i)’ or IIIb(i)’,
or to B, A or Y of formula III (ii), IIa(ii), IIb(ii), III (ii)', IIIa(ii)' or IIIb(ii)',
depending on the presence or absence of A and/or B.
In some preferred embodiments a Stretcher unit (Z) is comprised of a imide
, that when bonded to L is represented by the structure of a Xa’:
(Xa’)
wherein the wavy line adjacent to the carbonyl bonded to R17 indicates attachment to
B, A, or X of the Self Immolative Assembly Unit in formula II, IIa, IIb, II', IIa' or IIb',
or to B, A or W of formula III (i), IIa(i), IIb(i), III (i)’, IIIa(i)’ or IIIb(i)’,
or to B, A or Y of formula III (ii), IIa(ii), IIb(ii), III (ii)', IIIa(ii)' or IIIb(ii)',
depending on the presence or absence of A and/or B,
R17 is -C2-C5 alkylene-C(=O)-, wherein the alkylene is substituted by a Basic Unit
(BU), n BU is –(CH2 )xNH2, –(CH2 )xNHRop, or –(CH2 )xN(Rop)2, wherein x is an
integer of from 1-4 and each Ra is ndently selected from the group consisting of C1-6
alkyl and C1-6 haloalkyl, or both Rop together with the nitrogen to which they are attached
define an azetidinyl, pyrrolidinyl or piperidinyl group.
It will be understood that a Ligand-substituted succinimide may exist in hydrolyzed
form(s). Those forms are exemplified below for hydrolysis of Xa’ bonded to L, wherein the
structures representing the regioisomers from that hydrolysis are formula Xb’ and Xc’.
Accordingly, in other red embodiments a Stretcher unit (Z) is comprised of an acidamide
moiety that when bonded to L is ented by the following:
(Xb’)
(Xc’)
the wavy line adjacent to the carbonyl bonded to R17 is as defined for Xa’,
depending on the presence or absence of A and/or B; and
RZ is -C2-C5 alkylene-C(=O)-, wherein the ne is substituted by a Basic Unit
(BU),
wherein BU is –(CH2 )xNH2, –(CH2 )xNHRop, or –(CH2 )xN(Rop)2, wherein x is an
integer of from 1-4 and each Rop is independently selected from the group ting of C1-6
alkyl and C1-6 haloalkyl, or both Rop together with the nitrogen to which they are attached
define an azetidinyl, pyrrolidinyl or piperidinyl group.
In some embodiments a Stretcher unit (Z) is sed of an acid-amide moiety that
when bonded to L is represented by the structure of formula Xd' or Xe':
wherein the wavy line adjacent to the carbonyl is as defined for Xa’.
In red embodiments a Stretcher unit (Z) is comprised of a succinimide moiety
that when bonded to L is represented by the structure of
.
or is comprised of an acid-amide moiety that when bonded to L is represented by the
structure of:
or .
[0216] Illustrative Stretcher Units bonded to a Ligand Unit (L) and a Connector Unit (A)
have the following structures, which are comprised of the structure from Xa, Xa', Xb' or Xc',
n –RZ- or –RZ(BU)- is –CH2-, -CH2CH2- or –CH(CH2NH2)-:
,
wherein the wavy line adjacent to the carbonyl is as defined for Xa’.
Other Stretcher Units bonded to a Ligand Unit (L) and a tor Unit (A) have
the structures above wherein A in the above Z-A structures is replaced by a Connector Unit
having the structure of
wherein n ranges from 8 to 24; RPEG is a PEG Unit capping group, preferably–CH3 or –
CH2CH2CO2H, the asterisk (*) indicates covalent attachment to a Stretcher Unit
corresponding in ure to formula Xa, Xa', Xb' or Xc' and the wavy line indicates covalent
attachment to X of a Self-immolative Assembly Unit.
Illustrative Stretcher Units prior to conjugation to the Ligand Unit (i.e., her
Unit precursors) are comprised of a maleimide moiety and are represented by ures
including that of formula XIa:
(XIa)
wherein the wavy line adjacent to the carbonyl is as defined for Xa'; and
RZ is –(CH2)2, optionally substituted with a Basic Unit such as an optionally
substituted aminoalkyl, e.g., –(CH2 )xNH2, –(CH2 )xNHRop, and –(CH2 )xN(Rop) 2, wherein x
is an integer of from 1-4 and each Rop is independently selected from the group consisting of
C1-6 alkyl and C1-6 haloalkyl, or two Rop groups are combined with the nitrogen to which they
are attached to form an inyl, pyrrolidinyl or piperidinyl group.
In some preferred embodiments of formula XIa, a Stretcher Unit precursor (Z') is
ented by one of the ing structures:
wherein the wavy line adjacent to the carbonyl is as defined for Xa’.
[0220] In other preferred embodiments a Stretcher Unit precursor (Z') is comprised of a
maleimide moiety and is represented by the structure of formula XIa’:
(XIa’)
wherein the wavy line adjacent to the yl bonded to R17 is as defined for Xa’;
and
RZ is -C2-C5 alkylene-C(=O)-, n the alkylene is substituted by a Basic Unit
(BU), wherein BU is –(CH2 )xNH2, –(CH2 )xNHRop, or –(CH2 )xN(Rop)2, wherein x is an
integer of from 1-4 and each Rop is independently selected from the group consisting of C1-6
alkyl and C1-6 haloalkyl, or both Rop together with the nitrogen to which they are attached
define an azetidinyl, pyrrolidinyl or piperidinyl group.
In more red embodiments the Stretcher unit precursor (Z') is comprised of a
maleimide moiety and is represented by the structure of:
wherein the wavy line adjacent to the carbonyl is as defined for Xa'.
In Stretcher Units having a BU moiety, it will be understood that the amino
functional group of that moiety may be protected by an amino protecting group during
synthesis, e.g., an acid labile protecting group (e.g., BOC).
Illustrative Stretcher Unit precursors covalently attached to a Connector Unit which
are sed of the ure from XIa or XIa’ wherein –RZ- or –RZ(BU)- is –CH2-, -
CH2CH2- or –CH(CH2NH2)- have the ing structures:
wherein the wavy line adjacent to the carbonyl is as defined for Xa’.
Other Stretcher Unit precursors bonded a Connector Unit (A) have the have the
structures above wherein A in the above Z’-A structures is replaced by a Connector Unit
having the structure of
wherein n ranges from 8 to 24; RPEG is a PEG Unit g group, preferably–CH3 or –
CH2CH2CO2H, the asterisk (*) indicates covalent attachment to the Stretcher Unit precursor
corresponding in structure to formula XIa or XIa’ and the wavy line indicates covalent
attachment to X of a Self-immolative Assembly Unit.
In another embodiment, the her Unit is attached to the Ligand Unit via a
disulfide bond between a sulfur atom of the Ligand unit and a sulfur atom of the her
unit. A representative Stretcher Unit of this embodiment is depicted within the square
ts of Formula XIb:
(XIb)
wherein the wavy line indicates attachment to the Branching Unit (B), tor Unit (A), if
B is absent, or a self-immolative moiety (X) of a Self-Immolative Assembly Unit, if A and B
are absent as defined herein and R17 is -C1-C10 alkylene-, -C1-C10 heteroalkylene-, -C3-C8
carbocyclo-, -C8 alkyl)-, -arylene-, -C1-C10 alkylene-arylene-, -arylene-C1-C10
alkylene-, -C1-C10 alkylene-(C3-C8 yclo)-, -(C3-C8 carbocyclo)-C1-C10 alkylene-, -C3-
C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-C1-C10 alkylene,
-C1-C10 alkylene-C(=O)-, 0 heteroalkylene-C(=O)-, -C3-C8 carbocyclo-C(=O)-, -O-(C1-
C8 alkyl)-C(=O)-, -arylene-C(=O)-, -C1-C10 ne-arylene-C(=O)-, -arylene-C1-C10
alkylene-C(=O)-, -C1-C10 alkylene-(C3-C8 carbocyclo)-C(=O)-, -(C3-C8 yclo)-C1-C10
alkylene-C(=O)-, -C3-C8 heterocyclo-C(=O)-, -C1-C10 alkylene-(C3-C8 heterocyclo)-C(=O)-, -
(C3-C8 heterocyclo)-C1-C10 alkylene-C(=O)-, -C1-C10 alkylene-NH-, C1-C10 heteroalkylene-
NH-, -C3-C8 carbocyclo-NH-, -O-(C1-C8 alkyl)-NH-, -arylene-NH-, -C1-C10 alkylene-arylene-
NH-, -arylene-C1-C10 alkylene-NH-, -C1-C10 alkylene-(C3-C8 carbocyclo)-NH-, -(C3-C8
carbocyclo)-C1-C10 alkylene-NH-, -C3-C8 heterocyclo-NH-, -C1-C10 alkylene-(C3-C8
heterocyclo)-NH-, -(C3-C8 heterocyclo)-C1-C10 alkylene-NH-, -C1-C10 alkylene-S-, -C1-C10
heteroalkylene-S -, -C3-C8 carbocyclo-S -, -O-(C1-C8 alkyl)-S -, -arylene-S-, -C1-C10
ne-arylene-S-, -arylene-C1-C10 ne-S-, -C1-C10 alkylene-(C3-C8 carbocyclo)-S-, -
(C3-C8 carbocyclo)-C1-C10 alkylene-S-, -C3-C8 heterocyclo-S-, -C1-C10 alkylene-(C3-C8
heterocyclo)-S-, or -(C3-C8 heterocyclo)-C1-C10 alkylene-S-.
In yet another embodiment, the reactive group of a Stretcher Unit sor contains
a reactive site that can form a bond with a y or secondary amino group of a Ligand
Unit. Examples of these reactive sites include, but are not limited to, activated esters such as
succinimide esters, 4-nitrophenyl esters, luorophenyl esters, luorophenyl esters,
anhydrides, acid chlorides, sulfonyl chlorides, isocyanates and isothiocyanates.
Representative her Units of this embodiment are depicted within the square brackets of
Formulas XIIa, XIIb and XIIc:
L C(O)NH R17
(XIIa)
(XIIb)
L CNH R17
(XIIc)
wherein the wavy line indicates attachment to the Branching Unit (B), Connector Unit (A) or
a self-immolative moiety (X) of a Self-Immolative Assembly Unit and R17 is -C1-C10
ne-, -C1-C10 heteroalkylene-, -C3-C8 carbocyclo-, -O-(C1-C8 alkyl)-, -arylene-, -C1-C10
alkylene-arylene-, -arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8
carbocyclo)-C1-C10 alkylene-, -C3-C8 cyclo-, 0 ne-(C3-C8 heterocyclo)-, -
(C3-C8 heterocyclo)-C1-C10 alkylene-, -C1-C10 alkylene-C(=O)-, 0 heteroalkylene-
, -C3-C8 carbocyclo-C(=O)-, -O-(C1-C8 alkyl)-C(=O)-, -arylene-C(=O)-, -C1-C10
alkylene-arylene-C(=O)-, -arylene-C1-C10 alkylene-C(=O)-, -C1-C10 alkylene-(C3-C8
carbocyclo)-C(=O)-,-(C3-C8 carbocyclo)-C1-C10 alkylene-C(=O)-, -C3-C8 heterocyclo-C(=O)-
, -C1-C10 ne-(C3-C8 heterocyclo)-C(=O)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-C(=O)-,
-C1-C10 alkylene-NH-, C1-C10 heteroalkylene-NH-, -C3-C8 yclo-NH-, -O-(C1-C8 alkyl)-
NH-, ne-NH-, -C1-C10 alkylene-arylene-NH-, -arylene-C1-C10 alkylene-NH-, -C1-C10
alkylene-(C3-C8 yclo)-NH-, -(C3-C8 carbocyclo)-C1-C10 alkylene-NH-, -C3-C8
heterocyclo-NH-, -C1-C10 alkylene-(C3-C8 heterocyclo)-NH-, -(C3-C8 heterocyclo)-C1-C10
alkylene-NH-, -C1-C10 ne-S-, -C1-C10 heteroalkylene-S -, -C3-C8 carbocyclo-S -, -O-
(C1-C8 alkyl)-S -, -arylene-S-, -C1-C10 alkylene-arylene-S-, -arylene-C1-C10 alkylene-S-, -C1-
C10 alkylene-(C3-C8 carbocyclo)-S-, -(C3-C8 carbocyclo)-C1-C10 alkylene-S-, -C3-C8
heterocyclo-S-, -C1-C10 alkylene-(C3-C8 heterocyclo)-S-, or -(C3-C8 heterocyclo)-C1-C10
alkylene-S-.
In yet another aspect, the reactive group of the Stretcher Unit precursor contains a
reactive nucleophile that is capable of reacting with an electrophile present on, or introduced
to, a Ligand. For example, a ydrate moiety on a targeting ligand can be mildly
oxidized using a reagent such as sodium periodate and the resulting electrophilic functional
group (-CHO) of the oxidized ydrate can be condensed with a Stretcher Unit sor
that contains a reactive nucleophile such as a hydrazide, an oxime, a primary or secondary
amine, a hydrazine, a thiosemicarbazone, a hydrazine carboxylate, or an arylhydrazide such
as those described by Kaneko, T. et al. (1991) Bioconjugate Chem. 2:133-41. Representative
Stretcher Units of this embodiment are depicted within the square ts of Formulas
XIIIa, XIIIb, and XIIIc:
L N NH R17
(XIIIa)
L N O R17
(XIIIb)
(XIIIc)
wherein the wavy line indicates attachment to the Branching Unit or Self-Immolative
Assembly Unit, or Connector Unit as defined herein and R17 is 0 ne-, C1-C10
heteroalkylene-, -C3-C8 carbocyclo-, -C8 alkyl)-, -arylene-, -C1-C10 alkylene-arylene-, -
arylene-C1-C10 alkylene-, -C1-C10 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C10
alkylene-, -C3-C8 heterocyclo-, -C1-C10 alkylene-(C3-C8 heterocyclo)-, -(C3-C8 heterocyclo)-
C1-C10 alkylene-, -C1-C10 alkylene-C(=O)-, C1-C10 heteroalkylene-C(=O)-, -C3-C8
carbocyclo-C(=O)-, -O-(C1-C8 alkyl)-C(=O)-, ne-C(=O)-, -C1-C10 alkylene-arylene-
, -arylene-C1-C10 alkylene-C(=O)-, -C1-C10 alkylene-(C3-C8 yclo)-C(=O)-,-(C3-
C8 carbocyclo)-C1-C10 alkylene-C(=O)-, -C3-C8 heterocyclo-C(=O)-, -C1-C10 alkylene-(C3-C8
heterocyclo)-C(=O)-, -(C3-C8 heterocyclo)-C1-C10 alkylene-C(=O)-, -C1-C10 alkylene-NH-, -
C1-C10 heteroalkylene-NH-, -C3-C8 carbocyclo-NH-, -O-(C1-C8 alkyl)-NH-, -arylene-NH-, -
C1-C10 alkylene-arylene-NH-, -arylene-C1-C10 alkylene-NH-, -C1-C10 alkylene-(C3-C8
yclo)-NH-, -(C3-C8 carbocyclo)-C1-C10 alkylene-NH-, -C3-C8 cyclo-NH-, -C1-
C10 alkylene-(C3-C8 heterocyclo)-NH-, -(C3-C8 heterocyclo)-C1-C10 alkylene-NH-, -C1-C10
alkylene-S-, -C1-C10 heteroalkylene-S -, -C3-C8 carbocyclo-S -, -O-(C1-C8 alkyl)-S -, -
e-S-, -C1-C10 alkylene-arylene-S-, -arylene-C1-C10 alkylene-S-, -C1-C10 alkylene-(C3-C8
carbocyclo)-S-, -(C3-C8 carbocyclo)-C1-C10 alkylene-S-, -C3-C8 heterocyclo-S-, -C1-C10
alkylene-(C3-C8 heterocyclo)-S-, or 8 heterocyclo)-C1-C10 alkylene-S-.
In some aspects of the prevent invention the Stretcher Unit has a mass of no more
than about 1000 daltons, no more than about 500 daltons, no more than about 200 daltons,
from about 30, 50 or 100 daltons to about 1000 daltons, from about 30, 50 or 100 daltons to
about 500 daltons, or from about 30, 50 or 100 daltons to about 200 daltons.
Optional Branching Unit (B):
A Branching Unit (B) is included in Ligand-Drug Conjugates in instances where it
is desirable to have multiple Self-immolative Assembly Units in a Linker Unit, and thus have
multiple Drug Units for each inker moiety attached to the Ligand Unit of an LDC and,
ultimately, to se the number of Drug Units in an LDC beyond the number of ment
sites in its Ligand Unit. A Branching Unit provides a covalent bond between B and a
Stretcher Unit (Z) or precursor thereof (Z') and two, three or four Self-immolative (SI)
Assembly Units, optionally each via an independently selected intervening tor Unit,
A. The skilled artisan will appreciate that a Branching Unit is designed in such a way to
allow the required branching within the Linker Unit. For example, in order to act as a
Branching Unit for two Drug Units (i.e., t is 2), the Branching Unit has at least a first, second
and third ment site within the conjugate (i.e., a first attachment site to Z, and a second
and third attachment site for attachment to each A or X, depending on the presence or
absence of each A. In other words, the Branching Unit must be at least trifunctional.
Contemplated in the t invention are those LDCs and inker Compounds
wherein the subscript t is 3 or 4. In such aspects, the Branching Unit will have four or five
sites of covalent attachment within the conjugate. In some aspects, the Branching Unit is
comprised of one or more (e.g., 1 to 10, preferably from 1 to 5, e.g., 1, 2, 3, 4, or 5) natural or
non-natural amino acid, amino alcohol, amino aldehyde, or polyamine residues or
combinations thereof that collectively provide the required functionality for branching. In
some embodiment the Branching Unit is comprised of a tri-functional residue and may have
flanking residues that are bi-functional to provide the first and second ment sites. In
embodiments having branching to accommodate 3 or 4 Drug Units in a single Linker Unit,
the Branching Units is typically comprised of 2 or 3 tri-functional branching residues, and
may be further comprised of flanking and/or intervening residues that are bi-functional.
It will be iated that when referring to natural or non-natural amino acids,
amino alcohols, amino aldehydes, or polyamines as t in a Ligand Drug Conjugate or
ediates thereof such as a Drug Linker Compound (whether it be part of a Branching
Unit or other component of a LDC or Drug-Linker Intermediate thereof), the amino acid,
amino alcohol, amino aldehyde, or polyamines will exist in residual form. For example, in
embodiments, wherein the Branching Unit is two amino acids, the two amino acids will exist
as residues with a peptide bond n them.
In embodiments where the Branching Unit is comprised of an amino alcohol, the
amino alcohol will exist as a residue where, for example, its amino group is bonded to
another residue of the Branching Unit or another component of the LDC or Drug-Linker
Intermediate thereof through a carbonyl-containing onal group of that other
residue/component while its hydroxyl group is bonded as an ether to, or is bonded through a
yl-containing functional group, of yet r residue of the Branching Unit or another
component of the LDC or Drug-Linker Intermediate thereof.
[0233] In embodiments where the Branching Unit is comprised of an amino aldehyde, the
amino aldehyde will exist as a residue where, for example, its amino group is bonded to
another residue of the Branching Unit or another component of the LDC or Intermediate
thereof through a carbonyl-containing functional group of that other residue/component while
its aldehyde functional group is converted to an imino functional group or through its
subsequent reduction to provide a nitrogen-carbon bond when bonded to an amino group of
yet another residue of the Branching Unit or r component of the Conjugate. An amino
aldehyde may be derived from a natural or unnatural amino acid by partial reduction of its
carboxylic acid functional group to an aldehyde (i.e., -CHO) functional group.
To have a third functional group to serve as a tri-functional branching residue in a
Branching Unit, an amino acid or other amine-containing acid residue within Branching Unit
can have or can be substituted with a functionalized side chain to provide the ite three
points of attachment required for such a branching residue. For e, serine has three
functional groups, i.e., acid, amino and hydroxyl onal groups and may be viewed as a
combined amino acid and amino l residue for es of acting as a Branching Unit.
Tyrosine also contains a hydroxyl group, in this instance in its phenolic side chain, and may
also be view similarly to serine for purposes of its incorporation as a trifunctional branching
residue into a Branching Unit.
In another example, when the ctional branching residue of a Branching Unit is
cysteine, its amino and carboxylic acid group will exist in al form in a manner
previously discussed for amino acids or amine-containing acids to e two of the three
requisite points of attachment for a branching residue while its thiol group will exist in
residual form when bonded to a –X-D or -A-X-D moiety of a Linker Unit as a disulfide or in
a sulfur-carbon bond as, for example, when the cysteine thiol functional group reacts with a
ide-containing moiety of a Connector Unit precursor. In some ces, the residual
thiol group is in its oxidized form (i.e., –S(=O)- or –S(=O)2-) when bonded to another residue
of the Branching Unit or to another component of the Linker Unit. In yet another example,
the alpha amino and ylic acid group of a lysine will exist in residual form to provide
two of the three requisite points of ment required of a branching residue of a Branching
Unit while it n amino group in its residual form provides the third point of attachment.
Histidine may also be viewed as an amino acid with two amino groups, where the second
amino group is the NH of the ole-containing side chain.
[0236] In another example, when the ctional branching residue of a Branching Unit is
aspartic or glutamic acid, the alpha amino and C-terminal carboxylic acid groups of the
amino acid in their residual forms provide two of the three requisite points of attachment
required for a branching residue of a Branching Unit, while its beta or gamma carboxylic acid
group in its residual form provides the third point of attachment. In those ces when a
naturally occurring amino acid is a e of a Branching Unit, but does not naturally
contain a functionalized amino acid side chain, yet is required to be a trifunctional branching
residue within the Branching Unit, it is understood that the amino acid structure is modified
to have an onal functional group s its amino and carboxylic acid functional
groups when in residual form in order to provide the requisite third point of attachment. For
example, an amino acid having an aliphatic side chain may be substituted at a carbon of that
side chain with a hydroxyl, amino, aldehyde, thiol, carboxylic acid group or other functional
group or other moiety (e.g., an aryl or arylalkyl) substituted with any one of these functional
groups to provide an unnatural amino acid having the requisite three points of attachment.
Such unnatural amino acids are orated into a Branching Unit as described above for
amino acids and al forms of the introduced functional groups.
Similarly, when an amino aldehyde or amino alcohol is incorporated into a
Branching Unit as a trifunctional branching residue that amino aldehyde or amino alcohol
will have a third functional group to provide, along with its amino and aldehyde functional
groups, the requisite three points of attachment. In those instances, an amino aldehyde or
amino alcohol may correspond in structure to a natural amino acid that has a functionalized
side chain or an unnatural amino acid having an onal group that was introduced into the
side chain of a natural amino acid as described above in which a carboxylic acid of the
natural or unnatural amino acid is reduced to a hydroxyl or aldehyde functional group.
An amino acid orated into a ing Unit as a trifunctional ing
residue can be an alpha, beta, or gamma amino acid or other amine-containing acid
compound and can be in its D or L isomer if it contains a chiral carbon to which is bonded a
natural or unnatural amino acid side chain. When the Branching Unit is made up of more
than one natural or non-natural amino acid, amino alcohol, amino aldehyde, or polyamine
residues, the amino acids, amino alcohols, amino aldehydes, polyamine residues or
combinations thereof, wherein at least one of those residues is a trifunctional branching
residue, these residues are linked together via covalent bonds to form the Branching Unit.
The amino acid, amino alcohol, or amino aldehyde can be non-natural and can be
modified to have a functionalized side chain for attachment to components of the Conjugates
or Intermediate Compounds (as described above for a branching residue of a Branching
Unit), as the case may be. Exemplary functionalized amino acids, amino alcohols, or amino
des include, for example, azido or alkyne functionalized amino acids, amino alcohols,
or amino aldehydes (e.g., amino acid, amino alcohol, or amino aldehyde modified to have an
azide group or alkyne group for attachment using click chemistry). Methods for the
ndent activation and reaction of the functional groups t on an amino acid – e.g.,
the amine portion, the carboxylic acid portion and the side chain n (whether, for
example, an amino moiety, a hydroxyl group, another carboxylic acid, thiol, azide or alkyne)
are well known in the art.
[0240] A Branching Unit can comprise 1 or more (typically from 1 to 5 or 1 to 4 or 1 to 3
or 1 or 2) amino acids, optionally substituted C1-20 heteroalkylenes (preferably optionally
substituted C1-12 heteroalkylene), optionally substituted C3-8 heterocyclos, optionally
substituted C6-14 arylenes, optionally substituted C3-C8 carbocyclos, or combinations thereof.
In some embodiments, the Branching Unit comprises no more than 2 or no more than one
optionally substituted C1-20 heteroalkylene, optionally substituted C3-8 heterocyclo, ally
tuted C6-14 arylene, or ally substituted C3-C8 carbocyclo. Optional substituents
include (=O), -X, -R, -OR, -SR, -NR2, -NR3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=O, -
NCS, -NO, -NO2, =N2, -N3, O)R, -C(=O)R, -C(=O)NR2, -SO3-, -SO3H, -S(=O)2R, -
OS(=O)2OR, -S(=O)2NR, R, -OP(=O)(OR)2, - P(=O)(OR)2, -PO=3, , -AsO2H2,
-C(=O)R, -C(=O)X, - C(=S)R, -CO2R, -CO2-, -C(=S)OR, -C(=O)SR, -C(=S)SR, -C(=O)NR2,
-C(=S)NR2, or -C(=NR)NR2, where each X is independently a halogen: -F, -Cl, -Br, or -I;
and each R is independently hydrogen, or -C1 C20 alkyl, -C6 C20 aryl, or -C3 C14 heterocycle,
optionally substituted, or a protecting group or a prodrug moiety. Preferred optional
substituents are (=O), -X, -R, -OR, - SR, and -NR2. It will be understood that such moities
acting a branching residue will be tuted with functionality to provide the requisite sites
of attachment.
A Branching Unit or branching residue of a Branching Unit can be a straight chain
or branched chain and can be represented by Formula A:
Formula A
wherein
AA1 is a subunit of a ing Unit independently selected from an amino acid,
optionally substituted C1-20 alkylene (preferably optionally substituted C1-12
heteroalkylene), optionally substituted C3-8 heterocyclo, optionally substituted C6-14 arylene,
or optionally substituted C3-C8 carbocyclo;
and the ipt u is independently ed from 0 to 4; and the wavy line
indicates covalent attachment sites within the Ligand-Drug Conjugate or a Drug-Linker
Intermediate thereof. The optionally substituted heteroalkylene, heterocycle, arylene or
carbocyclo will have functional groups for attachments n the ts of the
ing Unit and within a Ligand-Drug Conjugate or Drug-Linker Intermediate thereof
having that Branching Unit.
In some embodiments at least one instance of AA1 is an amino acid. The subscript
u can be 0, 1, 2, 3, or 4. In some embodiments, AA1 is an amino acid and u is 0. In some
embodiments, a Branching Unit is sed of no more than 2 optionally substituted C1-20
heteroalkylenes, optionally substituted C3-8 heterocyclos, optionally substituted C6-14 arylenes,
or optionally substituted C3-C8 carbocyclos. In some aspects, wherein the Branching Unit
has formula A, the Branching Unit comprises no more than 1 optionally substituted C1-20
heteroalkylene, optionally substituted C3-8 heterocyclo, optionally substituted C6-14 arylene, or
optionally substituted C3-C8 carbocyclo.
A ing Unit or an amino acid subunit thereof can be an alpha, beta, or gamma
amino acid and can be natural or non-natural. The amino acid can be a D or L isomer.
Attachment within the Branching Unit or with the other components of the LDC or Drug-
Linker Intermediate thereof can be, for e, via amino, carboxyl, or other functional
groups. Methods for the independent activation and reaction of the functional groups are
well known in the art.
A Branching Unit or an amino acid subunit thereof can be independently selected
from the D or L isomer of a thiol-containing amino acid. The thiol-containing amino acid
can be, for example, cysteine, homocysteine, or penicillamine.
A Branching or an amino acid subunit thereof can be independently selected from
the group consisting of the L- or D-isomers of the following amino acids: e (including
β-alanine), arginine, aspartic acid, asparagine, cysteine, histidine, glycine, glutamic acid,
ine phenylalanine, lysine, leucine, methionine, serine, tyrosine, threonine, tryptophan,
proline, ine, penicillamine, B-alanine, aminoalkynoic acid, aminoalkanedioic acid,
heterocyclo-carboxylic acid, citrulline, statine, diaminoalkanoic acid, and derivatives thereof.
Preferred amino acids include cysteine, homocysteine, penicillamine, ornithine,
lysine, serine, threonine, glutamine, alanine, aspartic acid, ic acid, cysteine,
proline, glycine, isoleucine, leucine, methionine, valine, and alanine.
[0247] In some embodiments wherein the Branching Unit is capable of ting two
Self-immolative ly Units to a Stretcher Unit (each optionally via an independently
selected tor Unit, A), the ing Unit, once assembled, has the formula denoted
below:
wherein the wavy line indicates the attachment sites to components of the Linker Unit, i.e., to
the Stretcher Unit Z or its precursor Z' and to Self-immolative Assembly Unit(s) or the
intervening Connector ), and wherein R110 is
wherein the asterisk indicates attachment to the carbon labeled x and the wavy line
indicates one of the attachment sites;
each R100 is independently selected from hydrogen or -C1-C3 alkyl, preferably
hydrogen or CH3;
Y is independently selected from N or CH;
each Y' is independently selected from NH, O, or S; and
the ipt c is an integer independently selected from 1 to 10, preferably 1 to 3.
An exemplary Branching Unit or trifunctional ing residue in a Branching
Unit is lysine as shown below wherein the wavy line and asterisks indicate covalent linkage
within a the Linker Unit of a LDC or Drug-Linker intermediate thereof:
In some aspects of the prevent invention the Branching unit has a mass of no more
than about 1000 daltons, no more than about 500 daltons, no more than about 200 daltons,
from about 10, 50 or 100 s to about 1000 daltons, from about 10, 50 or 100 daltons to
about 500 daltons, or from about 10, 50 or 100 daltons to about 200 s.
Connector Unit (A)
A tor Unit, A, is ed in a Ligand-Drug Conjugate or Drug-Linker
Compound in instances where it is desirable to add additional distance between the Stretcher
Unit (Z) or precursor thereof (Z') and a self-immolative moiety (X) of a Self-immolative
ly Unit. In some aspects, the extra distance will aid with activation within X.
ingly, the Connector Unit (A), when present, extends the framework of the Linker
Unit. In that regard, a Connector Unit (A) is covalently bonded with the optional Branching
Unit or Stretcher Unit (or its sor) when B is absent at one us and is covalently
bonded to the self-immolative moiety (X) of a Self-Immolative Assembly Unit at its other
terminus. In one group of embodiments the self-immolative moiety (X) is comprised of a
self-immolative Spacer Unit (Y) and Activation Unit (W) so that A is bonded to Y. In another
group of embodiments the self-immolative moiety is comprised of a self-immolative Spacer
Unit (Y) and Activation Unit (W) so that A is bonded to W.
The skilled artisan will appreciate that the tor Unit can be any group that
serves to provide for attachment of the Self-immolative Unit to the remainder of Linker Unit.
The Connector Unit can be, for example, comprised of one or more (e.g., 1-10, preferably, 1,
2, 3, or 4) natural or non-natural amino acid, amino alcohol, amino aldehyde, diamino
residues. In some aspects, the Connector Unit is a single natural or non-natural amino acid,
amino alcohol, amino aldehyde, or diamino residue. An exemplary amino acid capable of
acting as Connector units is ine.
In some s, the Connector Unit has the formula denoted below:
n the wavy lines indicate attachment of the Connector Unit within the Ligand
Drug Conjugate or Drug-Linker Intermediate thereof;
n R111 is independently selected from the group consisting of en, phydroxybenzyl
, methyl, isopropyl, isobutyl, sec-butyl, -CH2OH, -CH(OH)CH3, -
CH2CH2SCH3, -CH2CONH2, -CH2COOH, -CH2CH2CONH2, -CH2CH2COOH, -
(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, -
(CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -
(CH2)3NHCONH2, -(CH2)4NHCONH2, 2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-
pyridylmethyl-, 4-pyridylmethyl-,
,
wherein the wavy line tes covalent attachment to the remainder of the
tor Unit;
each R100 is independently selected from en or -C1-C3 alkyl, preferably
hydrogen or CH3; and
c is independently selected integer ranging from 1 to 10, preferably 1 to 3.
A representative Connector Unit having a yl group for attachment to the
Activation Unit (W) or self-immolative Spacer Unit (Y) of a Self-immolative Assembly
Unit’s self-immolative moiety (X) is as follows:
wherein in each instance R13 is independently selected from the group consisting of -C1-C6
alkylene-, -C3-C8carbocyclo-, -arylene-, -C1-C10 heteroalkylene-, -C3-C8heterocyclo-, -C1-
C10alkylene-arylene-, -arylene-C1-C10alkylene-, -C1-C10alkylene-(C3-C8carbocyclo)-, -(C3-
ocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-, and -(C3-C8
heterocyclo)-C1-C10 alkylene-, and the subscript c is an integer ranging from 1 to 4. In some
embodiments R13 is -C1-C6 alkylene and c is 1.
A representative Connector Unit having a carbonyl group for attachment to the to
the Activation Unit (W) or Spacer Unit (Y) of a Self-immolative Assembly Unit’s selfimmolative
moiety (X) is as follows:
wherein R13 is -C1-C6 alkylene-, -C3-C8carbocyclo-, ne-, 0 heteroalkylene-, -C3-
C8heterocyclo-, -C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, -C1-C10alkylene-(C3-
C8carbocyclo)-, 8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-,
or -(C3-C8 heterocyclo)-C1-C10 ne-. In some embodiments R13 is -C1-C6 alkylene.
A representative Connector Unit having a NH moiety that es to the Activation
Unit (W) or Spacer Unit (Y) of a Self-immolative Assembly Unit’s self-immolative moiety
(X) is as follows:
wherein in each instance, R13 is independently selected from the group consisting of -C1-C6
alkylene-, -C3-C8carbocyclo-, -arylene-, -C1-C10 heteroalkylene-, -C3-C8heterocyclo-, -C1-
C10alkylene-arylene-, ne-C1-C10alkylene-, -C1-C10alkylene-(C3-C8carbocyclo)-, -(C3-
C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-, and -(C3-C8
heterocyclo)-C1-C10 alkylene-, and the subscript c is from 1 to 14. In some embodiments R13
is -C1-C6 alkylene and the subscript c is 1.
A representative Connector Unit having a NH moiety that attaches to the Activation
Unit (W) or Spacer Unit (Y) of a Self-immolative Assembly Unit’s self-immolative moiety
(X) is as follows:
wherein R13 is -C1-C6 alkylene-, carbocyclo-, -arylene-, -C1-C10 heteroalkylene-, -C3-
C8heterocyclo-, -C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, 0alkylene-(C3-
C8carbocyclo)-, -(C3-C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-,
or -(C3-C8 heterocyclo)-C1-C10 ne- or –C(=O)C1-C6 alkylene- or -C1-C6 ne-
C(=O)-C1-C6 ne.
ed embodiments of Connector Units include those having the following
structure
or
wherein the wavy line adjacent to the nitrogen indicates covalent attachment a Stretcher Unit
(Z) (or its precursor Z'), either directly or indirectly via B, and the wavy line adjacent to the
carbonyl indicates covalent attachment to Activation Unit (W) or Spacer Unit (Y) of a Selfimmolative
Assembly Unit’s self-immolative moiety (X), or the wavy line adjacent to the
carbonyl indicates covalent attachment to a Stretcher Unit (Z) (or its precursor Z'), either
directly or indirectly via B, and the wavy line adjacent to the nitrogen indicates covalent
attachment to Activation Unit (W) or Spacer Unit (Y) of a Self-immolative ly Unit’s
self-immolative moiety (X); and m is an integer ranging from 1 to 6, preferably 2 to 6, more
preferably 2 to 4.
Self-immolative Assembly Unit
The Self-Immolative Assembly Unit links the Drug Unit to the remainder of the
Conjugate or it’s Drug-Linker ediate. The main function of Self-immolative
Assembly Unit is to conditionally release free drug at the site ed by the Ligand Unit. In
that vein, the Self-immolative Assembly Unit comprises an activateable self-immolative
moiety (X) and a methylene carbamate linker. The activateable self-immolative moiety
comprises an Activation Unit (W) and a self-immolative Spacer Unit (Y). The selfimmolative
Spacer Unit may be a single unit or can comprise two or more self-immolative
subunits. Activation of W to induce mmolation of Y is via cleavage at that Activation
Unit and typically occurs at the bond between W and Y . Cleavage can be enzymatic (e.g.,
tumor associated protease or glycosidase such as glucuronidase) or via a disulfide reduction
(e.g., disulfide cleavage (e.g., by glutathione-SH)). Upon cleavage, a self-immolative
reaction sequence is initiated that leads to release of free drug. In one group of
embodiments, the mmolative Assembly Unit can be attached to the remainder of a
Ligand Drug ate’s Ligand Unit via the Activation Unit. In another group of
embodiments, the self-immolative Assembly Unit can be attached to the remainder of a
Ligand Drug ate’s Linker Unit via or the self-immolative Spacer Unit.
In certain embodiments a Self immolative Assembly Unit linked to a Drug Unit is
represented by formula ) or SIIa(ii):
wherein
W is an Activation Unit;
Y is a self-immolative Spacer Unit;
D is a Drug Unit enting drug having a functional group prior to incorporation
into the indicated methylene alkoxy carbamate unit;
T* is an optionally substituted heteroatom from said functional group that becomes
incorporated into the indicated methylene carbamate unit;
R, R1, and R2 are as previously defined herein; and
the wavy line indicates the point of attachment to the remainder of the LDC or Drug-
Linker Compound, wherein the Self-immolative Assembly Unit releases free drug following
activation of the Activation Unit.
As indicated herein, activation of the Activation Unit is via ge of that unit,
wherein ge is enzymatic (e.g., via tumor associated protease or glycosidase e.g.,
glucuronidase (e.g., beta-glucuronidase)) or via a disulfide reduction reaction (e.g., ide
cleavage by glutathione-SH).
In some aspects of the prevent invention, a Self-immolative Assembly Unit has a
mass of no more than about 5000 s, no more than about 4000 daltons, no more than
about 3000 daltons, no more than about 2000 daltons, no more than about 1000 daltons, no
more than about 800 s, or no more than about 500 daltons. In some aspects, a Selfimmolative
Assembly Unit has a mass of from about 100 daltons, or from about 200 daltons,
or from about 300 daltons to about 5000 daltons, from about 100 daltons, or from about 200
daltons, or from about 300 daltons to about 4000 daltons, from about 100 s, or from
about 200 daltons, or from about 300 daltons to about 3000 daltons, from about 100 daltons,
or from about 200 daltons, or from about 300 daltons to about 2000 daltons, from about 100
daltons, or from about 200 daltons, or from about 300 daltons to about 1000 daltons, from
about 100 daltons, or from about 200 daltons, or from about 300 daltons to about 800 daltons,
or from about 100 daltons, or from about 200 daltons, or from about 300 daltons to about 500
daltons.
One of skill in the art will understand that the components of Drug-Linker
Compounds can be linked in the same manner as Ligand-Drug ates wherein in
comparison to the corresponding LDC the Ligand Unit is absent and the Stretcher Unit (Z)
when present is replaced by its corresponding Stretcher Unit precursor (Z').
Activation Unit (W)
W is an activation unit and may be referred to as a “trigger” or “activateable”
trigger (i.e., e of activation); that when activated initiates a self-immolative reaction
sequence in a Spacer Unit (as a single unit or having 2 or more mmolative subunits). In
some s, the Activation Unit is an organic moiety attached via a cleavable bond to the
self immolative Spacer Unit. Accordingly, in such embodiments, the structure and/or
sequence of W is selected such that a cleavable bond is formed with the self-immolative
Spacer Unit. In the s embodiments discussed herein, the nature of W can vary. For
example, W can be designed such that the cleavable bond is cleaved by the action of s
present at the target site or via a reduction event in the case of a ide bond. Cleavable
bonds include, for example, disulfide bonds, amide bonds, and glycosidic bonds.
In some embodiments, the Activation Unit will comprise one amino acid or one or
more contiguous or non-contiguous sequences of amino acids (e.g., so that W has 1 to no
more than 12 amino . The Activation Unit can comprise or consist of, for example, a
monopeptide, a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide,
octapeptide, nonapeptide, decapeptide, undecapeptide or dodecapeptide unit. In some
aspects, in the presence of an enzyme (e.g., a associated protease), an amide e
between the Activation Unit (W) and the self-immolative Spacer Unit (Y) is cleaved, which
ultimately leads to e of free drug due to self-immolation of Y.
Each amino acid can be natural or unnatural and/or a D- or L-isomer provided of
course that there is a cleavable bond formed that upon cleavage initiates self-immolation in
Y. In some embodiments, the Activation Unit will comprise only natural amino acids. In
some aspects, the Activation Unit will have from 1 to no more than 12 amino acids in
contiguous sequence.
In some embodiments, each amino acid is independently selected from the group
consisting of alanine, arginine, aspartic acid, asparagine, histidine, glycine, glutamic acid,
glutamine, phenylalanine, lysine, leucine, serine, tyrosine, threonine, isoleucine, proline,
tryptophan, valine, cysteine, methionine, cysteine, ornithine, penicillamine, β-alanine,
aminoalkanoic acid, aminoalkynoic acid, aminoalkanedioic acid, aminobenzoic acid, aminoheterocyclo-alkanoic
acid, heterocyclo-carboxylic acid, citrulline, statine, diaminoalkanoic
acid, and tives thereof. In some embodiments, each amino acid is independently
selected from the group consisting of alanine, arginine, aspartic acid, gine, histidine,
e, glutamic acid, glutamine, phenylalanine, , leucine, serine, tyrosine, threonine,
isoleucine, proline, tryptophan, valine, cysteine, methionine, and selenocysteine. In some
embodiments, each amino acid is independently selected from the group consisting of
alanine, arginine, ic acid, asparagine, histidine, glycine, glutamic acid, glutamine,
phenylalanine, , leucine, serine, tyrosine, ine, isoleucine, e, tryptophan, and
valine. In some embodiments, each amino acid is selected from the proteinogenic or the nonproteinogenic
amino acids.
In another embodiment, each amino acid is independently selected from the group
consisting of the following L-(natural) amino acids: alanine, arginine, aspartic acid,
asparagine, histidine, glycine, glutamic acid, glutamine, phenylalanine, lysine, leucine, serine,
tyrosine, threonine, cine, tryptophan and .
In another embodiment, each amino acid is independently ed from the group
consisting of the following D-isomers of these l amino acids: alanine, arginine, aspartic
acid, asparagine, histidine, glycine, glutamic acid, glutamine, phenylalanine, lysine, e,
serine, tyrosine, threonine, isoleucine, phan and valine.
In certain embodiments, the Activation Unit is comprised only of natural amino
acids. In other embodiments, the Activation Unit is comprised only of non-natural amino
acids. In some embodiments, the Activation Unit is comprised of a natural amino acid
ed to a non-natural amino acid. In some embodiments, the Activation Unit is
comprised of a natural amino acid attached to a er of a natural amino acid.
Exemplary Activation Units include dipeptides with -Val-Cit-, ys- or –Val-
[0271] Useful tion Units can be designed and optimized in their selectivity for
enzymatic cleavage by a particular enzyme, for example, a associated protease. In
some embodiments, cleavage of a linkage r through an intervening functional group or a
bond) between the Activation Unit and the self-immolative Spacer Unit to initiate selfimmolation
in the self-immolative Spacer Unit is catalyzed by cathepsin B, C or D, or a
plasmin protease.
In some embodiments, the Activation Unit will be represented by -(–AA-)1, or (–
AA-AA-)1-6 wherein AA is at each occurrence ndently selected from natural or nonnatural
amino acids. In one aspect, AA is at each occurrence independently selected from
natural amino acids.
[0273] In some embodiments, the Activation Unit has the formula denoted below in the
square brackets, the wavy line adjacent to the carbonyl is attached to the self-immolative
Spacer Unit and the other wavy line is attached to a Stretcher Unit (Z) (or its precursor Z'),
directly or indirectly through an ening Connector Unit (A), and/or Branching unit (B),
and the subscript w is an integer ranging from 1 to 12:
wherein R19 is, in each instance, independently selected from the group consisting of
hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, -
CH3, -CH2CH2SCH3, NH2, -CH2COOH, -CH2CH2CONH2, -
CH2CH2COOH, 3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO,
-(CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -
(CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-
pyridylmethyl-, 4-pyridylmethyl-, phenyl, cyclohexyl,
Illustrative Activation Units are represented by as (XV), (XVI) and (XVII)
wherein R20 and R21 are as follows:
R20 R21
benzyl (CH2)4NH2;
methyl (CH2)4NH2;
isopropyl (CH2)4NH2;
isopropyl (CH2)3NHCONH2;
benzyl (CH2)3NHCONH2;
isobutyl (CH2)3NHCONH2;
sec-butyl (CH2)3NHCONH2;
NHCONH2;
benzyl methyl; and
benzyl (CH2)3NHC(=NH)NH2;
(XVI)
wherein R20, R21 and R22 are as follows:
R20 R21 R22
benzyl benzyl (CH2)4NH2;
isopropyl benzyl (CH2)4NH2; and
H benzyl (CH2)4NH2;
(XVII)
wherein R20, R21, R22 and R23 are as follows:
R20 R21 R22 R23
H benzyl isobutyl H; and
methyl isobutyl methyl isobutyl.
[0275] In some such aspects the mmolative moiety X is and is
represented by structure of formula XVIII:
(XVIII)
wherein the wavy line indicates nt attachment to the Stretcher Unit Z (or its precursor
Z'), either directly or ctly through the Connector Unit (A) or Branching Unit (B) or A
and B, and the hash mark (#) indicates covalent ment of the benzylic carbon to the
methylene carbamate unit.
In other aspects, self-immolation is activated from cleavage by a glycosidase of a
glycoside unit. The glycoside unit is another example of a self-immolative moiety (X) in
which X has the structure of –Y(W)- shown below
, wherein one wavy line indicates nt attachment to the Stretcher Unit Z (or
its precursor Z'), either directly or indirectly through the Connector Unit (A) or ing
Unit (B) or A and B), and the other wavy line indicates covalent attachment to the remainder
of the Self-immolative Assembly Unit (i.e., a methylene carbamate unit or MAC Unit).
A glycoside unit typically comprises a sugar moiety (Su) linked via an oxygen
glycosidic bond to a self-immolative spacer, Y, having the structure represented by –Y(W)-.
Cleavage of the oxygen glycosidic bond initiates the self-immolation reaction sequence that
result in release of free drug. In such ments, the sugar represents the Activation Unit
as it is attached to the self-immolative spacer via a cleavable bond and cleavage of that bond
initiates the self-immolation reaction sequence.
In some aspects, the activateable self-immolative moiety (X) represented by –Y(W)-
is activated from ge by β-glucuronidase of a Glucuronide unit, which is an ary
glycoside unit. The Glucuronide unit comprises an activation unit and a self-immolative
Spacer Unit. The Glucuronide unit comprises a sugar moiety (Su) linked via an oxygen
glycosidic bond to a self-immolative Spacer Unit. Cleavage of the oxygen idic bond
tes the self-immolation reaction sequence resulting in release of free drug. In such
embodiments, the sugar represents the Activation Unit as it is attached to the self-immolative
Spacer Unit via a cleavable bond and cleavage of that bond initiates the self-immolation
on sequence.
In some embodiments, a Glycoside Unit or Glucuronide Unit comprises a sugar
moiety (Su) linked via an oxygen ide bond (-O'-) to a self-immolative Spacer Unit (Y)
of the formula:
wherein the wavy lines indicate covalent attachment to the methylene carbamate unit and to
the Stretcher Unit (Z) or its precursor (Z'), either ly or indirectly through the Connector
Unit or Branching unit or Connector unit and Branching unit, as the case may be.
The oxygen glycosidic bond (-O'-) is lly a β-glucuronidase-cleavage site (i.e.,
Su is from glucuronide), such as a ide bond cleavable by human, lysosomal βglucuronidase.
The activateable self-immolative moiety X having the structure of that
is cleavable by a glycosidase to te the self-immolative reaction sequence can be
represented by formula XIXa or XIXb:
or ;
(XIXa) (XIXb)
wherein Su is a Sugar moiety, -O'- represents an oxygen glycosidic bond;
R1S, R2S and R3S independently are hydrogen, a halogen, -CN,-NO2, or other electron
withdrawing group, or an electron donating group; and
wherein the wavy line indicates attachment to a Stretcher Unit (Z) (or its precursor
(Z'), either directly or indirectly h a Connector Unit or Branching unit or Connector
unit and Branching unit);
and # indicates attachment to the methylene carbamate unit (either directly or
indirectly via an ening functional group or other ).
In preferred embodiments R1S, R2S and R3S are independently selected from hydrogen,
halogen, -CN, or - NO2. In other preferred embodiments, R1S, R2S and R3S are each hydrogen.
In other preferred embodiments R2S is an electron awing group, preferably NO2, and
R1S and R3S are each hydrogen.
[0283] In some such aspects the activateable self-immolative group capable of glycosidase
cleavage to initiate the self-immolative reaction sequence is represented by the formula
XIXc:
(XIXc)
wherein R4S is CH2OH or –CO2H, the wavy line indicates covalent attachment to a Stretcher
Unit (Z) (or its precursor Z'), either directly or indirectly h a Connector Unit or
Branching Unit or Connector unit and Branching unit, and the hash mark (#) indicates
covalent attachment to the methylene carbamate unit.
In some ments wherein the activateable self-immolative moiety is comprised
of a Glucuronide Unit, it is represented by the following formula XVId:
(XVId)
wherein the wavy line indicates covalent attachment to a Stretcher Unit (Z) (or its precursor
Z'), either directly or indirectly through a Connector Unit or Branching Unit or tor
unit and Branching unit and the hash mark (#) indicates covalent attachment of the benzylic
carbon of Y to the methylene carbamate unit.
[0285] Without being bound by theory, Scheme 1a depicts a mechanism of free drug e
from a Drug Unit attached to a methylene carbamate unit in an LDC having a self-immolative
moiety with the structure of –Y(W)- as in formula XVId, while Scheme 1b depicts an
analogous mechanism for free drug release from a LDC not having the benefit of an
intervening methylene carbamate unit.
Scheme 1a:
In some embodiments, the cleavage event that initiates a self-immolation reaction
sequence is cleavage of a disulfide bond. In some such aspects, a reducing agent (e.g.,
glutathione-SH) will act to cleave the disulfide bond y initiating the self-immolation
reaction sequence. Accordingly, in such embodiments, the Activation Unit is a chemical
moiety containing a sulfur atom that ipates in a cleavable disulfide bond n the
Activation Unit and the mmolative Spacer Unit.
Self-Immolative Spacer Unit (Y)
The self-immolative Spacer Unit is a chemical moiety that can undergo a self-
immolation reaction sequence (i.e., fragmentation) that results in release of free drug. They
are typically two types of self-immolative Spacer Units. The first can be referred to as an
onic cascade self-immolative Spacer Unit. The electronic cascade within such a self-
immolative Spacer Unit causes an elimination reaction as a consequence of shifting
conjugated electronic pairs. That rearrangement of electron pair is followed by spontaneous
decomposition of the methylene carbamate unit tely leading to e free drug from
the Drug Unit. Activation of the Activation Unit initiates the elimination reaction (e.g., 1,6-
or 1,4- elimination reaction) The second type of self-immolative Spacer Unit is a cyclization
self-immolative Spacer Unit. The cyclization self-immolative Spacer Unit acts by causing
spontaneous decomposition of a methylene carbamate unit following an intramolecular
cyclization reaction thereby leading to free drug release. Activation of the Activation Unit
initiates the cyclization reaction. ingly, the self-immolative Spacer Unit is a chemical
moiety that is capable of undergoing a fragmentation or cyclization reaction following
activation of the Activation Unit whereby the fragmentation or cyclization reaction s in
neous decomposition of the methylene carbamate unit and release of free drug.
In some aspects, a self-immolative Spacer Unit is a chemical moiety that is e
of covalently linking together three spatially distinct chemical es (e.g., an Activation
Unit (W), an methylene carbamate unit, and a Stretcher (Z) (or its precursor Z'), either
directly or ctly through a Connector Unit or Branching Unit, or Connector Unit and
Branching Unit. In other aspects, a Self-immolative Spacer Unit is a chemical moiety that is
capable of covalently linking together two spatially distinct chemical moieties (e.g., an
Activation Unit and a methylene carbamate unit) wherein attachment to a her Unit is
via the Activation Unit. In some such embodiments, an ary mmolative Spacer
Unit is a PAB group having the structure as shown below:
wherein the wavy line indicates covalent attachment to the Activation Unit and the hashtag
(#) tes covalent attachment of the benzylic carbon of the PAB group to the methylene
carbamate unit, Q is -C1-C8 alkyl, -O-(C1-C8 alkyl), or other electron donating group, -
halogen, -nitro or -cyano or other electron withdrawing group (preferably, Q is -C1-C8 alkyl, -
C8 alkyl), halogen, nitro or cyano); and m is an integer ranging from 0-4 (i.e., the
central arylene has no other substituents or 1-4 other substituents). In preferred embodiments
m is 0. In other preferred embodiments m is 1 or 2 and each Q is an independently selected
electron donating group.
Scheme 2 depicts a possible mechanism of Drug release of an exemplary PAB
group of a self-immolative Spacer Unit (Y) that is attached directly to -D via a methylene
carbamate unit, wherein the self-immolative moiety has the structure of –W-Y-.
Scheme 2
wherein Q is -C1-C8 alkyl or -O-(C1-C8 alkyl) or other electron donating group, or-halogen,
-nitro, –cyano or other electron awing group (Q is ably C1-C8 alkyl, -O-(C1-C8
alkyl), halogen, nitro, or cyano) ; and m is an integer ranging from 0-4; and R19,
independently selected, and aa are as defined for peptide-based Activation Units
Other examples of self-immolative Spacer Units e, but are not limited to,
aromatic compounds that are electronically similar to the PAB group such as 2-
midazolmethanol derivatives (see, e.g., Hay et al., 1999, Bioorg. Med. Chem. Lett.
9:2237) and ortho or para-aminobenzylacetals as well as five ring heterocycles and N-
heterocyclic quaternary ammonium salts. mmolative Spacer Units can also be used that
undergo cyclization upon amide bond hydrolysis, such as tuted and unsubstituted 4-
aminobutyric acid amides (see, e.g., Rodrigues et al., 1995, Chemistry Biology 2:223),
appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (see, e.g., Storm et
al., 1972, J. Amer. Chem. Soc. 94:5815) 2-aminophenylpropionic acid amides (see, e.g.,
Amsberry et al., 1990, J. Org. Chem. 55:5867), and trimethyl lock based spacers.
Elimination of amine-containing drugs that are substituted at the α-position of glycine (see,
e.g., Kingsbury et al., 1984, J. Med. Chem. 27:1447) are also examples of self-immolative
Spacer Units useful in exemplary Ligand Drug Conjugates as are thiophenols. ( see, e.g.
, P et al., 1990, J. Org. Chem. 55:2975).
Exemplary self-immolative Spacer Units further include, for example, a enyl,
whose sulfhydryl sulfur participates in a disulfide bond from which free drug is released as
shown below in Scheme 3:
Scheme 3
wherein the wavy line indicates the site of attachment to a Stretcher Unit (Z) (or its precursor
Z'), either directly or indirectly through a Connector Unit or Branching Unit or Connector
unit and Branching unit, and the asterisk (*) indicates the site of attachment of the benzylic
carbon of Y to the methylene carbamate unit.
Exemplary self-immolative Spacer Units r include, for example, a 5-ringed
heterocycle which es drug as shown below in Scheme 4.
Scheme 4:
wherein X is C, O, or S, W is an Activation Unit, the wavy line indicates the site of
attachment to a Stretcher Unit (Z) (or its sor Z'), either ly or indirectly through a
Connector Unit or ing Unit or tor unit and Branching unit, and the asterisk
indicates the site of attachment to the methylene carbamate unit.
In some aspects of the prevent invention the self-immolative Spacer Unit has a mass
of no more than about 1000 daltons, no more than about 500 daltons, no more than about 400
daltons, no more than about 300 daltons, or from about 10, 50 or 100 to about 1000 daltons,
from about 10, 50 or 100 to about 500 daltons, from about 10, 50 or 100 daltons to about 400
daltons, from about 10, 50 or 100 daltons to about 300 s or from about 10, 50 or 100
daltons to about 200 daltons.
The subscript ‘”p”
In one aspect of the invention, the subscript p represents the number of drug linker
moieties on a Ligand unit of an individual Ligand Drug Conjugate (LDC) and is an r
preferably g from 1 to 16, 1 to 12, 1 to 10, or 1 to 8. dual LDCs can be also be
referred to as a LDC compound. In any of the embodiments herein, there can be 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 drug linker moieties conjugated to a Ligand Unit of an
individual LDC. In another aspect of the invention, one group of ments describes a
tion of individual Ligand Drug Conjugates substantially identical except for the
number of drug linker moieties bound to each Ligand Unit (i.e., a LDC ition) so that p
represents the average number of inker moieties bound to the Ligand Units of the LDC
composition. In that group of embodiments, p is a number ranging from 1 to about 16, 1 to
about 12, 1 to about 10, or 1 to about 8, from 2 to about 16, 2 to about 12, 2 to about 10, or 2
to about 8. In some aspects, the p value refers to the average drug loading as well as the drug
loading of the predominate ADC in the composition.
In some aspects, conjugation will be via the interchain disulfides and there will from
1 to about 8 drug linker molecules conjugated to a ligand molecule. In some aspects,
conjugation will be via an introduced cysteine residue as well as interchain disulfides and
there will be from 1 to 10 or 1 to 12 or 1 to 14 or 1 to 16 drug linker molecules conjugated to
a ligand le. In some aspects, conjugation will be via an introduced cysteine residue
and there will be 2 or 4 drug linker molecules conjugated to a ligand molecule.
Ligand-Drug Conjugate Mixtures and Compositions
The present invention provides Ligand-Drug Conjugate mixtures and
pharmaceutical compositions comprising any of the Ligand-Drug Conjugates described
herein. The mixtures and pharmaceutical compositions comprise a plurality of ates.
In some aspects, each of the conjugates in the mixture or composition is identical or
substantially identical, however, the distribution of drug-linkers on the ligands in the mixture
or compositions may vary as well as the drug loading. For example, the conjugation
technology used to conjugate drug-linkers to antibodies as the targeting ligand can result in a
composition or e that is heterogeneous with t to the distribution of drug-linkers
on the dy Ligand Units within the mixture and/or composition and/or with respect to
loading of drug-linkers on the ligand molecules within the e and/or composition. In
some aspects, the loading of drug-linkers on each of the antibody molecules in a mixture or
composition of such molecules is an integer that ranges from 1 to 14.
In those aspects, when referring to the composition as a whole the loading of druglinkers
is a number ranging from 1 to about 14. Within the composition or mixture, there
may also be a small percentage of unconjugated antibodies. The e number of druglinkers
per Ligand Unit in the mixture or composition (i.e., average oad) is an
important attribute as it determines the m amount of drug that can be delivered to the
target cell. When the Linker Units in an LDC are not branched, the average number of druglinkers
in a mixture or composition of such LDCs ents the average drug load and is a
number that can range from 1 to about 14, preferably from about 2 to about 10 or about 8.
The average drug load can be 1, 2 or about 2, 3 or about 3, 4 or about 4, 5 or about 5, 6 or
about 6, 7 or about 7, 8 or about 8, 9 or about 9, 10 or about 10, 11 or about 11, 12 or about
12, 13 or about 13, 14 or about 14, 15 or about 15, 16 or about 16. When the Linker Units in
an LDC are branched, the average number of drug linkers in mixtures or compositions of
such LDCs have ranges corresponding to unbranched LDCs, but the average drug loading
will be some multiple of those average inker loads depending on the number of branch
points in each Linker Unit.
In some aspects, the mixtures and pharmaceutical compositions comprise a plurality
(i.e., population) of conjugates, however, the conjugates are identical or substantial identical
and are substantially nous with respect to the distribution of drug-linkers on the
ligand molecules within the mixture and/or composition and with respect to loading of druglinkers
on the ligand molecules within the mixture and/or composition. In some such aspects,
the loading of drug-linkers on the Antibody Ligand Unit is 2 or 4. Within the composition or
mixture, there may also be a small percentage of unconjugated antibodies. The average drug
load in such embodiments is about 2 or about 4. lly, such compositions and mixtures
result from the use of site specific ation techniques and conjugation is due to an
introduced cysteine residue.
The average number of Drugs units or Drug-Linkers per Ligand Unit in a
preparation from a conjugation reaction may be characterized by tional means such as
mass spectrometry, ELISA assay, HPLC (e.g., HIC). The quantitative distribution of Ligand-
Drug Conjugates in terms of p may also be determined. In some instances, separation,
purification, and characterization of homogeneous Ligand-Drug Conjugates may be achieved
by means such as reverse phase HPLC or electrophoresis.
In some aspects, the compositions are ceutical compositions comprising the
Ligand-Drug ates described herein and a pharmaceutically able carrier. In
some aspect, the pharmaceutical composition will be in liquid form. In some aspects, it will
be a lyophilized powder.
The compositions, including pharmaceutical itions, can be provided in
purified form. As used herein, “purified” means that when isolated, the isolate contains at
least 95%, and in another aspect at least 98%, of Conjugate by weight of the e.
Methods of Use
Treatment of Cancer
The Ligand-Drug Conjugates are useful for inhibiting the multiplication of a tumor
cell or cancer cell, causing apoptosis in a tumor or cancer cell, or for treating cancer in a
patient. The -Drug Conjugates can be used accordingly in a variety of settings for the
treatment of cancers. The Ligand-Drug ates can be used to deliver a drug to a tumor
cell or cancer cell. Without being bound by theory, in one embodiment, the Ligand unit of a
Ligand-Drug Conjugate binds to or associates with a cancer-cell or a tumor-cell-associated
antigen, and the -Drug ate can be taken up (internalized) inside the tumor cell
or cancer cell through receptor-mediated endocytosis or other internalization mechanism.
The antigen can be attached to a tumor cell or cancer cell or can be an extracellular matrix
protein associated with the tumor cell or cancer cell. Once inside the cell, via activation of
the tion Unit, the drug is released within the cell. In an alternative embodiment, the
free drug is released from the Ligand-Drug Conjugate outside the tumor cell or cancer cell,
and the free drug subsequently penetrates the cell.
[0303] In one embodiment, the Ligand Unit binds to the tumor cell or cancer cell.
In another embodiment, the Ligand Unit binds to a tumor cell or cancer cell antigen
which is on the surface of the tumor cell or cancer cell.
In another embodiment, the Ligand Unit binds to a tumor cell or cancer cell n
which is an extracellular matrix protein associated with the tumor cell or cancer cell.
The specificity of the Ligand Unit for a particular tumor cell or cancer cell can be
important for determining the tumors or cancers that are most effectively treated. For
e, -Drug Conjugates that target a cancer cell antigen present in hematopoietic
cancers can be useful treating hematologic ancies (e.g., anti-CD30, anti-CD70, anti-
CD19, anti-CD33 binding Ligand Unit (e.g., antibody) can be useful for treating hematologic
malignancies). Ligand-Drug ates that target a cancer cell antigen present on solid
tumors can be useful treating such solid tumors.
[0307] Cancers that can be treated with a Ligand-Drug Conjugate include, but are not
limited to, hematopoietic cancers such as, for example, lymphomas (Hodgkin Lymphoma and
Non-Hodgkin Lymphomas) and leukemias and solid tumors. Examples of hematopoietic
cancers include, follicular lymphoma, anaplastic large cell ma, mantle cell lymphoma,
acute myeloblastic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia,
diffuse large B cell lymphoma, and multiple myeloma. Examples of solid tumors include
fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma,
angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,
synovioma, mesothelioma, s tumor, leiomyosarcoma, rhabdomyosarcoma, colon
cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer,
ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer,
throat , squamous cell carcinoma, basal cell oma, adenocarcinoma, sweat gland
carcinoma, ous gland carcinoma, papillary carcinoma, papillary adenocarcinomas,
cystadenocarcinoma, ary carcinoma, bronchogenic carcinoma, renal cell carcinoma,
hepatoma, bile duct carcinoma, choriocarcinoma, ma, embryonal oma, Wilms’
tumor, cervical cancer, uterine cancer, testicular , small cell lung carcinoma, bladder
carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma,
medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic
neuroma, oligodendroglioma, ioma, skin cancer, melanoma, neuroblastoma, and
retinoblastoma.
[0308] In preferred embodiments, the cancers d are any one of the above-listed
lymphomas and leukemias.
Multi-Modality Therapy for Cancer
Cancers, including, but not limited to, a tumor, metastasis, or other disease or
disorder characterized by uncontrolled cell growth, can be d or ted by
administration of a Ligand-Drug Conjugate.
In other embodiments, methods for treating cancer are provided, including
administering to a patient in need thereof an effective amount of a Ligand-Drug Conjugate
and a chemotherapeutic agent. In one embodiment the chemotherapeutic agent is that with
which treatment of the cancer has not been found to be refractory. In another embodiment,
the chemotherapeutic agent is that with which the treatment of cancer has been found to be
refractory. The -Drug Conjugates can be stered to a patient that has also
undergone surgery as treatment for the cancer.
In some ments, the patient also receives an additional treatment, such as
radiation therapy. In a specific embodiment, the Ligand-Drug Conjugate is administered
concurrently with the chemotherapeutic agent or with ion therapy. In r specific
embodiment, the chemotherapeutic agent or radiation therapy is administered prior or
subsequent to administration of a Ligand-Drug Conjugate.
A chemotherapeutic agent can be administered over a series of sessions. Any one
or a combination of the chemotherapeutic agents, such a standard of care chemotherapeutic
agent(s), can be administered.
Additionally, s of treatment of cancer with a Ligand-Drug Conjugate are
provided as an alternative to chemotherapy or radiation therapy where the chemotherapy or
the radiation therapy has proven or can prove too toxic, e.g., results in unacceptable or
unbearable side effects, for the subject being treated. The patient being treated can,
optionally, be treated with r cancer treatment such as surgery, radiation therapy or
chemotherapy, depending on which treatment is found to be acceptable or bearable.
Treatment of Autoimmune Diseases
The -Drug Conjugates are useful for g or inhibiting the unwanted
replication of cells that produces an autoimmune disease or for treating an autoimmune
disease. The Ligand-Drug ates can be used accordingly in a variety of settings for the
treatment of an autoimmune disease in a patient. The Ligand-Drug ates can be used
to deliver a drug to a target cell. Without being bound by theory, in one embodiment, the
Ligand-Drug Conjugate associates with an antigen on the surface of a flammatory or
inappropriately-stimulated immune cell, and the Ligand-Drug Conjugate is then taken up
inside the targeted cell through receptor-mediated endocytosis. Once inside the cell, the
Linker unit is cleaved, resulting in release of the Drug or Drug unit. The released Drug is
then free to migrate in the cytosol and induce cytotoxic or atic activities. In an
alternative embodiment, the Drug is cleaved from the Ligand-Drug Conjugate outside the
target cell, and the Drug or Drug unit subsequently ates the cell.
In one embodiment, the Ligand Unit binds to an autoimmune antigen. In one
aspect, the antigen is on the surface of a cell involved in an autoimmune condition.
[0316] In one embodiment, the Ligand Unit binds to activated lymphocytes that are
associated with the mune disease state.
In a further embodiment, the -Drug Conjugate kills or inhibits the
multiplication of cells that produce an autoimmune antibody associated with a particular
autoimmune disease.
[0318] Particular types of autoimmune diseases that can be d with the Ligand-Drug
Conjugates include, but are not limited to, Th2 lymphocyte d disorders (e.g., atopic
dermatitis, atopic , onjunctivitis, allergic is, Omenn’s syndrome, systemic
sclerosis, and graft versus host disease); Th1 lymphocyte-related disorders (e.g., rheumatoid
arthritis, le sclerosis, psoriasis, en’s me, Hashimoto’s thyroiditis, Grave’s
disease, primary biliary cirrhosis, Wegener’s granulomatosis, and tuberculosis); and activated
B lymphocyte-related disorders (e.g., systemic lupus erythematosus, Goodpasture’s
syndrome, rheumatoid arthritis, and type I diabetes).
Multi-Drug Therapy of Autoimmune Diseases
[0319] Methods for treating an autoimmune disease are also disclosed including
administering to a patient in need thereof an effective amount of a Ligand-Drug Conjugate
and another therapeutic agent known for the treatment of an autoimmune disease.
itions and Methods of Administration
The present invention provides pharmaceutical compositions comprising the
Ligand-Drug Conjugates described herein and a pharmaceutically acceptable carrier. The
Ligand-Drug Conjugates can be in any form that allows for the compound to be administered
to a patient for treatment of a disorder associated with expression of the antigen to which the
Ligand unit binds. For example, the conjugates can be in the form of a liquid or solid. The
preferred route of administration is eral. eral administration includes
subcutaneous injections, intravenous, intramuscular, ternal injection or infusion
techniques. In one aspect, the compositions are administered parenterally. In one aspect, the
conjugates are administered intravenously. Administration can be by any convenient route,
for example by infusion or bolus injection
Pharmaceutical itions can be formulated so as to allow a compound to be
bioavailable upon administration of the composition to a t. Compositions can take the
form of one or more dosage units.
Materials used in preparing the ceutical compositions can be non-toxic in the
amounts used. It will be evident to those of ordinary skill in the art that the optimal dosage of
the active ingredient(s) in the pharmaceutical composition will depend on a variety of factors.
Relevant factors e, without limitation, the type of animal (e.g., human), the particular
form of the compound, the manner of administration, and the composition employed.
The composition can be, for example, in the form of a liquid. The liquid can be
useful for delivery by injection. In a ition for stration by injection, one or
more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer,
izer and isotonic agent can also be included.
The liquid compositions, whether they are solutions, suspensions or other like form,
can also include one or more of the following: e diluents such as water for injection,
saline solution, preferably physiological saline, ’s solution, isotonic sodium chloride,
fixed oils such as synthetic mono or digylcerides which can serve as the solvent or
suspending medium, hylene glycols, glycerin, cyclodextrin, propylene glycol or other
solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as
ic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid;
buffers such as amino acids, acetates, citrates or phosphates; detergents, such as nonionic
surfactants, polyols; and agents for the adjustment of tonicity such as sodium chloride or
dextrose. A parenteral composition can be enclosed in ampoule, a disposable syringe or a
le-dose vial made of glass, plastic or other material. Physiological saline is an
exemplary adjuvant. An injectable composition is preferably sterile.
The amount of the ate that is effective in the treatment of a particular er
or condition will depend on the nature of the disorder or condition, and can be determined by
standard clinical ques. In addition, in vitro or in vivo assays can optionally be
employed to help identify optimal dosage ranges. The precise dose to be employed in the
compositions will also depend on the route of administration, and the seriousness of the
disease or er, and should be decided according to the judgment of the tioner and
each t’s circumstances.
The compositions comprise an effective amount of a compound such that a suitable
dosage will be obtained. Typically, this amount is at least about 0.01% of a compound by
weight of the composition.
For intravenous administration, the composition can comprise from about 0.01 to
about 100 mg of a Ligand-Drug Conjugate per kg of the animal’s body weight. In one
, the composition can include from about 1 to about 100 mg of a Ligand-Drug
Conjugate per kg of the animal’s body weight. In another aspect, the amount administered
will be in the range from about 0.1 to about 25 mg/kg of body weight of a compound.
Depending on the drug used, the dosage can be even lower, for example, 1.0 µg/kg to 5.0
mg/kg, 4.0 mg/kg, 3.0 mg/kg, 2.0 mg/kg or 1.0 mg/kg, or 1.0 µg/kg to 500.0 µg/kg of the
t’s body .
Generally, the dosage of a conjugate stered to a patient is typically about
0.01 mg/kg to about 100 mg/kg of the subject’s body weight or from 1.0 µg/kg to 5.0 mg/kg
of the subject’s body weight. In some embodiments, the dosage administered to a patient is
between about 0.01 mg/kg to about 15 mg/kg of the subject’s body weight. In some
embodiments, the dosage administered to a patient is between about 0.1 mg/kg and about 15
mg/kg of the subject’s body weight. In some embodiments, the dosage administered to a
patient is between about 0.1 mg/kg and about 20 mg/kg of the subject’s body weight. In
some embodiments, the dosage administered is between about 0.1 mg/kg to about 5 mg/kg or
about 0.1 mg/kg to about 10 mg/kg of the subject’s body weight. In some embodiments, the
dosage administered is between about 1 mg/kg to about 15 mg/kg of the subject’s body
weight. In some embodiments, the dosage administered is between about 1 mg/kg to about
10 mg/kg of the t’s body weight. In some embodiments, the dosage administered is
between about 0.1 to 4 mg/kg, even more preferably 0.1 to 3.2 mg/kg, or even more
preferably 0.1 to 2.7 mg/kg of the subject’s body weight over a treatment cycle.
The term “carrier” refers to a diluent, adjuvant or excipient, with which a compound
is administered. Such pharmaceutical carriers can be liquids, such as water and oils,
ing those of petroleum, animal, vegetable or synthetic origin, such as peanut oil,
n oil, mineral oil, sesame oil. The carriers can be saline, gum acacia, gelatin, starch
paste, talc, keratin, colloidal silica, urea. In addition, auxiliary, stabilizing, thickening,
lubricating and coloring agents can be used. In one embodiment, when administered to a
patient, the nd or itions and pharmaceutically acceptable carriers are sterile.
Water is an exemplary carrier when the compounds are administered intravenously.
Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid
carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include
excipients such as , glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel,
sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol,
propylene, glycol, water, ethanol. The present compositions, if desired, can also n
minor amounts of wetting or emulsifying agents, or pH buffering agents.
[0331] In an embodiment, the conjugates are formulated in accordance with routine
procedures as a pharmaceutical composition adapted for intravenous administration to
s, particularly human beings. lly, the carriers or vehicles for intravenous
administration are sterile isotonic aqueous buffer ons. Where ary, the
compositions can also include a lizing agent. Compositions for intravenous
administration can optionally comprise a local anesthetic such as lignocaine to ease pain at
the site of the injection. Generally, the ingredients are supplied either separately or mixed
together in unit dosage form, for example, as a dry lyophilized powder or water free
concentrate in a hermetically sealed container such as an ampoule or sachets indicating the
quantity of active agent. Where a conjugate is to be administered by infusion, it can be
sed, for example, with an infusion bottle containing sterile pharmaceutical grade water
or saline. Where the conjugate is administered by injection, an ampoule of e water for
ion or saline can be provided so that the ingredients can be mixed prior to
administration.
The pharmaceutical compositions are generally formulated as sterile, substantially
ic and in full compliance with all Good Manufacturing ce (GMP) regulations of
the U.S. Food and Drug Administration.
Methods of Preparing Ligand-Drug Conjugates
The Ligand-Drug ates described herein can be prepared in either a serial
construction of antibodies, linkers, and drug units, or in a convergent fashion by assembling
portions followed by a completed assembly step. The Curtius Rearrangement or a
Chloramine sis can be used to provide a ene carbamate linker which is a
common feature of all of the Conjugates described herein.
Scheme 5: Preparation of Exemplary Drug-Linkers using the Curtius Rearrangement
Reaction:
Scheme 5 illustrates a synthetic strategy involving a Curtius rearrangement of an
acyl azide derivative of the free drug, wherein D is a drug unit representing having a
hydroxyl functional group whose hydrogen atom is incorporated into the methylene alkoxy
carbamate unit formed as a consequence of the rearrangement, Z' is a Stretcher Unit
precursor and LR is the remainder of the Linker Unit (e.g., -Y(W)-A or -Y-W-A-, n Y
is bonded to the carbamate oxygen and A is bonded to Z'). That gy may be applied to
drugs containing multiple alcohols, or other heteroatoms, as a means for acquiring
regioselectivity, as there a many complementary methods of tion to form an acyl azide
such as: halo ester alkylation, halo acid alkylation or metal e insertion with ethyl or
methyl diazoacetate, see Doyle, M. et al. Modern Catalytic Methods for Organic Synthesis
with Diazo Compounds; Wiley: New York, 1998. The acyl azide is then heated with at least
a stoichiometric amount of alcohol-containing Linker Unit ediate, such as structure 1.1.
(see examples).
Scheme 6: Preparation of Exemplary Drug-Linkers via N-chloromethylamine
synthesis:
[0337] The N-chloromethylamine synthesis is an alternative to the s rearrangement
in that it allows for the introduction of an unmodified alcohol or other heteroatom containingdrug
, whose use may not be compatible with the conditions required to form the acyl azide of
Scheme 5, and proceeds by condensation with a reactive N-chloromethylamine such as
structure 1.5 (see examples). That methodology is also more riate for introducing
certain types of methylene carbamate units as shown for example by Scheme 7.
Scheme 7 demonstrates synthesis of exemplary Drug-Linker Compounds of the
present ion having a Self-immolative ly Unit comprising an methylene
carbamate of formula Ib. Reaction of the p-nitro-phenyl carbonate with the cyclic aminol
provides a carbamate, which is then converted to the chlorcycloalkylamine for alkylation
with a nucleophile from the thiol, hydroxyl, amine or amide functional group of free drug.
Alternatively, the carbamate can be treated with acid in the presence of the drug moiety to
assemble the drug-linker intermediate shown. The alkylation product is deprotected followed
by condensation of the resulting free amine with imidopropionic acid N-
hydroxysuccimide ester, which introduces a Stretcher Unit precursor covalently attached to a
tor Unit thus providing Drug-Linker Compounds of a . The resulting Drug-
Linker Compounds are then condensed with a thiol-containing targeting ligand to provide
Ligand Drug Conjugates having a Self-immolative Assembly unit comprised of a -Y(W)-
self-immolative moiety and a methylene carbamate unit of formula Ib.
Scheme 7
CO2Me
HO H
OAc N CO2Me
O O
O O O OAc n HO O
HN O OAc N O O OAc
HN O OAc
NO2 NHFmoc
NHFmoc
dry HCl
H-T-D
CO2Me
CO2Me
D OAc
T O O OAc
Cl O O
H-T-D
N O O OAc
HN O OAc N O O OAc
n HN O OAc
DIPEA
NHFmoc
NHFmoc
D OH
T O O
N O O OH
HN O OH
O NH
For Drug Linker Compounds and Ligand Drug Conjugates having a methylene
carbamate unit wherein T* is the nitrogen heteroatom from an primary aliphatic amine or the
tuted heteroatom from a secondary aliphatic (cyclic or acyclic), direct alkylation with a
chlormethylamine following the generalized procedures provided by Scheme 6 or Scheme 7
may not be suitable due to excessive or undesired over-alkylation of the en heteroatom
from the amine onal group of free drug. In those instances the method embodied by
Scheme 8 may be used.
Scheme 8.
In Scheme 8 an intermediate carbamate is prepared already having a Basic Unit (i.e., the
dimethylaminoethyl moiety) as the R tuent for a formula Ia methylene ate unit.
The nitrogen of that carbamate is condensed with formaldehyde and the resulting
intermediate quenched with the amine functional group of an aliphatic amine-containing
drug. That condensation forms the methylene carbamate ntly attached to a Drug Unit
of formula Ia, wherein R1 is hydrogen and R is dimethylaminoethyl. The phenyl nitro group
is then reduced to by the l method of Example 8 to provide a handle for sequential
introduction of a Connector Unit (A) and a Stretcher Unit sor (Z’).
Numbered embodiments
The ing embodiments further exemplify the invention and are not meant to
limit the invention in any manner.
1. A Ligand-Drug ate Compound comprising a Ligand Unit, a Drug Unit and
a Linker Unit, wherein the Linker Unit is comprised of a Self-immolative (SI) Assembly Unit
having a methylene carbamate unit and an activateable self-immolative moiety wherein the
methylene carbamate unit is covalently attached to the Drug Unit, and wherein the SI
Assembly Unit covalently attached to the Drug Unit is represented by the structure of formula
SI: (SI), or a pharmaceutically acceptable salt thereof, wherein
the wavy line indicates covalent ment to the remainder of the Linker Unit; D is the
Drug Unit having a hydroxyl, thiol, amine or amide functional group that has been
incorporated into the methylene carbamate unit; T* is the oxygen, sulfur or optionally
substituted nitrogen heteroatom from said functional group that becomes incorporated into
the indicated methylene carbamate unit; X is the activateable self-immolative moiety; R, R1
and R2 independently are en, optionally substituted C1-C6 alkyl, optionally substituted
C6-14 aryl, or optionally substituted C-linked C3-C8 heteroaryl, or both R and R1 together with
the nitrogen and carbon atoms to which they are attached comprise an azetidinyl,
pyrrolodinyl, piperidinyl or homopiperidinyl moiety and R2 is hydrogen.
2. The Ligand-Drug Conjugate Compound of embodiment 1 wherein the SI
ly Unit covalently attached to the Drug Unit is represented by the structure of formula
SIa or SIb:
(SIa) (SIb),
or a pharmaceutically acceptable salt thereof, wherein s is 0, 1, 2 or 3.
3. The Ligand-Drug Conjugate Compound of claim 2 wherein R and R1 are
ndently selected from hydrogen, optionally substituted C1-C6 alkyl or optionally
substituted C6-14 aryl; and the ipt s is 0, 1, or 2.
[0346] 4. The -Drug Conjugate Compound of embodiment 1 having Formula II:
(II),
or a pharmaceutically able salt thereof, wherein L is a Ligand Unit; Z is a her
Unit; B is an optional branching unit and is present when t is r than 1 and is absent
when t is 1; A is an optional Connector Unit; the subscript t ranges from 1 to 4; and the
subscript p is an integer ranging from 1 to 16.
[0347] 5. The Ligand-Drug Conjugate Compound of embodiment 4 having Formula IIa or
(IIa)
(IIb)
or a pharmaceutically acceptable salt thereof, wherein s is 0, 1, 2, or 3.
[0348] 6. The Ligand-Drug Conjugate nd of embodiment 4 wherein R and R1 are
independently selected from hydrogen, optionally substituted C1-C6 alkyl or ally
substituted C6-14 aryl, and the subscript s is 0, 1, or 2.
7. The Ligand-Drug Conjugate Compound of embodiment 5 wherein R and R1 are
ndently selected from hydrogen, optionally substituted C1-C6 alkyl or optionally
substituted C6-14 aryl; and the subscript s is 0, 1, or 2.
8. The Ligand-Drug Conjugate Compound of any one of embodiments 4 to 7
wherein R1 is not substituted.
9. The Ligand-Drug Conjugate Compound of any one of embodiments 4 to 7
wherein R1 and R2 are not substituted.
10. The Ligand-Drug Conjugate Compound of ment 4 or 5 wherein R, R1
and R2 are not substituted.
11. The Ligand-Drug Conjugate Compound of any one of embodiments 4 to 9
wherein the optional substituents are independently selected from the group consisting of -X,
-Rop, -OH, -ORop , -SRop, -N(Rop)2, -N(Rop)3, =NRop, -CX3, -CN, -NO2, -NRopC(=O)Rop, -
C(=O)Rop, -C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, -OP(=O)(ORop)2, -
ORop)2, -PO3=, PO3H2, Rop, -C(=S)Rop, -CO2Rop, -CO2-, -C(=S)ORop, -
C(=O)SRop, -C(=S)SRop, N(Rop)2, - C(=S)N(Rop)2, and -C(=NRop)N(Rop)2, wherein
each X is independently selected from the group consisting of a n: -F, -Cl, -Br, and -I;
and each Rop is independently selected from the group consisting of hydrogen, -C1- C20 alkyl,
-C6-C20 aryl, -C3-C14 heterocycle, a protecting group, and a prodrug moiety.
12. The Ligand-Drug Conjugate Compound of embodiment 11 wherein the optional
tuents are selected from the group consisting of -X, -Rop, -OH, -ORop, -SRop, -N(Rop)2,
N(Rop)3, =NRop, -NRopC(=O)Rop, -C(=O)Rop, -C(=O)N(Rop)2, 2Rop, -S(=O)2NRop, -
S(=O)Rop, -C(=O)Rop, -C(=S)Rop, -C(=O)N(Rop)2, - C(=S)N(Rop)2, and -C(=NRop)N(Rop)2,
wherein each X is selected from the group consisting of –F and-Cl; and each Rop is
independently selected from the group consisting of hydrogen, -C1-C20 alkyl, -C6-C20 aryl, -
C3-C14 heterocycle, a protecting group, and a prodrug moiety .
13. The Ligand-Drug ate Compound of embodiment 11 wherein the optional
substituents are selected from the group consisting of -X, -Rop, -OH, -ORop, -N(Rop)2, -
N(Rop)3, -NRopC(=O)Rop, -C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, -C(=O)Rop, -
C(=O)N(Rop)2, and -C(=NRop)N(Rop)2, wherein X is –F.
14. The Ligand-Drug Conjugate Compound of embodiment 11 wherein the optional
substituent is selected from the group ting of –N(Rop)2, -N(Rop)3 and )N(Rop)2.
[0357] 15. The -Drug ate Compound of any one of embodiments 1 to 9
wherein R is C1-6 alkyl, optionally substituted with a basic group.
16. The Ligand-Drug Conjugate Compound of claim any one of claims 1 to 9
wherein R is a saturated C1-6 alkyl, optionally substituted with a basic group.
17. The Ligand-Drug Conjugate Compound of any one of embodiments 1 to 9
wherein R is a Basic Unit wherein the basic functional group of the Basic Unit is an amine or
a nitrogen-containing 3, 4, 5, or 6 membered heterocycle that is C-linked or N-linked and
can be optionally substituted.
18. The Ligand-Drug Conjugate Compound of embodiment 17 wherein R is a Basic
Unit, wherein the basic functional group of the Basic Unit is )2, wherein Rop are
independently selected from the group consisting of en and C1-6 alkyl.
19. The Ligand-Drug Conjugate nd of embodiment 17 wherein R is a Basic
Unit, wherein the basic functional group of the Basic Unit is –N(Rop)2, wherein Rop are
independently selected from the group consisting of hydrogen and methyl.
20. The Ligand-Drug Conjugate Compound of embodiment 17 wherein R is a Basic
Unit, wherein, the basic functional group of the Basic Unit is –N(Rop)2, wherein each Rop is
21. The Ligand Drug Conjugate Compound of embodiment 17 wherein R is a Basic
Unit, wherein the Basic Unit is –CH2CH2N(Rop)2, wherein Rop are independently selected
from the group ting of hydrogen and methyl.
[0364] 22. The Ligand-Drug ate Compound of any one of embodiment 15 to 21
wherein R1 is hydrogen.
23. The Ligand-Drug Conjugate Compound of any one of embodiment 1 to 22
wherein D is a Drug Unit corresponding to a drug having a hydroxyl functional group that
has been incorporated into the methylene carbamate unit so that T* represents the oxygen
heteroatom from that functional group.
24. The Ligand-Drug Conjugate nd of embodiment 23 wherein D is a Drug
Unit corresponding to an aliphatic l-containing drug, wherein attachment of D within
the conjugate is via the oxygen heteroatom of the hydroxyl functional group of the aliphatic
alcohol, so that T* ents the oxygen atom from that functional group.
[0367] 25. The Ligand-Drug Conjugate Compound of embodiment 23 wherein D is a Drug
Unit corresponding to an aromatic alcohol-containing drug, wherein attachment of D within
the ate is via the oxygen atom of the aromatic alcohol, so that T* represents the
oxygen atom from that functional group.
26. The Ligand-Drug Conjugate nd of embodiment 25 wherein the aromatic
alcohol is not a phenolic alcohol.
27. The Ligand-Drug Conjugate Compound of any one of embodiments 4 to 26
wherein B is absent and the subscript t is 1.
28. The Ligand-Drug Conjugate Compound of any one of ments 4 to 27
wherein the structure representing the indicated activateable self-immolative moiety (X)
within the Linker Unit is represented by formula (i) (i), wherein the way
line indicates covalent attachment of W to A, B or Z depending on the presence or absence of
A and/or B and the asterisk (*) indicates covalent attachment of Y to a methylene carbamate
unit and wherein; W is an Activation Unit; and Y is a self-immolative Spacer Unit, wherein
tion of mmolation of Y results in release of free drug.
[0371] 29. The Ligand-Drug Conjugate nd of embodiment 28 wherein activation
for self-immolation of Y is by enzymatic cleavage of a covalent bond between W and Y.
30. The Ligand-Drug Conjugate Compound of ment 29 wherein enzymatic
cleavage is by a tumor associated protease.
31. The Ligand-Drug Conjugate Compound of embodiment 30 wherein the tumor
associated protease is cathepsin B.
32. The Ligand-Drug Conjugate nd of embodiments 30 wherein W is -Val-
Cit-, -Phe-Lys- or –Val-Ala-.
33. The Ligand-Drug Conjugate Compound of embodiment 30 wherein –W-Y- is
ented by the structure of: or
, wherein the wavy bond to the nitrogen of W indicates
covalent linkage to Z, A or B, depending on the presence or absence of A and/or B, and the
hash mark (#) indicates nt attachment of the benzylic carbon of Y to a methylene
carbamate unit.
34. The Ligand-Drug Conjugate nd of any one of ments 4 to 27
wherein the ure representing the indicated teable self-immolative moiety (X)
within the Linker Unit is represented by a (ii): (ii), wherein the wavy line
indicates covalent attachment of Y to A, B or Z depending on the presence or absence of A
and/or B, and the asterisk (*) indicates covalent ment of Y to the methylene carbamate
moiety, and wherein; W is an Activation Unit; and Y is a self-immolative Spacer Unit,
wherein activation of self-immolation of Y results in release of free drug.
35. The Ligand-Drug Conjugate Compound of embodiment 34 wherein activation for
self-immolation of Y is by enzymatic cleavage of a nt bond between W and Y, wherein
enzymatic cleavage is by a glycosidase.
36. The Ligand-Drug Conjugate Compound of embodiment 35 wherein the
glycosidase is a onidase.
37. The Ligand-Drug Conjugate Compound of embodiment 35 wherein W is a sugar
moiety connected to Y via a glycosidic bond capable of cleavable by a glycosidase for
activation of self-immolation of Y.
38. The Ligand-Drug Conjugate Compound of ment 33 wherein –Y(W)- is
represented by the structure of: , wherein the wavy bond
adjacent to the nitrogen of Y indicates covalent attachment of Y to Z, A or B, depending on
the presence or absence of A and/or B, and the hash mark (#) indicates covalent attachment
of the benzylic carbon of Y to a methylene carbamate unit.
39. The Ligand-Drug Conjugate Compound of any one of embodiments 4 to 38
wherein the Stretcher unit (Z) comprises a succinimide moiety or an acid-amide moiety,
wherein that moiety is ed to a sulfur atom of the Ligand Unit.
40. The Ligand-Drug Conjugate Compound of ment 39 wherein the her
unit (Z) is comprised of a succinimide moiety and is represented by the structure of formula
Xa': (Xa'), wherein the wavy line adjacent to
the succinimide ring system indicates covalent attachment to a sulfur atom of a Ligand Unit;
the wavy line adjacent to the carbonyl indicates ment within the linker; and RN is -C2-
C5 alkylene, wherein the alkylene is optionally substituted by a Basic Unit (BU), wherein BU
is –(CH2 )xNH2, –(CH2 )xNHRop, or –(CH2 )xN(Rop)2, wherein x is an integer ranging from 1-
4; and Rop is C1-6 alkyl.
41. The Ligand-Drug Conjugate Compound of ment 39 wherein the Stretcher
unit (Z) is comprised of a succinimide moiety and is represented by the structure:
, wherein the wavy line adjacent to the
succinimide ring system indicates covalent attachment to a sulfur atom of a Ligand Unit, and
the wavy line adjacent to the carbonyl indicates attachment within the linker.
42. The Ligand-Drug Conjugate Compound of embodiment 39 wherein the Stretcher
unit (Z) is sed of a succinimide moiety or an acid-amide moiety and is represented by
the structure of: , or
43. The Ligand-Drug Conjugate Compound of any one of embodiments 2 to 42
wherein a Connector Unit (A) is present.
[0386] 44. The -Drug Conjugate Compound of embodiment 43 wherein A is:
NH R13 C
, wherein the wavy line adjacent to the carbonyl indicates
covalent attachment to the activateable self-immolative moiety X of the Self-immolative
Assembly Unit, and the other wavy line indicates attachment to B, if present, or to Z if B is
absent; and R13 is -C1-C6 alkylene-, carbocyclo-, -arylene-, -C1-C10 heteroalkylene-, -
C3-C8heterocyclo-, -C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, 0alkylene-(C3-
C8carbocyclo)-, -(C3-C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 cyclo)-,
or -(C3-C8 heterocyclo)-C1-C10 alkylene-.
45. The Ligand-Drug Conjugate Compound of embodiment 44 wherein A has the
formula .
[0388] 46. The Ligand-Drug Conjugate Compound of any one of embodiments 4 to 42
wherein A is .
47. The -Drug Conjugate Compound of any one of embodiments 4 to 46
wherein p ranges from 1 to 10.
48. The Ligand-Drug Conjugate Compound of any one of embodiments 4 to 46
wherein p ranges from 1 to 8.
49. The Ligand-Drug Conjugate Compound of any one of embodiments 1 to 48
n the Ligand Unit corresponds to a targeting dy.
50. A Drug-Linker compound, wherein the compound comprises a Drug Unit and a
Linker Unit, wherein the Linker Unit is comprised of a Self-Immolative Assembly Unit
having a methylene carbamate unit and an activateable self-immolative moiety wherein the
Drug Unit is covalently attached to the methylene carbamate unit, wherein the Drug-Linker
compound has the ure of formula V: (V), or a
pharmaceutically acceptable salt thereof; wherein D is a Drug Unit having a hydroxyl, thiol,
amine or amide functional group that has been orated into the indicated methylene
carbamate unit; T* is the oxygen, sulfur or optionally substituted nitrogen heteroatom from
said functional group that becomes incorporated into the indicated methylene carbamate unit;
R, R1 and R2 independently are hydrogen, optionally substituted C1-C6 alkyl, optionally
substituted C6-14 aryl, or optionally substituted C-linked C3-C8 heteroaryl, or both R and R1
together with the nitrogen and carbon atoms to which they are attached comprise an
azetidinyl, pyrrolodinyl, dinyl or homopiperidinyl moiety (preferably a pyrrolodinyl or
piperidinyl moiety) and R2 is hydrogen; X is an activateable self-immolative moiety; Z' is a
Stretcher Unit precursor to a Stretcher Unit (Z) and is sed of a functional group that
provides for covalent attachment of a Ligand Unit to Z; B is an optional Branching Unit that
is present when t is r than 1 and absent when t is 1; A is an optional Connector Unit;
and the subscript t ranges from 1 to 4.
51. The Drug-Linker compound of ment 50 wherein D is a Drug Unit
ponding to a drug having a hydroxyl functional group that has been incorporated into
the methylene carbamate unit of the Self-immolative Assembly Unit; and T* is the oxygen
atom from that functional group.
52. The Drug-Linker compound of embodiment 50 or 51 wherein X is ,
wherein –Y(W)- is represented by the structure of: , wherein
the wavy bond adjacent to the en of Y indicates covalent attachment to Z’, A or B,
depending on the presence or absence of A and/or B, and the hash mark (#) indicates covalent
attachment of the benzylic carbon of Y to the methylene carbamate unit.
53. The Drug-Linker compound of embodiment 50 or 51, wherein X is –W-Y,
wherein –W-Y- is represented by the structure of: , wherein
the wavy bond adjacent to the nitrogen heteroatom of W indicates covalent attachment of W
to Z’, A or B, ing on the presence or absence of A and/or B and the hash mark (#)
indicates covalent attachment of the benzylic carbon of Y to the methylene carbamate unit.
54. The Drug-Linker compound of any one of embodiments 50 to 53 wherein Z’
comprises a maleimide moiety.
55. The Drug-Linker compound of embodiment 54 wherein Z’ has the formula:
or , wherein the wavy line adjacent to the carbonyl
indicates covalent attachment of Z’ to A, B or X, ing on the presence or absence of A
and/or B.
56. The Drug-Linker compound any one of claims 50 to 55 wherein A is present and
has the formula .
57. The Drug-Linker compound of any one of ments 50 to 56 wherein B is
absent and t is 1.
[0400] 58. The Drug-Linker nd of any one of claims 50 to 56 wherein B is present
and t is 2.
59. A Ligand-Drug Conjugate composition comprising a plurality of conjugate
compounds, wherein each has the structure of a Ligand-Drug Conjugate Compound of any
one of claims 1 to 49, wherein the Conjugate Compounds are entiated by their p integer
values; and a pharmaceutically acceptable carrier.
60. The Ligand-Drug Conjugate composition of embodiment 59 wherein there is an
average of 2 to 10 inkers per Ligand Unit.
61. The Ligand-Drug Conjugate composition of embodiment 59 wherein there is an
average of 2 to 8 drug-linkers per Ligand Unit.
[0404] 62. The Ligand-Drug ate Compound of any one of embodiments 1-49, the
Drug-Linker compound of any one of claims 50-58 or the Ligand-Drug Conjugate
composition of any one of claims 59-61, wherein the Drug Unit corresponds in structure to a
nd having hydroxyl functional group whose oxygen heteroatom is capable of
oration into a methylene carbamate unit, wherein the compound binds to FKBP to
inhibit mTOR or calcineurin effector function.
63. The Ligand-Drug Conjugate Compound, Drug-Linker compound or Ligand-
Drug Conjugate composition of embodiment 62, wherein the FKBP binding nd is
everolimus, tacrolimus or sirolimus.
64. The Ligand-Drug ate Compound, Drug-Linker compound or Ligand-Drug
Conjugate composition of embodiment 62, wherein the compound or composition has the
structure of :
wherein the Ab-S- moiety is a Ligand Unit from a targeting antibody; R is hydrogen, ethyl or
–CH2CH2N(CH3)2; and p ranges from 1 to 20, 1 to 16 or 1 to 8.
[0407] 65. The Ligand-Drug Conjugate Compound, Drug-Linker compound or Ligand-Drug
Conjugate composition of embodiment 62, wherein the nd or composition has the
structure of :
wherein the Ab-S- moiety is a Ligand Unit from a targeting antibody; R is hydrogen, ethyl or
–CH2CH2N(CH3)2; and p ranges from 1 to 20, 1 to 16 or 1 to 8.
66. The Ligand-Drug Conjugate Compound, Drug-Linker compound or Ligand-Drug
Conjugate composition of ment 62, wherein the compound or composition has the
structure of :
wherein the Ab-S- moiety is a Ligand Unit from a targeting antibody; R is hydrogen, ethyl or
–CH2CH2N(CH3)2; and p ranges from 1 to 20, 1 to 16 or 1 to 8.
[0409] 67. The Ligand-Drug Conjugate Compound of any one of embodiments 1-49, the
Drug-Linker nd of any one of embodiments 50-58 or the Ligand-Drug Conjugate
composition of any one of embodiments 59-61, wherein the Drug Unit corresponds in
ure to a auristatin having hydroxyl functional group whose oxygen heteroatom is
capable of incorporation into a methylene carbamate unit, wherein the nd binds to
tubulin to disrupt tubulin function.
68. The Ligand-Drug ate Compound, Drug-Linker compound or Ligand-Drug
Conjugate composition of embodiment 67 wherein the auristatin is MMAE or auristatin T.
69. A method of treating cancer or an mune disease comprising administering
to a subject in need thereof, an effective amount of a Ligand-Drug Conjugate of any one of
embodiments 1 to 49 or a Ligand-Drug Conjugate ition any one of embodiments 59 to
70. A method of preparing a Drug-Linker Compound having the structure of
said method comprising: contacting a modified free drug having
the structure of: with an intermediate linker moiety represented by: Z’-A-X’-
OH under conditions sufficient for providing the indicated MAC unit through Curtius
rearrangement,wherein D is a Drug Unit having a hydroxyl functional group that has been
incorporated into the MAC, the oxygen heteroatom from which is designated by O*; Z' is a
stretcher unit precursor to a Stretcher Unit (Z) in a Ligand-Drug Conjugate and is comprised
of a functional group capable of conjugation to a targeting ligand; A is an optional Connector
Unit; X is an activeatable self-immolative moiety; X' is a self-immolative moiety sor to
X and has a hydroxyl functional group that participates in the s rearrangement; R is
hydrogen; and R1 is en, or C1-C6 alkyl, C6-C14 aryl or C-linked heteroaryl, optionally
substituted with le protection as required.
71. A method of preparing an intermediate of a Drug-Linker compound n the
intermediate has the structure of: , said method comprising:
ting a modified free drug having the structure of: with a self-immolative
intermediate represented by: A'-X-OH, under conditions sufficient for providing the indicated
MAC Unit through Curtius rearrangement,wherein D is a Drug Unit having a hydroxyl
functional group that has been orated into the MAC, the oxygen heteroatom from
which is designated by O*, A' is a tor Unit precursor to a tor Unit (A) and is
comprised of a functional group for bond formation to the remainder of the Linker Unit of the
Drug-Linker compound; X is an activeatable self-immolative moiety; R is hydrogen; and R1
is hydrogen, or C1-C6 alkyl, C6-C14 aryl or C-linked heteroaryl, optionally substituted with
suitable protection as required.
72. A method of preparing a Drug-Linker Compound wherein the compound has the
structure of : , said method comprising: contacting a drug having
a free hydroxyl functional group with a N-chloromethylamine having the structure of:
under conditions sufficient for substitution of the chorine atom with the
oxygen heteroatom from said free drug onal group, wherein Z' is a Stretcher Unit
precursor to a Stretcher Unit (Z) of the inker Compound and comprises a functional
group for attachment of a targeting ligand; A is an optional Connector Unit; X is an
activateable self-immolative moiety; R is hydrogen, or C1-C6 alkyl, C6-C14 aryl or C-linked
heteroaryl, ally substituted with suitable protection; and R1 is hydrogen, or C1-C6 alkyl,
C6-C14 aryl or C-linked heteroaryl, optionally substituted with suitable protection as required,
or R and R1 together with the nitrogen and carbon atoms to which they are ed comprise
a pyrrolodinyl or piperidinyl moiety.
73. A method of preparing an intermediate of a inker Compound wherein the
intermediate has the structure of: , said method sing:
contacting a drug having a free hydroxyl functional group with a N-chloromethylamine
having the structure of: under ions sufficient for substitution of
the chorine atom with the oxygen heteroatom from said free drug functional group,
wherein Z' is a Stretcher Unit precursor to a Stretcher Unit (Z) of the Drug-Linker
nd and ses a functional group for attachment of a targeting ligand; A’ is a
Connector Unit precursor to a Connector Unit (A) and is comprised of a functional group
for bond formation to the der of the Linker Unit of the Drug-Linker compound; X
is an activatable self-immolative moiety; R is en, or C1-C6 alkyl, C6-C14 aryl or C-
linked heteroaryl, optionally substituted with le protection; and R1 is hydrogen, or
C1-C6 alkyl, C6-C14 aryl or ed heteroaryl, optionally substituted with suitable
protection as required, or R and R1 together with the nitrogen and carbon atoms to which
they are attached comprise a pyrrolodinyl or piperidinyl moiety.
[0415a] In this specification where reference has been made to patent ications,
other external documents, or other sources of information, this is lly for the
purpose of providing a context for discussing the features of the invention. Unless
specifically stated otherwise, reference to such al documents is not to be construed
as an admission that such documents, or such sources of information, in any jurisdiction,
are prior art, or form part of the common l knowledge in the art.
EXAMPLES
Summary:
[0416] Examples 1 and 2 describe alternative preparations of a Drug-Linker Compound
having a Drug Unit (D) covalently attached to a methylene alkoxy carbamate unit of formula
Ia’ wherein the Drug Unit is from auristatin E. The resultant Drug-Linker Compound has the
generalized structure of formula V’:
wherein R and R’ are hydrogen and the activateable moiety X is –Y(W)- wherein –
Y(W)- has the structure of formula XVId:
(XVId)
wherein the wavy line to the en heteroatom of the mmolative Spacer Unit
(Y) indicates covalent attachment to the Connector Unit (A) and the hash mark (#) indicates
covalent attachment of the ic carbon of Y to the MAC Unit, wherein O* is the oxygen
heteroatom from the hydroxyl functional group of free drug.
Example 3, 4 and 5 describes the synthesis of Drug-Linker Compounds wherein the
Drug Units are from triptolide, everolimus and tacrolimus (FK-506), respectively, in which a
hydroxyl functional group of free drug is used in conjugation so that its oxygen heteroatom
becomes incorporated into a formula Ia’ MAC Unit. For two of those drugs (tacrolimus and
triptolide) the hydroxyl functional group is a ally hindered secondary hydroxyl
functional group.
Example 6 bes the synthesis of a Drug-Linker Compound having a Drug Unit
(D) covalently attached to a methylene ate unit of formula Ia wherein the Drug Unit is
from a ydroquinoline-containing compound (BMN-673). The resultant Drug-Linker
Compound has the generalized structure of formula V:
wherein R and R’ are hydrogen and the activateable moiety X is –Y(W)- having the
structure of formula XVId and wherein T* represents the cyclized nitrogen heteroatom from
the amine functional group (-NH-) in the tetrahydroquinoline ring system of BMN-673 that
has been incorporated into a methylene carbamate unit. The example demonstrates a variant
of the MAC Unit adapted for use for conjugation of amine-containing drugs, in this instance
where T* is a cyclic e nitrogen.
Example 7 describes the preparation of model Self-immolative Assembly Units each
comprised of a MAC Units and its variant covalently attached to a Drug Unit corresponding
to model drug compounds for thiol-containing drugs, primary, secondary and tertiary
aliphatic alcohol-containing drugs, and phenolic alcohol-containing drugs wherein each Self-
immolative Assembly Units is capable of ing the model drug compound subsequent to
tion of self-immolation within the Self-immolative Assembly Unit.
Example 8 describes the in vitro stability to spontaneous hydrolysis of MAC Units
and their variants in Self-immolative Assembly Units of drug-linker moieties in model
Ligand Drug Conjugates and the cted increase in half-life at pH 7.0 resulting from a
Basic Unit ed to the MAC unit’s carbamate nitrogen.
Example 9 describes in vitro stabilities of N-acetyl cysteine (NAC) conjugates
wherein the N-acetyl cysteinyl moiety is a stand-in for a Ligand Unit, to spontaneous
hydrolysis of its methylene carbamate unit.
Example 10 describes the ex vivo stability of an ADC to neous ysis of its
methylene carbamate unit.
Example 11 describes the release of drug or model compounds for a thiol-
containing drug, primary, secondary and tertiary aliphatic alcohol-containing drugs, and an
aromatic alcohol-containing drug from NAC-conjugates having a Self-immolative Assembly
Unit comprised of a MAC Unit or variant thereof subsequent to glucuronidase activation of
that unit.
Example 12 bes the efficient release of an tetrahydroquinoline-containing
compound (BMN-673) whose aromatic amine nitrogen corresponds to the optionally
substituted nitrogen heteroatom of a methylene ate unit ntly attached to a Drug
Unit from a NAC conjugate comprised of a Self-immolative assembly unit upon conditional
tion that initiates self-immolation within Self-immolative Assembly Units comprised of
these methylene carbamate units.
Example 13 describes the cytotoxicity of dy Drug ates to cancer cells
targeted by its antibody Ligand Unit each having a MAC Unit that conditionally releases a
cytotoxic free drug.
General Information:
The following information is applicable to the tic procedures described in this
section unless indicated otherwise. All commercially ble anhydrous solvents were used
without further cation. Analytical thin layer chromatography was performed on silica
gel 60 F254 um sheets (EMD Chemicals, Gibbstown, NJ). Radial chromatography
was performed on ChromatotronTM apparatus (Harris Research, Palo Alto, CA). Column
chromatography was med on a Biotage Isolera OneTM flash purification system
(Charlotte, NC). ical HPLC was performed on a Varian rTM 210 solvent
delivery system configured with a Varian ProStar 330 PDA detector. Samples were eluted
over a C12 Phenomenex SynergiTM 2.0 x 150 mm, 4 μm, 80 Ǻ reverse-phase . The
acidic mobile phase consisted of acetonitrile and water both containing either 0.05%
trifluoroacetic acid or 0.1% formic acid. Compounds were eluted with a linear gradient of
acidic itrile from 5% at 1 min post injection, to 95% at 11 min, followed by isocratic
95% acetonitrile to 15 min (flow rate = 1.0 mL/min). LC-MS was performed on a Waters
XevoTM G2 Tof mass spectrometer interfaced to a Waters 2695 Separations Module equipped
with a C12 Phenomenex Synergi 2.0 x 150 mm, 4 μm, 80 Å reverse phase column with a
Waters 2996 Photodiode Array Detector . The acidic eluent consisted of a linear gradient of
acetonitrile from 5% to 95% in 0.1% aqueous formic acid over 10 min, followed by isocratic
95% acetonitrile for 5 min (flow rate = 0.4 mL/min). UPLC-MS was med on a Waters
SQ mass detector interfaced to an Acquity Ultra PerformanceTM LC equipped with an
Acquity UPLC BEH C18 2.1 x 50 mm, 1.7µm reverse phase column. The acidic mobile
phase (0.1% formic acid) consisted of a gradient of 3% acetonitrile/97% water to 100%
acetonitrile (flow rate = 0.5 mL/min unless otherwise indicated). Preparative HPLC was
carried out on a Varian ProStar 210 solvent ry system configured with a Varian ProStar
330 PDA detector. Products were purified over a C12 Phenomenex Synergi 10.0 x 250 mm,
4 μm, 80 Å reverse phase column eluting with 0.1% trifluoroacetic acid in water (solvent A)
and 0.1% trifluoroacetic acid in acetonitrile (solvent B). The purification method consisted
of the following gradient of solvent A to solvent B: 90:10 from 0 to 5 min; 90:10 to 10:90
from 5 min to 80 min; followed by isocratic 10:90 for 5 min. The flow rate was 4.6 mL/min
with ring at 254 nm.
[0427] Example 1: Synthesis of an Auristatin E Drug-Linker Compound comprising
the MAC linker using the Curtius rearrangement
Synthesis of (2S,3R,4S,5S,6S)(2-(3-((((9H-fluoren
yl)methoxy)carbonyl)amino)propanamido)((7S,8R,11R,12R)((S)((3R,4S,5S)((S)-
2-((S)(dimethylamino)methylbutanamido)-N,3-dimethylbutanamido)methoxy
methylheptanoyl)pyrrolidinyl)-8,11-dimethyl-3,10-dioxophenyl-2,6,13-trioxa-4,9-
diazatetradecyl)phenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-2,3,4-triyl triacetate
(1.2) via Curtius ngement
To azido ketone 1.0 (30 mg, 37 μmol), synthesized from the corresponding free
auristatin alcohol (for synthesis of 1.1 see Jeffrey et al., Org. Lett. (2010) ) in of DMF
(250 μmol) at RT was added 1.1 (90 mg, 120 μmol) to the on followed by 5 μL of
dibutyl tin dilaurate. The reaction mixture was then stirred at 60 °C for 1 hour at which time
LC/MS showed the reaction was complete. Subsequently, the reaction was directly purified
by preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) to yield 22 mg of 1.2.
MS (m/z) [M + H]+ calc for C80H110N8O22 1535.77, found 1535.80.
Synthesis of (2S,3S,4S,5R,6R)(4-((7S,8R,11R,12R)((S)((3R,4S,5S)((S)-
2-((S)(dimethylamino)methylbutanamido)-N,3-dimethylbutanamido)methoxy
methylheptanoyl)pyrrolidinyl)-8,11-dimethyl-3,10-dioxophenyl-2,6,13-trioxa-4,9-
diazatetradecyl)(3-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)propanamido)propanamido)phenoxy)-4,5,6-trihydroxytetrahydro-2H-pyrancarboxylic
acid (1.3):
To a MeOH:Water 1:1 solution of 1.2 (15 mg, 10 μmol) was added LiOH (5 mg).
The resulting reaction e was vigorously stirred for 10 min at RT at which time LC/MS
showed the reaction was te. The reaction mixture was then directly purified by
preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) to yield 8 mg of
deprotected 1.2. Subsequently, DMF (100 μL) was added to a vial containing 8 mg of
deprotected 1.2 followed by 20 μL Hünig’s base and10 mg (40 mmol) 3-maleimidopropionic
acid N-hydroxysuccimide ester. The reaction was then stirred for 10 minutes at RT at which
time LC/MS indicated the reaction was complete. Afterwards, the reaction was directly
purified by preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) to yield 7 mg of
1.3, 60 yield. MS (m/z) [M + H]+ calc for C65H97N9O20, 1324.68, found 0.
e 2: Synthesis of an Auristatin E Drug-Linker Compound comprising
the MAC linker via N-chlormethylamine synthesis
Synthesis of (2S,3R,4S,5S,6S)(4-((((chloromethyl)(ethyl)carbamoyl)oxy)methyl)
nitrophenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (1.5):
To a solution of 1.4 (400 mg, 0.36 mmol) (for ation of 1.4 see Bosslet et al.,
1998, J. Med. Chem. 41:3572) in DCM (4 mL) was added paraformaldehyde (32 mg, 0.54
mmol) and TMSCl (0.212 mL, 1.1 mmol). The on was stirred for additional 2 hours at
RT with monitoring by utilizing ol as a diluent and following the formation of the
methanol adduct by LC/MS. Subsequently, the reaction was filtered and dried in vacuo 450
mg of crude 1.5, which was then used in the subsequent reaction without further purification
(see procedure from Barnes et al., 2009, Org. Lett. 11:273). MS (m/z) [M + H]+ calc for the
methanol adduct C25H32N2O15 601.18, found 601.21.
Synthesis of (2R,3S,4R,5R,6R)(4-((7S,8R,11R,12R)((S)((3R,4S,5S)((S)-
(dimethylamino)methylbutanamido)-N,3-dimethylbutanamido)methoxy
methylheptanoyl)pyrrolidinyl)ethyl-8,11-dimethyl-3,10-dioxophenyl-2,6,13-trioxa-
4,9-diazatetradecyl)nitrophenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl
triacetate (1.7) via N-chloromethylamine substitution:
To a solution of 1.5 (60 mg, 100 μmol) in DCM (300 μL) was added 1.6 (110 mg,
150 μmol) and Hünig’s base (50 μL). The reaction was stirred for an additional 90 minutes at
RT which time LC/MS showed the reaction was complete. The reaction was then directly
purified by preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) to yield 45 mg
of 1.7. MS (m/z) [M + H]+ calc C64H97N7O21 7, found 1300.71.
Synthesis of (2R,3S,4R,5R,6R)(2-amino((7S,8R,11R,12R)((S)
S,5S)((S)((S)(dimethylamino)methylbutanamido)-N,3-
dimethylbutanamido)methoxymethylheptanoyl)pyrrolidinyl)ethyl-8,11-dimethyl-
3,10-dioxophenyl-2,6,13-trioxa-4,9-diazatetradecyl)phenoxy)
(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (1.8):
To 1.7 (10 mg, 6 μmol) in of MeOH (200 μL) at RT was added samarium metal (10
mg, 66 μmol) and ammonium chloride (10 mg, 100 μmol). The on mixture was
sonicated for 10 minutes at which time LC/MS showed the reaction was complete. Hünig’s
base (50 μL) was then added to the reaction, which was subsequently filtered via a fritted
. The reaction mixture was then taken up in water and purified by preparatory HPLC
(gradient 5-95 acetonitrile/water 0.05 % TFA) to yield 22 mg of 1.8. MS (m/z) [M + H]+ cald
for N7O19 1448.75, found 1448.71.
The synthesis of (2R,3S,4R,5R,6R)(2-amino((7S,8R,11R,12R)((S)
((3R,4S,5S)((S)((S)(dimethylamino)methylbutanamido)-N,3-
dimethylbutanamido)methoxymethylheptanoyl)pyrrolidinyl)ethyl-8,11-dimethyl-
3,10-dioxophenyl-2,6,13-trioxa-4,9-diazatetradecyl)phenoxy)
(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (1.9)
To a 1 dram vial equipped with a stir bar was added 100 µL of DCM followed by 5
mg (4.0 µmol) 1.8, Fmoc β-alanine (3 mg, 14 µmol) and 5 mg (21 µmol) N-ethoxycarbonyl-
2-ethoxy-1,2-dihydroquinoline. The reaction mixture was then stirred for 3 h at RT at which
time LC/MS indicated the reaction was te. The reaction was purified ly by
preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) to yield 5 mg of 1.9, 83 %.
MS (m/z) [M + H]+ cald C82H114N8O22 1563.80, found 1563.84.
The synthesis of (2R,3R,4R,5S,6R)(4-((7S,8R,11R,12R)((S)((3R,4S,5S)
((S)((S)(dimethylamino)methylbutanamido)-N,3-dimethylbutanamido)methoxy
methylheptanoyl)pyrrolidinyl)ethyl-8,11-dimethyl-3,10-dioxophenyl-2,6,13-trioxa-
4,9-diazatetradecyl)(3-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)propanamido
)propanamido)phenoxy )-3,4,5-trihydroxytetrahydro-2H-pyrancarboxylic acid, (2.0)
To a MeOH:Water 1:1 solution of 1.9 (5 mg, 3 μmol) was added LiOH (5 mg). The
resulting reaction mixture was then vigorously stirred for 10 min at RT at which time LC/MS
showed the reaction was complete. Subsequently, the reaction mixture was ly purified
by atory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) to yield 4 mg of
deprotected 1.9. DMF (100 μL) was added to a vial containing 4 mg of deprotected 1.9
followed by Hünig’s base (20 μL) and 3-maleimidopropionic acid N-hydroxysuccimide ester
(10 mg, 40 μmol). The reaction was stirred for 10 minutes at RT at which time LC/MS
indicated the reaction was complete. The reaction mixture was subsequently purified directly
by preparatory HPLC by first quenching with 3 mL of 2 % TFA:water (HPLC gradient 5-95
itrile/water 0.05 % TFA) to yield 4.0 mg of 2.0. MS (m/z) [M + H]+ cald for
C67H101N9O20, 1351.72, found 1351.65.
Similarly to Examples 1 and 2 monomethyl auristatin E (MMAE) and auristatin T
Drug-Linker Compounds sing the MAC having the ing structures are prepared:
MAC Unit
Me O
Me Me Me
O Me O* N O OAc
H H R
N N AcO OAc
H N
N N
Me O Me OMe O OMe O Me
Me Me O O CO2Me
O NH
O NH
MMAE Drug Unit
O N O
wherein R is en or ethyl and O* is the oxygen heteroatom of the MAC unit
from the secondary hydroxyl functional group of auristatin T or MMAE.
Example 3: Synthesis of a Model Self-immolative Assembly unit having a cyclic
MAC Unit and its conditional self-immolation
NHFmoc NHFmoc
O O
O O OH
O O O N
HN H2N
OH HN
O DMF, 92% O
OAc N+
O –O OAc
O O
O O
OAc OAc
O OAc
3.0 O OAc 3.1
sis of (2S,3R,4S,5S,6S)(2-(3-((((9H-fluoren
yl)methoxy)carbonyl)amino)propanamido)((((4-
hydroxybutyl)carbamoyl)oxy)methyl)phenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-
3,4,5-triyl tate (3.1):
To a mixture of the para-nitrophenyl carbonate 3.0 (300 mg, 0.33 mmol) in DMF (5
mL) was added the 4-aminobutanol (58 mg, 0.66 mmol). Upon addition of the 4-
aminobutanol, the reaction was complete as judged by UPLC-MS. The e was
poured into ethyl acetate (100 mL) which was washed with water (3x50 mL) and brine (1x50
mL). The organic phase was dried over sodium sulfate, decanted and concentrated to a
residue which was purified by radial chromatography on a 2 mm radial chromatotron plate
eluting with ethyl acetate. Product-containing fractions were concentrated under reduced
pressure to give 260 mg (92%) of 3.1: 1H NMR (CDCl3) δ 8.40 (s, 1H), 8.07 (s, 1H)), 7.75
(d, 2H, J=7.9 Hz), 7.60 (d, 2H, J=7.4 Hz), 7.38 (t, 2H, J=7.4 Hz), 7.29 (m, 2H), 7.01 (d, 1H,
J=2.0Hz), 6.91 (d, 1H, J=6.2 Hz), 5.73 (bs, 1H), 5.4 (t, 1H, J=9.4 Hz), 5.29 (m, 2H), 5.05-
.03 (m, 3H), 4.95 (m, 1H), 4.38 (pent, 2H, J=7.5 Hz), 4.23 (t, 1H, J=7.1 Hz), 4.16 (d, 1H,
J=9.7 Hz), 3.73 (s, 3H), 3.65-3.50 (m, 7H), 3.21 (m, 2H), 2.73 (m, 2H), 2.06-2.04 (m, 9H),
1.65-1.59 (m, 4H); UPLC-MS (m/z) (AP+) 864.44 (M+H), tr =1.44 min (flow rate 0.7
mL/min).
(2S,3R,4S,5S,6S)(2-(3-((((9H-fluorenyl)methoxy)carbonyl)amino)propanamido)(((2-
hydroxypyrrolidinecarbonyl)oxy)methyl)phenoxy)(methoxycarbonyl)tetrahydro-2H-
pyran-3,4,5-triyl tate (3.2):
To a mixture of the alcohol 3.1 (50 mg, 0.056 mmol) in dichloromethane (2 mL) was
added Dess-Martin periodinane (30 mg, 0.067 mmol). The reaction mixture was stirred for
3h before being purified directly on a 1 mm radial chromatotron plate, eluting with 50% ethyl
acetate in hexanes, followed by 100% ethyl acetate to provide 19.4 mg (39%) of 3.2: 1H
NMR (CD3OD) δ 8.04 (d, 2H, J=6.3 Hz), 7.78 (d, 2H, J=7.4 Hz), 7.63 (d, 2H, J=7.5 Hz),
7.37 (t, 2H, J=7.4 Hz), 7.25 (q, 2H, J=7.4 Hz), 7.22 (m, 2H), 7.11 (t, 2H, J=8.2 Hz), 5.49 (t,
1H, J=10.2 Hz), 5.46 (bs, 1H), 5.40 (d, 1H, J=7.9 Hz), 5.19 (t, 1H, J=9.8 Hz), 5.06-5.00 (m,
2H), 4.76 (d, 1H, J=10.1 Hz), 4.37-4.30 (m, 2H), 4.25 (t, 1H, J=6.2 Hz) 3.69 (s, 3H), 3.55-
3.45 (m, 4H), 2.65 (pent, 2H, J=6.7 Hz), 2.07-1.95 (m, 11H), 1.24 (m, 3H); S (m/z)
(AP+) 884.41 ), tr = 1.48 min (flow rate 0.7 mL/min).
Synthesis of (2S,3R,4S,5S,6S)(2-(3-((((9H-fluoren
yl)methoxy)carbonyl)amino)propanamido)(((2-phenethoxypyrrolidine
carbonyl)oxy)methyl)phenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl
triacetate (3.3):
To a e of the pyrrolidinol 3.2 (19.4 mg, 22.4 μmol) in romethane (2 mL)
was added TMSCl (20 μL) and the reaction mixture was stirred for 1h. The mixture was
concentrated under reduced pressure, including high vacuum for 10 min. The resulting
residue was dissolved in dichloromethane (1 mL) followed by a 2-hydroxyethylbenzene (10
μL) along with DIPEA (10 μL). Immediately post addition of the alcohol and DIPEA, the
reaction was te as judged by UPLC-MS. The mixture was aspirated directly onto a 1
mm radial chromatotron plate and eluted with 50% ethyl acetate in hexanes to give 13.8 mg
(63%) of 3.3: 1H NMR (CD3OD) δ 8.13 (bs, 1H), 8.08 (bs, 1H), 7.76 (d, 2H, J=7.4 Hz), 7.61
(d, 2H, J=7.4 Hz), 7.35 (t, 2H, J=7.4 Hz), 7.27-7.03 (m, 8H), , 1H, J=9Hz), 5.37 (d, 1H,
J=7.9 Hz), 5.3-5.17 (m, 3H), 5.05-4.99 (m, 2H), 4.44 (d, 1H, J=9.8 Hz), 4.34-4.30 (m, 2H),
4.22 (bs, 1H), 3.79-3.67 (m, 1H), 3.66 (s, 3H), 3.64-3.55 (m, 2H), 3.49 (bs, 1H), 3.30 (m,
1H), 2.79 (bs, 1H), 2.66 (m, 3H), 2.01 (s, 6H), 1.96 (s, 3H), 1.81 (m, 2H), 1.75-1.65 (m, 2H);
Analytical UPLC-MS: MS (m/z) (ESI+) 988.48 (M+Na+), tr = 1.65 min (flow rate 0.7
mL/min).
sis of (2S,3S,4S,5R,6S)(2-(3-aminopropanamido)(((2-
phenethoxypyrrolidinecarbonyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-
pyrancarboxylic acid (3.4):
To a mixture of the pyrrolidine 3.3 (50 mg) in methanol (2 mL) and THF (2 mL) was
added drop-wise an aqueous solution of 1.0 N lithium hydroxide (2 mL). The reaction
mixture was stirred for 1h at an ambient temperature. Inspection of the reaction mixture by
UPLC-MS ed complete deprotection to a ~2:1 mixture of desired product 3.4 to
elimination product 3.5. The reaction mixture was neutralized to pH 7 by the drop-wise
addition of acetic acid. The mixture was concentrated under reduced pressure and the
resulting residue was taken up in deionized water (2 mL) and filtered. This solution was used
directly to assess in vitro stability using conditions described in example 8: Analytical UPLCMS
: MS (m/z) 604.35 (M+H+), tr (3.4) = 0.88 min (flow rate 0.7 mL/min).
Example 4: Synthesis of a Triptolide inker Compound comprising a
MAC Unit
Synthesis of (2S,3R,4S,5S,6S)(4-(((ethyl((((5bS,5cS,6aR,7S,7aR,8aS,8bS,9aS,9bS)-
7a-isopropyl-9b-methyloxo-1,3,5,5b,5c,6a,6b,7,7a,8a,8b,9b-dodecahydro-2H
tris(oxireno)[2',3':4b,5;2'',3'' :6,7;2''',3''':9 ,10] phenanthro[1,2-c]furan
yl)oxy)methyl)carbamoyl)oxy)methyl)nitrophenoxy)(methoxycarbonyl)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (4.1):
Following the chloramine procedure from Example 2 for preparing nd 1.7:
Utilizing 109 mg (0.17 mmol) of 250 mg (0.13 mmol) 1.5, (, of 7.0 and 65 µl (4.30 mmol) of
Hünig’s base provided 85 mg of 7.1, 72 % yield. Analytical UPLC-MS: tr = 2.21 min. MS
(m/z) [M + H]+ cald C44H52N2O20 929.31, found .
Synthesis of (2S,3R,4S,5S,6S)(2-amino(((ethyl((((5bS,5cS,6aR,7S,7
aR,8aS,8bS,9aS,9bS)-7a-isopropyl-9b-methyloxo-1,3,5,5b,5c,6a,6b,7,7a,8a,8b,9bdodecahydro-2H-tris
no) [2',3':4b,5;2'',3'':6,7;2''',3''':9,10]phenanthro[1,2-c]furan
yl)oxy) methyl)carbamoyl)oxy) methyl)phenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-
3,4,5-triyl triacetate (4.2):
A 25 mL round bottom flask was equipped with an argon balloon was charged with
370 µL of MeOH, 85 mg (0.1 mmol) of 4.1 and 5 mg of 10% Pd/C. The reaction mixture was
then vacuumed, purged and flushed with hydrogen via balloon 3 times. Equipped with a
hydrogen balloon the reaction mixture was vigorously stirred for 1 h at RT at which time
LC/MS indicated the reactions was complete. The reaction mixture was then filtered and
purified by preparatory HPLC (gradient 5-95 itrile/water 0.05 % TFA) to yield 35 mg
of 4.2, 44 % yield. Analytical UPLC-MS: tr = 2.14 min. MS (m/z) [M + H]+ cald
C44H54N2O18 899.34, found .
[0457] sis of (2S,3R,4S,5S,6S)(2-(3-((((9H-fluorenyl)methoxy)carbonyl)amino)
propanamido)(((ethyl((((5bS,5cS,6aR,7S,7aR,8aS,8bS,9aS,9bS)-7a-isopropyl-9b-methyl
oxo-1,3,5,5b,5c,6a,6b,7,7a,8a,8b,9b-dodecahydro-2H-tris(oxireno)[2',3':4b,5;2'',3'':6,
7;2''',3''':9,10] phenanthro[1,2-c]furanyl)oxy)methyl)carbamoyl)oxy)methyl)phenoxy)
(methoxycarbonyl )tetrahydro-2H-pyran-3,4,5-triyl triacetate (4.3):
To a 1 dram vial equipped with a stir bar was added 200 µL of DCM ed by 6
mg (7.0 µmol) 4.2, Fmoc β-alanine (8 mg, 28 µmol) and 7 mg (0. 28 µmol) N-
ethoxycarbonylethoxy-1,2-dihydroquinoline. The on mixture was then stirred for an
additional 3 h at RT at which time LC/MS indicated the reaction was complete. The reaction
was purified directly by preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) to
yield 6 mg of 4.3, 75 %. Analytical UPLC-MS: tr = 2.34 min. MS (m/z) [M + H]+ cald
C62H69N3O21 1192.44, found 1192.45.
Synthesis of (2S,3S,4S,5R,6S)(2-(3-aminopropanamido)(((ethyl((((5bS,5cS,6aR,
7S,7aR,8aS, 8bS,9aS,9bS)-7a-isopropyl-9b-methyloxo-1,3,5,5b,5c,6a,6b,7,7a,8a,8b,9b-
dodecahydro-2H-tris(oxireno) [2',3':4b,5;2'',3'': 6,7;2''',3''':9,10]phenanthro[1,2-c]furan
yl)oxy)methyl) oyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran
carboxylic acid (4.4):
Following the deprotection method in Example 2 for obtaining compound 2.0:
Compound 4.3 (4.0 mg, 3 µmol) was converted to 2.8 mg of 4.4, 95 % yield. Analytical
UPLC-MS: tr = 1.14 min. MS (m/z) [M + H]+ cald C40H51N3O16 830.33, found 830.32.
Synthesis of (2S,3S,4S,5R,6S)(2-(3-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)
propanamido)propanamido)(((ethyl((((5bS,5cS,6aR,7S,7aR,8aS,8bS,9aS,9bS)-7aisopropyl-9b-methyloxo1
,3,5,5b,5c,6a,6b,7,7a,8a,8b,9b-dodecahydro-2H xireno)
[2',3':4b,5;2'', 3'':6,7;2''',3''':9,10]phenanthro[1,2-c]furan-7yl)oxy)methyl) carbamoyl)
oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyrancarboxylic acid (4.5):
To a 1 dram vial ning 2 mg of 4.4 (2 µmol) was added 100 μL of DMF
followed by 20 μL (0.1 mmol) of Hünig’s base and 2.5 mg (9 μmol) of 3-maleimidopropionic
acid N-hydroxysuccimide ester. The reaction mixture was then stirred for an onal 10
minutes at RT at which time LC/MS indicated the reaction was complete. The reaction was
ly purified by preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) by first
quenching with 2 % TFA:water (3 mL) to yield 1.8 mg, 90 % yield, of 4.5. Analytical UPLCMS
: tr = 1.61 min. MS (m/z) [M + H]+ cald for C47H56N4O19, 981.35, found 981.38.
[0463] Example 5: sis of an Everolimus Drug-Linker Compound comprising a
MAC Unit
Synthesis of 2-(trimethylsilyl)ethyl 2-(2-{[(1R,2R,4R)[(2S)
[(1R,9S,12S,15R,16E,18R, 19R, 21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-
dimethoxy-15,17,21,23,29,35 hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa
azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraeny l]propyl]
methoxycyclohexyl]oxy}ethoxy)acetate (5.1):
A 1 dram vial ed with a septa screw cap and stir bar was charged with 1 mL
of dry DCM, 2 mg (1 µmol) rhodium diacetate and 100 mg (0.1 mmol) of everolimus (5.1).
Added dropwise to the reaction mixture with stirring at RT was 40 µL (0.2 mmol) trimethylethyl
diazoacetate (5.0). LC/MS indicated the reaction was complete after 1 hour. Afterwards,
1 mL of MeOH was added and the reaction was filtered and dried in vacuo. The resultant oil
and then purified by preparatory TLC (hexanes:ethyl acetate, 1:1, rf = 0.50) to yield 73 mg,
68 % yield, of 5.2. Analytical UPLC-MS: tr = 1.92 min. MS (m/z) [M + H]+ cald for
NO16Si, 1116.66, found 1116.66.
Synthesis [(1R,2R,4R)[(2S)-
2[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E, 28E,30S,32S,35R)-1,18-dihydroxy-19,30-
dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa
azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraenyl]propyl]
methoxycyclohexyl]oxy}ethoxy)acetic acid (5.3):
A 1 dram vial equipped with a septa screw cap and stir bar was charged with 1 mL
of dry DMF, 70 mg (63 µmol) of 5.2 and 52 mg (1.89 mmol) of
tris(dimethylamino)sulfonium difluorotrimethylsilicate. The stirred reaction at RT was
monitored by LC/MS and was complete after 20 min. The reaction mixture was then treated
with 5 mL of 10 M phosphate buffered saline and extracted ethyl ether 3 X 5 ml. The organic
layer was dried in vacuo. The resultant oil was then ed by preparatory TLC
(DCM:MeOH:AcOH, 0.1, rf = 0.45) to yield 57 mg, 89 % yield, of 5.3. Analytical
UPLC-MS: tr = 1.79 min. MS (m/z) [M + H]+ cald for C55H85NO16, 1016.59, found 1016.61.
[0468] Synthesis of {4-[(2R)[(2R)aminomethylbutanamido]-5(carbamoylamino)
pentanamido] phenyl}methyl N-[(2-{[(1R,2R,4R)[(2S)
[(1R,9S,12S,15R,16E,18R,19R,21R, 23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-
oxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa
azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraenyl]propyl]
methoxycyclohexyl]oxy}ethoxy)methyl]carbamate (5.5):
To a 1 dram vial containing 15 mg (15 µmol) of 5.3 was added 300 μL DMF
followed by 8 μL (30 µmol) of diphenylphosphoryl azide and 6 μL (45 µmol) of Hünig’s
base. The resulting e was d at RT for 1 h.at which time , 44 mg (75 µmol) of 5.4
and 2 μl (3 µmol) of dibutyltin dilaurate was added to the reaction mixture at 60 °C. The
reaction was stirred for an additional 2 h at 60 °C at which time LC/MS indicated the reaction
was complete. The reaction mixture was quenched with 100 µL of diethyl amine and then
directly purified by preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) to yield
mg, 47 % yield, of 5.5. Analytical UPLC-MS: tr = 1.49 min. MS (m/z) [M + H]+ cald for
C73H113N7O19, 1392.81, found 1392.80.
sis of {4-[(2R)(carbamoylamino)[(2R)[3-(2,5-dioxo-2,5-dihydro-1H-
pyrrolyl) propanamido]methylbutanamido]pentanamido]phenyl}methyl N-[(2-
2R,4R)[(2S)[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-
1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-
11,36-dioxaazatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraenyl]propyl]
methoxycyclohexyl] oxy}ethoxy) methyl]carbamate (5.6):
To a 1 dram vial containing 8 mg (5 µmol) of 5.5 was added 100 μL of DMF
followed by 20 μl (0.15 mmol) of Hünig’s base and 3-maleimidopropionic acid 5 mg (18
μmol) N-hydroxysuccimide ester. The reaction was then stirred for an onal 30 minutes
at RT at which time LC/MS indicated the on was complete. The reaction was directly
purified by preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) by first
quenching with 2 % TFA:water (3 mL) to yield 5 mg, 62 % yield, of 9.3. Analytical UPLCMS
: tr = 1.69 min. MS (m/z) MS (m/z) [M + H] + cald for C80H118N8O22, 1543.84, found
1543.86.
Example 6: Synthesis of a Tacrolimus Drug-Linker Compound comprising a
MAC Unit
Synthesis of 2-{[(1R,2R)[(1E)
[(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-23,25-dimethoxy-
13,19,21,27-tetramethyl-2,3,10,16-tetraoxo(propenyl)-11,28-dioxa
azatricyclo[22.3.1.0⁴,⁹]octacosenyl]propenyl]methoxycyclohexyl]oxy}acetic
acid (6.3):
To a 4 dram vial equipped with a septa screw cap and an argon balloon was charged
with 3 mL of dry DCM, 13 mg (60 µmol) of m diacetate and 500 mg (0.6 mmol) of
FK-506 (6.1). Afterwards, 200 µL (1.2 mmol) of tert-butyl cetate in 200 µL of DCM
was added dropwise to the stirred reaction mixture at 39 °C via syringe pump. LC/MS
indicated the reaction was complete after 1 hour whereupon 1 mL of MeOH was added. The
reaction mixture was then filtered and dried in vacuo. The resultant oil was d with 4 mL
of a DCM and trifluoroacetic acid (5:1) solution. The deprotection reaction was te
after 1 h as indicated by LC/MS. The resulting reaction mixture was then dried in vacuo and
purified by preparatory TLC (10 % MeOH:DCM, rf = 0.20) to yield 378 mg, 71 % yield, of
6.1. Analytical UPLC-MS: tr = 1.89 min. MS (m/z) [M + H]+ cald for C46H71NO14, 862.49,
found 862.52.
Synthesis S)[(2S)aminomethylbutanamido]-5(carbamoylamino)
pentanamido]phenyl}methyl N-({[(1R,2R)[(1E)[(1R,9S,12S,13R,14S,17R, 18E,21S,23S,
S,27R)-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-2,3,10,16-tetraoxo-
17-(propenyl)-11,28-dioxaazatricyclo[22.3.1.0⁴,⁹]octacosenyl]propen
yl]methoxycyclohexyl] oxy}methyl) carbamate (6.3):
H2N O O
Me Me
HN O O
MeO Me
O OH
N O
6.3 Me
HO O
Me OMe
OMe
To a 4 dram vial containing 50 mg (58 µmol) of 6.1 was added 300 μL of DMF
followed by 23 μl (87 µmol) of diphenylphosphoryl azide and 14 μL (1.2 mmol) of Hünig’s
base. The reaction mixture was then stirred at RT for 1 h. Afterwards, 52 mg (87 µmol) of
6.2, and 2 μL (3 µmol) of dibutyltin dilaurate was added at 60 °C. The reaction was then
stirred for an onal 2 h at 60 °C at which time LC/MS ted the reaction was
complete. After quenching with a 100 µL of diethyl amine, the on mixture was directly
purified by preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) to yield 15 mg,
21 % yield, of 6.3. Analytical UPLC-MS: tr = 1.82 min. MS (m/z) [M + H]+ cald for
C74H114N10O22, 1238.71, found 1238.70.
The synthesis of {4-[(2S)(carbamoylamino)[(2S)[3-(2,5-dioxo-2,5-dihydro-
1H-pyrrolyl)propanamido]methylbutanamido]pentanamido]phenyl}methyl-N-
({[(1R,2R)[(1E)-2[(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-
23,25-dimethoxy-13,19,21,27-tetramethyl-2,3,10,16-tetraoxo(propenyl)-11,28-
dioxaazatricyclo[22.3.1.0⁴,⁹]octacosenyl]propenyl]-2methoxycyclohexyl]
thyl)carbamate (6.4):
To a 1 dram vial containing 4 mg (3 µmol) of 6.3 was added 100 μL of DMF
followed by 20 μl (0.1 mmol) of Hünig’s base and 2.5 mg (9 μmol) 3-maleimidopropionic
acid N-hydroxysuccimide ester. Afterwards, the reaction was stirred for an additional 30
minutes at RT at which time LC/MS indicated the reaction was complete. The reaction was
directly purified by preparatory HPLC (gradient 5-95 acetonitrile/water 0.05 % TFA) by first
ing the reaction with 2 % TFA:water (3 mL) to yield 3.4 mg, 85 % yield, of 6.4.
Analytical UPLC-MS: tr = 1.78 min. MS (m/z) [M + H]+ cald for C71H104N8O20, 1389.74,
found 1389.77. Half-life in 0.1 M PBS buffer, pH 7.4 at 37 ͦ C determined according to the
method of Example 8 is 10 hrs.
Example 7: Synthesis of an tetrahydroquinoline-containing Drug-Linker
nd comprising a MAC Unit variant
[0480] Synthesis of ethyl 2-((8S,9R)fluoro(4-fluorophenyl)(1-methyl-1H-1,2,4-
triazolyl)oxo-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-7(3H)-yl)acetate (7.3):
A flame dried flask was charged with (8S,9R)fluoro(4-fluorophenyl)(1-
methyl-1H-1,2,4-triazolyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one (7.0, 49
mg, 129 µmol) in 2.2 mL anhydrous THF. The solution was stirred at -80 ͦ C under N2 and n-
butyl lithium (77 µL, 188 µmol) as a 2.5 M solution was added dropwise and the ing
reaction was stirred for an additional 10 min at -80 ͦ C. Ethyl iodoacetate (7.2, 31 µL, 258
µmol) was then added as a solution in 1 mL of anhydrous THF. Subsequently, the reaction
mixture was stirred under nitrogen at 0 ͦ C until LC/MS revealed conversion to product was
complete. The reaction mixture was then cooled to -80 ͦ C and quenched with saturated
ammonium chloride, d with romethane, and washed with sodium bicarbonate.
The s layer was then extracted with dichloromethane, and the combined organics were
washed with brine, dried over sodium sulfate, and concentrated to dryness. The crude
product was ed over silica via a Biotage column eluting with methanol:dichloromethane
mixtures to provide 7.3 (43 mg, 72%). Analytical UPLC-MS: tr = 1.79 min, m/z (ES+) found
467.55.
Synthesis of 2-((8S,9R)fluoro(4-fluorophenyl)(1-methyl-1H-1,2,4-triazol
yl)oxo-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-7(3H)-yl)acetic acid (7.4):
A flask was charged with 43 mg ester 7.3 (92 µmol) which was then dissolved in THF
(1.5 mL) and MeOH (1.5 mL). The resulting solution was stirred under N2 and cooled to 0
oC. Lithium hydroxide monohydrate (7.8 mg, 184 µmol) solubilized in H
2O (1.5 mL) was
then added dropwise. Afterwards, the reaction was d to warm to RT and stirred for 2
hours. The reaction was then quenched with acetic acid (10.5 µL, 184 µmol) and condensed
under reduced pressure. The residue was taken up in minimal DMSO and purified by
preparative LC to provide 7.4 (35 mg, 87%). Analytical UPLC-MS: tr = 1.47 min, m/z (ES+)
found 439.42.
Synthesis of 2-((8S,9R)fluoro(4-fluorophenyl)(1-methyl-1H-1,2,4-triazol
yl)oxo-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-7(3H)-yl)acetyl azide (7.5):
A flask was charged with free carboxylic acid (7.4, 28 mg, 64 µmol), which was then
dissolved in anhydrous THF (1.3 mL). Triethylamine (22 µL, 160 µmol) was added and the
resulting on mixture was d for 10 minutes at RT under nitrogen.
Diphenylphosphoryl azide (14 µL, 64 µmol) was then added and the resulting reaction
mixture was stirred for 2 hours at RT, at which time S ed conversion to
product. The material was then concentrated under reduced pressure to provide crude acyl
azide 7.5, which was d forward t further characterization. Analytical LC-MS: tr
= 12.80 min, m/z (ES+) found 436.16 (M+H-N2).
Synthesis of ,4S,5S,6S)(2-(3-((((9H-fluoren
yl)methoxy)carbonyl)amino)propanamido)((((((8S,9R)fluoro(4-fluorophenyl)(1-
methyl-1H-1,2,4-triazolyl)oxo-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-7(3H)-
yl)methyl)carbamoyl)oxy)methyl)phenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-
triyl triacetate (7.6):
To a flask containing acyl azide (7.5, 64 µmol) in anhydrous DMF (0.3 mL) was
added the previously described (Bioconjugate Chem. 2006, 17, 831-840) glucuronidecontaining
compound Fmoc-βAla-glucuronide benzyl alcohol (96 mg, 128 µmol).
uently, the reaction mixture was heated to and stirred at 65 ͦ C to e the
rearrangement of the acyl azide to the isocyanate with uent trapping to form the
carbamate onal group. After 2 hours, catalytic dibutyltin dilaurate was added.
Continued stirring at 65 ͦ C for 5 hours resulted in modest conversion to t. The
reaction was diluted in acetonitrile and dimethylsulfoxide and purified by preparative HPLC
to provide 7.6 (4.4 mg, 6%). Analytical UPLC-MS: tr = 2.27 min, m/z (ES+) found 1185.29.
Synthesis of (2S,3S,4S,5R,6S)(2-(3-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)propanamido)propanamido)((((((8S,9R)fluoro(4-fluorophenyl)(1-methyl-1H-
1,2,4-triazolyl)oxo-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-7(3H)-
yl)methyl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran
carboxylic acid (7.7):
A flask charged with 4.4 mg protected glucuronide linker intermediate 7.6 (3.7 µmol)
was dissolved in THF (0.13 mL) and MeOH (0.13 mL). The resulting solution was stirred
under N2 and cooled to 0 oC. LiOH · H2O (0.9 mg, 22 µmol) solubilized in H2O (0.13 mL)
was then added dropwise. The reaction was then allowed to warm to RT and stirred for an
additional 4 hours. The reaction mixture was then quenched with acetic acid (1.3 µL, 22
µmol) and condensed under reduced pressure. The residue obtained was taken up in minimal
DMSO and purified by preparative LC to e the deprotected glucuronide linker (1.6 mg,
53%). Analytical UPLC-MS: tr = 1.20 min, m/z (ES+) found . Maleimidopropionyl
NHS ester (0.8 mg, 2.9 µmol) was dissolved in anhydrous DMF (0.19) and added to a flask
containing the globally deprotected glucuronide linker (1.6 mg, 1.9 µmol). DIPEA (1.7 µL,
9.5 µmol) was then added and the reaction was stirred under nitrogen at RT for 3 hours.
Subsequently, the reaction was diluted in acetonitrile and dimethylsulfoxide and purified by
preparative HPLC to provide drug-linker 7.7 (2 mg, 97%). ical UPLC-MS: tr = 1.41
min, m/z (ES+) found 973.43.
Example 8: ation of drug-linker model systems having Self-immolative
Assembly Units that release hydroxyl and thiol-containing compounds as model free
drugs.
ary Self-immolative Assembly Units with covalent attachment to Drug Units
incorporating structures of model drugs were prepared via N-chlormethylamine synthesis
according to the following scheme, wherein each mmolative Assembly Unit prepared is
comprised of a self-immolative moiety of structure XVId (i.e., -PABA(gluc)-) and a MAC
Unit:
wherein variations in R and D-T*-H free drug, which is used in the synthesis and released
upon activation of the PABA(gluc) self-immolative moiety, are as s in Table 1:
Table 1. Hydroxyl- and thiol-containing compounds as model free drugs with
ion in MAC Unit substitution
D-T*-H R
-CH2CH3
HO -CH2CH2N(CH3)2
H3C CH3
General procedure for alkylation of a phile from D-T*-H with 1.5: To a round
bottom flask equipped with a stir bar, septa and argon balloon and charged with 5 mL of dry
DCM, 1 mmol of D-T*-H, 5 mmol of Hünig’s base was added followed by 2 mmol of N-
chlormethylamine compound 1.5 via syringe at once. The reaction was monitored by LC/MS
until starting material D-T*-H was consumed; ons were typically completed within 2 h.
The reaction mixture was dried in vacuo via rotoevaporation. The resultant oil was then
purified via Biotage FCC with ethyl acetate and hexanes gradient.
Synthesis of (2S,3R,4S,5S,6S)(4-(((ethyl(phenethoxymethyl)carbamoyl)oxy)methyl)-
2-nitrophenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.1):
Following general alkylation procedure: Utilizing (621 mg, 1.05 mmol) of 1.5, (250
µL, 2.1 mmol) of 8.0 and (939 µL, 5.25 mmol) of Hünig’s base provided 615 mg of 8.1, 85
% yield. MS (m/z) [M + H]+ cald C32H38N2O15 , found 691.25, 1H NMR (400 MHz,
CDCl3) δ = 7.80 (s, 1H), 7.52 (dd, J = 9.2, 8.1 Hz, 1H), 7.37-7.30 (m, 1H), 7.27 (t, J=3.5,
2H), 7.23-7.14 (m, 3H), 5.38-5.27 (m, 3H), 5.20 (d, J = 5.9, 1H), 5.12 (d, J = 5.4, 2H), 4.71
(d, J = 14.0, 2H), 4.20 (d, J =11.3, 1H), 3.73 (s, 3H), 3.65 (dt, J = 12.5, 3.5, 2H), 3.39-3.26
(m, 2H), 2.80 (m, 2H), 2.11 (s, 3H), 2.06 (s, 6H), 1.14-1.06 (m, 3H).
[0496] Synthesis of (2S,3R,4S,5S,6S)(4-(((ethyl(((1-phenylpropan-2yl)oxy)
methyl)carbamoyl)oxy) methyl)nitrophenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-
3,4,5-triyl tate (8.3):
[0497] Following general alkylation procedure: Utilizing (105 mg, 0.175 mmol) of 1.5, (47
µL, 0.35 mmol) of 8.2 and (156.6 µL, 0.87 mmol) of Hünig’s base provided 111 mg of 8.3,
90 % yield. MS (m/z) [M + H]+ cald C33H40N2O15 , found 705.65, 1H NMR (400 MHz,
CDCl3) δ = 7.80 (s, 1H), 7.52 (dd, J = 9.2, 8.1 Hz, 1H), 7.37-7.10 (m, 5H), 5.38-5.27 (m,
3H), 5.25-5.01 (m, 3H), 4.80-4.63 (m, 2H), 4.19 (d, J = 14.0, 2H), 4.20 (d, J =8.78, 1H), 3.73
(d, J=2.74, 3H), 03 (m, 2H), 2.80 (m, 2H), 2.60 (dd, J = 13.11, 4.64, 1H), 2.11 (s, 3H),
2.06 (s, 6H), 1.14-1.06 (t, J = 7.37, 3H).
Synthesis of ,4S,5S,6S)(4-(((ethyl(((2-methylphenylpropan
yl)oxy)methyl)carbamoyl)oxy)methyl)nitrophenoxy)(methoxycarbonyl)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (8.5):
Following general alkylation procedure: Utilizing (534 mg, 0.885 mmol) of 1.5,
(260 µL, 0.17 mmol) of 7.5 and (795 µL, 4.4 mmol) of Hünig’s base provided 390 mg of 7.6,
61 % yield. MS (m/z) [M + H]+ cald N2O15 719.26, found 719.24, 1H NMR (400 MHz,
CDCl3) δ = 7.80 (d, J=7.2 1H), 7.52 (dd, J = 9.7, 8.4 Hz, 1H), 7.40-7.29 (m, 1H), 7.25-7.13
(m, 5H), 5.37-5.26 (m, 3H), 5.12-5.09 (m, 2H), 4.81 (d, J = 32.0, 2H), 4.18 (m, 1H), 3.73 (s,
3H), 3.41-3.31 (m, 2H), 2.81-2.72 (d, J = 16.9, 2H), 2.11 (m, 3H), 2.11 (s, 3H), 2.05 (s, 6H),
1.19-1.10 (m, 9H).
Synthesis of (2S,3R,4S,5S,6S)(4-(((ethyl((naphthalen
yloxy)methyl)carbamoyl)oxy)methyl)nitrophenoxy)(methoxycarbonyl)tetrahydro-2H-
pyran-3,4,5-triyl tate (8.7):
Following general alkylation procedure: ing (791 mg, 1.3 mmol) of 1.5, (377
mg, 2.6 mmol) of 8.6 and (1.7 ml, 6.5 mmol) of Hünig’s base provided 768 mg of 8.7, 82 %
yield. MS (m/z) [M + H]+ cald C34H36N2O15 713.39, found 713.37, 1H NMR (400 MHz,
CDCl3) δ = 8.19 (dd, J = 16.3, 8.5 Hz, 1H), 7.80 (d, J = 7.2 1H), 7.47 (m, 3H), 7.34 (t, J =
.5 2H), 7.25 (m, 1H), 7.18 (m, 2H), 6.9 (dd, J = 39.5, 6.7 Hz, 1H) 5.49 (d, J = 14.9, 2H),
.30 (m, 3H), 5.21-5.02 (m, 3H), 4.18 (m, 1H), 3.73 (s, 3H), 3.64-3.49 (m, 2H), 2.31 (s, 2H),
2.12 (s, 3H), 2.06 (s, 6H), 1.32-1.18 (m, 3H).
[0502] Synthesis of (2S,3R,4S,5S,6S)(4-
(((ethyl((phenethylthio)methyl)carbamoyl)oxy)methyl)nitrophenoxy)
(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.9):
Following general alkylation procedure: Utilizing (43 mg, 0.070 mmol) of 1.5, (19
µL, 0.140 mmol) of 8.8 and (62 µL, 6.5 mmol) of Hünig’s base provided 42 mg of 8.9, 86 %
yield. MS (m/z) [M + H]+ cald C32H38N2O14S 707.20, found 707.18, 1H NMR (400 MHz,
CDCl3) δ = 7.79 (s, 1H), 7.50 (dd, J = 10.2, 8.7 Hz, 1H), 7.37-7.08 (m, 6H), 5.38-5.26 (m,
3H), .08 (m, 3H), 4.47 (d, J = 31.3, 2H), 4.17 (d, J = 9.6, 2H), 4.20 (d, J =11.3, 1H),
3.73 (s, 3H), 3.40 (m, 2H), 2.90-2.75 (m, 2H), 2.11 (s, 3H), 2.06 (d, J = 2.8, 6H), 1.14 (t, J =
6.6, 3H).
[0504] Synthesis of (2S,3R,4S,5S,6S)(4-((((2-
(dimethylamino)ethyl)carbamoyl)oxy)methyl)nitrophenoxy)
(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.11)
Compound 8.11 was synthesized using the procedure for 1.5. Utilizing (150 mg,
0.2 mM) 8.10 (for synthesis of 8.10 see Bosslet et al., 1998, J. Med. Chem. 2)
provided 155 mg of 8.11, 95 % yield. Analytical UPLC samples are prepared with MeOH to
quench the reactive chloride in 8.1. Analytical UPLC-MS: tr = 1.40 min, MS (m/z) [M + Na]+
cald for C27H37N3NO15 666.21, found 666.19.
Synthesis of (2S,3R,4S,5S,6S)(4-((((2-
hylamino)ethyl)(phenethoxymethyl)carbamoyl)oxy)methyl)nitrophenoxy)
(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl tate (8.12):
Following general alkylation procedure: Utilizing (97 mg, 0.150 mmol) of 8.11, (37
µL, 0.30 mmol) of 8.0 and (102 µL, 1.1 mmol) of Hünig’s base ed 76 mg of 8.12, 72
% yield. 1H NMR (400 MHz, CDCl 3) δ = 7.84-7.77 (m, 1H), 7.53 (dd, J = 46.5, 9.6 Hz, 1H),
7.35 (t, J = 8.2, 1H), 7.30-7.14 (m, 5H), 5.38-5.26 (m, 3H), 5.21 (t, J = 6.21, 3H), 5.12 (d, J
= 7.86, 2H), 4.76 (d, J = 15.7, 2H), 4.22 (dd, J =13.2, 7.4, 1H), 3.73 (s, 3H), 3.70-3.54 (m,
5H), 3.0 (t, J=5.9, 1H), 2.83 (t, J=6.6, 2H), 2.78 (s, 6H), 2.59 (s, 2H), 2.12 (s, 3H), 2.06 (d, J
=2.19, 6H).
Synthesis of (2S,3R,4S,5S,6S)(4-((((2-(dimethylamino)ethyl)(((2-methyl
phenylpropanyl)oxy)methyl)carbamoyl)oxy)methyl)nitrophenoxy)
(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.13):
Following general alkylation procedure: Utilizing (150 mg, 0.23 mmol) of 8.11,
(104 µL, 0.69 mmol) of 8.4 and (102 µL, 1.1 mmol) of Hünig’s base provided 118 mg of
8.13, 67 % yield. MS (m/z) [M + H]+ cald N4O15 , found 762.32, 1H NMR (400
MHz, CDCl3) δ = 7.80 (d, J = 24.6 1H), 7.53 (dd, J = 12.3, 8.4 Hz, 1H), 7.34 (t, J = 11.1,
1H), 7.26-7.13 (m, 5H), 5.38-5.26 (m, 3H), 5.21-5.09 (m, 3H), 4.47 (d, J = 27.2, 2H), 4.20 (t,
J = 9.74, 1H), 3.73 (s, 3H), 3.55 (td, J = 27.2, 7.7 2H), 2.84 (t, J = 9.7, 1H), 2.76 (t, J = 14.9,
2H), 2.84 (t, J = 9.0, 1H), 2.51 (s, 3H), 2.12 (s, 3H), 2.05 (s, 9H), 1.16 (d, J = 12.2, 6H).
[0510] Synthesis of (2S,3S,4S,5R,6S)(methoxycarbonyl)(4-(4-(methoxymethyl)oxo-
2,7,10,13,16,19,22,25,28-nonaoxaazanonacosyl)nitrophenoxy)tetrahydro-2H-pyran-
3,4,5-triyl triacetate (8.15)
Compound 8.15 was synthesized using the procedure for 1.5. Utilizing (500 mg,
0.56 mM) 8.14 (for synthesis of 8.14 see Bosslet et al., 1998, J. Med. Chem. 41:3572)
provided 516 mg of 8.15, 98 % yield. Analytical UPLC samples are ed with MeOH to
quench the reactive chloride in 8.15. Analytical UPLC-MS: tr = 1.91 min, MS (m/z) [M +
Na]+ cald for C40H62N2NO23 961.36, found 921.40.
Synthesis of (2S,3S,4S,5R,6S)(methoxycarbonyl)(2-nitro(3-oxo(((1-
phenylpropanyl)oxy)methyl)-2,7,10,13,16,19,22,25,28-nonaoxa
azanonacosyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.16):
Following general alkylation procedure: Utilizing (60 mg, 0.064 mmol) of 8.15, (17
µL, 0.128 mmol) of 8.2 and (41 µL, 0.32 mmol) of Hünig’s base provided 51 mg of 8.16, 84
% yield. MS (m/z) [M + H]+ cald C48H70N2O23 4, found 1043.47, 1H NMR (400 MHz,
CDCl3) δ = 7.79 (s, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.35 (dd, J = 9.9, 6.1 Hz, 1H), 7.26-7.07
(m, 5H), 5.38-5.27 (m, 3H), 5.20-5.16 (m, 3H), 4.80-4.70 (m, 1H), 4.20 (m, 1H), 3.73 (s, 3H),
3.66-3.49 (m, 32H), 3.45 (t, J = 7.08, 1H), 3.37 (s, 3H), 3.21 (m, 1H), 2.78 (m, 1H) 2.64 (dd,
J=13.1, 5.7, 1H), 2.12 (s, 3H), 2.05 (d, J = 2.12, 6H), 1.14 (m, 3H).
General procedure for reduction of the aryl nitro group to the aryl amine: A 1 dram
vial equipped with a stir bar and rubber septum was charged with 1 mmol of aryl nitro
compound and a 10:1 MeOH:AcOH (v/v %) for final concentration of 0.2 M. ted zinc,
mmol, was then added in one scoop and the resulting mixture was vigorously stirred at
RT. The reaction was monitored by LC/MS until its completion, which generally occurred
within 30 minutes. The reaction mixture was then filtered and the ant solid was washed
with excess MeOH. The filtrate was then azeotroped to dryness with toluene in vacuo. The
crude oil was then purified by e FCC with an ethyl e and hexanes gradient.
The synthesis of (2S,3S,4R,5R,6S)(2-amino
(((ethyl(phenethoxymethyl)carbamoyl)oxy)methyl)phenoxy)hydroxy
(methoxycarbonyl)tetrahydro-2H-pyran-3,4-diy ate (8.17):
Following general reduction procedure: In 400 µL of cOH 8.1 (52 mg,
0.075 mmol) was treated with zinc (96 mg, 1.5 mmol). Purification of the reaction mixture
yielded 43 mg of 8.17, 86 % yield. MS (m/z) [M + H]+ cald C32H40N2O13 661.25, found
661.23, 1H NMR (400 MHz, CDCl3) δ = 7.30-7.25 (m, 2H), 7.23-7.13 (m, 3H), 6.86 (dd, J =
13.6, 7.02, 1H), 6.66 (m, 2H), 5.38-5.27 (m, 3H), 5.00 (m, 3H), 4.77 (d, J = 15.5, 2H), 4.15
(d, J = 9.6, 1H), 3.80 (m, 2H), 3.74 (s, 3H), 3.68 (t, J = 7.02, 1H), 3.60 (m, 1H), 3.36-3.24
(m, 1H), 2.90-2.79 (m, 1H), 2.07 (s, 3H), 2.05 (d, J = 3.8 6H), 1.09 (q, 3H).
[0517] Synthesis of (2S,3R,4S,5S,6S)(2-amino(((ethyl(((1-phenylpropan
yl)oxy)methyl)carbamoyl)oxy)methyl)phenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-
3,4,5-triyl triacetate (8.18):
O Me O Me
MeO MeO
O O O N O O O O N O
AcO AcO
AcOAcO O Me AcOAcO O Me
O2N H2N
8.3 8.18
Following general reduction procedure: In 350 µL of MeOH:AcOH 8.3 (49 mg,
0.070 mmol) was treated with zinc (88 mg, 1.4 mmol). cation of the reaction e
yielded 44 mg of 8.18, 93 % yield. MS (m/z) [M + H]+ cald C3H42N2O13 , found
675.28, 1H NMR (400 MHz, CDCl3) δ = 7.92 (s, 1), 7.41-6.85 (m, 7H) 5.44-5.21 (m, 3H), 5.1
(m, 3H), 4.77 (d, J = 5.8, 2H), 4.18 (d, J = 8.7, 1H), 3.74 (d, J= 5.8, 2H), 3.73-3.45 (m, 2H),
3.34-3.23 (m, 2H), 2.89-2.78 (m, 2H), 2.45 (s, 1H), 2.21 (s, 2H), 2.00 (m, 9H), 1.09 (t, J =
6.7, 3H).
Synthesis of (2S,3R,4S,5S,6S)(2-amino(((ethyl(((2-methylphenylpropan
yl)oxy)methyl)carbamoyl)oxy)methyl)phenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-
3,4,5-triyl triacetate (8.19):
Following general reduction procedure: Compound 8.5 (56 mg, 0.074 mmol) in 390
µL of MeOH:AcOH was treated with zinc (90 mg, 1.42 mmol). Purification of the reaction
mixture yielded 44 mg of 8.19, 93 % yield. MS (m/z) [M + H]+ cald C34H44N2O13 689.28,
found 689.30, 1H NMR (400 MHz, CDCl3) δ = 7.26-7.14 (m, 5H), 6.86 (t, J = 7.0, 1H), 7.47
(m, 2H), 5.38-5.26 (m, 3H), 5.00 (s, 3H), .74 (d, J = 38.0, 2H), 4.14 (m, 1H), 3.80 (m,
2H), 3.74 (s, 3H), 3.49 (s, 6H), 3.35 (m, 2H), 2.77 (d, J = 22.0, 2H), 2.08 (s, 3H), 2.05 (d, J =
4.8, 6H), 1.13 (t, J = 6.7, 3H).
[0521] Synthesis of (2S,3R,4S,5S,6S)(2-amino(((ethyl((naphthalen
methyl)carbamoyl)oxy)methyl)phenoxy)(methoxycarbonyl)tetrahydro-2H-pyran-
3,4,5-triyl triacetate (8.20):
[0522] Following general reduction procedure: In 630 µL of cOH 8.7 (89 mg, 0.125
mmol) was treated with zinc (160 mg, 2.50 mmol). Purification of the reaction mixture
yielded 78 mg of 8.20, 88 % yield. MS (m/z) [M + H]+ cald C34H38N2O13 683.24, found
683.21, 1H NMR (400 MHz, CDCl3) δ = 8.23 (m, 1H), 7.80 (m, 1H), 7.48 (m, 2H), 7.36-7.27
(m, 1H), 7.26-6.40 (m, 5H), 4.4 (d, J = 36.0 2H), 5.38-5.27 (m, 3H), 5.00 (m, 3H), 4.15 (m,
1H), 3.80 (s, 3H), 3.66-3.45 (m, 2H), 2.36 (s, 3H), 2.05 (m, 9H), 3.60 (m, 1H), 1.25 (dt, J =
.0, 7.84, 1H).
Synthesis of (2S,3R,4S,5S,6S)(2-amino
(((ethyl((phenethylthio)methyl)carbamoyl)oxy)methyl)phenoxy)
xycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.21):
Following general reduction procedure: In 320 µL of MeOH:AcOH 8.9 (45 mg, 0.064
mmol) was treated with zinc (81 mg, 1.27 mmol). cation of the reaction mixture yielded
38 mg of 8.21, 84 % yield. MS (m/z) [M + H]+ cald C34H40N2O12S 677.23, found 677.20, 1H
NMR (400 MHz, CDCl3) δ = 7.81 (s, 1H), 7.51 (dd, J = 18.1, 8.6 Hz, 1H), 7.35-7.27 (m, 3H),
7.25-7.08 (m, 3H), 5.38-5.27 (m, 3H), 5.14 (m, 3H), 4.49 (d, J = 34.0, 2H), 4.20 (d, J = 7.90,
2H), 3.74 (s, 3H), 3.50 (s, 2H), 3.46-3.37 (m, 2H), 3.95-2.71 (m, 3H), 2.13 (s, 3H), 2.06 (d, J
= 2.8, 6H), 1.15 (t, J = 6.6, 3H).
[0525] Synthesis of (2S,3R,4S,5S,6S)(2-amino((((2-
(dimethylamino)ethyl)(phenethoxymethyl)carbamoyl)oxy)methyl)phenoxy)
(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.22):
[0526] Following general reduction procedure: Compound 8.12 (51 mg, 0.070 mmol) in 380
µL of MeOH:AcOH was treated with zinc (97 mg, 1.52 mmol). cation of the reaction
mixture yielded 40 mg of 8.22, 78 % yield. MS (m/z) [M + H]+ cald N3O13 ,
found 704.27, 1H NMR (400 MHz, DMSO) δ = 7.29-7.11 (m, 5H), 6.82 (t, J = 6.8, 1H), 6.62
(d, J = 1.8, 1H), 6.50 (t, J = 7.3, 1H), 5.52-5.42 (m, 2H), 5.13-5.01 (m, 2H), 4.72-4.63 (m,
5H), 3.62 (s, 3H), 3.54 (m, 2H), 3.24 (m, 2H), 2.75 (m, 2H), 2.40-2.29 (m, 2H), 2.16 (s, 3H),
2.09 (s, 3H), 2.02 (s, 3H), 1.99 (s, 6H).
Synthesis of (2S,3R,4S,5S,6S)(2-amino((((2-(dimethylamino)ethyl)(((2-methyl
phenylpropanyl)oxy)methyl)carbamoyl)oxy)methyl)phenoxy)
(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.23):
Following general reduction procedure: In 330 µL of MeOH:AcOH 8.13 (50 mg,
0.066 mmol) was treated with zinc (84 mg, 1.31 mmol). Purification of the reaction mixture
yielded 46 mg of 8.23, 92 % yield. MS (m/z) [M + H]+ cald C36H49N3O13 732.33, found
732.29, 1H NMR (400 MHz, CDCl3) δ = 7.39 (s, 1H), 7.42 (m, 2H), 7.19-7.11 (m, 4H), 6.89
(d, J = 8.4 Hz, 1H), 5.40-5.25 (m, 3H), 5.15-4.98 (m, 3H), 4.85 (d, J = 32.0 Hz, 2H), 3.73 (s,
2H), 2.89 (m, 2H), 2.77 (t, J = 24.0, 2H), 2.11 (m, 15H), 1.21 (s, 6H).
Synthesis of (2S,3S,4S,5R,6S)(methoxycarbonyl)(2-amino(3-oxo(((1-
phenylpropanyl)oxy)methyl)-2,7,10,13,16,19,22,25,28-nonaoxa
azanonacosyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.24):
To a 1 dram vial ed with septa screw top and an argon balloon was charged
with 8.16, (56 mg, 0.048 mmol), tin dichloride (54 mg, 0.288 mmol), ne (37 µL, 480
mmol) and 240 µL of ethanol. The reaction was stirred for 16 h at which time LC/MS
showed consumption of the starting materials. The reaction mixture was filtered over a Celite
plug and the te was purified by flash column chromatography to yield 22 mg of 8.24 as
clear oil, 44 %. MS (m/z) [M + H]+ cald C34H44N2O13 1013.46, found 1013.43.
[0531] General ure for acetamide formation followed by lithium hydroxide aryl
onide deprotection. To a 1 dram vial ed with a stir bar and PTFE lined cap was
added 1 mmol of aniline glucuronide, 5 mmol of acetic anhydride, 6 mmol of Hünig’s base
and 5 mL of dichloromethane at RT. The reaction was monitored by LC/MS to completion,
which generally occurred within 1 hour. Afterwards, the reaction mixture was azeotroped to
dryness with toluene in vacuo. The crude oil was then treated with a 1 mL of 1:1 MeOH and
saturated aqueous LiOH solution at RT. The hydrolysis deprotection on was monitored
by LC/MS and was generally complete within 1 hour. The reaction mixture was then purified
using preparatory HPLC (gradient 5-95 itrile/water 0.05 % TFA).
Synthesis of (2S,3S,4S,5R,6S)(2-acetamido
(((ethyl(phenethoxymethyl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-
pyrancarboxylic acid (8.25):
Following general procedure: Compound 8.17 (63 mg, 0.090 mmol) was converted to
40 mg of 8.25, 80 % yield. MS (m/z) [M + H]+ cald C27H34N2O11 563.22, found 563.18.
Synthesis of (2S,3S,4S,5R,6S)(2-acetamido(((ethyl(((1-phenylpropan
yl)oxy)methyl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran
carboxylic acid (8.26):
ing general procedure: Compound 8.16 (56 mg, 0.078 mmol) was converted to
33 mg of 8.24, 73 % yield. MS (m/z) [M + H]+ cald C28H36N2O11 577.23, found 577.25.
[0536] Synthesis of ,4S,5R,6S)(2-acetamido(((ethyl(((2-methylphenylpropan-
2-yl)oxy)methyl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran
carboxylic acid (8.27):
[0537] Following l procedure: Compound 8.19 (29 mg, 0.040 mmol) was converted to
18 mg of 8.27, 78 % yield. MS (m/z) [M + H]+ cald C29H38N2O11 591.25, found 591.27.
Synthesis of (2S,3S,4S,5R,6S)(2-acetamido(((ethyl((naphthalen
yloxy)methyl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran
carboxylic acid (8.28):
[0539] Following general procedure: Compound 8.20 (197 mg, 0.270 mmol) was converted
to 103 mg of 8.28, 66 % yield. MS (m/z) [M + H]+ cald C29H32N2O11 585.20, found 585.23.
Synthesis of (2S,3S,4S,5R,6S)(2-acetamido
(((ethyl((phenethylthio)methyl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-
2H-pyrancarboxylic acid :
Following general procedure: Compound 8.21 (48 mg, 0.067 mmol) was ted to
32 mg of 8.29, 71 % yield. MS (m/z) [M + H]+ cald C27H34N2O10S 579.79, found 579.76.
Synthesis of (2S,3S,4S,5R,6S)(2-acetamido((((2-
(dimethylamino)ethyl)(phenethoxymethyl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-
trihydroxytetrahydro-2H-pyrancarboxylic acid (8.30):
Following general procedure: Compound 8.22 (45 mg, 0.062 mmol) was converted to
28 mg of 8.30, 75 % yield. MS (m/z) [M + H]+ cald C29H39N3O11 606.26, found 606.25.
Synthesis of (2S,3S,4S,5R,6S)(2-acetamido((((2-(dimethylamino)ethyl)(((21-phenylpropanyl)oxy)methyl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-
trihydroxytetrahydro-2H-pyrancarboxylic acid (8.31):
Following general procedure: Compound 8.23 (50 mg, 0.066 mmol) was converted to
31 mg of 8.31, 72 % yield. MS (m/z) [M + H]+ cald N3O11 634.29, found 634.32.
Synthesis of (2S,3S,4S,5R,6S)(2-acetamido(3-oxo(((1-phenylpropan
yl)oxy)methyl)-2,7,10,13,16,19,22,25,28-nonaoxaazanonacosyl)phenoxy)-3,4,5-
trihydroxytetrahydro-2H-pyrancarboxylic acid (8.32):
Following general procedure: Compound 7.26 (52 mg, 0.050 mmol) was converted to
28 mg of 7.34, 62 % yield. MS (m/z) [M + H]+ cald C29H32N2O11 915.43, found 915.41.
[0547] Example 8: In vitro stability of model systems having Self-immolative Assembly
Units each comprising a MAC Unit, or t thereof, to spontaneous hydrolysis
The final N-acetyl products of Example 8 contain Self-immolative Assembly Units,
each having a methylene carbamate unit of formula I covalently attached to a Drug Unit from
a model drug nd, that have been capped off with acetyl in lieu of a Stretcher Unit. As
such, the compounds ent model Drug-Linker compounds. The stability of those
moieties to spontaneous hydrolysis was determined using the following general procedure.
General procedure for testing Drug-Linker stability: Final N-acetyl products of
Example 8 were ved in 1 mL 0.1 M ate buffered saline, pH 7.4, in a vial at 37
°C. LC/MS samples were prepared by adding 2 µL aliquots of incubated compound solution
to 100 µL of MeOH in an HPLC vial. Each conjugate was tested every 24 h for 7 days.
For model drug-linker compounds having a methylene carbamate unit of formula I
with R as ethyl or PEG, the ary aliphatic alcohol (standing in for an aliphatic alcoholcontaining
free drug) provided model Drug-Linker compounds (8.26 and 8.32, respectively)
that showed no signs of degradation after 7 days. The model Drug-Linker compound from
the thiol-containing model drug compound having a methylene carbamate unit with R as
ethyl (8.29) also showed no sign of ation after 7 days. With R as ethyl and the Drug
Unit from naphthol (standing in for an aromatic alcohol-containing drug) provided a model
drug-linker compound having a MAC unit ntly attached to a Drug Unit (8.28) that had
excellent stability, which was indistinguishable during the course of the study to the
corresponding model Drug-Linker compound (8.26) from the secondary aliphatic alcohol.
That outcome was unexpected since a MAC unit incorporating the oxygen heteroatom of an
ic alcohol may not be as hydrolytic stable as one incorporating a secondary alcohol
due to its lower pKa and thus the better leaving group ability of the H compared to
aliphatic-OH. In contrast, the primary and tertiary aliphatic alcohols standing in for primary
and secondary aliphatic alcohol-containing free drugs provided model Drug-Linker
compounds (8.25 and 8.27, respectively) with R as ethyl that had suitable ity but not to
the same extent as that ed for the model Drug Linker compound from the secondary
alcohol. Unexpectedly, when R is dimethylaminoethyl instead of ethyl, the primary and
tertiary alcohol model drug compounds provided model Drug-Linker compounds (8.25 and
8.27) that were shown to have the same excellent stability as the model Drug-Linker
compound (8.26) from the secondary aliphatic alcohol.
We believe that stability of a drug linker may be improved by substitution of the
carbamate nitrogen of its methylene carbamate unit with a Basic Unit as defined herein
including without limitation a dimethylaminoalkyl moiety.
[0552] Example 9: In vitro stability of Drug-Linker Compounds having a Selfimmolative
Assembly Unit to spontaneous hydrolysis of its methylene carbamate unit.
Stability of the MAC Unit variant in drug-linker moieties represented by
corresponding es within -Drug nds 4.5 (triptolide), 5.6 (everolimus), 6.4
(tricolimus) and 7.7 (BMN-673) of Examples 4, 5, 6 and 7 respectively, were evaluated in the
following manner.
For evaluation of in vitro stability of Compound 7.7 this Drug-Linker compound was
converted to its N-acetylcysteine ate (NAC-7.7), which provide a model LDC with
NAC serving as a surrogate for a targeting antibody Ligand Unit. For that e eight
microliters of a 8 mM DMSO stock of Drug-Linker Compound was d in phosphate-
buffered saline (0.39 mL). The maleimide moiety in each Drug-Linker Compound was then
quenched with N-acetylcysteine (0.8 µL, 100 mM stock), and the material was stored in a 37 ͦ
C incubator. Aliquots were drawn at various time points out to 14 days and analyzed by
UPLC-MS for drug-linker integrity.
Stability testing was conducted as in e 8. No indication of drug-linker
degradation was noted after 14 da incubation in 0.1 M PBS, pH 7.4, at 37 ͦ C for model Drug
Linker Compounds 4.5, 5.6 and 6.4, and the model conjugate NAC-7.7 in 4 mM PBS, pH
7.4, 37 ͦ C. In the case of 7, the corresponding acid-amide from hydrolysis of the
succinimide moiety was observed. Unexpectedly, the model Drug-Linker nd (8.26),
which orates the secondary aliphatic alcohol as the stand-in for a secondary ticalcohol
containing free had increase stability in comparison to the acceptable stability of the
Drug-Linker Compound 6.4, which derived form a secondary aliphatic-alcohol containing
free drug (tricolimus), Furthermore, the Drug-Linker Compound 5.6, which is derived from a
primary aliphatic alcohol-containing free drug (everolimus) was found to have even better
hydrolytic stability ed to the model Drug-Linker Compound (8.23), which was
derived from the primary aliphatic l as the stand-in for a primary aliphatic alcohol-
containing free drug.
Thus, each model drug compound provided a drug-linker moiety having a methylene
carbamate unit of acceptable stability, the degree of which appears to be independent on the
identity of the heteroatom T*, and thus of the functional group on the drug through which it is
conjugated, but may be also dependent on the remaining structure of the Drug Unit. Results
with methylene carbamate units that are N-substituted with a basic moiety provide drug
linker es of exceptional stability.
Example 10: Ex vivo stability of an dy Drug Conjugate having a Selfimmolative
Assembly Unit to spontaneous hydrolysis of its methylene carbamate unit.
ADC with four iner moieties from Drug-Linker nd 1.3 (i.e., an ADC
composition having an e drug loading of about 4), prepared as in Example 13, was
incubated at 1 mg/mL in 200 μL sterile aliquots of commercially available rat and mouse
plasma (Bioreclamation). Aliquots were incubated at 37 ͦ C and frozen at -80 ͦ C at each time
point. After the incubations were complete, s were thawed and 50 μL net IgSelect
resin (GE Healthcare) was added to each aliquot. Samples were rotated at 4 ͦ C for at least
three hours and erred to a 96-well filter plate (Seahorse) on a vacuum manifold. The
resin was washed three times with 3 mM PBS (Gibco) and eluted by centrifugation with two
50 μL aliquots of IgG Elution Buffer (Pierce). Purified ADC’s were neutralized with 15 μL
of 1M Tris (pH 7.4) and deglycosylated at 37 ͦ C for one hour using PNGaseF (New England
Biolabs). A 40 μL injection of each sample was resolved on a Polyhydroxyethyl A SEC
column (PolyLC) in-line with a QTOF (Agilent) mass spectrometer such that the ADC could
be analyzed in a native, intact state (see Valliere-Douglass, John et. al. “Native Intact Mass
Determination of Antibodies ated with Monomethyl atin E and F at Interchain
Cysteine Residues” Analytical try 2012, 84, 2843-2849). The raw mass spectrum of
the intact ADC was deconvoluted, and the area under each deconvoluted peak was integrated
to determine an average drug-antibody ratio for each sample. Figure 1 shows the plasma
stability of the AE drug conjugate as a function of drug-antibody ratio determined by the
above mass spectroscopy method over time in days .
The mass spectral data confirms that any drug loss that had occurred was due to
complete elimination of the drug- linker from the Ligand Unit and not due to linker
degradation attributable to hydrolytic instability the MAC Unit. The mass spectral data also
demonstrates that after complete hydrolysis of the succinimide ring system of the Stretcher
Unit’s succinimide moiety to the corresponding mide moiety the drug:antibody ratio
remained constant.
Stability data for various constructs described herein having a Self-immolative
Assembly unit having a methylene carbamate unit ntly attached to a Drug unit
corresponding in structure to a drug or model drug is ized in Table 4.
[0561] Table 4. Summary of Self-immolative Assembly Unit Stability
ve Degradation
Drug or model drug Construct
Half-life Observed by
(carbamate R) (drug functional group)
LC/MS
1.3 (H) cAC10-AE Conjugate (2 ͦ OH)* None Observed
4.5 (Et) Triptolide-Linker Compound (2 ͦ OH) None Observed
.6 (H) Everolimus-Linker Compound (2 ͦ OH) 7 days
6.4 (H) Tricolimus-Linker Compound (1 ͦ OH) None ed
7.7 (H) NAC-(BMN-673) Conjugate (2 ͦ NH) None ed
8.25 (Et) Model Drug-Linker Compound (1 ͦ OH) 7 days
8.30 (BU)** Model inker Compound (1 ͦ OH) None Observed
8.26 (Et) Model Drug-Linker Compound (2 ͦ OH) None Observed
8.32 (PEG8) Model Drug-Linker Compound (2 ͦ OH) None Observed
8.27 (Et) Model inker Compound (3 ͦ OH) 7 days
8.31 (BU) Model Drug-Linker Compound (3 ͦ OH) None Observed
8.28 (Et) Model Drug-Linker Compound (Ar- OH) None Observed
8.29 (Et) Model Drug-Linker Compound (1 ͦ SH) None Observed
* Incubated in rat or mouse plasma at 37 ͦ C, all others in 0.1 M PBS, pH 7.4, at 37 ͦ C
** BU is –CH2CH2-N(CH3)2
Example 11. Release of free drug or model compounds for containing
drugs, primary, secondary and tertiary aliphatic alcohol-containing drugs, and ic
alcohol-containing drug from NAC-conjugates having a Self-immolative Assembly Unit
comprised of a MAC Unit or variant thereof subsequent to glucuronidase activation of
that unit
Release of free drug from the NAC-7.7 conjugate derived from the Drug-Linker
Compound of Example 7 was evaluated in the following manner: An enzyme stock was
prepared by ving Type B-1 β-glucuronidase (bovine liver, 1,644,000 units/g solid) in
pH 5 100 mM sodium acetate buffer to a working tration of 0.5 mg/mL. Five
microliters of 8 mM drug-linker stock of compound 7.7 was added to 12.5 µL DMSO, 26.3
µL of phosphate-buffered saline, and 6.75 µL of 100 mM N-acetylcysteine. The quenched
linker was then diluted with 0.45 mL enzyme stock. The enzymatic reaction was then
incubated at 37 C, with multiple time points taken at 1, 10, 20, and 40 minutes. Each time
point sample consisted of 20 µL reaction diluted in 5 volumes ice cold methanol and cooled
to -20 C until all the samples were withdrawn. The samples were then centrifuged at 12,000 g
for 5 minutes and 20 µL of supernatant was analyzed by UPLC-MS. After 20 minutes of
enzyme digestion the inker was completely consumed. By 40 minutes, the majority of
the material was free drug, indicating ively complete drug release from the linker
system.
In contrast to the cAC10-2.0 conjugate, which y released free drug from the
MAC unit with no detectable intermediate after self-immolation of the Self-immolative
ly Unit, the NAC-7.7 conjugate showed build-up of an intermediate, NH2-CH2-7.0,
the structure for which is shown in the following scheme.
Releases of in “free drugs” from NAC conjugates incorporating the Drug-
Linker moieties from Example 8 were also studied. Those compounds were prepared by
replacing the yl capping group with N(propionoyl)-maleimide, which introduces a
maleimide her Unit precursor, in the amino intermediates used for the preparation of
model drug linker compounds 8.23-8.30. The maleimide moieties are then quenched with N-
acetyl-cysteine as previously described for the ation of NAC-7.7. The NAC-
conjugates derived from the amino intermediates of Example 8 have the generalized structure
wherein T* is the oxygen or sulfur heteroatom from
the hydroxyl or sulfhydryl functional group of the primary l or thiol-containing
compound or the oxygen heteroatom from the hydroxyl functional group of the secondary or
tertiary alcohol-containing compound or from the phenolic-containing compound of Table 3.
The time to complete D-T*-H release with variations in R and released compound are shown
in Table 5.
Table 5. Free Drug Release Efficiency Subsequent to Activation of Self-immolation
D-T*-H
(corresponding model drug- R Time to 100% Release
linker compd) (min.)
Primary alcohol (8.25) -CH2CH3 15
Primary alcohol (8.30) -CH 2CH2N(CH3)2 15
Secondary alcohol (8.26) -CH2CH3 45
Secondary alcohol (8.32) -PEG8 15
Tertiary l (8.27) -CH2CH3 15
Tertiary l (8.31) -CH2CH2N(CH3)2 15
Aromatic alcohol (8.28) -CH2CH3 25
Thiol (8.29) -CH2CH3 40
[0567] Example 12: Intracellular delivery of cytotoxic free drug to targeted cancer cells
released from a MAC Unit of an Antibody Drug Conjugate due to ional activation
of its Self-immolative Assembly Unit.
Lovo cells (human colon adenocarcinoma cell line) contacted with 8 drug loaded
cOKT9-7.7 conjugate, which targets CD70+ cells, having drug-linker moiety of Example 7
and prepared in the manner of Example 13, was found to have r amounts of
intracellular free drug (i.e., compound 7.0) than when contacted with an equivalent amount of
untargeted free drug as shown in Figure 3. Those results indicate that the ADC is targeting
the d cells and is efficiently ing free drug upon its cellular internalization.
Example 13: Preparation of ADC’s having a MAC Unit and their in vitro
cytotoxicities
The targeting antibody ligands cAC10 and h1F6 are bed in US 8,257,706 and
US 2009/0148942, respectively. cAC10 s CD30+ cells, which includes Karpas 299,
L540cy and L-428. h1F6 targets CD70+ cells, which includes 786-O, L-428 and Caki-1.
For ADC compositions having a homogeneous drug g of 8, full reduction of
interchain disulfide bonds of the targeting antibody ligand was accomplished by the method
of US 2003/00883263. Briefly, the targeting antibody (5-10 mg/mL) in phosphate buffered
saline with 1mM ethylenediaminetetraacetic acid (EDTA) was treated with 10 eq. tris(2-
carboxyethyl)phosphine (TCEP) neutralized to pH 7.4 using potassium phosphate dibasic and
incubated at 37 C for 45 minutes. Separation of low molecular weight agents is achieved by
size exclusion chromatography on a ex G25 column.
Partial ion of the targeting antibody ligand to provide ADC compositions
having an average drug loading of about 4 was accomplished using the method of US
2005/0238649. Briefly, the antibody in phosphate buffered saline with 1mM EDTA, pH 7.4,
was treated with 2.1 eq. TCEP and then incubated at 37 ͦ C for about 45 s. The
thiol/Ab value was checked by determining the reduced antibody concentration from the
absorbance at 280 nm of the solution and the thiol concentration by reaction with DTNB and
determination of the absorbance at 412 nm.
[0573] Drug-Linker compounds were conjugated to the fully and lly reduced ing
antibody ligands using the method of US 2005/0238649. Briefly, a Drug-Linker compound
in DMSO, was added to the reduced antibody in PBS with EDTA along with excess DMSO
to a total reaction co-solvent of 15%. After 30 minutes at ambient temperature, an excess of
n-acetyl cysteine was added to the e to quench all unreacted maleimide groups. The
reaction mixture was purified by desalting using Sephadex G25 resin into PBS buffer.
The protein concentration of the resulting ADC composition was determined at 280
nm. Bound drug was quantified by is using hydrophobic interaction (HIC) HPLC.
cAC10-1006 and hF16-1006, referenced in the following tables, is the chimeric AC10
antibody and the humanized F16 antibody, tively, ated to monomethyl auristatin
E (MMAE) at its N us via a carbamate functional group to a val-cit-PABA selfimmolative
moiety having formula XVIII and was used as a control. The resultant ADCs
were tested against multiple cell lines to determine in vitro ty, the results from which
are ized in Tables 5 and 6.
Table 6. In vitro cytotoxic activity of ADCs prepared with MAC linkers; values
represent IC50s in ng/mL.
ADC Dr/Ab Karpas 299 L540cy 786-0 Caki-1
CD30+ CD30+ CD70+ CD70+
CD70- CD70 (low)
.3 3.6 >1000 >1000* >1000** 19
cAC10-1.3 3.7 0.8 3 >1000 >1000
cAC10- 4.0 1 8 >1000 >1000
h1F6-1006 4.0 >1000 >1000 >1000** 7
Table 7. In vitro cytotoxic activity of ADCs prepared with MAC linkers; values represent
IC50s in ng/mL.
ADC Dr/Ab Karpas 299 L540cy L-428 HEL92.1.7
CD30+ CD30+ CD30 (med) CD30-
CD70- CD70- CD70 (low) CD70-
cAC10-2.0 8.0 0.4 3 65 >1000
cAC10- 4.0 0.6 9 >1000* >1000
h1F6-1006 4.0 >1000 >1000 >1000* >1000
*Cell lines are known to be resistant to MMAE
** Cell line known to be resistant to auristatins
The following numbered paragraphs define particular aspects of the present invention:
1. A Ligand-Drug Conjugate Compound comprising a Ligand Unit, a Drug Unit and a
Linker Unit, wherein the Linker Unit is comprised of a Self-immolative (SI) Assembly Unit
having a methylene carbamate unit and an activateable self-immolative moiety n the
methylene carbamate unit is covalently attached to the Drug Unit, and wherein the SI
Assembly Unit covalently attached to the Drug Unit is represented by the structure of formula
or a pharmaceutically acceptable salt thereof, wherein
the wavy line indicates covalent attachment to the remainder of the Linker Unit;
D is the Drug Unit having a hydroxyl, thiol, amine or amide functional group that has
been incorporated into the methylene ate unit;
T* is the , sulfur or optionally substituted nitrogen heteroatom from said
functional group that becomes incorporated into the indicated ene carbamate unit;
X is the activateable self-immolative moiety;
R, R1 and R2 independently are hydrogen, optionally tuted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally tuted C-linked C3-C8 heteroaryl, or
both R and R1 together with the nitrogen and carbon atoms to which they are ed
comprise an inyl, pyrrolodinyl, piperidinyl or homopiperidinyl moiety and R2 is
hydrogen.
2. The Ligand-Drug Conjugate Compound of paragraph 1 wherein the SI Assembly
Unit covalently attached to the Drug Unit is represented by the structure of formula SIa or
(SIa) (SIb),
or a pharmaceutically acceptable salt f, wherein s is 0, 1, 2 or 3.
3. The Ligand-Drug Conjugate Compound of paragraph 2 wherein R and R1 are
independently selected from hydrogen, ally substituted C1-C6 alkyl or optionally
substituted C6-14 aryl; and the subscript s is 0, 1, or 2.
4. The Ligand-Drug Conjugate Compound of paragraph 1 having Formula II:
(II),
or a pharmaceutically acceptable salt thereof, wherein
L is a Ligand Unit;
Z is a Stretcher Unit;
B is an optional branching unit and is present when t is greater than 1 and is absent
when t is 1;
A is an optional Connector Unit;
the subscript t ranges from 1 to 4; and
the subscript p is an r ranging from 1 to 16.
. The -Drug ate Compound of paragraph 4 having Formula IIa or IIb:
(IIa)
(IIb)
or a pharmaceutically acceptable salt thereof, wherein s is 0, 1, 2, or 3.
6. The Ligand-Drug Conjugate Compound of paragraph 4 wherein R and R1 are
independently selected from hydrogen, optionally tuted C1-C6 alkyl or optionally
substituted C6-14 aryl, and the subscript s is 0, 1, or 2.
7. The Ligand-Drug Conjugate Compound of paragraph 5 wherein R and R1 are
independently selected from hydrogen, optionally tuted C1-C6 alkyl or optionally
substituted C6-14 aryl; and the subscript s is 0, 1, or 2.
8. The Ligand-Drug Conjugate Compound of any one of paragraphs 4 to 7 wherein R1
is not substituted.
9. The Ligand-Drug Conjugate Compound of any one of paragraphs 4 to 7 wherein R1
and R2 are not substituted.
. The Ligand-Drug Conjugate Compound of paragraph 4 or 5 wherein R, R1 and R2
are not substituted.
11. The Ligand-Drug Conjugate Compound of any one of paragraphs 4 to 9 wherein the
al substituents are independently selected from the group consisting of -X, -Rop, -OH,
-ORop , -SRop, -N(Rop)2, -N(Rop)3, =NRop, -CX3, -CN, -NO2, -NRopC(=O)Rop, -C(=O)Rop, -
C(=O)N(Rop)2, 2Rop, -S(=O)2NRop, -S(=O)Rop, -OP(=O)(ORop)2, -P(=O)(ORop)2, -
PO3=, PO3H2, -C(=O)Rop, -C(=S)Rop, -CO2Rop, -CO2-, -C(=S)ORop, -C(=O)SRop, -C(=S)SRop,
-C(=O)N(Rop)2, - C(=S)N(Rop)2, and -C(=NRop)N(Rop)2, wherein each X is independently
selected from the group consisting of a halogen: -F, -Cl, -Br, and -I; and each Rop is
independently selected from the group consisting of hydrogen, -C1- C20 alkyl, -C6-C20 aryl, -
C3-C14 heterocycle, a protecting group, and a g moiety.
12. The Ligand-Drug Conjugate Compound of paragraph 11 wherein the optional
substituents are selected from the group consisting of -X, -Rop, -OH, -ORop, -SRop, -N(Rop)2,
N(Rop)3, =NRop, -NRopC(=O)Rop, -C(=O)Rop, N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -
op, -C(=O)Rop, Rop, -C(=O)N(Rop)2, - C(=S)N(Rop)2, and -C(=NRop)N(Rop)2,
n each X is selected from the group consisting of –F and-Cl; and each Rop is
independently selected from the group consisting of hydrogen, -C1-C20 alkyl, -C6-C20 aryl, -
C3-C14 heterocycle, a protecting group, and a prodrug moiety.
13. The Ligand-Drug Conjugate Compound of aph 11 wherein the optional
substituents are selected from the group consisting of -X, -Rop, -OH, -ORop, -N(Rop)2, -
N(Rop)3, -NRopC(=O)Rop, -C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, Rop, -
C(=O)N(Rop)2, and -C(=NRop)N(Rop)2, wherein X is –F.
14. The Ligand-Drug Conjugate Compound of paragraph 11 wherein the optional
tuent is selected from the group consisting of –N(Rop)2, -N(Rop)3 and -C(=NR)N(Rop)2.
. The Ligand-Drug Conjugate Compound of any one of paragraphs 1 to 9 wherein R is
C1-6 alkyl, optionally substituted with a basic group.
16. The Ligand-Drug ate Compound of paragraph any one of paragraphs 1 to 9
wherein R is a saturated C1-6 alkyl, ally substituted with a basic group.
17. The Ligand-Drug ate Compound of any one of paragraphs 1 to 9 wherein R is
a Basic Unit wherein the basic functional group of the Basic Unit is an amine or a nitrogencontaining
3, 4, 5, or 6 membered heterocycle that is C-linked or N-linked and can be
optionally substituted.
18. The Ligand-Drug Conjugate Compound of paragraph 17 wherein R is a Basic Unit,
wherein the basic functional group of the Basic Unit is –N(Rop)2, wherein Rop are
independently selected from the group consisting of hydrogen and C1-6 alkyl.
19. The Ligand-Drug Conjugate Compound of aph 17 wherein R is a Basic Unit,
wherein the basic functional group of the Basic Unit is –N(Rop)2, wherein Rop are
ndently selected from the group consisting of hydrogen and methyl.
. The Ligand-Drug Conjugate Compound of paragraph 17 wherein R is a Basic Unit,
wherein, the basic functional group of the Basic Unit is –N(Rop)2, wherein each Rop is methyl.
21. The Ligand Drug Conjugate Compound of paragraph 17 wherein R is a Basic Unit,
wherein the Basic Unit is –CH2CH2N(Rop)2, wherein Rop are independently selected from the
group consisting of hydrogen and .
22. The Ligand-Drug Conjugate Compound of any one of paragraphs 15 to 21 wherein
R1 is hydrogen.
23. The -Drug Conjugate Compound of any one of paragraphs 1 to 22 wherein D
is a Drug Unit corresponding to a drug having a hydroxyl functional group that has been
incorporated into the ene ate unit so that T* represents the oxygen heteroatom
from that functional group.
24. The Ligand-Drug ate Compound of paragraph 23 wherein D is a Drug Unit
ponding to an tic alcohol-containing drug, wherein attachment of D within the
conjugate is via the oxygen heteroatom of the hydroxyl functional group of the aliphatic
alcohol, so that T* represents the oxygen atom from that functional group.
. The Ligand-Drug Conjugate Compound of aph 23 wherein D is a Drug Unit
corresponding to an ic alcohol-containing drug, wherein attachment of D within the
conjugate is via the oxygen atom of the aromatic alcohol, so that T* ents the oxygen
atom from that functional group.
26. The Ligand-Drug Conjugate Compound of aph 25 wherein the ic
alcohol is not a phenolic alcohol.
27. The Ligand-Drug Conjugate Compound of any one of paragraphs 4 to 26 wherein B
is absent and the subscript t is 1.
28. The Ligand-Drug Conjugate Compound of any one of paragraphs 4 to 27 wherein the
structure representing the indicated activateable self-immolative moiety (X) within the Linker
Unit is represented by formula (i)
(i)
wherein the way line tes covalent attachment of W to A, B or Z depending on
the presence or absence of A and/or B and the asterisk (*) indicates covalent attachment of Y
to a methylene carbamate unit and wherein;
W is an Activation Unit; and
Y is a self-immolative Spacer Unit,
wherein activation of self-immolation of Y results in release of free drug.
29. The Ligand-Drug Conjugate Compound of paragraph 28 wherein activation for selfimmolation
of Y is by enzymatic cleavage of a covalent bond between W and Y.
. The -Drug Conjugate Compound of paragraph 29 wherein enzymatic
cleavage is by a tumor associated protease.
31. The Ligand-Drug Conjugate Compound of paragraph 30 wherein the tumor
associated protease is cathepsin B.
32. The Ligand-Drug Conjugate Compound of aph 30 wherein W is -Val-Cit-, -
s- or –Val-Ala-.
33. The Ligand-Drug Conjugate Compound of paragraph 30 wherein –W-Y- is
represented by the ure of:
wherein the wavy bond to the nitrogen of W indicates covalent linkage to Z, A or B,
depending on the presence or e of A and/or B, and the hash mark (#) indicates covalent
attachment of the benzylic carbon of Y to a methylene carbamate unit.
34. The Ligand-Drug Conjugate Compound of any one of aphs 4 to 27 wherein the
structure representing the indicated activateable self-immolative moiety (X) within the Linker
Unit is represented by a (ii):
wherein the wavy line indicates covalent ment of Y to A, B or Z depending on
the presence or absence of A and/or B, and the sk (*) indicates covalent attachment of Y
to the methylene carbamate moiety, and wherein;
W is an Activation Unit; and
Y is a self-immolative Spacer Unit,
wherein activation of self-immolation of Y results in release of free drug.
. The Ligand-Drug ate Compound of paragraph 34 wherein activation for selfimmolation
of Y is by enzymatic cleavage of a covalent bond between W and Y, wherein
enzymatic cleavage is by a glycosidase.
36. The Ligand-Drug Conjugate Compound of paragraph 35 wherein the glycosidase is a
glucuronidase.
37. The Ligand-Drug Conjugate nd of paragraph 35 wherein W is a sugar
moiety connected to Y via a glycosidic bond capable of cleavable by a glycosidase for
activation of self-immolation of Y.
38. The Ligand-Drug Conjugate Compound of paragraph 33 wherein –Y(W)- is
represented by the structure of:
wherein the wavy bond adjacent to the nitrogen of Y indicates covalent attachment of
Y to Z, A or B, depending on the presence or absence of A and/or B, and the hash mark (#)
indicates covalent attachment of the benzylic carbon of Y to a methylene carbamate unit.
39. The -Drug ate Compound of any one of paragraphs 4 to 38 wherein the
Stretcher unit (Z) comprises a succinimide moiety or an mide , wherein that
moiety is attached to a sulfur atom of the Ligand Unit.
40. The Ligand-Drug Conjugate nd of paragraph 39 wherein the Stretcher unit
(Z) is comprised of a succinimide moiety and is represented by the structure of formula Xa':
(Xa')
wherein the wavy line adjacent to the succinimide ring system indicates covalent
attachment to a sulfur atom of a Ligand Unit;
the wavy line adjacent to the carbonyl indicates attachment within the linker;
and RN is -C2-C5 alkylene, wherein the alkylene is optionally substituted by a Basic
Unit (BU), wherein BU is –(CH2 )xNH2, –(CH2 )xNHRop, or –(CH2 )xN(Rop)2, wherein x is an
integer ranging from 1-4; and Rop is C1-6 alkyl.
41. The Ligand-Drug Conjugate nd of paragraph 39 wherein the Stretcher unit
(Z) is comprised of a succinimide moiety and is represented by the structure:
wherein the wavy line adjacent to the succinimide ring system indicates covalent
attachment to a sulfur atom of a Ligand Unit, and
the wavy line nt to the carbonyl indicates attachment within the linker.
42. The Ligand-Drug Conjugate Compound of paragraph 39 n the Stretcher unit
(Z) is comprised of a succinimide moiety or an acid-amide moiety and is represented by the
structure of:
, or .
43. The Ligand-Drug Conjugate Compound of any one of aphs 2 to 42 wherein a
Connector Unit (A) is present.
44. The -Drug Conjugate Compound of paragraph 43 wherein A is:
NH R13 C
wherein the wavy line adjacent to the carbonyl indicates covalent attachment to the
activateable self-immolative moiety X of the Self-immolative ly Unit, and
the other wavy line indicates ment to B, if present, or to Z if B is ; and
R13 is -C1-C6 alkylene-, -C3-C8carbocyclo-, ne-, -C1-C10 heteroalkylene-, -C3-
C8heterocyclo-, -C1-C10alkylene-arylene-, ne-C1-C10alkylene-, -C1-C10alkylene-(C3-
ocyclo)-, -(C3-C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-,
or -(C3-C8 heterocyclo)-C1-C10 alkylene-.
45. The Ligand-Drug Conjugate Compound of paragraph 44 wherein A has the formula
.
46. The Ligand-Drug Conjugate Compound of any one of paragraphs 4 to 42 wherein A
is absent.
47. The Ligand-Drug Conjugate Compound of any one of paragraphs 4 to 46 n p
ranges from 1 to 10.
48. The Ligand-Drug Conjugate Compound of any one of paragraphs 4 to 46 wherein p
ranges from 1 to 8.
49. The Ligand-Drug Conjugate Compound of any one of paragraphs 1 to 48 wherein the
Ligand Unit corresponds to a targeting antibody.
50. A Drug-Linker compound, wherein the compound comprises a Drug Unit and a
Linker Unit, wherein the Linker Unit is comprised of a Self-Immolative Assembly Unit
having a methylene carbamate unit and an activateable self-immolative moiety wherein the
Drug Unit is covalently attached to the methylene carbamate unit,
wherein the Drug-Linker compound has the structure of formula V:
or a pharmaceutically acceptable salt thereof; wherein
D is a Drug Unit having a hydroxyl, thiol, amine or amide functional group that has
been incorporated into the indicated methylene carbamate unit;
T* is the oxygen, sulfur or optionally substituted nitrogen atom from said
functional group that s incorporated into the indicated methylene carbamate unit;
R, R1 and R2 independently are hydrogen, optionally substituted C1-C6 alkyl,
optionally substituted C6-14 aryl, or optionally substituted C-linked C3-C8 heteroaryl, or
both R and R1 together with the nitrogen and carbon atoms to which they are attached
comprise an azetidinyl, pyrrolodinyl, piperidinyl or peridinyl moiety (preferably a
pyrrolodinyl or piperidinyl moiety) and R2 is hydrogen;
X is an activateable self-immolative moiety;
Z' is a Stretcher Unit sor to a her Unit (Z) and is comprised of a
functional group that provides for covalent attachment of a Ligand Unit to Z;
B is an optional Branching Unit that is present when t is greater than 1 and is absent
when t is 1;
A is an optional Connector Unit; and
the subscript t ranges from 1 to 4.
51. The Drug-Linker compound of paragraph 50 wherein D is a Drug Unit corresponding
to a drug having a hydroxyl functional group that has been incorporated into the ene
carbamate unit of the Self-immolative Assembly Unit; and T* is the oxygen atom from that
functional group.
52. The inker compound of paragraph 50 or 51 wherein X is –Y(W)-, wherein –
Y(W)- is represented by the structure of:
wherein the wavy bond nt to the nitrogen of Y indicates covalent ment to
Z’, A or B, depending on the ce or absence of A and/or B, and the hash mark (#)
indicates covalent ment of the benzylic carbon of Y to the methylene carbamate unit.
53. The Drug-Linker compound of paragraph 50 or 51, wherein X is –W-Y, wherein –WY-
is represented by the structure of:
wherein the wavy bond adjacent to the nitrogen heteroatom of W indicates covalent
attachment of W to Z’, A or B, depending on the presence or absence of A and/or B and the
hash mark (#) indicates nt attachment of the benzylic carbon of Y to the methylene
carbamate unit.
54. The Drug-Linker compound of any one of paragraphs 50 to 53 wherein Z’ comprises
a maleimide moiety.
55. The Drug-Linker compound of paragraph 54 wherein Z’ has the formula:
wherein the wavy line adjacent to the carbonyl indicates covalent attachment of Z’ to
A, B or X, depending on the presence or absence of A and/or B.
56. The Drug-Linker compound any one of paragraphs 50 to 55 wherein A is present and
has the formula
57. The Drug-Linker compound of any one of paragraphs 50 to 56 wherein B is absent
and t is 1.
58. The Drug-Linker nd of any one of paragraphs 50 to 56 wherein B is present
and t is 2.
59. A -Drug Conjugate composition comprising a plurality of conjugate
compounds, wherein each has the structure of a Ligand-Drug Conjugate Compound of any
one of paragraphs 1 to 49, wherein the Conjugate nds are differentiated by their p
integer values; and a pharmaceutically acceptable carrier.
60. The Ligand-Drug Conjugate composition of paragraph 59 wherein there is an average
of 2 to 10 inkers per Ligand Unit.
61. The Ligand-Drug Conjugate composition of paragraph 59 wherein there is an average
of 2 to 8 drug-linkers per Ligand Unit.
62. The Ligand-Drug Conjugate Compound of any one of paragraphs 1-49, the Drug-
Linker compound of any one of paragraphs 50-58 or the Ligand-Drug Conjugate composition
of any one of paragraphs 59-61, wherein the Drug Unit corresponds in structure to a
compound having hydroxyl functional group whose oxygen heteroatom is capable of
incorporation into a methylene carbamate unit, wherein the compound binds to FKBP to
t mTOR or calcineurin or function.
63. The Ligand-Drug Conjugate Compound, Drug-Linker compound or Ligand-Drug
Conjugate composition of paragraph 62, wherein the FKBP binding compound is everolimus,
tacrolimus or sirolimus.
64. The Ligand-Drug Conjugate Compound, Drug-Linker nd or Ligand-Drug
Conjugate ition of paragraph 62, wherein the compound or ition has the
structure of :
wherein the Ab-S- moiety is a Ligand Unit from a targeting antibody; R is hydrogen,
ethyl or –CH2CH2N(CH3)2; and p ranges from 1 to 20, 1 to 16 or 1 to 8.
65. The Ligand-Drug Conjugate Compound, Drug-Linker compound or Ligand-Drug
Conjugate composition of paragraph 62, wherein the compound or ition has the
structure of :
wherein the Ab-S- moiety is a Ligand Unit from a targeting antibody; R is hydrogen,
ethyl or –CH2CH2N(CH3)2; and p ranges from 1 to 20, 1 to 16 or 1 to 8.
66. The Ligand-Drug Conjugate Compound, Drug-Linker compound or -Drug
Conjugate composition of paragraph 62, wherein the compound or composition has the
structure of :
wherein the Ab-S- moiety is a Ligand Unit from a targeting antibody; R is hydrogen,
ethyl or –CH2CH2N(CH3)2; and p ranges from 1 to 20, 1 to 16 or 1 to 8.
67. The Ligand-Drug ate nd of any one of paragraphs 1-49, the Drug-
Linker compound of any one of paragraphs 50-58 or the Ligand-Drug Conjugate composition
of any one of paragraphs 59-61, wherein the Drug Unit corresponds in structure to a auristatin
having hydroxyl functional group whose oxygen heteroatom is capable of incorporation into
a methylene carbamate unit, n the compound binds to tubulin to disrupt n
function.
68. The Ligand-Drug Conjugate Compound, Drug-Linker nd or Ligand-Drug
Conjugate ition of paragraph 67 wherein the auristatin is MMAE or atin T.
69. A method of treating cancer or an autoimmune disease comprising administering to a
t in need thereof, an ive amount of a Ligand-Drug Conjugate of any one of
paragraphs 1 to 49 or a Ligand-Drug Conjugate composition any one of paragraphs 59 to 65.
70. A method of preparing a Drug-Linker Compound having the structure of
said method sing:
contacting a modified free drug having the structure of:
with an intermediate linker moiety represented by: Z’-A-X’-OH,
under conditions sufficient for providing the indicated MAC unit through Curtius
rearrangement,
wherein D is a Drug Unit having a hydroxyl functional group that has been
incorporated into the MAC, the oxygen heteroatom from which is designated by O*;
Z' is a stretcher unit precursor to a Stretcher Unit (Z) in a Ligand-Drug Conjugate and
is comprised of a functional group capable of conjugation to a targeting ligand;
A is an optional Connector Unit;
X is an activeatable self-immolative moiety;
X' is a self-immolative moiety precursor to X and has a hydroxyl functional group
that participates in the Curtius rearrangement;
R is hydrogen; and
R1 is hydrogen, or C1-C6 alkyl, C6-C14 aryl or C-linked aryl, optionally
substituted with suitable protection as required.
71. A method of preparing an intermediate of a inker nd wherein the
intermediate has the structure of
said method comprising:
contacting a ed free drug having the structure of:
with a self-immolative intermediate represented by: A'-X-OH,
under conditions sufficient for ing the indicated MAC Unit through Curtius
rearrangement,
wherein D is a Drug Unit having a hydroxyl functional group that has been
incorporated into the MAC, the oxygen heteroatom from which is designated by O*;
A' is a Connector Unit precursor to a Connector Unit (A) and is comprised of a
functional group for bond formation to the remainder of the Linker Unit of the Drug-Linker
compound;
X is an activeatable self-immolative moiety;
R is hydrogen; and
R1 is hydrogen, or C1-C6 alkyl, C6-C14 aryl or C-linked aryl, optionally
substituted with suitable protection as required.
72. A method of preparing a Drug-Linker Compound wherein the compound has the
structure of
said method comprising:
contacting a drug having a free hydroxyl onal group with a N-
chloromethylamine having the structure of:
under conditions sufficient for substitution of the chorine atom with the oxygen
heteroatom from said free drug functional group,
wherein
Z' is a Stretcher Unit precursor to a Stretcher Unit (Z) of the Drug-Linker nd
and comprises a functional group for attachment of a targeting ligand;
A is an optional Connector Unit;
X is an activateable self-immolative moiety;
R is hydrogen, or C1-C6 alkyl, C6-C14 aryl or C-linked heteroaryl, optionally
substituted with suitable protection; and
R1 is hydrogen, or C1-C6 alkyl, C6-C14 aryl or C-linked aryl, optionally
substituted with suitable protection as required,
or R and R1 together with the nitrogen and carbon atoms to which they are attached
comprise a pyrrolodinyl or dinyl moiety.
73. A method of preparing an ediate of a Drug-Linker Compound wherein the
intermediate has the structure of
said method comprising:
ting a drug having a free hydroxyl functional group with a N-
chloromethylamine having the structure of:
under conditions sufficient for substitution of the chorine atom with the oxygen
heteroatom from said free drug functional group,
wherein
Z' is a her Unit sor to a Stretcher Unit (Z) of the Drug-Linker Compound
and comprises a functional group for attachment of a targeting ligand;
A’ is a Connector Unit precursor to a tor Unit (A) and is comprised of a
functional group for bond formation to the remainder of the Linker Unit of the inker
compound;
X is an activatable self-immolative moiety;
R is hydrogen, or C1-C6 alkyl, C6-C14 aryl or ed heteroaryl, optionally
substituted with suitable protection; and
R1 is hydrogen, or C1-C6 alkyl, C6-C14 aryl or C-linked heteroaryl, optionally
substituted with suitable protection as required,
or R and R1 together with the nitrogen and carbon atoms to which they are attached
comprise a pyrrolodinyl or piperidinyl moiety.
Claims (14)
1. A method of preparing an ediate of a inker compound, which has a Linker Unit and a Drug Unit covalently attached thereto, n the intermediate has the 5 structure of: said method comprising: contacting a modified free drug having the ure of: 10 with a self-immolative intermediate represented by: A'-X-OH, wherein any hydroxyl group within A’ or X is ted as an acetate, propionate or benzoate ester, a methyl or tetrahydropyranyl ether, a methoxymethyl or ethoxymethyl ether, or a trimethylsilyl, triethylsilyl, tert-butyldiphenylsilyl, tert-butyldimethylsilyl, triisopropylsilyl, or [2-(trimethylsilyl)ethoxy]-methylsilyl ether, 15 such that the indicated MAC Unit is produced through Curtius rearrangement, wherein D is the Drug Unit wherein the Drug Unit corresponds in structure to free drug in which a hydroxyl functional group has been incorporated into the MAC Unit, the oxygen heteroatom from which is designated by O*; A' is a Connector Unit sor to a Connector Unit (A) having a functional group 20 for bond formation to the remainder of the Linker Unit, wherein A is selected from the group consisting of: , , and , wherein the wavy lines indicate attachment of the Connector Unit within the Linker Unit, wherein in each ce R13 is independently selected from the group consisting of -C1-C6 25 alkylene-, -C3-C8carbocyclo-, -arylene-, -C1-C10 heteroalkylene-, -C3-C8heterocyclo-, -C1- ylene-arylene-, ne-C1-C10alkylene-, -C1-C10alkylene-(C3-C8carbocyclo)-, -(C3- C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-, and -(C3-C8 heterocyclo)-C1-C10 alkylene-, and the subscript c is an integer ranging from 1 to 4; or A is selected from the group consisting of: 5 , , , O , , , , and , wherein R13 is -C1-C6 alkylene-, -C3-C8carbocyclo-, -arylene-, -C1-C10 heteroalkylene- , -C3-C8heterocyclo-, -C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, -C1-C10alkylene- 10 (C3-C8carbocyclo)-, -(C3-C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-, or -(C3-C8 heterocyclo)-C1-C10 alkylene- or –C(=O)C1-C6 ne- or -C1-C6 alkylene-C(=O)-C1-C6 alkylene, wherein the wavy lines indicate attachment of the Connector Unit within the Linker Unit; 15 wherein R111 is ndently selected from the group consisting of hydrogen, phydroxybenzyl , methyl, isopropyl, yl, sec-butyl, -CH2OH, -CH(OH)CH3, - CH2CH2SCH3, -CH2CONH2, -CH2COOH, -CH2CH2CONH2, 2COOH, - (CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, - (CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, 4NHCHO, - 20 (CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3- pyridylmethyl-, 4-pyridylmethyl-, wherein the wavy line indicates covalent attachment to the der of the Connector Unit; each R100 is independently selected from hydrogen or -C1-C3 alkyl, ably en or CH3; and 5 c is independently selected integer ranging from 1 to 10; X is an activatable self-immolative moiety of formula (i): wherein the wavy line indicates nt attachment of W to A’, and the sk (*) indicates nt attachment of Y to a methylene carbamate unit; 10 W is an Activation Unit of the formula: wherein the wavy line adjacent to the carbonyl is attached to the self-immolative Spacer Unit and the other wavy line is attached to the Connector Unit precursor (A’), and the subscript w is an integer g from 1 to 12; and 15 wherein R19 is, in each instance, independently selected from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, - CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH, -CH2CH2CONH2, - CH2CH2COOH, -(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, -(CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, - 20 (CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3- pyridylmethyl-, 4-pyridylmethyl-, phenyl, cyclohexyl, , , , , , , , , and ; and Y is a self-immolative Spacer Unit having the structure: wherein the wavy line indicates covalent attachment to the Activation Unit and the g (#) indicates covalent attachment of the ic carbon to the methylene carbamate unit; and Q is C1-C8 alkyl, -O-(C1-C8 alkyl), halogen, nitro, or cyano, and m is an integer 10 ranging from 0 to 4; or X is a Glucuronide Unit having the structure of formula XIXa or XIXb: (XIXa) (XIXb) wherein Su is a Sugar , -O'- represents the oxygen atom of a glycosidic bond cleavable by a glycosidase to initiate e of the Drug Unit; and R1S, R2S and R3S independently are hydrogen, a halogen, -CN or -NO2, wherein the wavy line nt to the en atom indicates covalent attachment to 5 A’; and the asterisk (*) adjacent to the benzylic carbon atom indicates covalent attachment to the oxygen atom of the methylene carbamate unit, wherein activation of the activateable selfimmolative moiety releases the free drug; R is en; and 10 R1 is hydrogen, ally substituted C1-C6 alkyl, optionally substituted C6-C14 aryl, or ally substituted C-linked heteroaryl: wherein each optional substituent is selected from the group consisting of -X, -Rop, -OH, - ORop , -SRop, -N(Rop)2, -N(Rop)3, =NRop, -CX3, -CN, -NO2, (=O)Rop, -C(=O)Rop, - C(=O)N(Rop)2, -S(=O)2Rop, 2NRop, -S(=O)Rop, -OP(=O)(ORop)2, -P(=O)(ORop)2, - 15 PO3=, PO3H2, -C(=O)Rop, -C(=S)Rop, -CO2Rop, -CO2-, -C(=S)ORop, -C(=O)SRop, -C(=S)SRop, -C(=O)N(Rop)2, - C(=S)N(Rop)2, and -C(=NRop)N(Rop)2, wherein each X is independently selected from the group consisting of a halogen: -F, -Cl, -Br, and -I; and each Rop is independently selected from the group consisting of hydrogen, -C1- C20 alkyl, -C6-C20 aryl, and -C3-C14 heterocycle.
2. The method of claim 1, wherein R1 is hydrogen or optionally substituted C1-C6 alkyl, wherein each optional substituent is selected from the group consisting of -X, -Rop, - OH, -ORop , -SRop, -N(Rop)2, -N(Rop)3, =NRop, -CX3, -CN, -NO2, -NRopC(=O)Rop, - 25 C(=O)Rop, -C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, -OP(=O)(ORop)2, - P(=O)(ORop)2, -PO3=, PO3H2, -C(=O)Rop, -C(=S)Rop, -CO2Rop, -CO2-, -C(=S)ORop, - C(=O)SRop, -C(=S)SRop, N(Rop)2, - C(=S)N(Rop)2, and -C(=NRop)N(Rop)2, wherein each X is independently selected from the group consisting of a halogen: -F, -Cl, -Br, and -I; and each Rop is independently ed from the group consisting of hydrogen, -C1- C20 alkyl, 30 -C6-C20 aryl, and -C3-C14 heterocycle.
3. The method of claim 1, wherein R1 is not substituted.
4. The method of claim 1, wherein R1 is substituted, wherein each substituent is selected from the group consisting of -X, -Rop, -OH, - ORop , -SRop, -N(Rop)2, -N(Rop)3, =NRop, -CX3, -CN, -NO2, -NRopC(=O)Rop, -C(=O)Rop, - C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, )(ORop)2, -P(=O)(ORop)2, - PO3=, PO3H2, -C(=O)Rop, -C(=S)Rop, -CO2Rop, -CO2-, -C(=S)ORop, -C(=O)SRop, -C(=S)SRop,
5. -C(=O)N(Rop)2, - C(=S)N(Rop)2, and -C(=NRop)N(Rop)2, wherein each X is independently selected from the group consisting of a n: -F, -Cl, -Br, and -I; and each Rop is independently selected from the group consisting of hydrogen, -C1- C20 alkyl, -C6-C20 aryl, and -C3-C14 heterocycle. 10 5. The method of claim 1 or 2, wherein the Drug Unit corresponds in ure to free drug that is an auristatin compound having a hydroxyl functional group whose oxygen heteroatom has been incorporated into the MAC Unit, wherein the auristatin compound is capable of binding to tubulin to disrupt tubulin function. 15
6. The method of claim 5, wherein the auristatin compound is MMAE or auristatin T.
7. The method of any one of claims 1 to 6, wherein H has the ure of: 20
8. The method of claim 1, wherein the modified free drug has the structure of:
9. The method of claim 1, wherein the inker intermediate compound has the structure of:
10. A method of preparing an intermediate of a Drug-Linker Compound n the intermediate has the structure of: said method sing: contacting a drug having a free hydroxyl functional group with a N- chloromethylamine having the structure of: 10 under conditions such that the ne atom is substituted with the oxygen heteroatom from said free drug onal group, wherein any hydroxyl group within A’ or X is protected as an acetate, propionate or benzoate ester, a methyl or tetrahydropyranyl ether, a methoxymethyl or ethoxymethyl ether, or a trimethylsilyl, triethylsilyl, tert-butyldiphenylsilyl, tert-butyldimethylsilyl, 15 triisopropylsilyl, or [2-(trimethylsilyl)ethoxy]-methylsilyl ether, A’ is a Connector Unit precursor to a Connector Unit (A) having a functional group for bond formation to the remainder of the Linker Unit, wherein A is selected from the group consisting of: , , and , wherein the wavy lines indicate attachment of the Connector Unit within the Linker Unit, wherein in each instance R13 is independently selected from the group consisting of -C1-C6 alkylene-, -C3-C8carbocyclo-, -arylene-, -C1-C10 heteroalkylene-, heterocyclo-, -C1- C10alkylene-arylene-, -arylene-C1-C10alkylene-, -C1-C10alkylene-(C3-C8carbocyclo)-, -(C3- 5 C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-, and 8 heterocyclo)-C1-C10 alkylene-, and the subscript c is an integer g from 1 to 4; or A is selected from the group consisting of: , , , O , , , , 10 and , wherein R13 is -C1-C6 alkylene-, -C3-C8carbocyclo-, ne-, -C1-C10 heteroalkylene- , -C3-C8heterocyclo-, -C1-C10alkylene-arylene-, -arylene-C1-C10alkylene-, -C1-C10alkylene- (C3-C8carbocyclo)-, -(C3-C8carbocyclo)-C1-C10alkylene-, -C1-C10alkylene-(C3-C8 heterocyclo)-, or -(C3-C8 heterocyclo)-C1-C10 alkylene- or –C(=O)C1-C6 alkylene- or -C1-C6 15 alkylene-C(=O)-C1-C6 alkylene, wherein the wavy lines indicate attachment of the Connector Unit within the Linker Unit; wherein R111 is independently selected from the group consisting of hydrogen, phydroxybenzyl , methyl, isopropyl, yl, tyl, , -CH(OH)CH3, - 20 CH2CH2SCH3, -CH2CONH2, -CH2COOH, -CH2CH2CONH2, -CH2CH2COOH, - (CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, - (CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, - (CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3- pyridylmethyl-, 4-pyridylmethyl-, wherein the wavy line indicates covalent ment to the der of the Connector Unit; 5 each R100 is independently selected from hydrogen or -C1-C3 alkyl, preferably hydrogen or CH3; and c is independently selected integer ranging from 1 to 10; X is an activatable self-immolative moiety of a (i): 10 wherein the wavy line indicates covalent attachment of W to A’, and the asterisk (*) indicates covalent ment of Y to a ene carbamate unit; W is an Activation Unit of the formula: wherein the wavy line adjacent to the carbonyl is attached to the self-immolative 15 Spacer Unit and the other wavy line is attached to the Connector Unit precursor (A’), and the ipt w is an integer ranging from 1 to 12; and wherein R19 is, in each instance, independently selected from the group consisting of en, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, - CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH, -CH2CH2CONH2, - 20 CH2CH2COOH, -(CH2)3NHC(=NH)NH2, 3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, -(CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, - (CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3- pyridylmethyl-, 4-pyridylmethyl-, phenyl, cyclohexyl, , , , , , , , , and ; and Y is a self-immolative Spacer Unit having the ure: wherein the wavy line indicates covalent attachment to the Activation Unit and the hashtag (#) indicates covalent attachment of the benzylic carbon to the methylene ate unit; and Q is C1-C8 alkyl, -O-(C1-C8 alkyl), halogen, nitro, or cyano, and m is an integer 10 ranging from 0 to 4; or X is a Glucuronide Unit having the structure of formula XIXa or XIXb: (XIXa) (XIXb) wherein Su is a Sugar moiety, -O'- represents the oxygen atom of a glycosidic bond cleavable by a glycosidase to initiate release of the Drug Unit; and R1S, R2S and R3S ndently are hydrogen, a halogen, -CN or -NO2, wherein the wavy line adjacent to the nitrogen atom indicates covalent attachment to 5 A’; and the asterisk (*) adjacent to the benzylic carbon atom indicates covalent attachment to the oxygen atom of the methylene carbamate unit, wherein activation of the activateable selfimmolative moiety releases the free drug; R is hydrogen, tituted C1-C6 alkyl or unsubstituted C6-C14 aryl; and 10 R1 is hydrogen, optionally substituted C1-C6 alkyl, optionally tuted C6-C14 aryl, or optionally substituted C-linked heteroaryl, or R and R1 together with the nitrogen and carbon atoms to which they are ed form a pyrrolodinyl or piperidinyl moiety, wherein each optional substituent is selected from the group consisting of -X, -Rop, -OH, - ORop , -SRop, -N(Rop)2, -N(Rop)3, =NRop, -CX3, -CN, -NO2, (=O)Rop, -C(=O)Rop, - 15 C(=O)N(Rop)2, -S(=O)2Rop, -S(=O)2NRop, -S(=O)Rop, -OP(=O)(ORop)2, -P(=O)(ORop)2, - PO3=, PO3H2, -C(=O)Rop, -C(=S)Rop, -CO2Rop, -CO2-, ORop, -C(=O)SRop, -C(=S)SRop, -C(=O)N(Rop)2, - C(=S)N(Rop)2, and op)N(Rop)2, wherein each X is independently selected from the group consisting of a halogen: -F, -Cl, -Br, and -I; and each Rop is independently selected from the group consisting of hydrogen, -C1- C20 alkyl, 0 aryl, 20 and -C3-C14 heterocycle.
11. The method of claim 10 wherein R1 is hydrogen.
12. The method of claim 11, wherein the N-chloromethylamine has the ure of: wherein R is -CH2CH3 and wherein the nitro substituent is the functional group capable of bond formation.
13. A method as claimed in any one of claims 1 to 9 of preparing an intermediate of a Drug-Linker compound, substantially as herein described with reference to any example thereof and with or without reference to the accompanying drawings. 5
14. A method as claimed in any one of claims 10 to 12 of preparing an ediate of a inker compound, substantially as herein described with reference to any example thereof and with or without reference to the accompanying drawings. ex vivo plasma stability o • mouse plasma orm 4 rat plasma "D 3. < 2 - 0 2 4 6 8 10 Time (days)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361918539P | 2013-12-19 | 2013-12-19 | |
TW103144705A TWI727919B (en) | 2013-12-19 | 2014-12-19 | Methylene carbamate linkers for use with targeted-drug conjugates |
NZ721877A NZ721877A (en) | 2013-12-19 | 2014-12-19 | Methylene carbamate linkers for use with targeted-drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ760199A true NZ760199A (en) | 2022-07-01 |
Family
ID=82257968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ760199A NZ760199A (en) | 2013-12-19 | 2014-12-19 | Methylene carbamate linkers for use with targeted-drug conjugates |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ760199A (en) |
-
2014
- 2014-12-19 NZ NZ760199A patent/NZ760199A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020281140B2 (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
AU2021201636B2 (en) | Self-stabilizing linker conjugates | |
TWI680765B (en) | Self-stabilizing linker conjugates | |
EP3082878B1 (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
NZ760199A (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
CN111558049B (en) | Methylene carbamate linkers for use with target-drug conjugates | |
CN111569086B (en) | Methylene carbamate linkers for use with target-drug conjugates | |
EA039120B1 (en) | Methylene carbamate linkers for use with targeted-drug conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2023 BY COMPUTER PACKAGES INC Effective date: 20221130 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2024 BY COMPUTER PACKAGES INC Effective date: 20231130 |